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ABSTRACT 
As our understanding of the platelet’s systemic role continues to expand beyond 
hemostasis and thrombosis, interrogation of the platelet’s ability to affect diverse 
biological processes is required. Studies of the platelet’s non-traditional roles 
have focused on developing our understanding of the platelet’s relation to 
specific disease phenotypes as well as elucidation of platelet characteristics, 
content, and function. The generic content, traditional function and heterogeneity 
of platelets have long been accepted; more ambiguous and controversial has 
been how these factors are interrelated.  
 Investigation of platelet content revealed the presence of biologically 
functional RNA in anucleated platelets, the correlation of platelet RNA to distinct 
phenotypes, and the ability of platelets to transfer RNA to other vascular cells; 
however how these processes occur is unclear. To further interrogate platelet 
RNA processes, we utilized sorting and RNA sequencing to develop platelet 
subpopulation transcriptome profiles. We found that platelet heterogeneity 
extends to the platelet transcriptome: distinct RNA profiles exist dependent on 
platelet size. We hypothesized that this RNA heterogeneity is the result of RNA 
transfer between platelets and vascular cells. Using in vitro and in vivo modeling, 
we were able to show the novel ability of platelets to take up RNA from vascular 
cells, correlating to the unique functional profile associated with small platelet 
transcriptomes. These findings reveal a role for platelet RNA transfer in platelet 
RNA heterogeneity, with potential correlation to platelet functional diversity 
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previously proposed. The ability of the platelet to bidirectionally transfer RNA 
within circulation has implications for vascular health and beyond. 
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Summary 
Though first observed over 150 years ago, platelets are still a source of 
constant study today. While these small cellular fragments have now been shown 
to play integral roles across vast fields of human biology, how these cells act in 
such important and varied ways is still not fully understand. The more we learn 
about platelets, what they contain and what they can do, the more amazing it 
seems that these anucleate fragments control such intricate and delicate 
mechanistic pathways. Typically hemostatic cells but often referred to as the 
“barometers of the blood” (3) for their role in infection and immunity, whatever 
role these tiny cells play, platelets maintain a delicate balance between healing 
and response. Understanding how cells incapable of transcription can impact so 
many systemic responses without detrimental effects will not only expand our 
understanding of disease, but help development of therapeutic and diagnostic 
approaches in many fields. 
 
Introduction 
The Discovery of the Platelet 
While some scientific breakthroughs can be easily accredited to a specific 
researcher or publication, the official “discovery” of the platelet is difficult to 
ascribe, as it was actually observed by several researchers long before its 
relevance was understood. The establishment of the platelet as a novel cell type 
was hampered by a number of obstacles, mainly that initial observations of 
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platelets were secondary in studies focused on other aspects of hematology and 
that microscopic techniques sensitive enough to observe platelets were not 
available in many laboratories and minimally validated and, thus, not publicly 
accepted (4). Despite these issues, between 1840 and 1886, the further 
development of the microscope led to an explosion of our understanding of blood 
components, and eventually the discovery of the platelet. From 1840-1882, there 
were both written and drawn accounts of what were mostly termed “spherules” or 
“globules” (4), which can now be attributed to platelets. Some of these 
observations failed to recognize the significance of these small cells: George 
Gulliver and William Addison in 1841 and Friedrich Arnold in 1845 all described 
cellular elements of the same size and functionality as the platelet, but only in 
passing (4). Other observations recognized the distinct novelty of these 
structures; however, their hypotheses on their relevance were varied and 
inevitably incorrect. In 1842, Alfred Donné is credited with first establishing the 
existence of a third blood element (different from red or white blood cells); 
however, he believed these small cells were related to chyle globulins (4). While 
one study focused on the potential of these unknown globules to be related to 
infection (William Osler, 1873, described them as “peculiar types of bacteria” (4)), 
the majority focused on platelets as progenitors of other cells. In 1864 Lionel 
Beale gave a clear account of platelets but firmly stated their germinal nature 
while Franz Simon in 1842, Gustav Zimmerman in 1846 and George Hayem in 
1877 all believed strongly that these small elements were red blood cell 
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progenitors, Hayem going as far as naming them “haematoblasts” (4, 5). Max 
Schultze, often credited with the first true description of platelets in 1865, 
believed them to be derived from leukocyte granules (4). Though he did not go in 
depth, Schultze was able to point out platelet ubiquity (present in blood samples 
across numerous studies), size (0.001-0.002 mm) and nature (typically singular 
though often grouped) (5). Despite the confusion surrounding this third blood 
component, many illustrations from these studies show accurately what we today 
call platelets – both in their contributing role to fibrin clot formation and as 
individual units throughout circulation. Though they had little understanding at the 
time, even then many of these researchers observed some of the fundamental 
tenants of platelet biology. Thomas Wharton Jones described platelets present in 
the masses formed at sites of vessel wall trauma in 1850 (4, 5) and William Osler 
described how these small elements were singular when observed in circulation 
but formed masses quickly when blood was removed from the body (4). Max 
Schultze described how “under some circumstances the appearance is as if rays 
of finely granular protoplasm emerge from them, similar to the Amoeba 
porrectaVbut these appearances are only connected with the coagulation of 
fibrous material” (5). 
Despite initial observations, the man most often credited with the 
discovery of the platelet is Giulio Bizzozero, who, though undoubtedly not the first 
to describe platelets, wrote perhaps the first clear and most in-depth description. 
In 1881 and 1882, Bizzozero published several manuscripts on this third blood 
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component (5). As his work was first published in Italian, French and German, he 
called these cells piastrine (Italian), petite plaques (French) and Blutplättchen 
(German), all of which translate to “small plates” and eventually led to the English 
word “platelet” (5). Bizzozero described the structure of his “small plates” (“very 
thin platelets, disc-shapedV round or oval”) (5), size (“diameter two to three 
times smaller than the diameter or red cells”) (5), and distinct functional ability to 
form clots (4, 5). He showed what would become one of their most distinct 
features, their lack of a nucleus, as well as refuted claims of their role as red 
blood cell progenitors (4, 5). Finally, he established what would be studied over 
the next century, the role of platelets in thrombosis, or clotting, even describing 
the initial kinetics of clot formation, with illustrations that are accurate to today (4, 
5). Though controversial at the time, Bizzozero’s results were soon confirmed by 
Curt Schimmelbusch (1885) (4, 5) and publicly supported by Osler (1886) (4), 
thus, beginning the field of platelet biology. Over the next 100 years, the role 
platelets play in the cardiovascular system would be established, leading to 
countless insights and treatments; however, only recently have roles for platelets 
outside of clotting come to light. 
 
Platelet Biology and Biogenesis 
Platelets are the smallest of the human blood cells as well as the second most 
numerous in the bloodstream. They typically range in size from 1-5 µm and, in 
their resting state, have a biconvex discoid shape (6). Their unique structural 
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components include two types of secretory granules (dense and alpha) (7, 8), 
integral to their function in clotting and hemostasis, and a unique open 
canalicular membrane system, which allows them to interact with their 
environment (7). The term platelet specifically refers to mammalian cells, as 
there is a distinct difference between the mammalian platelet and what are called 
thrombocytes in other animals (6). While similar in shape, size and function, 
platelets are lacking one integral feature that thrombocytes and most typical cells 
possess, a nucleus (6). Standard human platelet counts range from 150,000 -
450,000 platelets/µL (9), with definitive disease states associated with too few 
(thrombocytopenia) or too many (thrombocytosis, thrombocytothemia) platelets.  
The most distinct feature of the platelet, their anucleate nature, is due to 
their biogenesis. Platelet progenitor cells, megakaryocytes are themselves a 
unique cell population. Though solely responsible for the production of platelets, 
they make up a minimal component of the bone marrow (<0.01%) (10-12), and 
this low cellular count has often hindered their past study. Despite their rarity, 
megakaryocytes can produce a significant number of platelets, approximately 
5000 per megakaryocyte (13), with typically 1011 platelets in circulation at any 
given time (12).  
Megakaryocytes develop from hematopoietic stem cells (HSCs), mainly in 
the bone marrow (though small populations exist in the fetal liver and spleen) 
(11). As they move from stem cell to early progenitor, they replicate as any other 
cells would, performing standard cell mitosis. This process is directed by 
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thrombopoietin (TPO), the primary hormone which drives megakaryocyte and 
platelet biogenesis (11, 13). Once a cell is fully committed to the megakaryocyte 
lineage, TPO signaling (through the megakaryocyte-specific receptor c-Mpl) 
induces the next stage of development, known as megakaryocyte maturation (11, 
13). Over the course of the next 4-5 days, megakaryocytes increase in size (up 
to 100 µm) and prepare for platelet biogenesis by producing excess platelet 
specific proteins (such as Von Willebrand factor, or vWF) and platelet specific 
granules (dense and α-granules) (11, 13). This maturation is marked by a shift 
from a typical mitotic cell cycle to an endomitotic cell cycle, forgoing cell division. 
During endomitosis, cells go through the typical stages of mitotic development 
until anaphase B, wherein, instead of continuing on to separation into two cells, 
telophase and cytokinesis are both aborted, the nuclear envelope reforms and 
the cell remains singular (6). Megakaryocytes going through endomitosis develop 
a large cytoplasmic content, full of platelet and cytoskeletal specific proteins, and 
a multilobed, polyploid nucleus containing nuclear content as high as 128N (6, 
11, 13). Maturation is also marked by the development of a specialized 
membrane system known as the invaginated membrane system (previously 
referred to as the demarcation membrane system), which is specifically required 
for platelet production and is believed to provide the phospholipid source material 
for both the platelet membrane and its open canalicular system (11, 13, 14).  
Once megakaryocytes have matured fully, platelet biogenesis begins, as 
these large megakaryocytes are again stimulated by TPO to extend pseudopodia 
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into the blood sinuses of the bone marrow, a process known as the “flow model 
of platelet formation” (11-13). The cytoplasm of the megakaryocytes is extended 
out into 100-500 µm-long pseudopodia, referred to as “proplatelets” (11-13). 
Though these proplatelets initially develop in a uniform direction, over the course 
of 4-10 hours, each proplatelet forms branched extrusions, each 2-4 µm in 
diameter, at the tip of which platelets can be assembled and released (11-13). 
This process of proplatelet formation and amplification through branching relies 
heavily on the cytoskeletal mechanisms within megakaryocytes, specifically on 
the development of microtubule bundles which run the length of the proplatelets 
(11-13, 15). Inhibition of microtubule assembly or knock down of tubulin subunits 
results in thrombocytopenia as well as misshaped and dysfunctional platelets, 
while inhibition of actin prevents the branching seen during development (11-13, 
15-17). While both tubulin and actin dependent mechanisms are clearly required 
for proper proplatelet formation, they do not solely drive the formation of these 
structures, as their inhibition does not entirely prevent platelet production (13).  
An additional protein, dynein, is also integral to proplatelet and platelet 
development (13, 18). Dynein directs a mechanism known as microtubule sliding, 
also essential to platelet production, as its inhibition prevents proplatelet 
formation (13, 18).  Microtubules, formed from polymerization of α and β tubulin 
dimers and concurrent proteins, not only help establish the overall structure of 
the proplatelet, but also act as the “highways” through which materials from the 
cytoplasm are specifically sorted to the platelet assembly regions (13, 19). 
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Granules and organelles travel along the microtubules (aided by additional 
proteins and microtubule sliding) and eventually gather in the tips of the 
proplatelets (13, 18, 19). Additionally, specific RNAs and proteins are sorted into 
these regions as well, for inclusion in nascent platelets (13, 20). As the 
proplatelets continue to develop (at an average rate of 0.85 µm/min), the entire 
cytoplasm of the megakaryocyte is converted into these 250-500 µm tubes, 
leaving the nuclear material to be compressed and degraded (13, 21, 22).  
After formation of the proplatelets, the next step in platelet biogenesis is 
release into the bloodstream. Proplatelets squeeze through the vascular lining 
and enter the blood sinuses and, as blood passes through the sinus, multiple 
forces act on the pseudopodia to encourage platelet release (11, 13). Historically, 
little has been known about the process of both elongation through the vascular 
lining and platelet release into the vasculature. Platelet release was believed only 
to occur through the effects of shear force, specifically, as blood passed the 
extended pseudopodia, the flow caused the ends to break off, forming new 
platelets (11-13). Though this mechanism is an essential form of platelet release, 
new studies have elucidated additional methods of release as well as more 
details on how proplatelets initially end up in the blood sinuses. Most recently, it 
has been shown that interaction between a high concentration blood protein 
(sphingosine 1 phosphate -S1P) and its receptor on megakaryocytes (S1pr1) not 
only results in release of proplatelets into circulation but is integral for the 
directional growth of the proplatelets into the sinusoidal space in the first place 
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(lack of S1pr1 signaling results in extravascular proplatelet and platelet 
development) (11, 23). Additionally, studies have revealed that actin-rich regions 
of the platelet plasma membrane, termed podosomes, pave the way for 
proplatelet protrusions through the sinus lining through degradation of the 
extracellular matrix (11, 24). Taken together, these recent studies have started to 
elucidate how precisely these protrusions get from the parental cell into the 
sinuses and begin to give a clearer image of this important step in platelet 
production. 
Once proplatelets are inside the sinuses, segments are released into the 
blood stream to produce the heterogeneous platelet population. While some of 
the proplatelet extrusions release fragments of typical mature platelet size and 
shape, others can break off into larger, less typical fragments. Sometimes an 
entire proplatelet is fragmented and enters the bloodstream (11-13). Once in the 
circulation, proplatelets form a distinct barbell structure, with platelet assembly 
regions at each end (11, 12, 25). These barbell structures will eventually split into 
smaller mature platelets in the circulation (11, 12, 25). Other times a structure 
known as a preplatelet may break off (11, 21). Preplatelets are 2-10 µm in 
diameter and can revert back to the structure of the circulating proplatelet and 
similarly create mature platelets in circulation (11, 26). This phenomenon of 
proplatelet reversion and mature platelet formation within the circulation appears 
microtubule dependent and results in very uniform sized platelets (11, 21, 27). 
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Additionally, as this process occurs within the circulation, it can result in platelet 
production far away from the bone marrow, such as in the lung (11).  
Though a historically controversial topic, many platelet biologists agree 
that even beyond the presence of the proplatelets and preplatelets in the 
bloodstream, the mature platelet population is heterogeneous (28). A number of 
studies in the 1970s and 1980s focused on defining the overall scope of this 
heterogeneity with contradicting results (28). These studies were not well 
standardized and used multiple model organisms and modes of isolation. 
Subsequently, results were extremely varied, especially when an association 
between platelet subpopulations and platelet circulating age was addressed. It 
was clear however that most studies agreed on the heterogeneous range of 
sizes and densities within a typical platelet population. Some conclusions 
focused on platelet size have become accepted in platelet biology. The 
association between platelet size and reactivity is now well established, with 
larger platelets having more prothrombotic tendencies than smaller platelets. 
Mean platelet volume positively correlates to platelet aggregation, higher 
expression of adhesion molecules and elevated associations with cardiovascular 
risk (11, 29-33). Some work has focused on the connection between platelet 
volume and gene expression, with the most recent findings suggesting a role for 
ITGA2 in determining platelet volume and, thus, reactivity (11, 34, 35). An 
additional large scale GWAS study by Gieger et al has associated 70 genes with 
platelet volume (11, 36). Understanding the heterogenic nature of the platelet 
13 
 
 
 
 
population will have implications not only on how we view the platelet’s traditional 
role in cardiovascular disease, but in its connections to non-vascular phenotypes 
and platelet therapies. 
 
Platelets Role in Hemostasis and Thrombosis 
As described, the historic role of platelets in clot formation was identified as early 
as the 1800s. Clinically, this function is both beneficial (hemostasis, the 
prevention of blood loss) and detrimental (thrombosis, the formation of clots 
within the vasculature), and thus requires delicate regulation with minor 
perturbations having catastrophic consequences. Once platelets enter the 
bloodstream, they circulate over the next 7-10 days (7, 8), responding to the 
microenvironment present in the sinuses. One of the best known responses is in 
the setting of exposed subendothelium at sites of vascular injury (37, 38). This 
hemostatic response is carefully regulated by a number of signaling events and 
feedback loops which can be loosely grouped into two phases, primary and 
secondary hemostasis; and described as platelet adhesion, platelet secretion 
and platelet aggregation (7, 8, 38).  
In primary hemostasis, platelets first identify vessel wall damage and 
begin adhesion to the injury site (7, 8, 38). This process occurs through a number 
of different signaling cascades and is significantly dependent on glycoproteins 
(GPs) expressed on the platelet surface (7, 8, 38). The inhibitory methods of 
intact endothelium (specifically production of prostacyclin and nitric oxide and 
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expression of CD39) are decreased upon vessel damage and extracellular matrix 
proteins, such as collagen, are exposed to the open circulation (7, 8). Platelet 
adhesion, or initial binding of platelets to the site, depends on the level of shear 
in circulation and can be dependent on binding of either plasma-derived von 
Willebrand factor (vWF, high shear) or platelet-expressed GP1A/2A (low shear) 
to this exposed collagen (7, 8, 38). vWF binding results in its own conformational 
change allowing platelet binding via GP1B/V/IX, resulting in platelets rolling along 
the exposed endothelium and interacting in a reversible manner (7, 8, 38). This 
interaction decreases platelet velocity allowing for the additional low shear 
interactions described, as well as interaction between platelet-expressed GPVI 
and collagen (7, 8, 38). These initial interactions and resultant platelet adhesion 
may lead to activation and a number of distinct physiological changes within the 
platelets themselves. The platelet cytoskeleton changes as activated platelets no 
longer hold their resting discoid shape, but instead transform to extend numerous 
pseudopodia further into the injury site and circulation (7, 8, 38). Platelet granular 
secretion occurs, with both dense and α-granules releasing a number of 
procoagulatory, platelet activating factors, as well as increasing platelet-GP 
surface expression (notably GP2B/3A, which binds fibrinogen and induces 
additional granule secretion) (7, 8, 38). Additional proteins can be activated as 
well and, taken together these events prime the platelets for eventual stable clot 
formation that characterizes secondary hemostasis.  
15 
 
 
 
 
In secondary hemostasis, the factors released from platelet granules, 
most importantly adenosine diphosphate (ADP) and serotonin (5-
hydroxytryptoamine, 5-HT), amplify the initial platelet signal, resulting in 
continued activation of platelets and induction of the coagulation cascade (7, 8, 
38). ADP specifically interacts with two platelet-expressed receptors, P2Y1 and 
P2Y12 (7, 8, 38). P2Y1 activation results in continued platelet shape change and 
reversible platelet aggregation while P2Y12 activation results in additional 
granule secretion and activation of GP2B/3A (7, 8, 38). While resting platelets 
express GP2B/3A on their surface, in its lower concentration and inactivated 
form, this receptor does not easily bind soluble ligands (7, 8, 38). However, once 
activated, GP2B/3A is primed to interact with soluble ligands and play an integral 
role in stable clot production (7, 8, 38). 
As changes occur within the platelets themselves, the original injury and 
platelet adhesion and activation also induce the initiation of the coagulation 
cascade.  The coagulation cascade is a series of signaling events that occur in 
the circulation resulting in the formation of a stable blood clot (7, 8, 38). This 
cascade is triggered by a number of factors, some from the exposure at the site 
of injury and some through platelet activation. Release of procoagulatory factors 
into circulation, such as tissue factor from the exposed endothelium or Factors V, 
VII, XI and XIII from granule secretion, sets off and propagates this signaling 
cascade, resulting in the production of thrombin from its precursor prothrombin 
(7, 8, 38). Thrombin is also produced in response to the exposure of negatively 
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charged phospholipids on the activated platelet membrane (8).  Thrombin is a 
serine protease that then can cleave soluble fibrinogen to produce insoluble 
strands of fibrin, an important building block, which combined with the presence 
of activated GP2B/3A on platelets leads to the formation a cross-linked stable 
fibrin-platelet clot at the site of injury (7, 8). This form of clot is irreversible, 
creating a hemostatic plug, and is regulated by a distinct feedback loop through a 
number of coagulation factors (specifically inhibition of Factor VII, thrombin and 
Factors V and VIII by tissue factor pathway inhibitor, TFPI, antithrombin and 
active protein C, respectively) (6-8). The formation of this hemostatic plug stably 
prevents blood loss and promotes wound healing at the site of injury. 
While the immediate and irreversible response of platelets to sites of injury 
is essential for prevention of blood loss and proper wound healing, if incorrectly 
regulated, it can have detrimental effects on cardiovascular health. If clot 
formation is left unchecked, thrombosis can occur, resulting in occlusion of the 
vessel, decrease of blood flow and cellular death, a paradigm that occurs in the 
setting of myocardial infarction and stroke. During atherosclerosis,  i.e. vessel 
wall disease characterized by development of fatty plaques within arteries which 
causes narrowing of the sinuses, even characteristic ”normal” clot formation can 
result in vessel occlusion, and acute cardiac ischemia (6). Accordingly, it is 
imperative that platelet regulation is not only location specific but tightly 
controlled, to provide the balance required for proper cardiovascular health. 
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Alternative Platelet Functions throughout the Circulation 
Platelets’ traditional role in hemostasis and their role in the chronic inflammatory 
disease atherosclerosis illustrate the link between platelets and inflammation and 
have been studied extensively. However, our understanding of platelets and their 
varied functions has increased alongside our knowledge of platelets’ roles in the 
body’s systemic responses. Deeper connections between local inflammation, 
infection and cancer progression were revealed by more recent studies of 
platelet biology. Patients with rheumatoid arthritis possess hyperactive platelet 
microparticles in their joint fluid, linking platelets to development of local 
inflammation (39-44). Similarly, platelets have been associated with the systemic 
response to infection, both viral and bacterial, through their expression of toll like 
receptors (TLRs), especially toll like receptor 4 (TLR4) and toll like receptor 7 
(TLR7) (3, 45-57). The expression of both these TLRs on platelets allows 
platelets to act as sentinels in the blood – early sensors detecting foreign 
pathogens (lipopolysaccharide expressed on Gram-negative bacteria in the case 
of TLR4 (3, 50, 58) and single-stranded RNA viruses in the case of TLR7 (55)). 
Activation of these receptors allows platelets to induce a number of immune 
responses, including neutrophil recruitment and bacterial removal, neutrophil 
extracellular trap (NET) formation and heterotypic aggregate development (3, 54, 
55, 59).  
 Studies have found a number of links between platelets, coagulation and 
cancer. It has been shown that tumors themselves can have a distinct effect on 
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coagulation through formation and release of a number of prothrombotic factors 
(such as tissue factor expression on the surface of cancer cells) (60-63), 
corresponding to data which shows select oncology patients suffer from 
coagulation disorders throughout their disease progression (64). These 
individuals subsequently face a greater risk both of thrombotic events, such as 
pulmonary embolism and deep vein thrombosis, and of platelet alterations in 
platelet counts and volume (65, 66). A variety of proangiogenic platelet factors, 
such as vascular endothelial growth factor (VEGF) and platelet-derived growth 
factor (PDGF), have been correlated to the required physiological processes for 
tumor metastasis, such as angiogenesis and chemotaxis (67-70). These 
correlations, along with the existence of activated platelets in tumor vasculature, 
suggest that platelets play a role in developing the essential blood supply for 
tumor growth (71, 72) and furthering tumor cell metastasis (potentially through 
concealing tumor development from systemic inflammatory reactions) (73).  An 
inverse relationship between platelet inhibition and thrombotic events and tumor 
growth further supports the role of platelets in tumor development (74-77). As our 
understanding of platelet capability expanded from its function in hemostasis to 
one in moderating systemic inflammation, immune response, and cancer 
progression, one uncertainty that emerged was how the anucleate platelet is 
capable of such versatile functions.  
 
Platelet Content  
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As described, platelet biogenesis occurs through the manual fragmentation of 
megakaryocytes, and thus, platelets do not contain nuclei and are incapable of 
transcription. Evaluation of platelet contents however revealed that platelets 
contain all the components required for signal-dependent translation including 
functional ribosomes, signaling proteins, messenger RNAs (mRNAs), and 
microRNAs (miRNAs) (78-80). The mechanism of platelet biogenesis combined 
with their lack of transcriptional ability implied that the platelet profile reflected 
that of their parental cells and was, therefore, inherently invariable; however, 
further analysis of this concept questions this assumption. Megakaryocytes are 
capable of transcription and altering their own transcriptome, allowing for the 
potential to similarly produce diverse platelets under different circumstances. 
Additionally, it was found that megakaryocytes specifically sorted and packaged 
material into platelets in the final stages of thrombopoiesis (20). A study of matrix 
metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) revealed that, 
though megakaryocytes expressed 10 MMP family members at the mRNA level, 
only 7 of these were found in platelets (20). Additionally, one of these transcripts 
not found in platelets, MMP2, was expressed at the protein level in platelets (20). 
This suggests that megakaryocytes can selectively sort mRNAs into platelets 
during platelet biogenesis (20).  Therefore, although platelet contents at the time 
of biogenesis are derived from megakaryocytes, it may not directly reflect the 
entire profile of the parental megakaryocytes. These findings suggested an 
expansive evaluation of the platelet transcriptome and proteome was necessary 
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to better understand the functional capabilities of platelets, especially under 
specific physiological settings where an altered platelet profile might be present.  
 Initial microarray-based studies estimated only 1500-4000 transcripts in 
healthy human platelets (81, 82); however the development of deep sequencing 
allowed for full detection of 9500 mRNA transcripts (80, 83-85). Platelets also 
contain various forms of small RNAs, with microRNAs (miRNAs) accounting for 
80% of the small RNA expressed (86).  MiRNAs, 19 to 24-nucleotide (nt) non-
coding RNAs, regulate mRNA translation through sequence-specific recognition 
of non-coding regions in the 3’ untranslated region (UTR) of target mRNAs (87) . 
miRNAs can regulate several targets at once and thus can have a profound 
effect on cellular environments with minimal material. The presence of 
megakaryocyte derived precursor and mature miRNAs as well as the presence of 
the machinery necessary to perform pre-miRNA processing in platelets led to 
complementary research evaluating the platelet miRNA profile (86, 88). This 
profiling of platelets identified 532 miRNAs in healthy patient platelets, 40 of 
which were novel miRNAs, with members of the let-7 family being the most 
represented (86).   
 
Platelet RNA Content and Disease Associations 
While initial studies focused on healthy platelet profiling, follow up focused on 
correlating platelet RNA profiling to platelet reactivity, species variability and 
disease modeling. Differential expression analysis of healthy patient miRNA 
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profiles revealed a correlation between platelet reactivity and miRNA and mRNA 
expression (89, 90). 74 miRNAs were differentially expressed in platelets, with 
the majority showing increased expression in hyper-reactive platelets (89). This 
corresponded to an increased differential expression of mRNAs in hyporeactive 
platelets (89). Analysis of their findings in hyper-reactive platelets to identify 
differentially expressed increased miRNAs with corresponding decreased target 
mRNAs revealed 12  miRNA-mRNA pairs, establishing a role for miRNA 
regulation of mRNA (and thus protein) expression in platelet reactivity (89). 
Examples of miRNA links to platelet reactivity in the context of cardiovascular 
disease are also abundant (91-94).  
Similarly, an early comparison study between human and mouse platelets, 
evaluated potential roles RNA may play in platelet functional diversity (80). This 
study identified a large amount of conservation (approximately 4990 transcripts) 
between species, with 58% of human platelet transcripts conserved in the mouse 
platelet profile, and 83% of the mouse profile found in the human profile; 
however, it also revealed distinct expression variants between the two species 
which reflected previously described functional differences between human and 
mouse platelets (80).  Specifically, expression of protease-activated receptor 
(PAR) transcripts in human and mouse platelets directly reflected previously 
known information about human and mouse platelet signaling (80).  This study 
found the transcript for PAR1, the primary thrombin receptor in human platelets, 
was expressed in human platelets at 13.5 times the level it is in mouse platelets, 
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and mouse platelets expressed an alternative PAR transcript, PAR3 (80, 95-97). 
This corresponds to and explains previous data showing knockdown of PAR1 in 
mice having no effect on the mouse platelet thrombin response (80, 95, 96). 
Similarly, previous studies showing differential response to platelet activating 
factor (PAF) in human and mouse platelets (human platelets responded, mouse 
platelets did not), is explained by the presence of platelet activating factor 
receptor (PTAFR) transcript in only human platelets, not mouse platelets (80, 98, 
99). Finally, the presence of CD68 transcript in human platelets and not mouse 
platelets, correlates to CD68 platelet protein expression (80). Taken together, 
these studies demonstrate the functional relevance of platelet RNA to platelet 
reactivity.   
The ability of megakaryocytes to alter their transcriptome and 
preferentially sort platelets led to further evaluation of platelet RNA profiles under 
various physiological conditions.  An abundant amount of correlations exist 
between platelet RNA expression and physical phenotypes and pathologies. 
Studies have identified specific differential profiles associated with patient age 
(129 mRNAs and 15 miRNAs), patient gender (54 mRNAs and 9 miRNAs) and 
patient race (100, 101). Body mass index was significantly (P<0.005) linked to 
higher expression of 11 of 48 transcripts analyzed in platelets from the 
Framingham Heart Study (FHS), highlighting differential expression of platelet 
inflammatory transcripts such as intercellular adhesion molecule 1 (ICAM1), 
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S100 calcium-binding protein A9 (S100A9), interleukin 6 (IL6), interleukin 1 
receptor 1 (IL1R1) and TLR2 (53).   
Similar differential profiles exist under various pathologies as well. 
Systemic lupus erythematosus (SLE) patients’ platelets displayed the type 1 
interferon (IFN) gene signature, with increased expression of type 1 IFN related 
transcripts (PRKRA, IFITM1, SELP and/or CD69), especially in patients with a 
history of vascular disease, myocardial infarction, or arterial or venous 
thrombosis (42, 102). This correlates to known interferon secretion by platelets 
post immune cell activation, which plays a role in SLE development (42, 43). A 
characterization of sickle cell disease (SCD) shows an increased risk of 
cardiovascular complications specifically linked to increased endothelial damage, 
inflammation and platelet activation (103). Increased platelet activation directly 
affects SCD progression through a number of mechanisms, such as creation of 
microparticles and increased plasma expression of pro-coagulation and adhesion 
factors (103). Coinciding with previous reports linking platelet reactivity to distinct 
miRNA profiles, a study identified 40 differentially expressed miRNAs (16 
upregulated, 24 downregulated) in SCD patient platelets and correlated these 
patterns to specific miRNA families and resulting regulation of SCD platelet 
mRNA (103). 
 Unsurprisingly, platelet RNA expression correlations exist for 
cardiovascular and platelet related disease as well. RNA comparison of platelets 
from acute ST-elevation myocardial infarction (STEMI) patients and stable 
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coronary artery disease (CAD) patients revealed 54 differentially expressed RNA, 
29 increased and 25 decreased in STEMI patients, with the most significantly 
increased transcripts being CD69 and MRP-14 (104). Increased platelet 
transcript expression of MRP-14 correlated to plasma protein levels of MRP-8/14 
and a prospective case study utilizing the Women’s Healthy Study correlated 
MRP-8/14 plasma protein levels to incidence of female patients experiencing an 
initial cardiovascular event (104). Additional studies comparing the 
transcriptomes of non-STEMI patient platelets to STEMI patient platelets similarly 
revealed distinct differential expression between the two patient subtypes (105). 
Thrombocytosis, high platelets counts in the blood, can be differentiated in to 
different classes, specifically essential thrombocythemia (ET), a 
myeloproliferative disorder, and reactive thrombocytosis (RT) (106). Definitive 
diagnosis of the etiology of thrombocytosis is often difficult and as the two types’ 
prognoses and associated complications differ, this lack of clear differentiation 
can impede treatment (106). RNA sequencing of thrombocytotic patients 
identified unique RNA profiles of the two phenotypes of thrombocytosis and 
allowed for selection of an 11 transcript biomarker set which can be used to 
differentiate RT, ET and normal patients (106). Additional studies by the same 
group identified a 21-miRNA biomarker set for distinguishing ET patients from 
normal patients, which could be narrowed to a 3 miRNA subset (miR-10a, miR-
148a and miR-490-5p) using statistical analyses (107). The identification of these 
unique mRNA and miRNA signatures to the forms of thrombocytosis may allow 
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for better detection, diagnosis and treatment in patients. With the presence of 
unique platelet RNA expression profiles associated with such widespread clinical 
phenotypes in the realms of disease and inflammation, the study of the functional 
roles of platelet RNA has developed into an increasingly relevant field of 
research. 
 
Roles for Platelet RNA 
Translational Capacity of Platelet RNA 
Initial assumptions centered on platelet RNA being integral to platelet protein 
production and subsequent platelet function alteration in response to their 
microenvironment. Platelets have the capacity to execute both pre-mRNA 
processing and protein translation in a signal-dependent manner (78, 88, 108). 
Lipopolysaccharide (LPS) signaling in platelets catalyzes a number of reactions, 
resulting in the upregulation of mature IL1β protein. Platelet LPS stimulation 
results in the processing of stored pro-IL1β mRNA; intronic regions are spliced to 
form the mature mRNA form of the precursor protein. LPS also stimulates 
translation of the newly formed mature mRNA and cleavage of the precursor 
protein to form functional, mature Il1β protein,  affecting platelet response to 
bacterial infection (88, 109-111). Additionally, platelets possess the ability to 
process pre-miRNA to mature miRNA, allowing for platelet miRNA regulation of 
platelet mRNA expression (88); this is demonstrated in studies where the 
existence of a miRNA network affects expression of the P2Y12 receptor within 
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platelets and alters the ability of the platelet to aggregate (90). Despite these 
findings, analysis and comparison of the platelet transcriptome to the platelet 
proteome revealed that the platelet transcriptome was not completely 
represented at the proteome level, with estimates ranging from 70-90% coverage 
(108, 112, 113).  
 
Platelet RNA Transfer  
Platelets utilize many types of cell-to-cell communication, including direct – 
moving through the platelet canalicular membrane system that allows passage of 
small molecules out of the cell – and indirect – discharging microvesicles and 
exosomes– methods (114-119). The possibility of a functional role of platelet 
RNA being platelet-cell communication was hypothesized due to the existence of 
these cellular communication capabilities and the presence of the unexplained 
fraction of platelet RNA post transcriptome-proteome correlation studies. This 
hypothesis has been investigated by several different labs, resulting in several 
publications on the topic (Table 1.1), with the ability of the platelet to transfer its 
RNA to other cells first being described by our lab.  
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Table 1.1: Summary of studies demonstrating definitive platelet RNA transfer. 
 
Title 
Journal 
Information 
Transfer 
Shown Cell Effect Authors 
Platelets and 
platelet-like particles 
mediate intercellular 
RNA transfer.(114) 
Blood, 
2012 Jun 
28; 
119(26): 
6288-95. 
mRNA Platelet-like 
particles can 
transfer active 
mRNA to 
endothelial cells in 
vitro and in vivo. 
Risitano, A. 
et al 
Platelets activated 
during myocardial 
infarction release 
functional miRNA, 
which can be taken 
up by endothelial 
cells and regulate 
ICAM1 expression. 
(120) 
Blood, 
2013 May 
9; 121(19): 
3908-17 
miRNA miRNA released 
from platelets 
during myocardial 
infarction can 
regulate ICAM1 
expression in 
endothelial cells. 
Gidlöf, O. et 
al 
Activated platelets 
can deliver mRNA 
regulatory 
Ago2microRNA 
complexes to 
endothelial cells via 
microparticles. (121) 
Blood, 
2013 May 
7 [Epub 
ahead of 
print] 
miRNA miR-223 is shed 
from activated 
platelets into 
microparticles in 
Ago2miR-223 
complexes. These 
microparticles are 
taken up by 
endothelial cells 
and actively affect 
gene expression. 
Laffont, B. 
et al 
MicroRNA-223 
delivered by platelet-
derived 
microvesicles 
promotes lung 
cancer cell invasion 
via targeting tumor 
suppressor 
EPB41L3.(122) 
Mol 
Cancer, 
2015 Mar 
11; 14-58 
miRNA Transfer of miR-
223, typically 
overexpressed in 
platelets of non-
small cell lung 
cancer patients, 
from platelet-
derived 
microvesicles 
regulated EPB41L3 
expression, 
resulting in 
increased tumor cell 
invasion. 
Liang, H, et 
al 
28 
 
 
 
 
Horizontal RNA 
transfer mediates 
platelet-induced 
hepatocyte 
proliferation. (123) 
Blood, 
2015 Aug 
6: 
126(6):798-
806 
mRNA Inhibition of platelet 
and platelet-like 
particle 
internalization and 
RNA transfer blocks 
hepatocyte 
proliferation 
Kirschbaum, 
M, et al 
Platelet 
microparticles 
reprogram 
macrophage gene 
expression and 
function. (124) 
Thromb 
Haemost, 
2016 Jan; 
115(2): 
311-23 
miRNA Delivery of platelet-
derived miR-126-3p 
to macrophages 
resulted in 
significant 
differential gene 
expression and 
increased 
phagocytic 
phenotypes.  
Laffont, B. 
et al 
Platelet 
microparticles 
infiltrating solid 
tumors transfer 
miRNAs that 
suppress tumor 
growth. (125) 
Blood, 
2017 May 
12 [Epub 
ahead of 
print] 
miRNA Delivery of platelet-
derived miR-24 
impacts tumor 
growth 
Michael, JV, 
et al 
 
Initially, in order to investigate the possibility of platelet RNA transfer, we created 
an in vitro modeling system using cultured cell lines to mimic the vascular 
environment (114). By treating MEG-01 cells, a human megakaryocyte cell line, 
with thrombopoietin (TPO), a megakaryocyte maturation hormone that induces 
thrombopoiesis in vivo (13), we created platelet-like particles (PLPs). PLPs are 
structures similar to platelets but with some phenotypic differences (126). These 
PLPs allowed us to observe how platelets interact with vascular cells in vitro and 
to monitor platelet RNA during these interactions. In this study, PLPs containing 
fluorescent RNA were created by nucleofecting MEG-01 cells before TPO 
stimulation (114). Upon incubation of these fluorescently labeled PLPs with either 
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human umbilical vein endothelial cells (HUVEC), or a monocyte cell line, THP-1, 
we observed RNA transfer to both types of target cells, using both flow cytometry 
and fluorescence microscopy for analysis (114). Additionally, using microarray 
analysis, cells treated with non-labeled PLPs had specific transcript expression 
increases, the most prevalent of which were globins (114). Upon infusion of wild 
type platelets into Tlr2 -/- mice and aggregation induced by lipopolysaccharide, 
the Tlr2 transcript was observed in the monocytes of Tlr2 -/- host animals, 
confirming the in vitro phenomenon in vivo (114). Additional studies utilizing in 
vitro co-incubation modeling support the transfer of a range of platelet mRNA 
(notably, platelet marker transcripts) from human platelets to cells (unpublished 
data, Appendix B, Table B.1). Taken together, these studies support the transfer 
of platelet RNA from platelets to vascular cells, specifically endothelial cells and 
monocytes.  
Initially, additional platelet RNA transfer studies focused on the transfer of 
platelet miRNA to recipient cells, as the miRNA’s mode of regulation could result 
in profound and broad effects on other cells of the vascular system. Gidlöf et al. 
looked at the role miRNAs play in platelets during myocardial infarction (120). 
During myocardial infarction, blood flow is disturbed by thrombosis and oxygen 
supply to cardiac tissue is blocked, resulting in damage or death to the 
myocardium. In this setting, there is activation of platelets at the site of injury, 
thus, Gidlöf et al. hypothesized that miRNA content of platelets and the release 
and subsequent uptake of these miRNA played a role in the evolution of 
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myocardial injury (120). Initial studies focused on identifying if ST elevation 
myocardial infarction (STEMI) patients possessed a unique miRNA profile as 
compared to healthy subjects (120). In this study, STEMI patients had 9 miRNAs 
with significantly different expression levels as compared to controls (120).  In 
addition, 8 miRNAs were significantly downregulated in patients while miR-320a 
was upregulated (120). Since the majority of differentially expressed miRNAs 
decreased in platelets in STEMI patients, Gidlöf hypothesized that this was due 
to platelet release of miRNAs upon aggregation (120). They choose 4 candidate 
miRNAs from the 8 described above (based on the relevance of their possible 
targets to cardiovascular disease) and showed that post thrombin stimulation of 
platelets, these miRNAs significantly increased in the supernatant (120). This 
insight was confirmed through further analysis of healthy donor platelets, STEMI 
patient peripheral blood platelet and STEMI patient platelets from the site of 
occlusion (120). Platelets from the actual thrombus showed decreased levels of 
these 4 miRNAs as compared to both healthy individuals and STEMI peripheral 
platelets (120). They further investigated whether these miRNAs released from 
platelets during aggregation transferred to endothelial cells (120). By transfecting 
platelets with a synthetic exogenous miRNA, as well as a synthetic fluorescently 
labeled miRNA, they showed transfer from platelets to HMEC-1 cells in a time 
and activation dependent manner (120). 
 Several reports have shown microparticle dependent miRNA transfer 
between cells (115, 117-119, 127). Platelets have also been shown to release 
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microparticles (0.1 – 1 µm) into the bloodstream upon activation (116). Based on 
these reports as well as the initial findings described above, Gidlöf investigated 
the role microparticles potentially play in platelet RNA transfer. Preliminary 
studies by Gidlöf focused on monitoring fluorescent synthetic miRNA transfer to 
platelet microparticles as well as blocking microparticle production using 
Brefeldin A (120). Gidlöf demonstrated significant enrichment of the fluorescent 
miRNA in platelet derived microparticles post thrombin activation (120). This 
enrichment was abated with pretreatment with Brefeldin A to block microparticle 
formation (120). He additionally showed that blocking platelet microparticle 
production significantly decreased transfer of a fluorescently labeled miRNA from 
platelets to HMEC-1 cells upon coincubation (120). 
Laffont, et al. further investigated the role of platelet miRNA in transfer and 
the role microparticles may play (121). Laffont was able to show that miR-223, a 
miRNA highly expressed in platelets, was shed post platelet thrombin activation 
(121). Thrombin induced activation results in over a 60 fold increase in miR-223 
expression in platelet derived microvesicles (121). The shed miR-223 is 
complexed with Ago2 protein in microvesicles and is functional in RISC activity 
assays (121). Laffont also showed platelet-derived microparticle uptake into 
HUVEC cells, with the microparticle persisting for 48 hours within cells before 
slowly diffusing (121). Follow up studies utilizing the same approach focused on 
an additional miRNA highly expressed in platelets, miR-126-3p. They showed 
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similar uptake and enrichment, this time in macrophages, independent of the 
macrophage-dependent transcription (124).  
 The relevance of platelet RNA transfer strongly depends on the 
functionality of the transferred RNA in the target cells. Several labs have 
demonstrated the functional relevance of platelet RNA transfer. Risitano, et al. 
demonstrated RNA functionality through transfer of a GFP labeled vector from 
platelets to recipient HUVEC and THP-1 cells (114). Kirschbaum, et al. showed 
the first endogenous example of functional platelet mRNA transfer (123). 
Platelets were shown to be internalized and localized to the perinuclear region of 
hepatocytes, while labeled platelets-like particle (PLP) RNA was shown to 
accumulate in the hepatocyte cytoplasm (123). The ability of the platelet to 
stimulate hepatocyte proliferation proved dependent on functional RNA transfer 
from platelets to hepatocytes (123). Interestingly, Kirschbaum also noted that this 
phenomenon was not seen if only platelet-derived microvesicles were used, 
suggesting a potential microparticle-independent mechanism of transfer (123). 
Gidlöf demonstrated transfer of functional miRNAs from platelets to endothelial 
cells (120). Gidlöf introduced luciferase reporter constructs designed with the 3’-
UTRs of the predicted targets of their 4 miRNAs of interest (miRNAs 22, 185, 
320b and 423-5p, mRNA targets ICAM-1, eNOS, VEGFA and VEGFB, 
respectively) into target HEK293 cells in culture (120). After incubation with 
thrombin-activated platelets, the ICAM1 reporter signal was quenched compared 
to a scrambled pre-miRNA introduced supporting the transfer of functional miR-
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22 and miR-320b (120). Additionally, HMEC-1 cells incubated with platelet 
releasate after thrombin activation showed ICAM1 downregulation by 30%, 
confirming the construct results (120). Upon knockdown of endogenous miR-
320b, platelet releasate could rescue miR-320b induced ICAM1 degradation 
(120). These experiments were confirmed with direct miRNA overexpression of 
miR-320b in HMEC-1 cells (120). Similarly, Laffont et al. showed miRNA-Ago2 
complexes present in platelets were functional post transfer from thrombin 
activated platelets to HUVEC cells (121). Transfected reporter constructs in 
HUVEC cells showed 44% degradation post platelet coincubation and thrombin 
activation (121). Additionally, endogenous mRNA targets of miR-223 in HUVECs 
showed >50% degradation post platelet microparticle incubation (121). Follow up 
studies by Laffont  revealed that similar transfer of platelet-derived miR-126 to 
macrophages resulted in functional gene regulation (124). Utilizing a similar 
approach to Gidlöf, transfection of a reporter construct in macrophages showed 
that uptake of platelet microparticle-derived miR-126-3p resulted in functional 
regulation, with a 23% decrease in construct expression (124). Exposure and 
uptake of platelet-derived microparticles also resulted in significant 
transcriptome-wide expression changes (66 miRNAs and 653 RNAs) and altered 
functional capacity of macrophages (increased phagocytic phenotype) (124). 
Most recently, Liang et al. and Michael, et al. showed that impact of platelet 
microparticle miRNA transfer on cancer progression, though their results show 
opposite impact on tumor development. Liang et al. demonstrated that miR-223, 
34 
 
 
 
 
one of the most abundant miRNAs in platelets, is increased in the platelets of 
patients with non-small cell lung cancer (122). Evaluation of the role platelet-
derived miR-223 may play in cancer progression revealed its transfer from 
platelet-derived microvesicles to cancer cells, resulting in downregulation of 
tumor suppressor EPB4L13 and concurrent increase in tumor cell invasion (122). 
Alternatively, Michael et al. showed that transfer of platelet-derived miR-24 to 
solid tumor cells resulted in disrupted mitochondrial function, resulting in tumor 
cell death and proliferation decline (125).  All these studies support the 
hypothesis that platelet RNA may affect vascular cell function through cell-cell 
communication and RNA regulation. 
 
Potential Platelet RNA Disease Relevance and Research Applications 
As previously outlined, correlations exist between specific platelet profiles and 
several physiological and disease states. The response of megakaryocytes to 
their acute environment and pathophysiological alterations in the body may 
influence the type of platelet produced during thrombopoiesis, with specific 
platelet transcripts reflecting the overlying condition. New diagnostic and 
therapeutic tools could arise if the function that these specific transcripts have in 
the disease state were more fully understood. If these transcripts are specifically 
sorted by megakaryocytes into platelets in response to a systemic stimulant, it 
may suggest a role for the transcript in platelet function and disease development 
which could shed light on the disease itself (such as sorting of a specific 
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signaling transcript into platelets to allow for platelets to respond to a particular 
form of infection or inflammation occurring systemically). An example of research 
development through platelet RNA profiling involves gray platelet syndrome 
(GPS), or platelet alpha-granule deficiency, a bleeding disorder associated with 
platelets lacking alpha granules (128). GPS platelet RNA sequencing showed 
abnormal results for a specific transcript, NBEAL2 (128). Further analysis 
revealed mutations in this gene resulted in abnormal pre-mRNA processing, 
defective protein sorting in megakaryocytes and impaired alpha granule 
biogenesis in platelets,  causally linking NBEAL2 expression to disease 
development (128-132).   
Alternatively, the presence of a specific transcript in platelets under certain 
conditions or during a disease state may not reflect a role in platelet function and 
disease development; instead, it may simply represent the upregulation of these 
transcripts by megakaryocytes responding to stimuli and the subsequent 
increase in platelet expression due to subsequent platelet release. Though not 
causally linked to disease development, this scenario still poses advantages to 
researchers, as platelet transcripts could be used as biomarkers. Conventional 
biomarker research concentrates on identifying protein biomarkers, but given the 
availability and accessibility of platelets and the correlation of distinct platelet 
mRNA and miRNA profiles to physiological conditions, platelet RNA-based 
biomarkers could be utilized to identify disease states, aid research and develop 
therapeutic targets. Examples of therapeutic monitoring already exist; as 
36 
 
 
 
 
described, specific platelet RNA profiling can be used in differentiating the 
classical phenotypes associated with thrombocytosis. Additionally, as 
connections between platelets and cancer were explored, associations between 
tumor RNA and platelets were also discovered. Several studies have shown 
association between tumor-derived RNAs and platelets in liquid biopsies, 
supporting an additional role for platelet RNA analysis in biomarker diagnostics 
(133-136). Further identification of platelet biomarkers and their correlation to 
disease states may allow for future development of disease screening, especially 
relevant for diseases that are difficult to diagnose or characterize. 
Full elucidation of systemic platelet capabilities depends on our clear 
comprehension of platelet RNA function.  If platelet transcripts directly impact 
platelet and vascular function through either translational control or RNA transfer, 
realizing how these transcripts influence disease development will shed light 
upon both the given disease and possible treatments. For example, as 
described, the correlation between increased presence of MRP-8/14 protein (and 
the corresponding increase in MRP-14 transcript) and future cardiovascular 
events in women (104), not only reveals information about the development of 
cardiovascular disease in women but also potential diagnostic and therapeutic 
targets. Furthermore, the ability of platelets to transfer RNA to vascular cells has 
possible therapeutic implications. Recent studies have utilized platelet 
membranes to improve nanoparticle drug delivery (137) and, once the 
mechanism and relevance of platelet RNA transfer and its subsequent effect on 
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recipient cells is fully understood, there may be potential to develop platelet RNA 
transfer via an individualized therapeutic delivery system.  
 
Conclusions 
The systemic relevance of platelets is no longer limited to their conventional roles 
in hemostasis and thrombosis; our understanding of platelet biology has 
broadened to include correlations and connections to physiological states, 
diseases and cellular communication. These additional connections and links 
between platelets and diverse systemic responses suggest the potential impact 
of platelets on vascular cell phenotypes, disease, and therapeutic development. 
Accordingly, greater comprehension of platelet RNA transcripts bolsters our 
understanding of both platelets’ conventional thrombotic functions and their non-
conventional roles, potentially having extensive implications in a variety of 
diseases and research areas. As we begin to understand how the platelet RNA 
transcriptome varies both over time and within a set population, we may be able 
to better understand how this anucleate cell has such broad systemic impact. 
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CHAPTER TWO: PLATELET TRANSCRIPTOME DIFFERENTIAL EXPRESSION IN 
RESPONSE TO INFECTION 
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Preface 
As described in Chapter 1, the platelet’s role in immunity and infection has been 
elucidated in recent years. An explanation for the platelet’s ability to play such 
diverse systemic roles could lie in better clarification of the intersection between 
platelets and their RNA. Platelets’ integral roles in immune detection, as well as 
their capacity for translational regulation, suggest that the mechanism by which 
platelets adapt to disease and infection could depend on how platelet RNA 
changes throughout its’ life span and in response to environmental stimuli. To 
better comprehend these interactions, we need to understand not only the role of 
the platelet in these responses, but how the overall platelet RNA content 
changes in response to the distinct phenotypic microenvironments.  
 
Summary 
Diverse and multi-factorial processes contribute to the progression of 
cardiovascular disease. These processes affect cells involved in the 
development of this disease in varying ways, ultimately leading to 
atherothrombosis. The goal of our study was to compare the differential effects of 
specific stimuli - two bacterial infections and a Western diet - on platelet 
responses in ApoE-/- mice, specifically examining inflammatory function and 
gene expression. Results from murine studies were verified using platelets from 
participants of the Framingham Heart Study (FHS; n = 1819 participants). Blood 
and spleen samples were collected at weeks 1 and 9 from ApoE-/- mice infected 
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with Porphyromonas gingivalis or Chlamydia pneumoniae and from mice fed a 
Western diet for 9 weeks. Transcripts based on data from a Western diet in 
ApoE-/- mice were measured in platelet samples from FHS using high throughput 
RT-qPCR. At week 1, both bacterial infections increased circulating platelet-
neutrophil aggregates. At week 9, these cells individually localized to the spleen, 
while Western diet resulted in increased platelet-neutrophil aggregates in the 
spleen only. Microarray analysis of platelet RNA from infected or Western diet-
fed mice at week 1 and 9 showed differential profiles. Genes, such as Serpina1a, 
Ttr, Fgg, Rpl21, and Alb, were uniquely affected by infection and diet. Results 
were reinforced in platelets obtained from participants of the FHS. Using both 
human studies and animal models, results demonstrate that variable sources of 
inflammatory stimuli have the ability to influence the platelet phenotype in distinct 
ways, indicative of the diverse function of platelets in thrombosis, hemostasis, 
and immunity. 
 
Introduction 
Cardiovascular disease (CVD) is a chronic inflammatory process with multiple 
etiologies, including genetic and environmental factors. Bacterial infections and 
obesity are two known pro-inflammatory contributors to the development of CVD. 
The effects of these inflammatory stimuli on vascular cells have been extensively 
studied, with the exception for the second most abundant cell in circulation, the 
platelet. Particularly, in light of work which shows the relationship between 
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platelet transcripts and CVD in FHS (53, 138) and their new role in inflammation 
(139-141), questions still remain as to how platelets contribute to the 
development of CVD. The goals of our study were to characterize the differential 
effects of two common bacterial infections and a Western diet on platelet 
inflammatory function and gene transcripts in ApoE-/- mice and in human 
samples.  These results will help to better understand the connections between 
inflammatory stimuli, cardiovascular disease, and platelets.  
One bacterium associated with CVD is the gram-negative oral pathogen 
Porphyromonas gingivalis (P. gingivalis), which induces low-grade chronic 
inflammation associated with oral bone loss, clinically known as periodontal 
disease. This bacterium expresses several outer membrane proteins which are 
recognized by the innate immune system through Toll-like receptor 2 (TLR2). In 
ApoE-/- mice, P. gingivalis accelerates atherosclerotic plaque size (142-144), with 
accumulation of lipids, T cells, and macrophages compared to uninfected mice 
(143). Plaque collagen and elastin content is also altered with infection, 
suggesting that P. gingivalis infection affects the stability of atherosclerotic 
plaques (143). In humans, P. gingivalis is detected in atherosclerotic plaques 
(145, 146) and is associated with the development of carotid artery 
atherosclerosis (147).  
Another bacterium associated with CVD is the obligate intracellular gram-
negative bacterium, Chlamydia pneumoniae (C. pneumoniae). It is associated 
with atypical pneumonia, as well as pharyngitis, bronchitis, and sinusitis in 
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humans. This bacterium is also recognized in part by TLR2 on innate immune 
cells. It  has also been demonstrated to increase atherosclerotic plaque size, lipid 
content, and dendritic cells in ApoE-/- mice compared to uninfected mice (148). In 
humans, C. pneumoniae antibody seropositivity is associated with the 
progression of coronary artery calcification (149) and risk of coronary heart 
disease and myocardial infarction (150). C. pneumoniae has also been identified 
through PCR methodology in atherosclerotic plaques in humans (151, 152). 
Obesity, having a body mass index (BMI) ≥30 kg/m2, is another key risk 
factor associated with CVD. In the US, 35% of adults are considered obese 
(153). For individuals ≥20 years of age surveyed between 2009 and 2010, 35.8% 
were obese and 72.5% had a health score of 0-1, classifying them in poor 
cardiovascular health (153). Consistent with the importance of weight and diet, in 
animal models of atherosclerosis, feeding animals a high fat diet increases 
atherosclerotic plaque size, number, and severity (154-156). 
We have previously demonstrated that in human and mouse platelets, P. 
gingivalis is recognized by TLR2 and induces aggregation (157) and heterotypic 
aggregate formation (139, 140). C. pneumoniae also binds to platelets to induce 
aggregation and P-selectin expression (158). A Western diet in C57BL/6J mice 
increases thrombin-induced platelet adhesion (139). The goal of this study was to 
characterize the differential effects of these two common bacterial infections and 
a Western diet on platelet inflammatory function and gene transcripts at different 
timepoints in a well-established atherosclerosis murine model prior to the 
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formation of plaques. These results were also correlated with recent observations 
from aortic tissue following exposure to the same inflammatory stimuli (159). Our 
results suggest that both inflammatory stimuli and the kinetics of the response 
differentially influence platelet transcripts and inflammatory function. 
Furthermore, our results were corroborated in human studies and provide insight 
into how platelets alter the development of CVD. 
 
Materials and Methods 
Animals 
Mice were cared for at the Boston University School of Medicine (BUSM) 
Vivarium. All work was approved by BUSM Institutional Animal Care and Use 
Committee. Mice were housed in a 12 hour light cycle at constant temperature 
and humidity with free access to food and water. During procedures, mice were 
monitored and removed if exhibiting signs of distress. P. gingivalis strain 381 and 
C. pneumoniae strain AO3 were grown and purified as previously described 
(160, 161). One set of ApoE-/- male mice (Jackson Laboratories) were treated 
with 4% sulfamethoxazole in their drinking water for 10 days to clear normal oral 
microflora (159). These mice were then challenged 5 times per week for 3 weeks 
on the buccal surface of their maxilla with 1x109 CFU P. gingivalis in 2% 
carboxymethyl cellulose. An additional set of ApoE-/- male mice were challenged 
intranasally once per week for three weeks with 2x106 IFU C. pneumoniae 
suspended in sucrose-phosphate-glutamate buffer while under light anesthesia 
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of ketamine and xylazine (159). Mice were sacrificed by CO2 asphyxiation 
followed by cervical dislocation at an early timepoint 1 day after the last P. 
gingivalis challenge (~9 weeks of age at start) and 4 days after the last C. 
pneumoniae exposure (~9 weeks of age at start), with n=3 for each group (159). 
Another group was sacrificed 9 weeks later (~6 weeks of age at start for both 
groups), with n=3 for each group, prior to the formation of overt aortic plaque 
formation as seen at later timepoints with these stimuli (143, 148, 159, 162). A 
final group of ApoE-/- male mice (~16 weeks of age at start) were fed a Western 
diet (17.3% protein, 48.5% carbohydrates, 1.2% fat, and 0.2% cholesterol; 
Teklad Harlan) for 9 weeks and then sacrificed with n=6 for the Western diet 
(159). Analysis was performed on samples collected from mice at each timepoint. 
 
Whole Blood Cell and Platelet Counts 
Blood collected from each mouse was analyzed for white blood cell (WBC) and 
platelet content using a COULTER® AC.T Series Analyzer (Becton Dickinson) 
(139).  
 
Heterotypic Aggregate Formation 
A sample of whole blood from each mouse was dual stained with anti-mouse 
CD41 FITC-conjugated and anti-mouse Ly6G PE-Cy7-conjugated antibodies and 
appropriate isotype controls (eBioscience; Cat# 11-0411 and 25-5931, 
respectively). The percent of platelet-positive neutrophils was determined using a 
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FACSCalibur Flow Cytometer with Cell Quest Software (BD Bioscience) (139, 
140). 
 
Spleen Sectioning and Staining 
Frozen spleen sections were stained with anti-mouse CD41 (Abcam; Cat# 
ab63983) and anti-mouse Ly6G and Ly6C (BD Bioscience; Cat# 553123) 
antibodies and appropriate isotype controls, followed by anti-rabbit IgG Alexa 
Fluor 405-conjugated and anti-rat Texas Red ®-X secondary antibodies (Life 
Technologies; Cat# A-31556 and T-6392, respectively). Samples were visualized 
using Leica TCS SP5 II Confocal Microscope with Leica Application Suite 
Advanced Fluorescence Version 2.6.0.7266 software then analyzed with ImageJ 
(v1.46r) and Adobe Photoshop CS3 (v13.0.1). 
 
Platelet RNA Isolation 
Platelets were isolated from blood samples using a series of centrifugation steps. 
Briefly, samples were centrifuged at 450xg for 7 minutes. The top layer 
consisting of platelet rich plasma (PRP) was removed and diluted 2.33X with 
platelet wash buffer (10 mM sodium citrate, 150 mM sodium chloride, 1 mM 
EDTA, 1% dextrose, pH 7.4) and 1:10000 prostaglandin E1 (Calbiochem). 
Samples were centrifuged at 300xg for 4 minutes to remove any contaminating 
WBC. The supernatant was further diluted 3X with platelet wash buffer and 
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PGE1, then centrifuged at 3500xg for 10 minutes (139). The resulting platelet 
pellet was lysed and RNA was isolated using the miRNeasy Kit (Qiagen).  
 
RNA Microarray and Analysis 
RNA from each mouse in each condition was pooled to generate at least 50 ng of 
RNA per sample. Samples were reverse transcribed using Ovation Pico WTA 
System V2 (Nugen) and purified using Agencourt RNA Clean XP Purification 
Beads. After SPIA amplification and purification, samples were labeled using the 
Encore Biotin Module (Nugen) and hybridized to the GenChip Mouse Gene 1.0 
ST Array (Affymetrix), stained, and scanned using an Affymetrix GeneArray 
Scanner 3000 7G Plus. All procedures were performed by the Microarray 
Resource Facility at Boston University. Affymetrix CEL files were normalized to 
produce gene-level expression values using the Robust Multiarray Average 
(RMA) (163) in the Affymetrix Bioconductor (v1.28.1) (164) and an Entrez Gene-
specific probe set (v14.0.0) mapping from the Molecular Behavioral 
Neuroscience Institute at the University of Michigan 
(http://brainarray.mbni.med.umich.edu/ Brainarray/Database/CustomCDF) (165). 
Array quality was assessed by computing Relative Log Expression (RLE) and 
Normalized Unscaled Standard Error (NUSE) using the AffyPLM Bioconductor 
(v1.26.1) (166). All microarray analyses were performed using the R environment 
(v2.15.1) for statistical computing. Gene Set Enrichment Analysis (GSEA; 
v2.0.13) (167) was used to identify biological terms, pathways, and processes. 
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By using the normalized enrichment score (NES) of ≥2/-2, the false discovery 
rate (FDR) of ˂0.05, and the nominal p-value (Nom p) of ˂0.05, we identified 
gene sets that were significantly enriched for and would have been affected the 
most by treatment. The Entrez Gene identifiers of the mouse homologs of the 
genes (as determined using HomoloGene v65 (168)) were ranked according to 
the log2-transformed fold change computed for each comparison; in cases where 
a given mouse gene mapped to more than one human gene, one homolog was 
randomly chosen. These ranked lists were then used to perform pre-ranked 
GSEA analyses (default parameters with random seed 1234) using Entrez Gene 
versions of the Biocarts, KEGG, Reactome, and Gene Ontology (GO) gene sets 
obtained from the Molecular Signature Database (MsigDB; v3.0) (169). Post 
analysis information on transcript alternative names and functions were 
determined using genecard.org and ncbi.nlm.nih.gov. Original publication 
heatmaps were created using MeV v4.9.0 (170). Heatmaps presented here 
created using Microsoft Excel 2010. 
 
RT-qPCR Verification 
Isolated RNA was converted to cDNA using High-Capacity cDNA Reverse 
Transcription Kit (Life Technologies), followed by pre-amplification using 
TaqMan® PreAmp Master Mix (Life Technologies). RT-qPCR was performed on 
the Applied Biosystems 7900 HT Fast Real-Time PCR System with SDS 2.2.2 
Software (Life Technologies) using primers and probes for the following genes 
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(Life Technologies): microfibrillar-associated protein 1a (MFAP1A), 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), β-actin (ACTB), and β2-
microglobulin (B2M). Analysis included correcting by the mean of the three 
housekeeping genes (∆Ct) – GAPDH, ACTB, and B2M – followed by calculating 
the difference between treatment and untreated controls (∆∆Ct). Fold change 
(graphed) was then determined by calculating 2-∆∆Ct.  
 
Framingham Heart Study 
As previously described (53, 138, 139), platelet RNA was isolated from 1819 
participants of the FHS Offspring Cohort Examination 8 using miRNeasy kit 
(Qiagen) and converted to cDNA. Pre-amplification was performed using 
TaqMan® PreAmp Master Mix (Life Technologies). Quantitative RT-PCR was 
performed using the BioMarkTM System (Fluidigm) with primers and probes from 
Life Technologies. Results were compared to data collected from the medical 
history and physical examination of each participant. Individuals were 
categorized as having hypertension if they had systolic blood pressure ≥140 mm 
Hg, diastolic blood pressure ≥90 mm Hg, or were receiving treatment for 
hypertension. They were categorized as having diabetes if their fasting blood 
glucose was ≥126 mg/dL, their non-fasting blood glucose was ≥200 mg/dL, or 
were being treated with insulin or hypoglycemic drugs. Finally, individuals were 
categorized as smokers if they had smoked 1 cigarette a day in the year prior to 
examination. All of this work with the FHS was approved by the University of 
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Massachusetts Medical School and Boston University Medical Center 
Institutional Review Boards and all participants gave written informed consent 
(53, 138, 139). Interleukin 6 (IL6) and C-reactive protein (CRP) levels were 
measured as previously described (138).  
 
Statistics 
Data from ApoE-/- mouse studies were reported as the mean ± the standard 
deviation. In some cases, the percent compared to untreated controls, which was 
set to 100%, was reported. All data were analyzed by ANOVA followed by 
Tukey’s Multiple Comparison Test using GraphPad Prism 5 software. Data were 
considered normally distributed, with a two-sided p<0.05 being significant. 
For the FHS, descriptive statistics were reported as the mean ± standard 
deviation for continuous variable or the count (percent) for binary variables. 
Quantitative RT-PCR cycle threshold (Ct) values were corrected (∆CT) by the 
geometric mean of three housekeeping genes – GAPDH, ACTB, and B2M. 
Genes not expressed and failing to report a Ct value within a set period were 
assigned the maximum Ct value allowed in our procedure (28 cycles). 
Multivariable linear regression models for gene expression (∆Ct) were fitted 
adjusting for the following confounders – BMI, smoking status, total cholesterol, 
HDL cholesterol, triglycerides, systolic blood pressure, diastolic blood pressure, 
glucose levels, diabetes, coronary heart disease [angina pectoris, coronary 
insufficiency, myocardial infarction adjudicated by a review panel], lipid-lowering 
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therapy, hormone replacement therapy, antihypertensive therapy, and regular 
aspirin therapy (at least 3 times a week). All statistical analysis was performed 
using Stata 12.0 software (53, 138, 139). Statistical significance was assessed 
using two-sided p-value, with those <0.05 being considered statistically 
significant. 
 
Results 
Differential platelet gene expression in ApoE-/- mice infected with bacteria 
or fed a Western diet 
ApoE-/- mice (n = 3) were infected orally with P. gingivalis or intranasally 
with C. pneumoniae. One day after the last oral infection with P. gingivalis and 4 
days after the last intranasal infection with C. pneumoniae (week 1), platelet RNA 
was isolated and pooled to generate a sufficient amount of RNA per condition for 
microarray analysis. Due to the small sample size, only genes up- or 
downregulated 2-fold or greater and pathways with a normalized enrichment 
score (NES) ≥ ~2/-2, nominal p-value (Nom p) <0.05, and a false discovery rate 
(FDR q) <0.05 were considered. Additionally, this data was intended to generate 
hypotheses on how platelets and platelet transcripts are affected by different 
inflammatory stimuli over time. During Week 1, we observed increased 
expression of 129 genes and decreased expression in 59 genes following P. 
gingivalis infection compared to untreated controls (Figure 2.1). The top five 
upregulated genes with known function were Serpina1a (27.09-fold), Alb (17.83-
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fold), Ttr (15.84-fold), Apoa2 (15.08-fold), and Kng1 (13.01-fold). The top 5 
downregulated genes were Stard6 (-5.49-fold), Spic (-5.42-fold), Hmox1 (-4.60-
fold), Igk-v21-4 (-3.08-fold), and Rassf4 (-2.89-fold). Using Gene Set Enrichment 
Analysis (GSEA), we identified gene sets with increased expression following P. 
gingivalis infection with an NES ≥2, a Nom p <0.05, and an FDR q <0.05. These 
gene sets included coagulation, lipids, signaling pathways, RNA/gene 
expression, and inflammation (Table 2.1). Gene sets, which exhibited decreased 
expression, included those involved in enzyme activity, differentiation, 
metabolism, extracellular matrix related, signaling, and cytoskeleton pathways; 
however, these gene sets were not significant (NES ˃-2, FDR q ˃0.05; Table 
2.2).In ApoE-/- mice infected with C. pneumoniae at week 1, there were 87 
platelet transcripts increased and 70 transcripts decreased 2-fold or more 
compared to untreated control (Figure 2.1). The top 5 genes that exhibited an 
increase in expression were Serpina1a (13.17-fold), Alb (7.75-fold), Serpina3k 
(6.47-fold), Ttr (6.20-fold), and Kng1 (5.14-fold). The top 5 genes that exhibited a 
decrease in expression were Nono (-10.89-fold), Spic (-6.92-fold), Hmox1 (-5.15-
fold), Pcdhgb7 (-4.09-fold), and Stard6 (-4.09-fold). GSEA identified the following 
positively enriched gene sets: coagulation, lipids, metabolism, signaling 
pathways, cytoskeleton, and RNA/gene expression (NES ≥2, Nom p <0.05, FDR 
q <0.05; Table 2.3). As seen with P. gingivalis, negatively enriched genes, 
including those involved in enzyme activity, signaling, and extracellular matrix, 
were affected but not significantly (NES >-2, FDR q >0.05; Table 2.4). 
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Figure 2.1: Genes upregulated and downregulated at week 1 in ApoE-/- mice with 
bacterial infection. Heatmap shows the transcripts identified through microarray as 
upregulated or downregulated 2-fold or more with either P. gingivalis (Pg) or C. 
pneumoniae (Cp) infection compared to untreated control in the ApoE-/- mice. Each 
condition represents RNA from 3 mice pooled.  
 
 
  
54 
 
 
 
 
Table 2.1: Positively enriched gene sets in platelets from ApoE-/- mice infected 
with P. gingivalis compared to untreated control – at Week 1.  
 
NAME SIZE ES NES NOM p-val FDR q-val 
PLATELET DEGRANULATION 80 0.731 2.302 <0.001 <0.001 
LIPOPROTEIN METABOLISM 26 0.888 2.272 <0.001 <0.001 
INTRINSIC PATHWAY 23 0.903 2.249 <0.001 <0.001 
COMPLEMENT AND 
COAGULATION CASCADES 
62 0.744 2.232 
<0.001 <0.001 
REGULATION OF GENE 
EXPRESSION IN BETA CELLS 
56 0.732 2.149 
<0.001 <0.001 
PEPTIDE CHAIN ELONGATION 38 0.763 2.093 <0.001 <0.001 
FORMATION OF FIBRIN CLOT 
CLOTTING CASCADE 
31 0.798 2.104 
<0.001 <0.001 
REGULATION OF BETA CELL 
DEVELOPMENT 
69 0.683 2.070 
<0.001 <0.001 
CHYLOMICRON MEDIATED 
LIPID TRANSPORT 
17 0.885 2.104 
<0.001 <0.001 
GENE EXPRESSION 357 0.553 2.074 <0.001 <0.001 
RIBOSOME 39 0.743 2.079 <0.001 <0.001 
AMI PATHWAY 19 0.890 2.109 <0.001 <0.001 
INFLUENZA LIFE CYCLE 87 0.659 2.080 <0.001 <0.001 
INFLUENZA VIRAL RNA 
TRANSCRIPTION AND 
REPLICATION 
54 0.703 2.086 
<0.001 <0.001 
VIRAL MRNA TRANSLATION 39 0.757 2.114 <0.001 <0.001 
FORMATION OF A POOL OF 
FREE 40S SUBUNITS 
49 0.737 2.114 
<0.001 <0.001 
RNA BINDING 195 0.580 2.051 <0.001 <0.001 
STRUCTURAL CONSTITUENT 
OF RIBOSOME 
44 0.726 2.033 
<0.001 0.001 
LIPID TRANSPORT 26 0.788 2.023 <0.001 0.001 
REACTOME GTP 
HYDROLYSIS AND JOINING 
OF THE 60S RIBOSOMAL 
SUBUNIT 
58 0.679 1.995 
<0.001 0.002 
HIV1 TRANSCRIPTION 
ELONGATION 
37 0.713 1.991 
<0.001 0.002 
PLATELET ACTIVATION 158 0.571 1.978 <0.001 0.003 
PLATELET AGGREGATION 
PLUG FORMATION 
26 0.779 1.981 
<0.001 0.003 
PROTEIN 
HETERODIMERIZATION 
ACTIVITY 
71 0.639 1.982 
<0.001 0.003 
GRB2 SOS LINKAGE TO MAPK 15 0.884 1.976 <0.001 0.003 
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SIGNALING TO INTERGRINS 
TRANSLATION 71 0.643 1.983 <0.001 0.003 
NEGATIVE REGULATION OF 
MULTICELLULAR 
ORGANISMAL PROCESS 
28 0.741 1.959 
<0.001 0.003 
INTEGRIN αIIB β3 SIGNALING 23 0.794 1.957 <0.001 0.003 
EXTRACELLULAR SPACE 209 0.545 1.938 <0.001 0.004 
FORMATION OF PLATELET 
PLUG 
177 0.556 1.936 
<0.001 0.004 
P130CAS LINKAGE TO MAPK 
SIGNALING FOR INTEGRINS 
15 0.851 1.930 
<0.001 0.005 
TRANSLATION INITIATION 
COMPLEX FORMATION 
38 0.689 1.927 
0.002 0.005 
REGULATION OF PROTEIN 
STABILITY 
18 0.811 1.924 
<0.001 0.005 
TAT MEDIATED HIV1 
ELONGATION ARREST, 
RECOVERY 
27 0.739 1.901 
<0.001 0.007 
RIBONUCLEOPROTEIN 
COMPLEX BIOGENESIS, 
ASSEMBLY 
71 0.628 1.903 
<0.001 0.007 
CYTOKINE SECRETION 15 0.848 1.905 <0.001 0.007 
NUCLEOLUS 105 0.572 1.893 <0.001 0.007 
INTEGRIN CELL SURFACE 
INTERACTIONS 
80 0.606 1.896 
<0.001 0.007 
FORMATION OF TERNARY 
COMPLEX AND 43S COMPLEX 
32 0.720 1.893 
<0.001 0.007 
INSULIN SYNTHESIS AND 
SECRETION 
81 0.600 1.882 
<0.001 0.009 
TRANSCRIPTION OF THE HIV 
GENOME 
55 0.639 1.881 
<0.001 0.009 
OXYGEN BINDING 19 0.799 1.874 <0.001 0.010 
PEPTIDYL TYROSINE 
MODIFICATION 
27 0.723 1.875 
<0.001 0.010 
FORMATION AND 
MATURATION OF mRNA 
TRANSCRIPT 
137 0.551 1.868 
<0.001 0.011 
IMMUNE EFFECTOR 
PROCESS 
33 0.700 1.859 
0.002 0.012 
RNA POLII CTD 
PHOSPHORYLATION AND 
INTERACTION WITH CE 
24 0.744 1.854 
0.002 0.013 
HIV LIFE CYCLE 94 0.573 1.850 <0.001 0.013 
LATE PHASE OF HIV LIFE 
CYCLE 
82 0.597 1.851 
<0.001 0.013 
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LIPID TRANSPORTER 
ACTIVITY 
23 0.729 1.847 
<0.001 0.013 
ELONGATION, PROCESSING 
OF CAPPED TRANSCRIPTS 
119 0.552 1.845 
<0.001 0.014 
HEMOSTASIS 262 0.505 1.839 <0.001 0.014 
PEPTIDYL TYROSINE 
PHOSPHORYLATION 
25 0.724 1.831 
<0.001 0.016 
ATP DEPENDENT HELICASE 
ACTIVITY 
24 0.736 1.826 
0.002 0.017 
PPAR SIGNALING PATHWAY 67 0.596 1.819 <0.001 0.018 
mRNA PROCESSING 30 0.695 1.816 0.002 0.019 
RNA POLYMERASE II 
TRANSCRIPTION 
84 0.569 1.808 
0.002 0.020 
REGULATION OF HYDROLASE 
ACTIVITY 
65 0.599 1.810 
<0.001 0.020 
ANTIGEN BINDING 16 0.766 1.787 0.004 0.027 
METABOLISM OF 
XENOBIOTICS BY 
CYTOCHROME P450 
52 0.615 1.783 
<0.001 0.028 
PHASE II CONJUGATION 44 0.617 1.772 0.004 0.031 
LIPID BINDING 73 0.586 1.773 <0.001 0.032 
FURTHER PLATELET 
RELEASATE 
19 0.756 1.774 
<0.001 0.032 
tRNA AMINOACYLATION 40 0.631 1.766 0.002 0.034 
STEROID BINDING 17 0.755 1.754 0.006 0.036 
FORMATION OF THE EARLY 
ELONGATION COMPLEX 
29 0.673 1.758 
0.004 0.036 
INTRINSIC PATHWAY 17 0.745 1.759 0.002 0.036 
PROTEIN RNA COMPLEX 
ASSEMBLY 
56 0.604 1.757 
0.002 0.036 
RHO PROTEIN SIGNAL 
TRANSDUCTION 
34 0.645 1.760 
<0.001 0.036 
REGULATION OF CELL 
MIGRATION 
26 0.693 1.754 
0.006 0.036 
MAINTENANCE OF 
LOCALIZATION 
19 0.733 1.752 
0.004 0.036 
RNA POLYMERASE I 
TRANSCRIPTION 
TERMINATION 
19 0.732 1.754 
0.006 0.037 
miRNA BIOGENESIS 17 0.750 1.748 0.010 0.038 
PD1 SIGNALING 18 0.740 1.744 0.002 0.039 
PPARα PATHWAY 56 0.583 1.737 <0.001 0.042 
IMMUNE RESPONSE 205 0.486 1.733 <0.001 0.042 
PROCESSING OF CAPPED 
INTRON CONTAINING PRE 
123 0.521 1.736 
<0.001 0.043 
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SIZE – Number of genes; ES – Enrichment Score; NES – Normalized Enrichment Score; 
NOM p-val – Nominal p-value; FDR q-val – False Discovery Rate. 
 
  
MRNA 
mRNA SPLICING 95 0.549 1.733 <0.001 0.043 
REGULATION OF SECRETION 36 0.631 1.733 0.004 0.043 
REGULATION OF PROTEIN 
SECRETION 
18 0.724 1.721 
0.006 0.048 
DOWNSTREAM TCR 
SIGNALING 
36 0.638 1.722 
0.005 0.048 
EXTRACELLULAR REGION 
PART 
297 0.471 1.718 
<0.001 0.048 
RNA PROCESSING 146 0.502 1.716 <0.001 0.049 
MEDIATOR COMPLEX 18 0.730 1.713 0.004 0.050 
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Table 2.2: Negatively enriched gene sets in platelets from ApoE-/- mice infected 
with P. gingivalis compared to untreated control – at Week 1. 
 
 
SIZE – Number of genes; ES – Enrichment Score; NES – Normalized Enrichment Score; 
NOM p-val – Nominal p-value; FDR q-val – False Discovery Rate. 
  
NAME SIZE ES NES 
NOM  
p-val 
FDR  
q-val 
METALLOPEPTIDASE ACTIVITY 49 -0.505 -1.541 0.016 0.834 
ACTIVATION OF NMDA 
RECEPTOR UPON GLUTAMATE 
BINDING AND POSTSYNAPTIC 
EVENTS 
33 -0.547 -1.547 0.020 0.860 
β-ALANINE METABOLISM 22 -0.613 -1.553 0.029 0.897 
TRAFFICKING OF AMPA 
RECEPTORS 
29 -0.555 -1.503 0.029 0.979 
CONTRACTILE FIBER 21 -0.591 -1.512 0.052 0.982 
MUSCLE DEVELOPMENT 90 -0.434 -1.493 0.007 0.994 
EXTRACELLULAR MATRIX 
STRUCTURAL CONSTITUENT 
24 -0.608 -1.553 0.029 0.996 
THIOLESTER HYDROLASE 
ACTIVITY 
16 -0.676 -1.612 0.022 1.000 
MEIOTIC CELL CYCLE 33 -0.567 -1.593 0.020 1.000 
LYSOSOME 116 -0.453 -1.589 0.002 1.000 
OTHER GLYCAN DEGRADATION 16 -0.681 -1.577 0.022 1.000 
EXOPEPTIDASE ACTIVITY 30 -0.578 -1.563 0.014 1.000 
PROPANOATE METABOLISM 29 -0.588 -1.559 0.025 1.000 
SMOOTH MUSCLE 
CONTRACTION 
17 -0.638 -1.558 0.025 1.000 
CALCIUM ION BINDING 88 -0.460 -1.555 0.002 1.000 
MUSCLE CELL DIFFERENTIATION 21 -0.585 -1.477 0.049 1.000 
SYNAPTIC VESICLE 15 -0.634 -1.457 0.054 1.000 
AMINO SUGAR AND NUCLEOTIDE 
SUGAR METABOLISM 
43 -0.489 -1.452 0.034 1.000 
GLYCOPROTEIN METABOLIC 
PROCESS 
81 -0.435 -1.451 0.013 1.000 
MEIOSIS I 20 -0.574 -1.450 0.056 1.000 
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Table 2.3: Positively enriched gene sets in platelets from ApoE-/- mice infected 
with C. pneumoniae compared to untreated control – at Week 1. 
 
NAME SIZE ES NES 
NOM  
p-val 
FDR 
q-val 
LIPOPROTEIN METABOLISM 26 0.775 2.083 <0.001 0.008 
LIPID TRANSPORT 26 0.738 1.986 <0.001 0.015 
PLATELET DEGRANULATION 80 0.597 1.994 <0.001 0.017 
AMI PATHWAY 19 0.780 1.924 <0.001 0.026 
ORGANELLE LOCALIZATION 24 0.731 1.893 0.002 0.027 
INTRINSIC PATHWAY 23 0.731 1.909 <0.001 0.030 
MAINTENANCE OF 
LOCALIZATION 
19 0.758 1.895 <0.001 0.030 
COMPLEMENT AND 
COAGULATION CASCADES 
62 0.610 1.925 <0.001 0.032 
CHYLOMICRON MEDIATED LIPID 
TRANSPORT 
17 0.769 1.898 0.002 0.032 
PROTEIN 
HETERODIMERIZATION 
ACTIVITY 
71 0.569 1.871 <0.001 0.034 
TRANSCRIPTION OF THE HIV 
GENOME 
55 0.594 1.855 <0.001 0.040 
P130CAS LINKAGE TO MAPK 
SIGNALING FOR INTEGRINS 
15 0.777 1.837 0.002 0.043 
RESPONSE TO NUTRIENT 
LEVELS 
28 0.688 1.839 <0.001 0.046 
STEROID BINDING 17 0.744 1.802 <0.001 0.065 
HELICASE ACTIVITY 46 0.595 1.779 <0.001 0.065 
REGULATION OF PROTEIN 
STABILITY 
18 0.732 1.794 <0.001 0.067 
GRB2 SOS PROVIDES LINKAGE 
TO MAPK SIGNALING FOR 
INTERGRINS 
15 0.771 1.788 0.002 0.067 
CYTOKINE SECRETION 15 0.762 1.779 0.004 0.068 
FORMATION AND MATURATION 
OF MRNA TRANSCRIPT 
137 0.493 1.781 <0.001 0.070 
SELENOAMINO ACID 
METABOLISM 
26 0.662 1.766 0.006 0.075 
 
SIZE – Number of genes; ES – Enrichment Score; NES – Normalized Enrichment Score; 
NOM p-val – Nominal p-value; FDR q-val – False Discovery Rate. 
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Table 2.4: Negatively enriched gene sets in platelets from ApoE-/- mice 
infected with C. pneumoniae compared to untreated control – at Week 1. 
 
NAME SIZE ES NES 
NOM 
p-val 
FDR  
q-val 
CALCIUM ION BINDING 88 -0.535 -1.789 <0.001 0.256 
MITOCHONDRIAL RIBOSOME 20 -0.699 -1.742 0.002 0.260 
IL1R PATHWAY 32 -0.658 -1.834 <0.001 0.266 
EXTRACELLULAR MATRIX 
STRUCTURAL CONSTITUENT 
24 -0.709 -1.803 <0.001 0.282 
ORGANELLAR RIBOSOME 20 -0.699 -1.745 0.008 0.290 
TOLL PATHWAY 36 -0.616 -1.758 <0.001 0.296 
GSK3 PATHWAY 27 -0.636 -1.689 0.004 0.422 
GLYCOSAMINOGLYCAN 
DEGRADATION 
21 -0.742 -1.848 <0.001 0.424 
RIBOSOMAL SUBUNIT 18 -0.690 -1.679 0.008 0.426 
RIBOSOME 30 -0.598 -1.651 0.008 0.468 
ACETYLCHOLINE BINDING 17 -0.688 -1.631 0.013 0.475 
LYSOSOME 116 -0.465 -1.614 0.004 0.486 
LEISHMANIA INFECTION 61 -0.512 -1.637 0.002 0.487 
NTHI PATHWAY 23 -0.640 -1.654 0.008 0.498 
NEGATIVE REGULATION OF 
CELL DIFFERENTIATION 
25 -0.611 -1.602 0.022 0.505 
REGULATION OF CELL 
DIFFERENTIATION 
55 -0.524 -1.617 0.004 0.508 
REGULATION OF MYELOID 
CELL DIFFERENTIATION 
16 -0.670 -1.586 0.015 0.555 
DIGESTION 36 -0.566 -1.579 0.017 0.556 
CATION BINDING 188 -0.423 -1.560 <0.001 0.624 
NFκB PATHWAY 23 -0.604 -1.549 0.023 0.653 
 
SIZE – Number of genes; ES – Enrichment Score; NES – Normalized Enrichment Score; 
NOM p-val – Nominal p-value; FDR q-val – False Discovery Rate. 
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Nine weeks following the last infection with P. gingivalis, C. pneumoniae, 
or 9 weeks of feeding a Western diet, ApoE-/- mice were sacrificed in order to 
understand the changes in platelet transcripts before the formation of overt 
plaques. Following P. gingivalis infection, only 41 genes were increased and 32 
were decreased (Figure 2.2). The top 5 genes that exhibited increased 
expression were Mfap1a (5.31-fold), Trbv4 (4.21-fold), Polr2c (3.99-fold), Cidec 
(3.97-fold), and Sms (3.75-fold). Top 5 genes that exhibited decreased 
expression were S100a8 (-4.15-fold), S100a9 (-4.08-fold), Olfr135 (-3.45-fold), 
Fcf1 (-3.26-fold), and Agk (-3.01-fold). GSEA identified numerous gene sets 
positively enriched, including coagulation and signaling pathways; however, 
these gene sets were not significantly altered by P. gingivalis infection (NES >-2, 
FDR q >0.05; Table 2.5). It was the negatively enriched gene sets that were 
more significantly affected, including RNA/gene expression (NES ≤-2, Nom p 
<0.05, FDR q <0.05; Table 2.6). 
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Figure 2.2: Genes upregulated and downregulated at week 9 in ApoE-/- mice with 
bacterial infection or a Western diet. Heatmap shows the transcripts identified through 
microarray as upregulated or downregulated 2-fold or more by infection with P. gingivalis 
(Pg), C. pneumoniae (Cp), or fed a Western diet (WD) compared to untreated control in 
the ApoE-/- Mice. Each condition represents RNA from 3 mice pooled. 
 
  
63 
 
 
 
 
Table 2.5: Positively enriched gene sets in platelets from ApoE-/- Mice infected 
with P. gingivalis compared to untreated control – at Week 9. 
 
NAME SIZE ES NES NOM p-val FDR q-val 
NEUROPEPTIDE 
RECEPTOR ACTIVITY 
21 0.750 1.912 0.002 0.052 
COMPLEMENT AND 
COAGULATION 
CASCADES 
62 0.623 1.942 <0.001 0.060 
NEUROPEPTIDE 
BINDING 
22 0.721 1.821 0.002 0.093 
PEPTIDE RECEPTOR 
ACTIVITY 
48 0.605 1.802 <0.001 0.100 
GLUCONEOGENESIS 28 0.685 1.822 0.002 0.116 
PLATELET 
DEGRANULATION 
80 0.560 1.836 <0.001 0.128 
COMPLEMENT 
CASCADE 
18 0.727 1.752 0.018 0.172 
RESPONSE TO 
NUTRIENT 
16 0.738 1.738 0.009 0.180 
AMI PATHWAY 19 0.702 1.709 0.007 0.227 
RESPONSE TO 
EXTRACELLULAR 
STIMULUS 
32 0.585 1.636 0.011 0.248 
COMP PATHWAY 16 0.708 1.666 0.006 0.252 
G-PROTEIN 
COUPLED 
RECEPTOR ACTIVITY 
172 0.448 1.651 <0.001 0.255 
METABOLISM OF 
BILE ACIDS AND BILE 
SALTS 
26 0.613 1.638 0.016 0.256 
RESPONSE TO 
NUTRIENT LEVELS 
28 0.622 1.658 0.009 0.257 
PROTEIN SECRETION 28 0.620 1.678 0.004 0.262 
INTRINSIC PATHWAY 23 0.648 1.669 0.007 0.265 
PEPTIDE BINDING 79 0.500 1.639 0.002 0.268 
RHODOPSIN LIKE 
RECEPTOR ACTIVITY 
123 0.480 1.682 <0.001 0.276 
DETECTION OF 
CHEMICAL STIMULUS 
15 0.706 1.608 0.027 0.309 
STRUCTURAL 
CONSTITUENT OF 
MUSCLE 
26 0.603 1.598 0.015 0.324 
 
SIZE – Number of genes; ES – Enrichment Score; NES – Normalized Enrichment Score; 
NOM p-val – Nominal p-value; FDR q-val – False Discovery Rate.  
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Table 2.6: Negatively enriched gene sets in platelets from ApoE-/- mice infected 
with P. gingivalis compared to untreated control – at Week 9. 
 
NAME SIZE ES NES NOM p-val FDR q-val 
TRANSPORT OF MATURE 
mRNA DERIVED FROM AN 
INTRON CONTAINING 
TRANSCRIPT 
45 -0.641 -1.847 <0.001 0.036 
TRANSPORT OF THE SLBP 
INDEPENDENT MATURE 
mRNA 
29 -0.701 -1.840 <0.001 0.036 
SPLICEOSOME 108 -0.579 -1.911 <0.001 0.038 
FORMATION OF THE 
TERNARY COMPLEX, 43S 
COMPLEX 
32 -0.709 -1.887 <0.001 0.038 
FORMATION OF A POOL OF 
FREE 40S SUBUNITS 
49 -0.641 -1.831 <0.001 0.038 
ATP DEPENDENT RNA 
HELICASE ACTIVITY 
15 -0.807 -1.854 <0.001 0.039 
TRANSLATION INITIATION 
COMPLEX FORMATION 
38 -0.669 -1.872 <0.001 0.042 
GTP HYDROLYSIS, JOINING 
OF 60S RIBOSOMAL 
SUBUNIT 
58 -0.626 -1.859 <0.001 0.043 
RNA HELICASE ACTIVITY 22 -0.776 -1.926 <0.001 0.055 
RNA DEPENDENT ATPASE 
ACTIVITY 
16 -0.779 -1.789 0.002 0.060 
ATP DEPENDENT HELICASE 
ACTIVITY 
24 -0.705 -1.793 0.002 0.061 
ACTIVATION OF NFκB 
TRANSCRIPTION FACTOR 
18 -0.752 -1.798 0.004 0.062 
SPLICEOSOME 38 -0.642 -1.782 0.002 0.062 
RNA SPLICING 76 -0.572 -1.776 <0.001 0.064 
GENE EXPRESSION 357 -0.468 -1.759 <0.001 0.067 
RNA BINDING 195 -0.495 -1.765 <0.001 0.070 
POSITIVE REGULATION OF 
TRANSCRIPTION FACTOR 
ACTIVITY 
24 -0.694 -1.759 0.006 0.070 
tRNA METABOLIC PROCESS 18 -0.735 -1.738 0.004 0.080 
ANTIGEN PROCESSING AND 
PRESENTATION 
49 -0.604 -1.741 <0.001 0.081 
POSITIVE REGULATION OF 
BINDING 
28 -0.655 -1.734 0.002 0.081 
SIZE – Number of genes; ES – Enrichment Score; NES – Normalized Enrichment Score; 
NOM p-val – Nominal p-value; FDR q-val – False Discovery Rate. 
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Nine weeks following the last infections with C.pneumoniae, there was 
differential effects on gene expression profiles as compared to that observed 
early after infection. Twenty-seven genes were increased and 109 decreased at 
week 9 compared to untreated control (Figure 2.2). The top 5 genes with 
increased expression at week 9 were Rpl21 (5.52-fold), Trav13-3 (4.34-fold), 
Tmx2 (4.16-fold), Nup62-il4i1 (3.81-fold), and Aph1a (3.48-fold). The top 5 genes 
with decreased expression at week 9 were Alb (-16.46-fold), S100a9 (-9.38-fold), 
S100a8 (-9.38-fold), Nono (-6.79-fold), and Ttr (-5.46-fold). Similarly to P. 
gingivalis at week 9, GSEA identified numerous gene sets positively enriched but 
that were not significantly affected by C. pneumoniae (Table 2.7). Gene sets 
negatively enriched at week 9 were significant, including coagulation, RNA/gene 
expression, and inflammation (NES <-2, Nom p <0.01, FDR q <0.05 Table 2.8). 
In mice fed a Western diet for 9 weeks, there were 67 genes increased 
and 67 genes decreased (Figure 2.2). The top 5 genes that exhibited increased 
expression as a result of a Western diet were Trbv4 (7.14-fold), Trav13-3 (3.90-
fold), Tmx2 (3.74-fold), Sms (3.14-fold), and Gnpnat1 (3.05-fold). The top 5 
genes with decreased expression with a Western diet were Alb (-18.34-fold), 
Fabp1 (-6.89-fold), Ttr (-5.51-fold), Serpina1b (-4.95-fold), and Apoa2 (-4.95-
fold). Numerous gene sets were positively enriched, including those associated 
with DNA/proliferation, inflammation, RNA/gene expression, and signaling (NES 
>2, Nom p <0.05, FDR q <0.05; Table 2.9). Only a few gene sets were negatively 
enriched, including those involved in coagulation and lipid (NES <-2, Nom p 
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<0.01, FDR q <0.05; Table 2.10). As a way to verify these results, RT-qPCR was 
run on week 9 samples for MFAP1A. As seen in Figure 2.3, there is an increase 
in its expression with P. gingivalis infection that is greater than the increase with 
C. pneumoniae infection or a Western diet, similar to the findings in the 
microarray. 
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Table 2.7: Positively enriched gene sets in platelets from ApoE-/- mice infected 
with C. pneumoniae compared to untreated control – at Week 9. 
 
NAME SIZE ES NES 
NOM  
p-val 
FDR  
q-val 
NEUROTRANSMITTER 
RECEPTOR ACTIVITY 
49 0.658 2.007 <0.001 0.017 
NEUROPEPTIDE RECEPTOR 
ACTIVITY 
21 0.771 1.966 <0.001 0.018 
NEUROTRANSMITTER BINDING 52 0.604 1.848 0.003 0.058 
NEUROPEPTIDE BINDING 22 0.737 1.849 <0.001 0.073 
APICAL PART OF CELL 17 0.764 1.850 <0.001 0.094 
PEPTIDE RECEPTOR ACTIVITY 48 0.587 1.771 <0.001 0.139 
ACETYLCHOLINE BINDING 17 0.738 1.737 <0.001 0.160 
ANION CATION SYMPORTER 
ACTIVITY 
15 0.737 1.745 0.009 0.164 
RESPONSE TO NUTRIENT 16 0.725 1.711 0.012 0.197 
 PHOSPHOLIPASE C ACTIVITY 15 0.719 1.675 0.010 0.261 
STRUCTURAL CONSTITUENT OF 
MUSCLE 
26 0.617 1.642 0.005 0.306 
SYNAPTIC VESICLE 15 0.701 1.648 0.017 0.311 
NEGATIVE REGULATION OF DNA 
METABOLIC PROCESS 
16 0.685 1.611 0.020 0.385 
SECRETORY GRANULE 17 0.648 1.578 0.032 0.424 
SYMPORTER ACTIVITY 30 0.576 1.590 0.010 0.432 
RHODOPSIN LIKE RECEPTOR 
ACTIVITY 
123 0.445 1.581 0.004 0.440 
TRANS GOLGI NETWORK 18 0.647 1.541 0.030 0.464 
SECONDARY ACTIVE 
TRANSMEMBRANE 
TRANSPORTER ACTIVITY 
44 0.509 1.544 0.019 0.477 
LYSOSOME 116 0.437 1.545 0.007 0.500 
REGULATION OF PEPTIDYL 
TYROSINE PHOSPHORYLATION 
16 0.653 1.547 0.031 0.520 
 
SIZE – Number of genes; ES – Enrichment Score; NES – Normalized Enrichment Score; 
NOM p-val – Nominal p-value; FDR q-val – False Discovery Rate. 
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Table 2.8: Negatively enriched gene sets in platelets from ApoE-/- mice infected with 
C. pneumoniae compared to untreated control – at Week 9. 
 
NAME SIZE ES NES 
NOM  
p-val 
FDR  
q-val 
TRANSLATION 71 -0.753 -2.207 <0.001 <0.001 
GTP HYDROLYSIS, JOINING OF 
60S RIBOSOMAL SUBUNIT 
58 -0.780 -2.194 <0.001 <0.001 
PEPTIDE CHAIN ELONGATION 38 -0.819 -2.169 <0.001 <0.001 
FORMATION OF A POOL OF 
FREE 40S SUBUNITS 
49 -0.798 -2.155 <0.001 <0.001 
VIRAL MRNA TRANSLATION 39 -0.801 -2.135 <0.001 <0.001 
RIBOSOME 39 -0.807 -2.115 <0.001 <0.001 
REGULATION OF GENE 
EXPRESSION IN BETA CELLS 
56 -0.741 -2.095 <0.001 <0.001 
SPLICEOSOME 108 -0.660 -2.065 <0.001 <0.001 
STRUCTURAL CONSTITUENT OF 
RIBOSOME 
44 -0.758 -2.042 <0.001 <0.001 
TRANSLATION INITIATION 
COMPLEX FORMATION 
38 -0.770 -2.052 <0.001 <0.001 
RNA SPLICING 76 -0.689 -2.021 <0.001 <0.001 
REGULATION OF BETA CELL 
DEVELOPMENT 
69 -0.700 -2.033 <0.001 <0.001 
PLATELET DEGRANULATION 80 -0.675 -1.997 <0.001 0.001 
FORMATION OF THE TERNARY 
COMPLEX, 43S COMPLEX 
32 -0.787 -1.998 <0.001 0.001 
RNA BINDING 195 -0.600 -1.986 <0.001 0.001 
RNA HELICASE ACTIVITY 22 -0.836 -1.982 <0.001 0.001 
ANTIGEN PROCESSING AND 
PRESENTATION 
49 -0.724 -1.986 <0.001 0.001 
INFLUENZA LIFE CYCLE 87 -0.652 -1.967 <0.001 0.001 
ATP DEPENDENT HELICASE 
ACTIVITY 
24 -0.811 -1.968 <0.001 0.001 
REGULATION OF LIPID 
METABOLISM BY PPARα 
60 -0.688 -1.954 <0.001 0.001 
GENE EXPRESSION 357 -0.563 -1.955 <0.001 0.001 
PPAR SIGNALING PATHWAY 67 -0.679 -1.956 <0.001 0.001 
INFLUENZA VIRAL RNA 
TRANSCRIPTION, REPLICATION 
54 -0.689 -1.958 <0.001 0.001 
RNA PROCESSING 146 -0.607 -1.944 <0.001 0.001 
LIPOPROTEIN METABOLISM 26 -0.783 -1.937 <0.001 0.002 
PPARα PATHWAY 56 -0.680 -1.928 <0.001 0.002 
SIZE – Number of genes; ES – Enrichment Score; NES – Normalized Enrichment Score; 
NOM p-val – Nominal p-value; FDR q-val – False Discovery Rate. 
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Table 2.9: Positively enriched gene sets in platelets from ApoE-/- mice on a 
Western diet compared to untreated control – at Week 9. 
 
NAME SIZE ES NES 
NOM 
p-val 
FDR  
q-val 
M-G1 TRANSITION 59 0.678 2.125 <0.001 <0.001 
ORC1 REMOVAL FROM 
CHROMATIN 
61 0.665 2.084 <0.001 0.001 
CDT1 ASSOCIATION WITH THE 
CDC6 ORC ORIGIN COMPLEX 
50 0.687 2.072 <0.001 0.001 
P53-INDEPENDENT DNA DAMAGE 
RESPONSE 
41 0.727 2.096 <0.001 0.001 
HOST INTERACTIONS OF HIV 
FACTORS 
108 0.590 2.033 <0.001 0.001 
DNA REPLICATION PRE INITIATION 73 0.631 2.041 <0.001 0.001 
PD1 SIGNALING 18 0.843 2.045 <0.001 0.001 
STABILIZATION OF P53 44 0.715 2.056 <0.001 0.001 
VIF MEDIATED DEGRADATION OF 
APOBEC3G 
43 0.718 2.096 <0.001 0.002 
SIGNALING BY WNT 56 0.639 1.995 <0.001 0.002 
DOWNSTREAM TCR SIGNALING 36 0.711 1.979 <0.001 0.003 
REGULATION OF ORNITHINE 
DECARBOXYLASE 
46 0.667 1.961 <0.001 0.003 
PROTEASOME 42 0.675 1.965 <0.001 0.003 
AUTODEGRADATION OF CDH1 BY 
CDH1 APC 
54 0.642 1.963 <0.001 0.003 
SYNTHESIS OF DNA 86 0.594 1.966 <0.001 0.004 
SCF β TRCP MEDIATED 
DEGRADATION OF EMI1 
46 0.660 1.927 <0.001 0.005 
TRANSLATION INITIATION 
COMPLEX FORMATION 
38 0.660 1.909 0.002 0.006 
TCR SIGNALING 52 0.627 1.911 <0.001 0.007 
CDC20 PHOSPHO-APC MEDIATED 
DEGRADATION OF CYCLIN A 
60 0.613 1.897 <0.001 0.009 
FORMATION OF THE TERNARY 
COMPLEX, 43S COMPLEX 
32 0.686 1.875 <0.001 0.012 
PHOSPHORYLATION OF CD3 AND 
TCR ζ CHAINS 
15 0.803 1.869 <0.001 0.013 
REGULATION OF APC 
ACTIVATORS BETWEEN G1-S, 
EARLY ANAPHASE 
67 0.580 1.857 <0.001 0.015 
T CELL ACTIVATION 42 0.633 1.846 0.002 0.017 
SCF SKP2 MEDIATED 
DEGRADATION OF P27 P21 
50 0.615 1.847 <0.001 0.017 
PREFOLDIN MEDIATED TRANSFER 25 0.686 1.842 <0.001 0.018 
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OF SUBSTRATE TO CCT TRIC 
GENERATION OF SECOND 
MESSENGER MOLECULES 
25 0.715 1.833 <0.001 0.019 
DNA DAMAGE RESPONSE SIGNAL 
TRANSDUCTION 
33 0.665 1.821 <0.001 0.021 
TRANSLATION 71 0.567 1.816 <0.001 0.022 
ASTHMA 21 0.706 1.807 0.002 0.024 
GTPASE REGULATOR ACTIVITY 55 0.583 1.802 <0.001 0.024 
REGULATION OF ACTION 
POTENTIAL 
16 0.768 1.808 0.004 0.024 
REACTOME S PHASE 100 0.532 1.804 <0.001 0.024 
MITOSIS 80 0.546 1.797 <0.001 0.025 
CELL CYCLE CHECKPOINTS 105 0.530 1.788 <0.001 0.027 
RAS GUANYL NUCLEOTIDE 
EXCHANGE FACTOR ACTIVITY 
17 0.749 1.768 0.006 0.032 
M PHASE OF MITOTIC CELL CYCLE 82 0.540 1.766 <0.001 0.033 
HEMATOPOIETIC CELL LINEAGE 73 0.553 1.772 <0.001 0.033 
CYCLIN E ASSOCIATED EVENTS 
DURING G1-S TRANSITION 
56 0.577 1.768 0.002 0.033 
HIV INFECTION 168 0.496 1.770 <0.001 0.033 
INFLUENZA VIRAL RNA 
TRANSCRIPTION AND 
REPLICATION 
54 0.570 1.757 <0.001 0.036 
MITOTIC M M-G1 PHASES 151 0.494 1.754 <0.001 0.037 
PROTEIN MODIFICATION BY 
SMALL PROTEIN CONJUGATION 
41 0.596 1.750 0.002 0.038 
B CELL RECEPTOR SIGNALING 
PATHWAY 
73 0.534 1.739 <0.001 0.041 
CHAPERONIN MEDIATED PROTEIN 
FOLDING 
46 0.575 1.741 <0.001 0.042 
UBIQUITIN CYCLE 46 0.595 1.739 <0.001 0.042 
METABOLISM OF PROTEINS 162 0.482 1.735 <0.001 0.042 
CYSTEINE TYPE ENDOPEPTIDASE 
ACTIVITY 
37 0.615 1.730 <0.001 0.045 
M PHASE 109 0.510 1.727 <0.001 0.046 
 
SIZE – Number of genes; ES – Enrichment Score; NES – Normalized Enrichment Score; 
NOM p-val – Nominal p-value; FDR q-val – False Discovery Rate.  
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Table 2.10: Negatively enriched gene set in platelets from ApoE-/- mice on a 
Western diet compared to untreated control – at Week 9. 
 
NAME SIZE ES NES 
NOM  
p-val 
FDR 
q-val 
PLATELET DEGRANULATION 80 -0.665 -2.147 <0.001 0.001 
LIPOPROTEIN METABOLISM 26 -0.749 -1.971 <0.001 0.021 
OXYGEN BINDING 19 -0.776 -1.951 <0.001 0.022 
P130 CAS LINKAGE TO MAPK 
SIGNALING FOR INTEGRINS 
15 -0.778 -1.791 0.004 0.069 
CYTOKINE SECRETION 15 -0.768 -1.774 0.006 0.074 
REGULATION OF PROTEIN 
SECRETION 
18 -0.733 -1.791 0.002 0.075 
AMI PATHWAY 19 -0.748 -1.797 <0.001 0.076 
PPAR SIGNALING PATHWAY 67 -0.591 -1.860 <0.001 0.080 
PPAR PATHWAY 56 -0.601 -1.844 <0.001 0.080 
IMMUNE EFFECTOR 
PROCESS 
33 -0.664 -1.820 <0.001 0.080 
ANTIGEN BINDING 16 -0.771 -1.774 0.004 0.080 
REGULATION OF PROTEIN 
STABILITY 
18 -0.749 -1.800 0.002 0.082 
COMPLEMENT AND 
COAGULATION CASCADES 
62 -0.581 -1.807 0.002 0.085 
LIPID TRANSPORT 26 -0.695 -1.824 <0.001 0.089 
GAP JUNCTION ASSEMBLY 17 -0.747 -1.744 0.004 0.100 
PROTEIN SECRETION 28 -0.643 -1.732 <0.001 0.109 
COLLAGEN 23 -0.676 -1.720 <0.001 0.112 
METABOLISM OF BILE ACIDS 
AND BILE SALTS 
26 -0.641 -1.721 0.006 0.117 
REGULATION OF MAP3K 
CASCADE 
17 -0.718 -1.709 0.010 0.120 
REGULATION OF HEART 
CONTRACTION 
22 -0.664 -1.704 0.008 0.121 
 
SIZE – Number of genes; ES – Enrichment Score; NES – Normalized Enrichment Score; 
NOM p-val – Nominal p-value; FDR q-val – False Discovery Rate. 
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Figure 2.3: Verification of microarray analysis through RT-qPCR. Gene expression 
for Mfap1a at Week 9 identified through the microarray were verified using RT-qPCR. 
Each condition represents RNA from 3 mice pooled. 
 
 
 
 
 
Differential physiological effects of bacterial infections or a Western diet in 
ApoE-/- mice 
There were no changes in body mass (Figure 2.4), or increases in white blood 
cell (WBC) counts (Figure 2.5a) at week 1 in ApoE-/- mice infected with either P. 
gingivalis or C. pneumoniae. Only C. pneumoniae altered platelet counts (Figure 
2.5b) compared to untreated control, although not significantly, suggesting this 
bacterial infection altered megakaryocyte maturation and platelet production 
and/or platelet clearance. Circulating heterotypic aggregates (platelet-neutrophil 
aggregates) were significantly increased in C. pneumoniae infected mice at week 
1 (Figure 2.6); however, there were inconsistencies with the P. gingivalis-infected 
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ApoE-/- mice, but the data suggest that there was an increase in aggregate 
formation as well. Analysis of spleen sections from P. gingivalis or C. 
pneumoniae infected mice revealed increased CD41 levels, a platelet marker, 
and Ly6G levels, a neutrophil marker (Figure 2.7a-c; IgG controls in Figure 2.8). 
However, there were no heterotypic aggregates as indicated by the lack of 
overlap between the two signals when merged (Figure 2.7a,d). 
 
Figure 2.4: Change in ApoE-/- mouse body mass with infection and diet.  
Mass was measured on Week 1, which was 24 h after the last P. gingivalis challenge 
and 4 days after C. pneumoniae exposure (n = 3 for each group), and on Week 9 (n = 3 
for Untreated Control, P. gingivalis-Infected, and C. pneumoniae-Infected; n = 6 for 
Western diet). Data is normally distributed and analyzed using an ANOVA. 
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Figure 2.5: WBC and platelet count changes with infection and diet in the ApoE-/- 
mice. Whole blood cell counts were assessed to determine the number of WBC and 
platelets. Measurements were performed on Week 1, which was 24 h after the last P. 
gingivalis challenge and 4 days after exposure to C. pneumoniae (n = 3 for each group), 
and on Week 9 (n = 3 for untreated control, P. gingivalis-Infected, and C. pneumoniae-
Infected; n = 6 for Western diet). Data is normally distributed and analyzed using an 
ANOVA. 
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Figure 2.6: Heterotypic aggregate formation in ApoE-/- mice with infection and diet. 
Whole blood samples taken on Week 1 (24 h after the last P. gingivalis challenge and 4 
days after exposure to C. pneumoniae; n = 3 for each group) and on Week 9 (n = 3 for 
each group) and dual stained for platelet marker (CD41) and neutrophil marker (Ly6G). 
The percent of platelet-positive neutrophils were determined through flow cytometry and 
normalized to untreated control at each timepoint. Data is normally distributed and 
analyzed using an ANOVA. *p<0.05 compared to untreated control at Week 1. 
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Figure 2.7: Platelet and neutrophil content in spleens in ApoE-/- mice with infection 
and diet. (A) Spleen sections from ApoE-/- mice at week 1 and week 9 were stained for 
CD41 (platelet marker; Alexa Fluor 405) and Ly6G (neutrophils; Texas Red) and 
visualized by confocal microscopy at 63X. The amount of CD41 staining (area; B), Ly6G 
staining (area; C), and the overlap of each signal (% pixels with overlapping signal); (D) 
were quantified. Data is normally distributed and analyzed using an ANOVA. n = 3 for 
each condition; ***p<0.001 compared to untreated control. Scale Bar in merged images 
= 50.0 µm. 
 
 
 
A)
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Figure 2.8: IgG staining for spleen sections. Spleen sections from ApoE-/- mice 
stained with corresponding isotype control antibodies for CD41 and Ly6G antibodies, 
followed by fluorescent secondary antibodies. Samples visualized using a confocal 
microscope at 63X. Scale bar in merged image = 50.0 µm. 
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At week 9, P. gingivalis or C. pneumoniae infections did not alter ApoE-/- 
mouse body mass (Figure 2.4). However, in mice fed a Western diet, there was 
an increase in body mass by 5.2g. There was no effect on WBC counts at week 
9 with either bacteria or a Western diet (Figure 2.5a). Platelet counts were still 
elevated following C. pneumoniae infection (Figure 2.5b). The increased 
circulating heterotypic aggregates seen with bacterial infections at week 1 were 
gone by week 9 (Figure 2.6). There were a greater number of platelets in the 
spleen sections from P. gingivalis or C. pneumoniae infected mice at week 9 as 
compared to week 1 (Figure 2.7a,b). P. gingivalis infection maintained the same 
amount of neutrophils in the spleen from week 1 to 9 (Figure 2.7a,c). For C. 
pneumoniae, there was a significantly greater number of neutrophils compared to 
untreated control at week 9 than that observed at week 1 (Figure 2.7a,c). A 
Western diet at week 9 did not increase circulating heterotypic aggregate 
formation. There was a significant increase in platelets in the spleens of mice fed 
a Western diet (Figure 2.7a,b) and a non-significant increase in neutrophils 
(Figure 2.7a,c). Unlike that observed following bacterial infections, there were 
heterotypic aggregates present in the spleens of mice fed a Western diet (Figure 
2.7a,d). 
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Changes in platelet transcripts due to diet in participants of the 
Framingham Heart Study 
To verify the relevance of the in vivo mouse observations, select platelet 
transcripts altered by a Western diet in the ApoE-/- mice were measured in 
participants of the FHS (n = 1819; Table 2.11). These genes were either 
increased or decreased in the ApoE-/- mice fed a Western diet, including albumin 
(Alb), α-1-microglobulin (Ambp), chemokine ligand 3 (Ccl3), CD3 antigen (Cd3d), 
CD53 antigen (Cd53), fatty acid binding protein 1 (Fabp1), fatty acid binding 
protein 5 (Fabp5), fibrinogen γ chain (Fgg), mitochondrial ribosomal protein S26 
(Mrps26), nuclear receptor subfamily 2 (Nr2f6), ribosomal protein L21 (Rpl21), α-
1-antitrypsin (Serpina1), and vitronectin (Vtn). These genes encompass various 
functional groups identified in the microarray, including coagulation, gene 
expression, inflammation, and lipids. These transcripts were compared to 
variables measured in the FHS that were associated with increased obesity (53, 
171) and a Western diet (162, 172) in prior publications, including cholesterol, 
BMI, lipids, and triglyceride levels. A complete list of genes and their relationship 
with all studied clinical variables is found in Table 2.12. 
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Table 2.11 Framingham Heart Study Offspring Cohort Examination 8 
characteristics. 
 
Variables Mean ± Standard 
Deviation/Number (%) 
Sample Size 1819 
Women 993 (51) 
Age (y) 67±9 
BMI (kg/m2) 28.3±5.3 
Systolic Blood Pressure 
(mm Hg) 
129±17 
Diastolic Blood Pressure 
(mm Hg) 
73±10 
Lipid Treatment 798 (44) 
Total Cholesterol/HDL 
Ratio (mg/100 mL) 
3.5±1.1 
Triglycerides (mg/100 mL) 116±67 
Glucose (mg/dL) 107±25 
Antihypertensive 
Treatment 
919 (51) 
Aspirin (3 times/week) 823 (45) 
Current Hormone 
Replacement Therapy 
104 (6) 
Diabetes mellitus 255 (14) 
Prevalent Coronary Heart 
Disease 
199 (11) 
Smoker 155 (8.5) 
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Table 2.12: Relations between gene expression and clinical variables in FHS. 
Gene 
Symbol 
FHS Clinical 
Variable 
Fold 
Change1 
p-value 
Regression 
Coefficient 
Lower 
95% CI 
Upper 
95% CI 
ALB Men 1.356 0.01 -0.439 -0.752 -0.127 
ALB Triglycerides 0.895 0.03 0.003 <0.001 0.006 
ALB Aspirin 3X/Week 1.276 0.03 -0.352 -0.664 -0.040 
AMBP Men 0.661 <0.01 0.598 0.254 0.943 
AMBP Antilipid Rx 0.675 <0.01 0.567 0.202 0.932 
AMBP BMI 0.874 0.02 0.039 0.007 0.071 
AMBP Aspirin 3X/Week 1.318 0.02 -0.398 -0.741 -0.054 
CCL3 Age 1.182 <0.01 -0.024 -0.040 -0.008 
CCL3 Men  1.245 0.01 -0.316 -0.561 -0.070 
CCL3 
Antihypertensive 
Rx 
1.231 0.02 -0.299 -0.557 -0.042 
CCL3 Diabetes 1.318 0.03 -0.398 -0.748 -0.048 
CD3D Men  1.940 <0.01 -0.956 -1.212 -0.699 
CD3D BMI 1.097 0.03 -0.027 -0.051 -0.003 
CD3D Diabetes 1.307 0.04 -0.386 -0.751 -0.022 
CD53 Men 1.747 <0.01 -0.805 -1.047 -0.562 
CD53 
Total 
Cholesterol:HDL 
Ratio 
1.127 0.02 -0.172 -0.316 -0.028 
CD53 Triglycerides 0.923 0.04 0.002 <0.001 0.005 
FABP1 Men 0.684 <0.01 0.547 0.221 0.873 
FABP1 Antilipid Rx 0.679 <0.01 0.559 0.214 0.904 
FABP5 
Total 
Cholesterol:HDL 
Ratio 
1.148 <0.01 -0.200 -0.337 -0.062 
FABP5 Men 1.244 0.01 -0.315 -0.547 -0.084 
FABP5 Age 1.129 0.02 -0.018 -0.033 -0.002 
FABP5 Diabetes 1.276 0.04 -0.352 -0.682 -0.022 
FABP5 Diastolic Bp 0.906 0.04 0.014 <0.001 0.028 
FGG Men 0.656 <0.01 0.608 0.277 0.940 
FGG Antilipid Rx 0.679 <0.01 0.560 0.208 0.911 
FGG BMI 0.870 0.01 0.040 0.009 0.071 
FGG Aspirin 3X/Week 1.324 0.02 -0.405 -0.735 -0.074 
MRPS26 Men 1.607 <0.01 -0.684 -0.920 -0.448 
NR2F6 Men 1.692 <0.01 -0.759 -1.001 -0.516 
NR2F6 BMI 1.112 0.01 -0.031 -0.053 -0.008 
NR2F6 
Total 
Cholesterol:HDL 
Ratio 
1.151 0.01 -0.203 -0.347 -0.060 
NR2F6 Diastolic Bp 0.895 0.03 0.016 0.002 0.030 
NR2F6 Triglycerides 0.921 0.04 0.002 <0.001 0.005 
RPL21 Men 1.709 <0.01 -0.773 -1.000 -0.547 
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RPL21 BMI 1.106 0.01 -0.029 -0.050 -0.008 
RPL21 Diastolic Bp 0.899 0.02 0.015 0.002 0.029 
RPL21 Diabetes 1.258 0.04 -0.331 -0.653 -0.009 
SERPINA1 Men 1.360 <0.01 -0.444 -0.712 -0.176 
SERPINA1 BMI 1.131 0.01 -0.036 -0.061 -0.010 
SERPINA1 Age 1.160 0.02 -0.021 -0.039 -0.004 
SERPINA1 Diastolic Bp 0.886 0.03 0.017 0.002 0.033 
VTN Aspirin 3X/Week 1.382 <0.01 -0.467 -0.764 -0.171 
VTN Triglycerides 0.872 <0.01 0.004 0.001 0.007 
 
1Fold Change for FHS – regression coefficient transformed (2-β) to express fold change 
in gene expression associated with 1 unit change in clinical covariate, with the exception 
in triglycerides (50 points), systolic and diastolic blood pressure (10 points), age (10 
years), and BMI (5 points). 
 
Abbreviations – BMI – Body Mass Index, BP – Blood Pressure, CI – Confidence Interval, 
HDL – High Density Lipoprotein, Rx - Medication 
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Of the genes decreased in ApoE-/- mice fed a Western diet, 4 out of the 7 
(ALB, AMBP, FGG, and VTN) were also significantly decreased with a higher 
mean BMI or triglycerides in the FHS (Table 2.13 and Table 2.12). FABP1 was 
not associated with cholesterol, BMI, or triglycerides, while FABP5 and 
SERPINA1 were increased with a higher mean in cholesterol or BMI. As for the 
genes that increased with a Western diet in the ApoE-/- mice, 4 of the 5 (CD3D, 
CD53, NR2F6, and RPL21) were also increased significantly with a higher mean 
BMI, triglycerides, and/or cholesterol (Table 2.13 and Table 2.12). CD53 and 
NR2F6 were increased significantly with an increased mean total 
cholesterol:HDL ratio and BMI but decreased significantly with increased mean 
triglyceride levels. One transcript, CCL3, although increased in the mice, was not 
increased in individuals in the FHS with these variables but was associated with 
other factors, such as diabetes (Table 2.12).   
  
 
 
 
Table 2.13:The relation between gene expression, clinical variables, and inflammatory markers in the FHS. 
 
   FHS Fold Change (95% Conference Interval) 
Gene Gene Function 
Mouse Microarray 
Data (Fold Change 
Compared to UC) 
Total 
Cholesterol: 
HDL1 Triglycerides1 BMI2 CRP2 IL62 
ALB 
Fatty Acid 
Transport 
0.055 
-- 
0.90 (0.81, 
0.99)* -- -- -- 
FABP1 
Fatty Acid 
Transport/ 
Metabolism 
0.15 
-- -- -- 
0.82 
(0.74, 
0.91)*** 
0.71 
(0.60, 
0.83)*** 
SERPINA1 Inflammation 
0.20 
-- -- 
1.13 
(1.04, 
1.23)** 
1.29 
(1.19, 
1.40)*** 
1.50 
(1.32, 
1.72)*** 
FGG Coagulation 
0.26 
-- -- 
0.87 
(0.78, 
0.97)* 
0.83 
(0.74, 
0.92)*** 
0.68 
(0.58, 
0.80)*** 
AMBP Coagulation 
0.35 
-- -- 
0.87 
(0.78, 
0.98)* 
0.80 
(0.72, 
0.89)*** 
0.68 
(0.57, 
0.81)*** 
FABP5 
Fatty Acid 
Transport/ 
Metabolism 
0.39 1.15 (1.04, 
1.26)** -- -- 
1.10 
(1.02, 
1.18)* 
1.12 
(1.00, 
1.26)* 
MRPS26 
Gene 
Expression- 
Mitoribosomes 
0.43 
-- -- -- 
1.14 
(1.05, 
1.22)*** 
1.22 
(1.09, 
1.38)*** 
VTN Coagulation 
0.49 
-- 
0.87 (0.79, 
0.96)** -- -- 
0.85 
(0.73, 
0.99)* 
CCL3 Inflammation 
2.40 
-- -- -- 
1.14 
(1.05, 
1.23)** 
1.27 
(1.13, 
1.44)*** 
  
 
 
 
CD53 Inflammation 
2.48 1.13 (1.02, 
1.24)* 
0.92 (0.85, 
1.00)* 
1.08 
(1.00, 
1.17)* 
1.14 
(1.05, 
1.23)*** 
1.24 
(1.10, 
1.40)*** 
NR2F6 
Gene 
Expression –
Inflammation 
2.55 1.15 (1.04, 
1.27)** 
0.92 (0.85, 
1.00)* 
1.11 
(1.03, 
1.20)** 
1.17 
(1.09, 
1.26)*** 
1.26 
(1.12, 
1.42)*** 
CD3D Inflammation 
2.63 
-- -- 
1.10 
(1.01, 
1.19)* 
1.14 
(1.05, 
1.24)** 
1.21 
(1.07, 
1.38)** 
RPL21 Translation 
3.00 
-- -- 
1.11 
(1.03, 
1.19)** 
1.12 
(1.04, 
1.20)** 
1.21 
(1.08, 
1.35)** 
 
1Fold Change for FHS: Total Cholesterol:HDL, BMI, Triglycerides – regression coefficient transformed (2-β) to express fold 
change in gene expression associated with 1 unit change in clinical covariate, with the exception in BMI (5 points) and 
triglycerides (50 points). *p<0.05, **p<0.01, ***p<0.001. 
2 Fold Change for FHS: CRP and IL6 – regression coefficient transformed (2-β) to express fold change in gene expression 
associated with loge-CRP or loge-IL6 serum levels adjusted for multiple covariates. *p<0.05, **p<0.01, ***p<0.001. 
Abbreviations: BMI – Body mass index, CRP – C-reactive protein, FHS – Framingham Heart Study, HDL – High density 
lipoprotein, IL6 – Interleukin 6, Total Cholesterol:HDL – Ratio between total and HDL cholesterol, UC – untreated control. 
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Transcripts altered by a Western diet that were examined in FHS were 
also compared to circulating levels of CRP and IL6 (Table 2.13), inflammatory 
markers shown to be increased in individuals with CVD (173, 174), obesity (171, 
175), and a Western diet (172, 176, 177). As previously shown, these cytokines 
also associated significantly with inflammatory-related transcripts from platelets 
in FHS (138). All but one transcript was significantly associated with higher mean 
levels of CRP and/or IL6. AMBP, FABP1, FGG, and VTN levels decreased with a 
higher mean level of CRP and/or IL6, which were all decreased in ApoE-/- mice 
fed a Western diet and some in the FHS. CCL3, CD3D, CD53, FABP5, MRPS26, 
NR2F6, RPL21, and SERPINA1 were increased significantly with a higher mean 
CRP and/or IL6, which the majority were also increased in either FHS or in ApoE-
/- mice fed a Western diet. Only expression of ALB was not significantly 
associated with either of these cytokines. 
 
Discussion 
The goal of the study was to characterize the effects of inflammatory 
stimuli – bacterial infections and a Western diet – on platelet transcripts and 
inflammatory function over time in a murine model of CVD. Similar effects on 
platelets were observed following infection with P. gingivalis and C. pneumoniae 
early after infection as determined by both transcriptional profiles and heterotypic 
aggregate formation. However, at a later timepoint (week 9), their effects on 
transcription diverged, with C. pneumoniae infection affecting platelets more 
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similarly to a Western diet. The effects of a Western diet on platelet transcripts 
were confirmed in platelet samples from FHS.  
Platelet transcripts and inflammatory function were measured at week 1 
following either P. gingivalis or C. pneumoniae infection to establish the early 
responses to each bacterium in ApoE-/- mice. Platelet transcripts were affected 
similarly by each bacterial infection, which suggests that each stimuli was 
activating through common pathways, most likely the TLR2-NFκB pathway via 
the megakaryocyte, which we previously published on (178). It is hypothesized 
that bacteria are recognized by megakaryocytes through their innate immune 
receptors. This hypothesis has been explored using Pam3CSK4, a TLR2 
synthetic agonist, in human and mouse megakaryocytes, showing upregulation 
of inflammatory and coagulation related transcripts (178). Genes associated with 
RNA/gene expression and molecular transport, were also increased in platelets 
following infection with P. gingivalis and C. pneumonia. It is hypothesized the 
increase in gene expression correlates to an increase in mRNA translation within 
the platelets, as has been seen with platelets in response to cytokines (110, 
138). Additionally, the increased number of transcripts in both of these groups 
could be transferred to other vascular cells, such as endothelial cells or 
monocytes (114), to increase translation in these cells in response to infection. 
We hypothesized transcriptional changes would be reflective with functional 
modifications in the platelets. As seen at week 1, there was an increase in 
circulating heterotypic aggregates and positive enrichment of inflammatory gene 
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sets (i.e., complement cascade). Not only is platelet production affected but so is 
platelet response. As previously shown, platelets respond to Pam3CSK4, P. 
gingivalis (139, 140), and C. pneumoniae (data not shown) through TLR2 and 
IL1R1. This results in platelets binding to neutrophils to form heterotypic 
aggregates, as well as increased P-selectin surface expression, and adhesion to 
collagen, increasing the risk of thrombosis as seen in human studies (158, 179).  
At week 9, following P. gingivalis and C. pneumoniae infections, before 
overt plaque formation had yet to occur in the aorta, alterations in both platelet 
transcripts and inflammatory function are still occurring. Although not directly 
measured in our study, previous work by our group and others has shown that 
each bacterium is still present in the systems of these mice. An increase in 
circulating P. gingivalis-specific IgG has been detected through 13 weeks post 
infection (180) and by 24 weeks, this bacterium is identified in aorta, heart, and 
liver tissue (181). As for C. pneumoniae, there is a measurable serum IgG level 
up to 16 weeks, with bacteria detected in the lungs, aorta, heart, and spleen 
(182). Overall, both bacteria upregulated fewer genes at the later timepoint 
compared than observed at week 1 (Figure 2.9).  
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Figure 2.9: Comparison of genes affected by both bacterial infections at week 1 
and week 9. Heatmap shows the transcripts identified through microarray as 
upregulated or downregulated 2-fold or more with either P. gingivalis (Pg) or C. 
pneumoniae (Cp) infection compared to untreated control in the ApoE-/- mice at week 1 
and 9. Each condition represents RNA from 3 mice pooled. 
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Infection with C. pneumoniae resulted in more downregulation in gene 
expression, which was further supported by GSEA, showing significant negative 
enrichment in gene sets. Unlike with C. pneumoniae, P. gingivalis infection 
alterations in gene transcript changes were diminished at week 9. It is 
hypothesized that over the course of the infection, megakaryocytes are slowly 
returning to baseline in terms of the types of RNA produced, with fewer genes 
and gene groups being altered. Further, changes in transcripts are also reflective 
of platelet function. Platelet-neutrophil aggregates are no longer in circulation at 
week 9. The cells were individually present in the spleens obtained from these 
mice. It is possible that we no longer see these cells as aggregates even in the 
spleens because the interaction between the platelets and neutrophils is 
transient, a brief interaction that results in activation of either/both cells and 
transfer of information on the current environment. With more platelets in the 
spleen, it is expected that there would be a decrease in circulating platelet levels. 
Instead, the platelet concentrations stay steady if not increase. This data suggest 
megakaryocytes are still responding to the infection, directly or indirectly.  
With a Western diet, it was expected that lipid associated genes would be 
upregulated in platelets, but instead, as seen in FHS (53, 138, 139), there was an 
increase in inflammatory related transcripts, as well as signaling and proliferation. 
As previously seen with the FHS (53), the changes associated with a Western 
diet on platelets can either be due to the diet, change in body weight, or the 
proinflammatory setting. Further work is needed to understand this relationship. 
92 
 
 
 
 
Interestingly, many genes and/or gene function groups altered by a Western diet 
were also altered following a C. pneumoniae infection. Genes downregulated 
following a Western diet or C. pneumoniae infection included Ttr, Gc, Alb, Apoa2, 
and Fabp1. Functionally, the Western diet did not produce circulating heterotypic 
aggregates but did promote the formation of aggregates to the vessel wall, as 
seen in the spleens. It is hypothesized that a Western diet, promotes platelets 
adhesion to the blood vessels, which promotes adhesion of immune cells as well, 
leading to the formation of atherosclerosis (183).  
The effects of a Western diet in the ApoE-/- mice were verified using 
platelet transcripts from the FHS. Thirteen genes were identified from the 
microarray data, including ALB, AMBP, CCL3, CD3D, CD53, FABP1, FABP5, 
FGG, MRPS26, NR2F6, RPL21, SERPINA1, and VTN. Twelve out of the 13 
genes had altered gene expression that correlated to one or more clinical 
variables associated with adiposity, including BMI, triglycerides, and cholesterol. 
Additionally, inflammatory related cytokines, CRP and IL6, which are increased 
with CVD and associate significantly with inflammatory related transcripts from 
platelets in FHS (138), were associated with changes in 12 of the 13 identified 
transcripts, again, supporting the notion that platelets react with an inflammatory 
stimuli resembles their reaction to a Western diet.  
In conjunction with the analysis of platelets in these ApoE-/- mice, aortic 
tissue, consisting of endothelial cells, immune cells, and smooth muscle cells, 
were also examined by microarray.  At week 1, P. gingivalis infection had little 
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effect on gene expression in the aortic tissue. C. pneumoniae infection 
upregulated genes associated with GPCR signaling, viral myocarditis, antigen 
processing/presentation, and membranes in the entire aortic tissue (159), which 
is in contrast to what is shown here in platelets. When comparing the platelet 
data to the results from the aortic tissue at week 9, we see there are no gene 
sets similarly affected with either bacterial infection (159). In fact, two pathways 
positively enriched in aortic tissue, PPAR signaling and peptide chain formation, 
are negatively enriched in platelets. As for a Western diet, there were only 4 
similarities found in the positively enriched gene sets, which consisted of B cell 
receptor signaling pathways, host interactions of HIV factors, cell cycle 
checkpoints, and M-G1 transition.  
 
Strengths and Limitations 
Our study has substantial advantages including a translational breadth with 
experimental and epidemiological data relating transcripts from mouse and 
human platelets and mouse platelet function, human lipid, adiposity, and 
inflammatory data from FHS. However, we note the following caveats in our 
study. Our bacterial and Western diet exposure data were conducted in 3 mice, 
so we may have been underpowered to detect modest effect sizes. We could not 
verify any confounding attributions due to antibiotic pre-treatment with the P. 
gingivalis group for all genes identified; however, we were able to show in a 
couple of genes they were not altered by antibiotics (sham treatment) compared 
94 
 
 
 
 
to untreated control in C57BL/6J mice (Figure 2.10). Additionally, there are 
discrepancies between human and mouse data due to species differences (80). 
Our FHS data were observational and cross-sectional–we cannot rule out 
residual confounding or establish the temporality or causal nature of the 
associations we report. In addition, our cohort was constituted of largely middle-
aged to older adults of European ancestry; we cannot determine the 
generalizability of our findings to younger individuals or other races/ethnicities. 
Finally, it should be noted that we did not correct for the number of statistical 
comparisons made when examining the relationships between each gene and 
clinical covariates in the FHS samples. To reduce the probability of type I error, 
we focused interpretation on only those covariates of most relevance given the 
mouse experiments examining a Western diet. 
 
Figure 2.10: Effects of antibiotics (sham) on gene expression in C57BL/6J. 
Comparison of gene expression of Tmx2 and Mfap1a between untreated control and 
sham (with 4% sulfamethoxazole in their drinking water for 10 days to clear normal oral 
microflora) in C57BL/6J mice. Each condition consists of n=3 mice with RNA pooled.  
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Conclusions 
Overall, as has been seen with other immune cells, platelets respond 
differentially to distinct inflammatory etiologies. Platelets early response to an 
infection with an oral bacterium or a respiratory bacterium, both associated with 
CVD, were similar; however, over time, the effects on platelets by each 
bacterium diverge. Interestingly, C. pneumoniae alters platelet transcripts 
similarly to a Western diet at week 9. In conclusion, the inflammatory-induced 
transcriptional and functional changes measured in platelets appear to reflect 
systemic changes occurring with disease development, and provides insight into 
progression and regression. 
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CHAPTER III: THE ROLE OF RNA UPTAKE IN PLATELET HETEROGENEITY 
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Summary 
The role of platelets in regulating vascular homeostasis has expanded beyond 
mediation of hemostasis and thrombosis. The discovery of platelet RNA and the 
presence of subpopulations of platelets containing varying amounts of RNA 
suggest a role for platelet transcripts in vascular function. As the RNA in 
anucleated platelets is biologically functional and may transfer to other vascular 
cells, we hypothesized that platelet RNA diminishes over the lifespan of the 
platelet with diminishing platelet size due to horizontal cellular transfer. The 
purpose of this study is to determine if platelet RNA variance is the result of 
horizontal cellular transfer between platelets and other vascular cells. 
Utilizing platelet sorting and RNA sequencing, we found that smaller platelets 
contained a more diverse set of transcripts than larger platelets. Further 
investigation using fluorescence imaging, gene expression analyses and in vitro 
and in vivo modeling revealed that platelets take up RNA from other vascular 
cells in a complex manner, revealing a dynamic role for platelets in modulating 
vascular homeostasis through bidirectional RNA transfer. The resultant RNA 
profile heterogeneity suggests unique functional roles for platelets dependent on 
size and complexity.  
This study expands our basic understanding of platelet function and 
heterogeneity and is the first to evaluate endogenous vascular RNA uptake and 
its relation to platelet processes. Our findings describe a novel endogenous 
phenomenon that can help elucidate the platelet’s role in these non-thrombotic 
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and hemostatic fields, as well as present potential for diagnostic and therapeutic 
development. 
 
Introduction 
Platelets, anucleate blood borne cells generated from megakaryocytes, play a 
central role in the regulation of vascular homeostasis. Recent studies have 
expanded the functional roles of the platelet to several non-
hemostatic/thrombotic fields, including immune response, tumor progression, 
tumor metastasis, and other non-vascular diseases (184). As described in 
Chapter 1, as our understanding of the diverse functional capacity of platelets 
expanded, so did the need to understand the platelet’s content fully. The 
elucidation of the standard platelet RNA profile, as well as correlations between 
platelet RNA and specific disease states, fueled our interest in the role this RNA 
plays in various functional settings. Initial investigation into the role of RNA in 
platelets focused on the platelet’s translational capacity. Platelets contain all of 
the components necessary to perform pre-mRNA processing and signal-
dependent translation (88, 109-111); however, this translational capacity of 
platelets appears limited (78, 79), the stability of platelet mRNA transient (185), 
and the correlation to the platelet proteome partial and controversial (113). As an 
alternative explanation for the presence of RNA in platelets, several studies have 
recently shown that platelets have the ability to transfer their RNA to other 
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vascular cells, where these transcripts are both intact and functional (114, 120, 
124).  
In this study, by analyzing platelet RNA content, we aimed to investigate 
which transcripts are actively transferred by platelets and how this transfer may 
affect vascular homeostasis. Canonically, platelets range in size: new platelets 
recently released to the bloodstream, or “reticulated”, are larger while those that 
have been in circulation for some time are smaller (186, 187). Historically, this 
size difference has been used to demonstrate bone marrow response in the 
setting of thrombocytopenia; the presence of reticulated platelets marks the 
repopulation of platelets after depletion (187). There is evidence, however, that 
larger platelets can become smaller after release through the process of budding 
(13). Though the connections between platelet size and age remain controversial 
(28), it is generally accepted that larger, presumably younger, platelets contain 
more RNA content as compared to smaller, presumably older, platelets (186). 
We hypothesized that the difference in size and RNA content between platelet 
populations coincides with the observation that platelets transfer RNA to other 
vascular cells. Whether due to age, budding or RNA transfer, it stands to reason 
that the smaller platelet RNA transcriptome would be a subset of the larger 
platelet profile; those transcripts missing from the smaller platelet profile would 
represent either the transferred transcripts or those degraded during the 
platelet’s 7-10 day lifespan (37). Surprisingly, our initial RNA sequencing analysis 
revealed that instead of smaller platelet RNA profiles reflecting a subset of the 
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larger platelet profile, smaller platelets contained a unique and more expansive 
transcriptome than larger platelets, specifically containing diverse transcripts of 
unknown origin. Based on this finding and our previous work showing that 
platelets can transfer RNA to vascular cells, we hypothesized that platelets can 
also take up mRNA from vascular cells. Here, we report for the first time that 
platelets are capable of taking up RNA from other vascular cells in a complex 
and multifaceted manner and this results in distinct platelet subpopulations with 
divergent RNA profiles. This novel RNA uptake function expands our 
understanding of platelet RNA transfer to a bidirectional phenomenon and 
implies that platelets could play a much broader systemic role in the vasculature 
than previously understood.  
 
Materials and Methods 
Cell cultures  
Human umbilical vein endothelial cells (HUVECs; #CC-2519, Lonza, 
Walkersville, MD, USA), were cultured in endothelial growth medium (#CC-3124, 
Lonza) and used between second and eighth passages. THP-1 cells (#TIB-202, 
ATCC, Manassas, VA, USA) were grown in suspension in RPMI 1640 
supplemented with L-glutamine, 10% heat-inactivated fetal bovine serum, and 
1% antibiotic/antimycotic (#11875-093, Life Technologies, Grand Island, NY, 
USA).  
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Animals 
C57BL/6J (wild type -WT) and B6.129-Tlr2tm1Kir/J (TLR2−/−) mice were purchased 
from The Jackson Laboratory (#000664; #004650, Bar Harbor, ME, USA) and 
housed in the animal facility at the University of Massachusetts Medical School 
(UMMS). All methods for mouse work were approved by UMMS Institutional 
Animal Care and Use Committee.   
 
Platelet isolation 
Human platelets were isolated from freshly drawn venous blood collected in ACD 
SolutionA tubes (#364606, BD, Franklin Lakes, NJ, USA) from healthy donors 
taking no medication. All work was approved by the Institutional Review Board of 
UMMS and all participants gave informed consent. Blood samples were 
centrifuged at 150g for 15 minutes with no brake. Upper layer (platelet rich 
plasma) was isolated and diluted 1:1 times the volume with platelet wash buffer 
(10 mmol/L sodium citrate, 150 mmol/L sodium chloride, 1mmol/L EDTA, and 1% 
dextrose, pH 7.4) with prostaglandin E1 (PGE1- 1:10,000, #538903-1MG, EMD 
Millipore, Billerica, MA, USA). Samples were centrifuged at 750g for 15 minutes 
on low brake. The resulting pellet contains platelets. Washed platelets were 
resuspended in HEPES buffer (140 mmol/L NaCl, 6.1 mmol/L KCl, 2.4 mmol/L 
MgSO4.7H20, 1.7 mmol/L Na2HPO4, 5.8 mmol/L sodium HEPES, supplemented 
with 0.35% BSA and 0.1% dextrose) when noted. Mouse platelets were similarly 
processed from whole blood collected from cardiac puncture into tubes 
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containing citrate-phosphate-dextrose solution (15.6 mmol/L citric acid 
anhydrous, 89.4 mmol/L sodium citrate, 18.5 mmol/L sodium phosphate, and 
2.56% dextrose, pH 7.35). Samples were centrifuged at 250g for 10 minutes with 
no brake. Samples were checked for platelet count and purification using Coulter 
® AC.T Series Analyzer (BD). If additional wash was required, platelets were 
diluted 2.33x with  platelet wash buffer (10 mmol/L sodium citrate, 150 mmol/L 
sodium chloride, 1mmol/L EDTA, and 1% dextrose, pH 7.4) with PGE1 
(1:10,000). Samples were centrifuged at 250g for 15 minutes with no brake. The 
resulting supernatant was removed and centrifuged at 3500g for 10 minutes with 
a low brake to concentrate platelets in pellet.  
 
Platelet Population Sorting 
Initial Sorting for Sequencing Run: Whole blood was obtained from 2 healthy, 
male donors (one under the age of 35, one over the age of 35) and platelets 
were individually sorted directly from whole blood into two populations: larger, 
RNA rich (“large/young platelet population”) and smaller, RNA poor (“small/old 
platelet population”) using initial red blood cell lysis, followed by staining and 
positive selection, negative selection and size and complexity gating using 
FACSAria with FACSDiva v6.1.3 software (BD Biosciences). Whole blood from 
fresh donors was obtained and red blood cells were lysed using RBC lysis 
solution (#11814389001, Roche, Basel, Switzerland). Using both negative 
(Vybrant DyeCycle Violet Stain for DNA –#V35003, Life Technologies, Grand 
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Island, NY, USA; CD62P activated platelet population –#555524, BD 
Biosciences) and positive (CD61, platelet marker –#130-098-578, Miltenyi Biotec, 
San Diego, CA, USA) selection, the resting platelet population was identified. 
This resting platelet population was further analyzed based on size staining 
(Calcein AM –#C3100-MP, Life Technologies,) and complexity (side scatter). 
Corresponding IC controls were used for all antibodies. The smallest 10% 
(“small/old platelet population”, ~1-2 µm diameter based on flow cytometry bead 
comparison) and the largest 10% (“large/young platelet population”, ~ 6 µm 
diameter based on flow cytometry bead comparison) of the resting population 
were collected and used for population specific RNA isolation. Experiment 1 
yielded 17.4 x 106 small platelets and 16.4 x 106 large platelets. Experiment 2 
yielded 18.8 x 106 small platelets and 17.1 x 106 large platelets.  
Sorting for follow up qPCR: Whole blood was obtained from two healthy males 
(one <35 years old, one >35 years old) and two healthy females (one <35 years 
old, one >35 years old) and sorted as described above. The 10% smallest and 
10% largest platelets were sorted and isolated for further analysis. The yield of 
each of these additional sorts was: 3.5 x 106, 3.0 x 106, 2.6 x 106 and 1.7 x 106 
small platelets and 3.1 x 106, 2.8 x 106, 2.0 x 106 and 1.5 x 106 large platelets. All 
sorting was performed in conjunction with the UMMS Flow Cytometry Core. 
 
RNA Isolation  
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Total RNA was isolated from cells and platelets using the miRNeasy Mini kit with 
on column DNase1 digest (#217004, Qiagen, Germantown, MD, USA) according 
to the manufacturer's directions unless noted in methods. 
 
Sequencing: Total RNA was extracted from platelet sorting samples as described 
in “RNA Isolation.” After RNA isolation, large platelet RNA and small platelet RNA 
from individual sortings was combined together to create one large platelet RNA 
sample (8.4 ng) and one small platelet RNA sample (5.6 ng). Both samples were 
submitted to Otogenetics Corporation (Norcross, GA, USA) for RNA-Seq assays. 
Briefly, the integrity and purity of total RNA were assessed using Agilent 
Bioanalyzer (RNA Integrity Numbers – RIN – calculated to be 6.4 for the large 
platelet sample and 6.0 for the small platelet sample) and OD260/280 and 1-2 µg 
of cDNA was generated using Clontech SMARTer PCR cDNA kit (Cat# 634925, 
Clontech Laboratories, Inc., Mountain View, CA). cDNA was fragmented using 
Covaris (Covaris, Inc., Woburn, MA), profiled using Agilent Bioanalyzer, and 
subjected to Illumina library preparation using NEBNext reagents (Cat# E6040, 
New England Biolabs, Ipswich, MA). The quality, quantity and the size 
distribution of the Illumina libraries were determined using an Agilent Bioanalyzer 
2100. The libraries were then submitted for Illumina HiSeq2000 sequencing 
according to the standard operation. Paired-end 90 or 100 nucleotide (nt) reads 
were generated and checked for data quality using FASTQC (Babraham 
Institute, Cambridge, UK). The small platelet library generated 13.6 million reads 
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while the large platelet library generated 19.1 million reads. The data were then 
subjected to data analysis using the platform provided by DNAnexus (DNAnexus, 
Inc, Mountain View, CA) or the platform provided by Center for Biotechnology 
and Computational Biology (University of Maryland, College Park, MD) as 
previously described (Nature Protocols 7:562-578, 2012). Sequencing data 
analysis was performed using Tophat (v2.0.5) against reference assembly USCS 
hg19 (downloaded from Illumina iGenome) (transcript mapping) and 
Culllinks.cuffdiff (v.2.0.2) defined by the annotation file genes.gtf (from Illumina 
iGenome) (expression level calculation). For sequencing data, see Appendix C. 
 
DAVID Analysis 
The Database for Annotation, Visualization and Integrated Discovery (DAVID) 
v6.7 was used to analyze the functional relevance of young versus old platelet 
sequencing data. Differential gene expression files were obtained from 
Otogenetics (see “Sequencing”) and genes were selected for analysis first based 
on Cuffdiff output (NOTEST, HIDATA, LOWDATA and FAIL results were 
excluded) and then based on expression changes between samples. Specifically, 
genes were determined to be young or old platelet specific if they were 
expressed at < 0.1 FPKM in 1 population and > 1 FPKM in the other population. 
This cutoff was based on a 0.3 FPKM expression threshold used in a previous 
platelet RNA sequencing study(80). 
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In Vivo TLR2 (Pam3CSK4) stimulation experiment 
C57BL/6J (WT) mice were injected intraperitoneally with either sterile saline or 
Pam3CSK4 (4 mg/kg; #tlrl-pms, Invivogen, San Diego, CA, USA). After 3 hour 
incubation time, blood was harvested via cardiac puncture into citrate-phosphate-
dextrose solution. Platelets were isolated from whole blood by centrifugation as 
described in “Platelet Isolation”. Isolated platelets were processed for RNA 
isolation, cDNA preparation, and RT-qPCR by high throughput gene expression 
analysis as described. 
 
In vivo platelet RNA transfer 
Peripheral blood mononuclear cells (PBMCs) from WT and TLR2−/− mice were 
isolated using LymphoPrep (#AXS-1114544, Stem Cell Technologies, 
Vancouver, BC, Canada) and SepMate (#15415, Stem Cell Technologies) 
protocols. In brief, whole blood was collected as described above. Samples were 
diluted 1:1 in 1x PBS with 2% FBS and layered on top of LymphoPrep media in 
SepMate conicals. Samples were centrifuged at 1200g for 10 minutes with brake. 
The top layer of plasma above the interphase was removed and the remaining 
interphase portion above the SepMate barrier was poured into a separate 
conical. Interphase samples were diluted by 1:1 in 1x PBS, 2% fetal bovine 
serum (FBS) and centrifuged at 150g for 10 minutes, with no brake. The resultant 
pellet was additionally washed in 1x PBS/2% FBS and recentrifuged at 150g for 
10 minutes. The resulting pellet contains PBMCs.  Approximately 2 × 106 PBMCs 
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were resuspended in sterile saline solution and injected into each TLR2−/− mice 
via tail-vein injection (total volume, 200 µL). After 1 hour, TLR2−/− mice were 
intraperitoneally injected with 5 µg/g lipopolysaccharide (LPS; #tlrl-3pelps, 
InvivoGen) or saline. Blood samples were collected via cardiac puncture as 
above 3 hours after LPS injection. Platelets were isolated as previously 
described in “Platelet isolation” and processed for RNA isolation, cDNA 
preparation, and RT- qPCR as described. Taqman gene expression assay for 
TLR2 detection: Mm00442346_m1. 
 
Isolation of platelet fraction post in vivo control experiment 
Control experiment was run to check the purity of platelet fractions isolated from 
whole blood post in vivo experimentation. C57BL/6J (WT) mice were 
intraperitoneally injected with 5 µg/g lipopolysaccharide (LPS; #tlrl-3pelps, 
InvivoGen) or saline. Blood samples were collected via cardiac puncture 3 hours 
after LPS injection, as in “In vivo platelet RNA transfer”. Platelets were isolated 
as previously described in “Platelet isolation” and checked by flow cytometry for 
size (FSC), complexity (SSC) and CD41 expression (CD41–#17-0411, 
ThermoFisher Scientific (Affymetrix/eBioscience), Waltham, MA, USA). 
 
In Vitro Simulated Clot Experiments 
In vitro simulated clot experiments were conducted in 6 well culture plates at 
37C, 5% CO2. For all experiments, HUVECs were plated at 5000 cells/cm2 and 
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cultured as described until >85% confluent. Platelets were isolated as described 
in “Platelet Isolation”. Cells were washed one time with 1x phosphate buffered 
saline (PBS)( #10010-049, Life Technologies) and put in low phenol red 
endothelial cell medium (#CC-3129, Lonza, Walkersville, MD, USA). Cells were 
pretreated with or without thrombin stimulation (1 hr, 0.1U/mL; #HT-1002a, 
Enzyme Research Laboratories, South Bend, IN, USA), washed and co-
incubated for 2 hours with resting platelets or thrombin-stimulated (0.1 U/mL) 
platelets. After co-incubation, platelets were removed from wells, pelleted and 
resuspended in Qiazol for RNA isolation. HUVECs were washed 2x in PBS and 
then resuspended in Qiazol for RNA isolation. Transcription shutdown in vitro 
simulated clot experiments followed the same protocol as above with additional 
α-amanitin pretreatment of HUVECs before thrombin stimulation. Cells were pre-
treated with either α-amanitin (4 hours, 10 µg/mL; #129741-1MG, EMD Millipore), 
thrombin (1 hr, 0.1U/mL), both (4 hour alpha-amanitin treatment with thrombin 
bolus after 3 hours) or neither. Transcription shutdown in HUVECs treated with α-
amanitin was confirmed with Click-iT® RNA AlexaFluor 488 Imaging Kit 
(#C10329, Life Technologies).  Brefeldin A inhibition simulated clot experiments 
followed same protocol as above with two exceptions: co-incubation time was 10 
minutes and HUVECs were pretreated with brefeldin A (10 µg/mL, #00-4506-51, 
eBioscience, San Diego, CA) or methanol control. Pretreatment was 2 hours long 
with thrombus stimulation 1 hour post inhibitor addition. Conditioned media 
experiments followed a similar protocol to above. HUVECs were plated at 5000 
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cells/cm2 and cultured as described until >85% confluent. Platelets were isolated 
as described in “Platelet isolation”. Cells were washed one time with 1x PBS and 
put in low phenol red endothelial cell medium. Cells were pretreated with or 
without thrombin stimulation (1 hr, 0.1U/mL), after which conditioned media was 
moved to a new 6-well plate. Conditioned media was combined with either 
additional media or with resting platelets or thrombin-stimulated (0.1 U/mL) 
platelets and incubated for 2 hours at 37C, 5% CO2. After co-incubation, media 
and platelets were removed from wells, pelleted and resuspended in Qiazol for 
RNA isolation. HUVECs were washed 2x in PBS and then resuspended in Qiazol 
for RNA isolation. Control experiments to check cellular contamination in isolated 
platelet fractions followed the same protocol as initial clot experiments listed 
above, followed by flow cytometric analysis of platelets for size (FSC), complexity 
(SSC) and CD42b expression (CD42b – #11-0429, ThermoFisher Scientific 
(Affymetrix/eBioscience), Waltham, MA, USA). 
 
Click-iT® Simulated Clot Experiments 
Click-iT® RNA Capture kit (#C10365, Life Technologies) was used to label 
cellular-RNA prior to incubation. Cells were first treated with 5’-ethynyl uridine (5’-
EU) at 0.2 mmol/L overnight then stimulated with either thrombin (HUVEC, 
0.1U/mL) or Pam3CSK4 (THP1, 10 µg/mL) for 1 hour, resulting in all nascent 
cellular RNA incorporating this unique nucleotide. Cells were washed twice with 
PBS and incubated with platelet rich plasma (PRP) as described in “In Vitro 
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Simulated Clot Experiments. Post incubation, platelet fraction was separated 
from cellular fraction (HUVEC experiments - removed platelets manually, THP1 - 
separated through centrifugation at 750g for 15 minutes with low brake). Once 
platelet fraction was obtained, performed RNA Capture was performed according 
to manufacturer’s method to isolate cellular-derived RNA. RNA was converted to 
cDNA as described in “cDNA Reaction”. Gene expression was assessed using 
the TaqMan Gene Expression Platform as described in “RT-qPCR” and “High-
Throughput RT-qPCR”.  
 
cDNA Reaction 
RNA was converted to cDNA with the High-Capacity cDNA Reverse 
Transcription kit (#4368813, Life Technologies). cDNA was preamplified prior to 
real time (RT)-qPCR reaction using TaqMan PreAmp Master Mix (#4391128, Life 
Technologies) and TaqMan Gene Expression assays (#4331182, #4351372, Life 
Technologies) according to the manufacturer’s protocol. 
 
RT-qPCR 
Gene expression was assessed using TaqMan Gene Expression assays with 
Real Time PCR instrument (Applied Biosystems 7900 HT Fast Real-Time PCR 
System with SDS Version 2.2.2 software; Life Technologies) or via High-
Throughput RT-qPCR (see “High-Throughput RT-qPCR”). RT-qPCR results were 
calculated using the ∆∆Ct method, with background cycle threshold (Ct) set to 
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35. Platelet RT-qPCR array results were normalized using housekeeping genes 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), glucose-6-phosphate 
isomerase (GPI) and/or vesicle associated membrane protein 3 (VAMP3) as 
noted in individual results. HUVEC RT-qPCR array results were normalized using 
CD63 and CD81. These genes were selected for normalization using the geNorm 
analysis module of qbase+ software version 2.6 (www.qbaseplus.com, 
Biogazelle, Zwijnaarde, Belgium). The software is based on the qBase 
quantification model(188) and contains the geNorm module for identification of 
stably expressed reference genes(189). In vivo mouse experiment RT-qPCRs 
were normalized to beta-actin (β-actin) or GAPDH as noted with results. 
 
High-Throughput RT-qPCR 
TaqMan gene expression assays and TaqMan Gene Expression Master Mix 
(#4369542, Life Technologies) were used to run Dynamic Array 96.96 chips 
(Fluidigm, South San Francisco, CA) on BioMark System (Fluidigm) for high-
throughput gene expression analysis. Differential expression analysis and 
statistical analysis performed using the RT2 Profiler PCR Array Data Analysis tool 
version 3.5 (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php, 
Qiagen).  Normalization performed using housekeeping genes as described in 
“RT-qPCR” in the Online Methods. 
 
Fluorescent RNA transfer in flow adhesion model 
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HUVEC RNA was stained using SYTO® RNASelectTM fluorescent green stain 
(#S32703, Life Technologies) at 1:125 dilution for 1 hour in serum free media. 
After incubation, stain was removed and cells were washed twice with 1x PBS. 
Cells were then used in the flow adhesion model (55). Human platelets, isolated 
from whole blood, as described, were run over cells for noted time at 3 mL/min in 
1x PBS, pH 7.4. After the run was complete, platelets were recovered from 
buffer, concentrated, fixed in IC fixative buffer (#00-8222-49, eBioscience, San 
Diego, CA, USA) and mounted on slides using ProLong Gold (#P36930, Life 
Technologies). HUVECs were washed once with PBS, pH 7.4, fixed with cold 
methanol and mounted on slides using ProLong Gold. For indirect transfer 
experiment, PBS pH 7.4 alone was flowed over HUVECs under designated 
sample conditions. Buffer was then recovered and incubated with platelets with 
or without stimulation for a specified time. Platelets were then recovered and 
analyzed as described. 
 
Whole Blood Counts 
Blood collected from each mouse was analyzed for white blood cell (WBC) and 
platelet content using a Coulter ® AC.T Series Analyzer (BD).  
 
Confocal microscopy 
Fluorescent imaging samples were analyzed by confocal microscopy. Imaging 
was performed on TCS SP5II confocal microscope and captured using Leica 
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Confocal Version 2.5 software (Leica Microsystems; Buffalo Grove, IL, USA). 
Image quantification was performed by selecting individual cells across the field 
(n=20) per sample and using Image J (1.48V) software to measure mean 
fluorescence.  
 
Flow cytometry 
Flow cytometry was performed on a BD LSRII using BD FACSDiva v6.2 software 
(BD) and analyzed using FlowJo Version X.  
 
Fragment analysis 
Fragment analysis and RNA integrity number (RIN) calculation of sequencing 
samples performed by Otogenetics as described in “Sequencing”. Fragment 
analysis and RNA quality number (RQN) calculation of additional sorting samples 
used for RT-qPCR analysis performed via the UMMS DNA Fragment Analysis 
Service using an Advanced Analytical instrument with a Total RNA 
assay, running PROSize 2.0 analysis software. 
 
Data analysis 
All values are expressed as the mean (SD) of at least 3 different experiments. 
RT-qPCR fold changes were calculated using ∆∆Ct method. Statistical analyses 
were performed using Prism software (GraphPad Prism v6; La Jolla, CA, USA). 
Individual statistical analysis tests noted in figure legends. Statistical analyses of 
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samples examined with RT2 Profiler PCR Array Data Analysis tool version 3.5 
analyzed by student’s t-test of the replicate 2^ (-∆∆Ct) with p<0.05. For additional 
statistical tests not included in original text, please see Appendix D. 
 
Results 
Size differentiated platelet subpopulations show distinct RNA profiles with 
diverse functionalities   
To interrogate the impact of platelet size on RNA content, we identified and 
isolated large and small platelet subpopulations from human whole blood using 
flow cytometry. Removal of cells through lysis, negative selection, positive 
selection and gating based on size and cellular complexity allowed for isolation of 
the 10% largest and 10% smallest resting platelet populations (Figure 3.1).  
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Figure 3.1: Workflow of fluorescence-activated cell sorting (FACS) of large and 
small platelet populations. Large and small platelets were separated by FACS and 
analyzed for RNA content via RNA sequencing. (A) FACS sorting approach to isolate 
larger platelet and smaller platelet subpopulations. Representative images of sorting 
technique show selection of CD61+, DNA-, CD62P- population to obtain resting platelet 
population. This was followed by CD61+ confirmation and FSC/SSC gating to isolate 
10% smallest and 10% largest platelet subpopulations. Events in representative flow 
cytometry images color-coded for convenience: resting platelets (red/pink), 10% smallest 
platelets (blue), 10% largest platelets (orange).  
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RNA sequencing of these specific subpopulations revealed that, although the 
majority of RNA transcripts identified were shared by both populations, each 
subpopulation had a distinct set of platelet transcripts unique to itself. Cuffdiff 
analysis of RNA sequencing results identified 7500 successfully mapped 
transcripts (Appendix C), of which 5027 were present in both populations, 378 
were specific to the younger, larger platelet population and 2314 were specific to 
the older, smaller platelet population (Figure 3.2).  
 
Figure 3.2: Differential RNA expression in large and small platelet populations. 
Large and small platelets were separated by FACS and analyzed for RNA content via 
RNA sequencing. (B) Venn diagram of DAVID analysis results of large versus small 
platelet RNA sequencing data. 
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Contrary to our anticipated results, the transcripts specific to the smaller platelet 
population represented a distinctly different and more varied transcript profile 
than larger platelets. DAVID (Database for Annotation, Visualization and 
Integrated Discovery v6.7) functional annotation analysis of the two 
subpopulations’ transcriptomes showed distinct functional association differences 
between the two groups. While the 378 transcripts present only in larger platelets 
were loosely associated with 129 functional clusters, they were only enriched 
(enrichment score > 3) in 1 (platelet/vesicle association) (Figure 3.2). Larger 
platelet transcripts were associated with 142 gene ontology (GO) terms, with 8 
terms correlated with a Benjamini corrected p<0.05 (Table 3.1).  
 
Table 3.1: DAVID Gene Ontology (GO) functional analysis of small and large 
platelet RNA profiles. Overall representation of GO categories and associated terms 
for large and small platelet RNA DAVID analysis.  
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The smaller platelet specific transcripts were associated with 451 functional 
clusters and enriched in 16 of them, the most enriched of which included protein 
transport and mitochondrial function (Figure 3.2). Smaller platelet transcripts 
were associated with 469 GO terms, with 91 terms with a Benjamini corrected 
p<0.05 (Table 3.1). In-depth analysis of the biological processes associated with 
individual platelet populations also revealed a distinct trend: while the larger 
platelet profile included typical platelet-associated functions, such as platelet 
activation, hemostasis and wound healing, these functions were not associated 
with the smaller platelet profile (Appendix E). The smaller platelet profile, in turn, 
had a number of functions distinctly associated with vascular cell function, such 
as T cell, lymphocyte and B cell activation, proliferation, differentiation and/or 
apoptosis (Appendix E). We repeated this initial sorting experiment, performing 
four additional rounds of sorting, to validate the results comparing small and 
large platelet specific RNA profiles using real time quantitative polymerase chain 
reaction (RT-qPCR). Several targets covering a span of expression levels in 
initial RNA sequencing were validated by RT-qPCR, including those genes 
typically considered stable in cells (such as β-actin, B2M, and GAPDH, though 
these genes are notably differentially expressed here), those equally expressed 
in initial sequencing results (such as GUK1, LSP1, NFKBIA and SELL) and those 
with higher expression in large platelet RNA than in small platelet RNA (such as 
BCL2L1, PF4, CD40 and SELP) (Figure 3.3, Table 3.2).  
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Figure 3.3: RT-qPCR validation and analysis of platelet subpopulation RNA 
profiles. RT-qPCR validation of RNA from small and large platelet subpopulation 
sorting. Raw Cq values for n=4 biological replicates, error bars representing mean (SD). 
Black bars represent small platelet RNA results, gray represent large platelet RNA 
results. P-values calculated by unpaired two-tailed T-test with p<0.05 (*P<0.05, 
**P<0.01, ***P<0.001, ****P<0.0001).  
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Table 3.2: Sequencing results for select targets validated using RT-qPCR. 
Sequencing FPKM (fragments per kilobase of transcript per million mapped reads) (and 
RPKM – reads per kilobase of transcript per million mapped reads) for targets selected 
for RT-qPCR validation. 
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Analysis of the coverage tracks of these targets from initial sequencing revealed 
similar coverage patterns between platelet subpopulations (Figure 3.4, panels 1-
3).  
 
Figure 3.4: Integrative Genomics Viewer (IGV) analysis of platelet subpopulation 
RNA profiles. IGV (1, 2) coverage tracks for select gene targets analyzed during RT-
qPCR validation. Blue trace represents larger platelet RNA, pink trace represents small 
platelet RNA, and black trace represents gene reference sequence. 
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Interestingly, validation of targets with higher expression values in smaller 
platelet RNA was not possible by RT-qPCR. Analysis of the coverage tracks of 
these genes revealed that these targets showed significantly different coverage 
between platelet subpopulations, with the smaller platelet sample often covering 
more of the overall transcript than the large (Figure 3.4, panels 4-5). Despite 
these coverage differences, targeted RT-qPCR did not validate sequencing 
results (data not shown). Interestingly, analysis of the overall RNA quality of the 
original sequencing samples as well as the validation samples (either through 
calculation of RNA integrity (RIN) or RNA quality (RQN) number) revealed a 
distinct pattern – the smaller platelet subpopulation RNA was always of lesser 
quality than the larger platelet population (Table 3.3).  
 
Table 3.3: Fragment analysis results for sequencing and RT-qPCR validation of 
FACS samples. RNA integrity number (RIN) (sequencing sample) or RNA quality 
number (RQN) for samples from platelet subpopulation study. ǂ denotes sample with 
particularly low concentration which we believe resulted in false negative RQN. 
 
 
 
This suggests RT-qPCR validation was unsuccessful due to the fragmented 
nature of the smaller platelet RNA. These findings support that small and large 
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platelet subpopulations show distinct transcript diversity associated with discrete 
functionalities, as well as differing RNA quality, which may reflect novel functional 
differences between these subpopulations.  
 
Stimulation of vascular cell interaction leads to increased platelet 
transcript   uptake in vivo. 
Based on the observations of increased transcript diversity in the smaller platelet 
population, the lack of transcription in platelets, and previous work on the uptake 
of microvesicles by platelets (133, 135, 190), we investigated whether platelets 
take up RNA from other cells throughout the vasculature in vivo. To study this 
question, we induced platelet and white blood cell (WBC) interaction in C57BL/6J 
mice by treating them with Pam3CSK4, a toll-like receptor 1/toll-like receptor 2 
(TLR1/TLR2) ligand (114, 140, 191, 192). Post stimulation, platelets were 
harvested and analyzed for RNA content for various adhesion and inflammatory 
transcripts. Several transcripts showed distinct increases post Pam3CSK4 
treatment (Figure 3.5).  
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Figure 3.5: Increased transcript expression in platelets post in vivo stimulation. 
Significant (* P<0.05; ** P< 0.01) transcript fold changes (expressed as 2−∆∆Ct) in wild 
type platelet transcript expression levels post Pam3CSK4 stimulation. All samples were 
normalized to β-actin with n=3 mice per group, values expressed as mean (SD). P-
values calculated using individual unpaired t-test  
 
 
 
The increase in interleukin 1 beta (IL1β) mRNA post stimulation draws a parallel 
to previous publications that show pro-IL1β is processed in toll-like receptor 4 
(TLR4)-stimulated platelets (88, 109-111). As there is no evidence for a similar 
phenomenon based on TLR2 signaling or with these other targets, the increase 
of these transcripts supports the hypothesis that, under appropriate stimulation, 
platelets can take up transcripts from other vascular cells.  
 To confirm that these transcripts come from other vascular cells and not 
through platelet internal RNA processing, we developed an infusion model to 
better track transcript origin, allowing us to monitor expression of Tlr2 after 
platelet stimulation. Peripheral blood mononuclear cells (PBMCs) were isolated 
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from C57BL/6J mice. These PBMCs were then infused into Tlr2-/- mice. After 
stimulation of WBC and platelet interaction with lipopolysaccharide (LPS) (114), 
platelets were isolated from mice and analyzed for RNA content. The presence of 
wild type Tlr2 transcript in platelets from Tlr2-/- mice post infusion and stimulation 
supports the transfer of RNA in vivo from the wild type PBMCs to platelets in 
response to inflammation (Figure 3.6). 
 
Figure 3.6: Increased transcript expression in platelets post platelet transfusion 
and in vivo stimulation. Presence of wild type Tlr2 in platelets from transfused mice. 
Tlr2 fold changes (expressed as 2−∆∆Ct) in platelets. All samples were normalized against 
GAPDH with n=3 mice per group, values expressed as mean (SD). The transfer of Tlr2 
mRNA from PBMCs to platelets under LPS stimulation was significant compared to 
control infusions (*P =0.023, assessed by one-way ANOVA with Tukey’s multiple 
comparisons test post analysis, α = 0.05). 
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As a control, we performed additional rounds of this experiment and platelet 
isolation to analyze isolated platelet fractions for potential cellular contamination. 
Flow cytometry analyses revealed the main population isolated was CD41 
positive with no significant shift in size or complexity due to treatment (Figure 3.7, 
panels 1-2). There was a slight decrease in CD41 expression between saline and 
LPS treated mice (Figure 3.7, panel 3); however, with no significant shift in 
population, this suggests shedding of CD41 in response to stimulation, as 
previously seen with other platelet markers (193). 
 
Figure 3.7: Confirmation of platelet isolation during in vivo stimulation 
experiments. Flow cytometric analysis of isolated platelet population post in vivo 
stimulation. Mice were treated and samples isolated as performed in Tlr2-/- experiments. 
Samples were then stained for CD41 and analyzed by flow cytometry for changes in 
complexity (SSC), size (FSC) and CD41 expression. A) Percentage of total events within 
designated platelet gate. B) Percentage of events within designated gate which were 
CD41 positive. C) Geometric mean of fluorescence corresponding to CD41 expression 
of events within designated gate. All results were analyzed using unpaired t-test 
(p<0.05). Error bars represent mean (SD) of n=5 for each group.  
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Taken together, these results confirm the novel ability of platelets to take 
up cellular RNA from endothelial cells and leukocytes and suggest potential for 
platelet based communication throughout the vasculature.  
 
Platelet transcript levels are increased after in vitro co-incubation with 
endothelial cells 
To further study the phenomenon of platelet RNA transfer, we co-incubated 
resting or activated human platelets with human umbilical vein endothelial cells 
(HUVECs) under various conditions and measured platelet transcript levels by 
RT-qPCR post incubation. To mimic a clot environment, we combined HUVEC 
and platelets under low-dose thrombin stimulation. We analyzed ninety-six 
inflammatory and adhesion transcripts in platelets under four conditions: platelets 
with and without stimulation, alone or in the presence of HUVECs. Table 3.4 
highlights the 38 transcripts that showed notable increases in expression levels 
when comparing platelets alone to platelets post incubation with endothelial cells. 
Sixteen genes were increased in platelets solely upon incubation with HUVECs 
with a less than 10% increase in expression with stimulation (Table 3.4a). The 
remaining 22 genes, showed increased expression with HUVEC incubation and 
an even greater fold change when stimulated (Table 3.4a). Additionally, 18 
transcripts showed fold regulation changes that were statistically significant when 
compared to platelet expression levels alone (noted in red, Table 3.4a).  
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Table 3.4: Differential gene expression in platelets after in vitro simulated clot 
experiments. RT-qPCR results for genes that show upregulation in platelets after 
incubation with unstimulated or stimulated endothelial cells (ECs) under normal 
conditions (A) or with pretreatment transcription shutdown in ECs through α-amanitin 
treatment (B). RT-qPCR results were normalized to three housekeeping genes (GAPDH, 
GPI and VAMP3) with platelet alone samples set as experimental controls. Gray color 
coding denotes magnitude of fold regulation across samples for a given gene. Cells and 
genes in red text signify P < 0.05 (based on a Student’s t-test of the replicate 2(- ∆∆Ct) 
values for each gene in the control group and treatment groups) for given value. Legend 
below table describes sample setup conditions. A) Results represent n=6 experiments. 
B) Results represent n=3 experiments.  
 
Magnitude of Fold Regulation 
 
 
Min               Max  
130 
 
 
 
 
A) 
Platelets 
Alone 
Stimulated 
Platelets 
Unstimulated 
Platelets Post  
ECs Incubation 
Stimulated Platelets 
Post Stimulated 
ECs Incubation 
CXADR 1.0 -1.0 2709.8 2264.3 
COL18A1 1.0 -1.7 950.4 1251.7 
SELE 1.0 -1.0 566.8 9080.5 
ICAM1 1.0 -2.9 401.1 918.4 
ITGA5 1.0 3.1 160.7 186.5 
TLR3 1.0 -3.1 115.1 79.5 
CXCL1 1.0 -1.5 67.1 230.1 
CXCL12 1.0 5.6 57.0 45.8 
TLR4 1.0 -1.1 33.9 40.5 
KIAA1462 1.0 -2.7 27.6 25.9 
CX3CL1 1.0 -10.8 27.2 155.1 
IL6 1.0 2.3 21.5 43.5 
VCAM1 1.0 -2.3 19.5 508.4 
CD81 1.0 -3.3 18.1 22.2 
CXCL2 1.0 23.8 17.6 59.2 
EIF4G1 1.0 2.1 15.2 17.4 
TNFSF10 1.0 2.7 12.8 12.0 
CALR 1.0 -1.3 12.2 13.9 
ASGR1 1.0 -1.0 11.7 12.3 
VEGFA 1.0 -1.6 8.1 17.1 
IL8 1.0 4.6 6.2 16.3 
SIRPA 1.0 -2.9 5.3 5.1 
VEGFB 1.0 -1.0 5.0 5.2 
VAMP5 1.0 -3.2 5.0 4.7 
VIP 1.0 -1.5 4.8 6.5 
CRP 1.0 -1.0 4.8 15.3 
IFNA1 1.0 -1.0 4.4 15.3 
TNFRSF1B 1.0 -1.2 4.2 4.3 
CCL7 1.0 3.1 3.8 3.0 
NFKBIA 1.0 1.4 3.1 5.3 
CD63 1.0 -1.2 2.8 2.9 
SELENBP1 1.0 -3.4 2.7 1.5 
DICER1 1.0 2.7 2.6 2.8 
KIAA0232 1.0 -1.2 2.6 2.2 
IFITM3 1.0 1.1 2.3 2.0 
MAP4K4 1.0 -1.1 2.2 2.8 
CXCL6 1.0 -6.4 2.1 18.8 
VEGFC 1.0 1.0 1.8 2.0 
Platelets + + + + 
Platelet Thrombin 
Stimulation 
- + - + 
EC Incubation - - + + 
EC Transcription 
Shutdown 
- - - - 
EC Thrombin 
Stimulation 
- - - + 
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B) 
Platelets 
Alone 
Stimulated 
Platelets 
Unstimulated 
Platelets Post EC 
Incubation 
Stimulated Platelets 
Post Stimulated ECs 
Incubation 
CXADR 1.0 -1.3 5361.9 12880.0 
COL18A1 1.0 -2.7 251.2 477.3 
SELE 1.0 -1.3 266.3 10342.8 
ICAM1 1.0 -8.8 570.9 2625.8 
ITGA5 1.0 1.2 52.4 88.5 
TLR3 1.0 -11.3 1.7 2.3 
CXCL1 1.0 -9.4 7.0 24.2 
CXCL12 1.0 1.4 1.9 35.5 
TLR4 1.0 -1.8 14.9 21.6 
KIAA1462 1.0 -15.3 4.3 7.8 
CX3CL1 1.0 -139.6 14.4 19.6 
IL6 1.0 -2.8 1.1 38.0 
VCAM1 1.0 1.1 196.3 33.6 
CD81 1.0 -1.3 16.0 30.3 
CXCL2 1.0 88.1 156.3 380.4 
EIF4G1 1.0 -1.2 3.5 5.6 
TNFSF10 1.0 -1.4 3.2 4.7 
CALR 1.0 1.0 9.5 14.9 
ASGR1 1.0 -1.3 -1.3 49.2 
VEGFA 1.0 -2.3 7.3 8.2 
IL8 1.0 22.7 21.4 205.8 
SIRPA 1.0 -1.0 10.2 13.6 
VEGFB 1.0 1.2 6.7 7.5 
VAMP5 1.0 -1.0 3.9 6.7 
VIP 1.0 14.4 29.8 54.2 
CRP 1.0 -1.3 -1.3 -1.8 
IFNA1 1.0 -1.3 8.2 9.3 
TNFRSF1B 1.0 1.1 3.2 2.6 
CCL7 1.0 -1.3 -1.3 4.9 
NFKBIA 1.0 1.2 4.0 4.9 
CD63 1.0 -1.2 1.9 2.8 
SELENBP1 1.0 1.1 -1.1 -1.3 
DICER1 1.0 -1.2 -1 -1.2 
KIAA0232 1.0 -1.1 -1 -1 
IFITM3 1.0 1.1 2.4 2.8 
MAP4K4 1.0 -1.2 1.8 2.6 
CXCL6 1.0 -7.2 1.3 -3.4 
VEGFC 1.0 -1.1 2.2 2.2 
Platelets + + + + 
Platelet Thrombin 
Stimulation 
- + - + 
EC Incubation - - + + 
EC Transcription 
Shutdown 
- - + + 
EC Thrombin 
Stimulation 
- - - + 
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To ensure our platelet isolation approach resulted in minimal cell contamination 
post co-incubation, we performed control experiments analyzing the resultant 
platelet fractions from both conditioned media alone and platelet co-incubation 
setups. Analysis of total event count and CD42b+ expression via flow cytometry 
found minimal contribution of endothelial microparticles in the platelet fraction as 
prepared (Figure 3.8, Figure 3.9). These results highlight the increase of specific 
transcripts in platelets after interaction with endothelial cells and suggest that the 
increase in platelet RNA may be transcript specific. 
Figure 3.8: Contribution of microvesicles to isolated platelet fraction during in 
vitro simulated clot experiments. Flow cytometric analysis of isolated platelet fraction 
post co-incubation in vitro with HUVEC. Co-incubation experiments were conducted as 
described. Post co-incubation, platelet fractions from conditioned media alone and co-
incubation wells were analyzed for total number of events and total number of CD42b+ 
events. Percentage of total events which were CD42b+. Comparison was only 
performed using unstimulated samples due to known shedding of CD42b+ by platelets in 
response to stimulation (194). Results analyzed using unpaired two tailed t-test (p<0.05). 
Error bars represent mean (SD) of n=3.  
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Figure 3.9: Contribution of microvesicles to isolated platelet fraction total cell 
count during in vitro simulated clot experiments.  Flow cytometric analysis of 
isolated platelet fraction post co-incubation in vitro with HUVEC. Co-incubation 
experiments were conducted as described. Post co-incubation, platelet fractions from 
conditioned media alone and co-incubation wells were analyzed for total number of 
events and total number of CD42b+ events. Fold change of event concentration as 
compared to unstimulated platelet co-incubation sample. Total events, total run time and 
constant flow rate of flow cytometer was used to calculate events/mL for each sample. 
Fold change was then calculated using unstimulated platelet co-incubation sample as 
control (set to 1). Results analyzed using ordinary one-way ANOVA with Tukey’s 
multiple comparison test post analysis (*P<0.05, ***P<0.001, ****P<0.0001).  
 
 
 Next we sought to investigate if the increases in platelet transcript levels 
were dependent on HUVECs being transcriptionally active. We repeated the 
simulated clot experiments using HUVECs that had been treated with α-amanitin 
to halt transcription. Of the 38 transcripts, 25 transcripts held the patterns seen 
with active transcription; however 13 transcripts showed altered expression 
patterns with cessation of HUVEC transcription, 9 showing almost complete 
attenuation of expression in all conditions (Table 3.4b). 10 of the transcripts 
which initially showed significant expression changes post incubation were no 
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longer significant while 3 alternative transcripts now showed significant changes 
(significant genes and samples noted in red, Table 3.4b). These data suggest 
that the impact of HUVEC transcription on the increase in RNA expression in 
platelets post co-incubation is transcript dependent. 
 
Transcripts present in platelets post incubation with vascular cells are of 
cellular origin 
Though platelets cannot transcribe new mRNAs, they are capable of performing 
pre-mRNA processing (78, 79, 88, 109-111). After observing transcript increases 
in platelets post incubation with endothelial cells, we wanted to confirm that these 
transcripts were of endothelial origin. We performed simulated clot experiments 
utilizing Click-iT® technology to pre-label HUVEC RNA. After co-incubation, the 
platelet and HUVEC fractions were separated and the Click-iT® capture 
technology was used to isolate out only HUVEC-RNA from the platelet RNA 
fraction. Of the 96 targets analyzed, 78 showed expression of HUVEC-RNA in 
platelets post incubation; this was denoted by a decrease in raw Cq value when 
comparing platelets alone to platelets post Click-iT® labeled HUVEC incubation. 
29 of these transcripts had raw Cq value decreases with p<0.005 (data not 
shown) with12 of these transcripts’ significance p<0.0001 (Figure 3.10a, Table 
3.5a). Because platelets could interact with other vascular cells in vivo, this 
experiment was repeated using a monocyte cell line, THP1, as the donor cell and 
Pam3CSK4 stimulation, previously shown to result in platelet-monocyte 
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activation (114, 140, 191, 192). Results showed 62 THP1-derived transcripts 
present in platelets post incubation, 19 of the transcripts with a significance of 
p<0.005 (data not shown), 12 of which with a significance p<0.0001. (Figure 
3.10b, Table 3.5b). This suggests the transfer of multiple vascular cell-derived 
transcripts into platelets post interaction. 
 
Figure 3.10: Gene expression levels of cell-derived RNA in platelets post 
incubation with cells. Endothelial cell (EC) or monocyte cell RNA was labeled with 5’-
ethynyl uridine (EU) and, post incubation with platelets, the platelet fraction was isolated 
and cell specific RNA captured using the Click-iT® RNA capture method. 96 transcripts 
were investigated by high throughput RT-qPCR. Results given as raw Cq values. 
Results show transcripts with P <0.0001(****) for unpaired t-test using Sidak-Bonferroni 
method (α = 0.05) comparing stimulated platelets alone to stimulated platelets after 
incubation with cells A) Endothelial cell, B) Monocyte cell. Toll-like receptor 9 (TLR9) in 
A) and vesicle associated membrane protein 5 (VAMP5) in B) representative examples 
of non-significant genes (ǂ). Error bars represent mean (SD) of n=4 experiments.  
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Table 3.5: Gene expression levels of cell-derived RNA in platelets and cells post 
incubation. Corresponding data to Figure 3.10. Given as raw Cq values ± SD. A) 
Endothelial cell experiment results. B) Monocyte cell experiment results. P value 
calculated using unpaired individual t-test with Sidak-Bonferroni method (α=0.05).  
 
 
Transcript level increases in platelets occur under both static and flow 
conditions  
To visualize the transfer of mRNA from cells to platelets, we used SYTO® 
RNASelectTM, a RNA specific fluorescent dye, to label HUVEC total RNA. 
Platelets were then incubated with the labeled HUVECs, with and without 
thrombin stimulation. Post static incubation, platelets showed fluorescence 
expression by flow cytometry (Figure 3.11).  
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Figure 3.11: Platelet RNA uptake from endothelial cells under static conditions via 
flow cytometry. A) Unstimulated or stimulated human platelets post static incubation 
with RNASelect-treated endothelial cells analyzed by flow cytometry (n=3). Legend 
denotes experimental conditions for each sample, error bars represent mean (SD). B) 
Representative flow cytometry images of each sample setup. Y axis: SSC (complexity); 
X axis: RNASelect (FITC) expression (denotes HUVEC-derived RNA within platelets). 
Panels in order of legend in A) from left to right.  
 
  
We expanded this study to look at RNA transfer under flow conditions, better 
reflecting what occurs in vivo. SYTO® RNASelectTM labeled HUVECs were 
grown on slides and platelets were flowed over the slides, with or without 
thrombin stimulation. We recovered these platelets and analyzed them for 
fluorescent RNA expression using confocal microscopy. At 10 minutes, 
unstimulated platelets showed minimal, but evident, fluorescence expression, 
A) 
B) 
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while there was a distinct increase in fluorescence under stimulation (Figure 
3.12-i, ii). At 30 minutes, both unstimulated and stimulated conditions showed 
fluorescence expression but the visible spike seen at 10 minutes with stimulation 
was diminished (Figure 3.12-iii, iv). Quantification of the fluorescent mean of 
individual cell from these images highlights the upsurge at 10 minutes with 
stimulation (significantly higher than all other samples) and reveals that at 30 
minutes with stimulation there is also a significant increase over unstained and 
unstimulated controls (Figure 3.13). Confocal Z-axis profiling supports the 
internalization of HUVEC-derived RNA within these platelets (Figure 3.14).These 
trends were consistent across several biological replications. Though inter-
individual platelet reactivity most likely accounts for the variance in expression 
spike, these data support the transfer of distinct HUVEC RNA into platelets under 
the minimal, but necessary, contact achieved during flow conditions. 
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Figure 3.12: RNA transfer from endothelial cells to platelets via fluorescence 
imaging. Endothelial cell RNA was labeled with SYTO® RNASelectTM green fluorescent 
cell stain. Unstimulated (i, iii) or stimulated (ii, iv) human platelets were flowed over 
RNASelect-treated endothelial cells for noted time. After incubation, platelets were 
recovered for analysis by confocal microscopy. Scale bar denotes 25 µm. Panels are 
representative of one experiment from n=5-6 experiments generated from different 
donors, and show fluorescent image top panel, DIC-Pol image bottom panel for each 
conditions.  
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Figure 3.13: Quantification of RNA transfer from endothelial cells to platelets via 
fluorescence imaging. Endothelial cell RNA was labeled with SYTO® RNASelectTM 
green fluorescent cell stain. Quantification of images from Figure 3.12.  Image 
quantification was performed using Image J (1.48V) software to measure mean 
fluorescence. Values represent mean (SD) of n=20 individual cells from each image. 
Analysis of results by one-way ANOVA with Tukey’s multiple comparisons test post 
analysis (α = 0.05): Overall p<0.0001. Additional significant comparisons noted in figure 
legend (* P<0.05; ** P< 0.01; ***P<0.01; ****P<0.001).  
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Figure 3.14: Uptake and internalization of RNA from endothelial cells by platelets 
via fluorescence imaging. Endothelial cell RNA was labeled with SYTO® RNASelectTM 
green fluorescent cell stain. Confocal Z-axis profile (created using ImageJ) of 
representative image from flow adhesion experiment. Confocal stack images taken from 
1 µm below and 1 µm above center of cell (set to 0.0 µm), with each z-step equal to 0.15 
µm.  
 
 
 
Platelet transcript uptake is a complex, multifaceted process 
Upon confirmation of the presence of cellular-derived mRNAs in platelets as well 
as the occurrence of this phenomenon under flow conditions, we aimed to 
investigate the mechanism of uptake. It is known that vascular cells and platelets 
release microvesicles, especially in response to stimulation (116, 195). There is 
also evidence to support microvesicle-based miRNA transfer from platelets to 
cells (120, 124), as well as platelet-microvesicle interaction and uptake (133, 
135, 190). Based on this, we hypothesized that platelet uptake may occur via a 
microparticle dependent mechanism. Initial experiments adapting our 
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fluorescence flow adhesion experiments to see if transfer could occur indirectly 
revealed similar results as seen in our direct model, with the exception of 
attenuation of the spike seen at 10 minutes under stimulation. These initial 
findings suggested that uptake is partially occurring through microparticles; 
however, the expression and uptake increases seen in vitro with stimulation are 
either dependent on direct platelet-endothelial cell interaction or the 
microenvironment normally present in the vasculature.  
To further tease apart the mechanism of platelet RNA uptake, we 
developed two adaptations of our in vitro simulated clot experiments to 
investigate the role microparticles may play in this phenomenon. The first set of 
experiments utilized brefeldin A, a microparticle inhibitor previously demonstrated 
to impact exosome-like vesicle regulation as well as platelet miRNA transfer to 
endothelial cells (120, 196). Experiments were conducted with 10 minute co-
incubation periods to try and capture the transfer spike identified in fluorescence 
experiments. Expression of E-selectin (SELE) mRNA, previously shown 
increased in platelets post endothelial cell incubation (Table 3.4) was significantly 
decreased in platelets after incubation with brefeldin A/thrombin treated 
endothelial cells as controlled to methanol/thrombin treated HUVECs (Figure 
3.15).   
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Figure 3.15: The effects of endothelial cell microparticle production on differential 
gene expression in platelets post incubation. Analysis of the ability of endothelial-
derived microparticles to impact E-selectin expression in platelets post incubation. RT-
qPCR results for e-selectin (SELE) expression in platelets after incubation with 
unstimulated or stimulated endothelial cells (ECs) pretreated with brefeldin A or control 
methanol. RT-qPCR results (expressed as 2−∆∆Ct) were normalized to β-actin and 
controlled against individual platelet background expression, with error bars representing 
n=3, mean (SD). P-values calculated using one-way ANOVA with Tukey’s multiple 
comparison test post analysis (*P<0.05, ***P<0.001, ****P<0.0001).  
 
 
Interestingly, HUVEC brefeldin treatment did not reduce expression levels 
completely to basal level, but instead to an intermediate expression level. 
Additional analysis of another mRNA, COL18A1 (collagen type XVIII, Alpha 1), 
identified in Table 3.4 did not show a significant expression difference when 
comparing incubation with brefeldin-treated HUVECs and methanol-treated 
HUVECs (data not shown). Similar experiments with alternative microparticle 
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inhibitors (Y-27632, a ROCK inhibitor, and zVAD-FMK, a pan caspase inhibitor) 
did not show significant effects on platelet SELE expression post incubation (data 
not shown). Taken together, these data suggest a role for exosome vesicular 
secretion in platelet RNA uptake, as well as an aspect of transcript specificity to 
what is taken up. 
The second set of adapted experiments addressed the ability of 
microparticles alone to cause expression changes in platelets, as well as the 
potential issue of cell contamination in co-incubation studies. Instead of direct 
incubation with cells, platelets were co-incubated with conditioned media from 
endothelial cells treated under the same conditions as the co-incubation 
experiments. Samples were isolated from both co-incubation wells as well as 
conditioned media only wells and SELE expression was again analyzed. qPCR 
results confirmed that, though there is a percentage of expression change in the 
platelet fraction that may be due to endothelial microparticles, the expression 
change with platelets present was significantly higher (Figure 3.16). Taken 
together, these results suggest that platelet uptake from vascular cells can occur 
through microparticle transfer and that this may be a multifaceted process, 
dependent on exosome secretion and transcript specificity.  
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Figure 3.16: The effects of endothelial cell microparticle exposure on differential 
gene expression in platelets post incubation. Analysis of the ability of endothelial-
derived microparticles to impact E-selectin expression in platelets post incubation. RT-
qPCR results for SELE expression in platelet isolated fractions from either conditioned 
media alone wells (columns 3 and 4) or co-incubation wells (columns 5 and 6). RT-
qPCR results were normalized to GAPDH and controlled against individual platelet 
background expression (column 1) (expressed as 2−∆∆Ct). Error bars represent n=4 
experimental replicates using the same individual’s platelets, mean ± SD. An additional 3 
biological replicates support this finding. P-values calculated using one-way ANOVA with 
Tukey’s multiple comparison test post analysis (*P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001), overall P=0.0001.  
 
 
 
Platelet transcript uptake results in changes to the apoptotic signature of 
platelets  
Analysis of the smaller platelet RNA profile revealed a number of functional 
connections to apoptosis and cell death regulation (Appendix Eb). Based on 
these findings, we hypothesized that one functional role for platelet RNA uptake 
may be to clean up debris being released into circulation by dying or dead 
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vascular cells. To address this hypothesis, we reanalyzed samples from the 
direct in vitro simulated clot experiments, the Pam3CSK4 in vivo experiments, as 
well as the conditioned media simulated clot experiments for changes in known 
apoptotic mRNAs. Interestingly, for the conditioned media and Pam3CSK4 
experiments, though there seemed to be some changes in apoptotic mRNA 
expression, none of the results were significant (data not shown); however, for 
the traditional in vitro direct incubation experiments, two targets, BCL2-Like 11 
(BCL2L11 or BIM) and BCL2 Associated X Protein (BAX), both pro-apoptotic 
mRNAs, showed significant expression increases in platelets after incubation 
with endothelial cells (Figure 3.17).  
 
Figure 3.17: The effect of platelet co-incubation with endothelial cells on the 
platelet apoptotic profile. RT-qPCR results (expressed as 2−∆∆Ct) for BIM and BAX 
expression in platelets after incubation with unstimulated or stimulated endothelial cells.  
RT-qPCR results were normalized to GAPDH and controlled against average individual 
platelet background expression (column 1). Error bars represent n=4 experimental 
replicates using the same individual’s platelets, mean ± SD. An additional 5 biological 
replicates support this finding. P-values calculated using two-way ANOVA with Tukey’s 
multiple comparison test post analysis (*P<0.05, **P<0.01,  ***P<0.001, ****P<0.0001).  
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Both BIM and BAX have previously been linked to platelet clearance and 
vascular cell apoptosis, though the extent of the role they play is not fully 
understood (197-201). The increase in these transcripts in platelets post 
incubation, as well as the findings suggesting increased fragmentation in small 
platelet RNA, reveals a potential role for platelets as “housekeepers” in the blood, 
though further analysis needs to be performed to understand the total impact of 
these target expression changes to the platelets themselves as well as to the 
vasculature overall.  
 
Discussion 
The presence of large and small platelet subpopulations and the potential 
correlation to platelet age and RNA content has been established (186, 187). As 
an explanation for the importance of platelet RNA, we and others have 
demonstrated platelet RNA transfer to vascular cells (114, 120, 124) and 
assumed that this observation, coupled with RNA degradation, explains the 
decrease of platelet RNA in the older, smaller platelet subpopulation.  Upon 
investigation of which transcripts are actively transferred by platelets, we 
uncovered that, despite their decreased RNA content, the smaller platelet 
population contains a diverse transcript profile. In nucleated cells, this 
observation would not be that surprising due to active transcription; however, as 
platelets are anucleated and cannot alter their own transcriptome, the origin of 
these transcripts before this study was unknown. This data led us to hypothesize 
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that platelets’ RNA transfer capability is actually bidirectional: the deposition of 
RNA to vascular cells, coupled with RNA uptake from vascular cells would 
explain the decreased amount of total RNA with increased variability in smaller 
platelets. Supportive of our hypothesis, there are several studies that 
demonstrated the ability of platelets to sequester tumor-derived RNA biomarkers 
from tumor microvesicles (133, 135); however, none of these studies adequately 
described this phenomenon in platelets. Though our initial platelet subpopulation 
analysis was performed on a small sample size, a potential limitation to our 
study, follow up experiments supported not only the RNA heterogeneity of 
platelet subpopulations but also the ability of platelets to take up RNA from other 
cells in a dynamic manner. This is the first focused evaluation showing the 
uptake of endogenous cellular transcripts in vitro and in vivo from vascular cells 
to platelets. Thus, these findings expand our understanding of platelet RNA 
transfer to a dynamic bidirectional process between platelets and vascular cells. 
Here, we report that platelets can uptake RNA from endothelial and WBCs and 
this ability not only results in distinct platelets subpopulations but also presents a 
novel mechanism by which platelets may regulate vascular homeostasis and 
systemic responses during infection or inflammation.  
Taken in light of platelets’ canonical roles in thrombosis and hemostasis, 
the ability of platelets to take up RNA from other cells may suggest additional 
mechanisms for regulating thrombotic events beyond the release of miRNA (120, 
124). We can hypothesize three potential functional roles for platelet RNA 
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uptake: the manipulation of the platelet protein profile, a bidirectional 
communication system in the vasculature, or a debris cleaning mechanism 
allowing for the fine tuning of vascular cell responses to stimuli.  
As previously described, though capable of protein production, platelet 
translational capacity is modest and signal-dependent (78, 79). We observed 
platelet mRNA expression changes post cellular co-incubation even in the 
absence of stimulation, suggesting that platelet protein regulation may not fully 
explain the functional relevance of platelet RNA. Additionally, we further analyzed 
our findings to determine if the transcripts we identified as being involved in 
platelet RNA uptake had previously been linked to the platelet transcriptome or 
platelet proteome. We compared the 38 transcripts noted to transfer from 
HUVECs in in vitro simulated clot experiments to the PlateletWeb resource (202). 
This revealed that the transcripts of interest were divided: 18 transcripts were 
present in platelets either at the transcriptome level, the proteome level or both 
while 20 associated transcripts had not been detected in the platelet at any 
expression level (data not shown). PlateletWeb analysis of the top 100 large 
versus 100 small platelet transcripts from our sequencing analysis also revealed 
an interesting pattern; while both populations contained about 50 transcripts with 
no protein representation in platelets at all, the larger platelet transcripts’ 
associated proteins were evenly divided in representation among the 
transcriptome and proteome level (14 transcriptome, 18 proteome, 21 both) while 
the smaller platelet transcripts were heavily represented at the proteome level (3 
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transcriptome, 28 proteome, 8 both) (202). This comparison of our transcripts of 
interest to the PlateletWeb resources is complicated - it does not take 
endogenous platelet protein production or protein uptake into account. Moreover, 
the evaluation of the small versus large platelets expression levels may have 
allowed for genes which are usually overshadowed in large heterogeneous 
populations to be identified. However, it is clear that not all transcripts identified 
here as present in platelets either in post transfer experiments or in 
subpopulations correlate to proteome changes. The heterogeneity of platelet 
subpopulation mRNA expression may help explain previous difficulties in 
correlating the platelet transcriptome to the platelet proteome (113).  
Our previous publication showed the functional relevance of platelet 
mRNA transfer to vascular cells and has since been validated by several other 
publications focusing on the miRNA and mRNA transfer of platelet to cells (120, 
123, 124). Further analysis of the functional capabilities of smaller platelet RNA 
revealed a large number of associations with distinct vascular cell applications, 
ranging from T cell and B cell activation, to lymphocyte and erythrocyte 
differentiation to apoptosis and cell death (Appendix Eb). Taken in combination, 
the presence of these widely diverse functional transcripts in platelets, and the 
ability of platelets to transfer RNA to other vascular cells creates the potential for 
a new cell-cell communication pathway to allow for RNA transfer across the 
vasculature. The platelet would present a unique communication vehicle both 
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due to its universal access as well as due to its clear connections to varying 
systemic responses. 
Finally, platelet RNA uptake may represent a debris cleaning mechanism 
by which platelets help attenuate and fine tune vascular cell response to stimuli. 
Previous work has cited the release of caspase-3 protein from HUVECs in 
microparticles as imperative to cell health, with accumulation of the protein 
potentially leading to cell death (203). Platelet mRNA uptake from cells may allow 
cells to respond to stimuli quickly and mitigate adverse off-target effects. Several 
of our results support this potential functional role. Our studies focusing on the 
functions associated with each subpopulations’ RNA content revealed that, while 
larger platelets had a more historically hemostatic profile, smaller platelets lacked 
these hemostatic markers (results which agree with previous work on smaller, 
older platelet functionality (28, 204-206)). Instead, the small platelet RNA profile 
was enriched in mRNAs typically associated with vascular cells. Additional 
experiments focusing on the apoptotic profile of these subpopulations revealed 
the smaller platelet profile is composed of a number of transcripts associated 
with various vascular cell apoptotic pathways. In vitro analysis revealed that two 
transcripts in particular, BIM and BAX, are significantly upregulated in platelets 
after incubation with endothelial cells. Both BIM and BAX are pro-apoptotic 
factors previously associated with platelet clearance and endothelial health (197-
199, 201, 207). Finally, our analyses of the coverage of specific targets during 
sequence mapping as well as the overall fragmentation level of platelet 
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subpopulations’ RNA suggests that the smaller platelet RNA is more fragmented 
than that of the larger platelet population. The presence of this fragmented 
mRNA would, further support a role for the platelet as a debris collector, as it 
would likely be untranslatable and have little impact on protein production (and 
sequentially on other vascular cells post RNA transfer). The impact that these 
transcripts may have on the platelet itself (especially on platelet life span) as well 
as overall vascular health needs to be further analyzed; however, the potential 
for the platelet to be regulating the vasculature through this “cleaning 
mechanism” is quite clear. Further experimentation will focus on the functional 
capacity of donor cells after incubation and interaction with platelets, to 
determine if platelet uptake affects donor cell protein level and function. 
Understanding the purpose of platelet RNA uptake and its connections with 
platelet RNA transfer may elucidate new ways platelets help regulate systemic 
responses to stimuli. Additionally, elucidating the full scope of platelet 
transcriptome variability may also have interesting implications for biomarker and 
therapeutic development.  
 
Strength and Limitations 
Uncovering the ability of platelet to uptake RNA from other vascular cells opens a 
unique and exciting avenue of how vascular homeostasis may be regulated 
though a transcription-independent and intercellular communication-dependent 
mechanism. In evaluating this phenomenon, a number of factors were identified 
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as being beyond the scope of this study. Platelet sorting, though achievable, is a 
difficult and laborious process; the time requirements of sorting and the fragility of 
platelets ex vivo limits the overall duration of experimentation, while the minimal 
RNA content of platelets results in very little viable material for analysis. 
Additionally, our understanding of how brefeldin A impacts the mechanism of 
platelet RNA uptake is difficult to discern. The impact of brefeldin A on exosome 
production has previously been evaluated (196); however, exact quantification of 
the impact on exosome number is generally difficult due to size limitations. 
Specifically, exosome contribution in co-incubation studies is confounded by the 
expression of numerous exosome markers on platelets endogenously (data not 
shown, PlateletWeb). Further study of these issues will require advanced 
technology to yield more RNA and allow for more in-depth analysis of 
fragmentation and gene expression, as well as better analytical methods for 
small particles.  
 
Conclusions    
In summary, this study is the first conclusive demonstration of the platelets’ ability 
to take up mRNA from vascular cells and enhances our fundamental 
understanding of how platelets interact with the vasculature. Our data provides 
surprising findings that older, smaller platelets contain a unique transcriptome 
reflective of vascular cells and demonstrates the platelet’s capacity for 
bidirectional horizontal RNA transfer. These findings further clarify previous 
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observations that platelet subpopulations are distinct, especially in relation to 
reactivity and disease (205, 208-211), as well as expand the role of platelets in 
vascular communication and regulation.  
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CHAPTER 4: DISCUSSION AND FUTURE STEPS 
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While the historic importance of platelets to cardiovascular health and 
disease has been long understood, their relevance to multiple non-vascular fields 
of human biology was overlooked until recently. Since their discovery in the 
1800s, scientific interest in platelets never waned but the research focus was in 
understanding fundamental hemostasis or the detrimental effect they play in 
acute cardiovascular disease (CVD). While numerous therapies now exist in 
regulating the platelet’s role in the various forms of CVD, it has only been during 
the past 50 years that we truly began to delve into the circulatory mechanistic 
underpinnings. As our understanding of what platelets are and what they can do 
expanded, the scientific questions surrounding them grew accordingly. A better 
understanding of how platelets interact, not only in CVD but in immune and non-
vascular disease settings may help elucidate how the platelet plays such diverse 
systemic roles. 
It is easy to understand how the platelet’s non-hemostatic functions were 
overlooked. With most cell types, any deviation from their known role or function 
are most likely attributed to cell self-regulation, through controlled transcription 
and directed differential gene expression. Whole fields of study now focus on 
what happens when certain genes are turned on or off in specific cell types and 
how this impacts not only cell function and development, but disease 
phenotypes. Without a nucleus, and thus incapable of transcription, it would be 
easier to assume the platelet’s function was straightforward; respond to specific 
vascular injury, with a pre-determined order of reactions to produce clot formation 
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and prevention of blood loss. One can easily comprehend how this process may 
be dysregulated and therefore result in thrombosis formation. To look beyond this 
simple assumption has required huge leaps in scientific research; just as the 
original identification of the platelet was hindered by microscopic techniques, so 
too was our understanding of the platelet limited by molecular biological 
methods. As more and more sensitive and reliable ways to interrogate cellular 
content (specifically transcriptome expression) and cellular function have been 
developed, our ability to look at the platelet in a different capacity has arisen. 
When we think beyond the original platelet paradigm as static bits of cytoplasm 
and instead view them in light of their roles in dynamic cellular processes, it 
becomes evident that, despite their lack of nucleus, platelets conserve the ability 
to respond to their environments in alternative ways; post transcriptional 
modifications, translation and post translational regulation all imbue the platelet 
with the ability to alter their own transcriptome and perhaps their function. 
As described, once the connections between platelets and non-vascular 
systemic responses were made, it became clear that an interrogation of the 
specific contents within these fragments was needed. Discovery of platelet RNA 
(along with the platelet’s translational capacity) and correlation of specific platelet 
transcriptomes to relevant disease settings suggested that RNA may play a role 
in how platelets can operate in such diverse capacities. Additional studies on the 
importance of RNA in cell-cell communication and the impact this transfer has on 
cellular function hinted that platelet RNA may serve the same purpose. The 
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discovery of platelet RNA transfer confirmed this hypothesis. Initial investigation 
in our lab revealed a number of distinct expression changes in HUVEC cells post 
incubation with platelets (Appendix B, Table B.1). The easiest results to interpret 
were those transcripts which corresponded to distinct platelet markers (such as 
CD40 ligand, P-selectin and GP1BB) which showed a notable increase in 
expression in HUVECs post incubation with minimal or no basal expression in 
untreated HUVECs (Appendix B).  Other differential expression changes were 
more difficult to understand. With transcripts that are endogenously highly 
expressed in HUVECs, it would be difficult to see any changes in expression due 
to platelet transfer, as the overall impact of transferred material on the total 
expression level would be minimal (based on the distinctly different amounts of 
total RNA in HUVECs and platelets). Even if the fold change of expression was 
significant compared to background HUVEC profiling, HUVEC are capable of full 
transcriptional regulation and thus these changes could not be attributed to RNA 
transfer. We observed differential expression within HUVECs stimulated alone, 
with plasma treatment alone as well as with platelet rich plasma treatment alone, 
and these changes seemed to be transcript specific. Even in the simulated clot 
wells (platelet rich plasma with thrombin stimulation), it is difficult to rule out that 
changes in gene expression are not just caused by platelet-endothelial cell 
signaling and corresponding transcription upregulation within the cells (though it 
is of note that there are still distinct changes in HUVEC cells post incubation 
even with transcription inhibition, again in a transcript specific manner; Appendix 
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B, Table B.1). The examination of how platelets and HUVECs interact externally 
is especially important when considering that platelets are specifically designed 
to interact with vascular cells (through various GPs expression) to induce 
signaling cascades during normal hemostatic regulation. Despite these issues, 
understanding which transcripts are affected by endothelial-platelet interaction 
and potentially identifying those that change due to transfer as opposed to 
signaling will be central in truly comprehending how platelet and endothelial cells 
interact on the cellular level. 
More interestingly, these initial experiments showed that platelet fractions 
themselves exhibit distinct expression changes. As expected, a number of 
transcripts decreased, coinciding with platelet activation and secretion; however, 
expression of several transcripts increased significantly (Table 3.4). Notably, 
several of these transcripts were not present in the basal platelet transcriptome. 
With no ability to perform transcription and an unlikelihood that increases seen 
were all due to mRNA processing (based on overall total RNA content, extensive 
fold changes observed and number of genes affected), the source of these new 
transcripts was unknown. When concurrent data from platelet subpopulation 
studies suggested that small platelets also contained transcripts of unknown and 
distinctly non-platelet origin (Figure 3.2, Table 3.1, Appendices C and E), we 
hypothesized that the origin of these transcripts was platelet RNA uptake from 
other vascular cells. Previously published studies had suggested that this 
phenomenon could occur in oncological settings (with tumor specific RNA 
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associating with the platelet fraction (133-136)) and further analysis here 
revealed that platelets were indeed capable of taking up endogenous RNA from 
the vascular system.  
 
The purpose of platelet RNA uptake 
The ability of platelets to take up RNA presents more questions when 
considering how the platelet functions systemically. The circulatory system allows 
wide platelet distribution and suggests that the platelet may act as a transport 
vessel throughout the body, picking up and transferring RNAs between cells,. 
Many recent studies have focused on microvesicles in the circulation and how 
extracellular RNA not only impacts disease development but may function 
similarly as communicators across large distances (212-215). Our labs, as well 
as others, have identified unique extracellular RNA expression profiles that 
coincide with various disease, phenotype and infectious states (212, 216-218). 
One question of interest would be; if transfer can occur across distances via 
microparticles, is there a partially redundant mechanism with platelets? Or, 
alternatively, are these two systems not redundant but part of one system? As 
suggested in our studies, it appears possible that microvesicle development and 
transfer affects platelet RNA uptake (inhibition of exosome release from HUVECs 
through brefeldin A treatment results in decreased uptake of SELE transcript in 
endothelial-exposed platelets, Figure 3.15, while incubation of HUVEC-derived 
microparticles with platelets mimicked co-incubation studies, Figure 3.16). 
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However, this observation is not true for all transcripts seen increased in platelets 
post co-incubation and other microvesicle inhibitors have inconsistent effects on 
platelet RNA uptake. As we discover connections between various diseases and 
extracellular RNA and already know platelets play a role in similar responses, it is 
conceivable that platelets alter disease development and response through 
interaction with extracellular RNA. One such example is in response to infection. 
Our lab has recently shown the presence of viral miRNAs in circulation (Appendix 
F) and it is well established that platelets themselves play a role in early 
detection and response to viral and bacterial infections. Could the mechanism by 
which platelets help regulate the infectious response involve a form of platelet-
microvesicle cross communication? Alternatively, as our results suggest that 
microvesicle inhibition does not affect uptake of all transcripts equally, there may 
be an alternative microvesicle-independent mechanism which contributes to RNA 
uptake and transfer, as has been seen with other studies (123, 219). 
The above theory of a platelet based communication system is dependent 
on the functional capability of the transferred RNA and corresponding translation 
and protein regulation, by either platelets themselves or by vascular cells; 
however, it is possible that this may not be the case. There may be no relevant 
use for the transcripts moving in and out of platelets. Studies do support that 
transcripts transferred out of platelets to other cells are not only functional but 
can impact cellular expression (114, 120-125). On the other hand, as discussed 
further in the next section, preliminary results of different platelet subpopulations’ 
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profiles suggest that the RNA that seems to be picked up from circulation may be 
fragmented and of minimal quality and, thus, irrelevant for translation. Though 
the connection between these subpopulation profiles and RNA uptake still needs 
to be solidified and these studies are only preliminary, it suggests that platelet 
transfer to cells serves a functional expression-based purpose to recipient cells 
while uptake may not. It is unknown though, as discussed in Chapter 3, if the 
purpose of uptake may be to remove these non-functional RNA from the vascular 
system as a whole, and if the process were inhibited or non-existent, could result 
in detrimental vascular hemostasis. 
 
The role of platelet RNA uptake in platelet subpopulation transcriptome 
heterogeneity 
As described, platelet subpopulations studies revealed distinct RNA 
transcriptomes correlating to platelet size. As previous studies revealed mRNA 
degradation correlated to platelet circulating age (108, 185), this differential 
expression was originally attributed to mere mRNA breakdown; however, our 
studies showed that the smaller platelet population contained a much more 
diverse transcriptome than large platelets, made up of significantly more 
transcripts with more diverse functional associations (Figure 3.2, Table 3.1, 
Appendices C and E). Preliminary results examining the quality of the RNA in 
these subpopulations suggest that while the smaller platelet transcriptome is 
more diverse, its transcripts may be fragmented and thus irrelevant for translation 
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(Table 3.3). These findings present an interesting possibility, that the more 
diverse transcripts within the small platelet population correlating to other 
vascular cells are merely remnant RNA discarded by vascular cells and removed 
from the circulation by platelets. This would allow the platelets to act as a unique 
debris cleaner, clearing the circulation of remnant RNA. Taken with several other 
conjectures about platelet subpopulations, this could further describe an 
interesting aspect to platelet biology. It is known that platelets newly derived in 
circulation tend to be larger in size (28, 186, 187, 205, 220); it is also known that 
these larger platelets are more functionally hemostatic (28, 204-206, 220), and 
based on our preliminary results here, more hemostatic at the RNA level . 
Additionally, these large, more hemostatic platelets have been shown to be 
increased in patients with CAD (221). One could hypothesize that, over time as 
these large platelets interact within the circulation, they exchange RNA – picking 
up debris transcripts and dropping off other transcripts in turn (Figure 4.1a). As 
their time in circulation passes, they become smaller and contain more vascular 
and apoptosis related RNA and less hemostatic transcripts. This would present a 
novel way by which platelets can help circulatory hemostasis and, as they are 
removed from circulation, assist in debris removal. 
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Figure 4.1: Depiction of potential relevance of RNA uptake on platelet 
subpopulation transcriptome and functional heterogeneity.  
 
 
 This hypothesis likely only represents one explanation for platelet 
subpopulation diversity. The idea of platelet size correlating with platelet 
circulatory time has long been very controversial. While most researchers agree 
that the newest platelets to enter circulation are larger in size (28, 186, 187, 205, 
220) (this has been shown in studies of platelet repopulation after systemic 
ablation (187)), many disagree on the origin of small platelets (28). There are 
some studies that support that large platelets become small platelets overtime 
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(28); there are some that suggest that small and large platelets are actually 
separately derived from different size megakaryocytes (with smaller 
megakaryocytes producing smaller platelets) (28); and there are some that 
assume small platelets merely bleb off larger platelets over time (13). 
Clarification of the origin of small platelets will have to occur before we can truly 
understand why their transcriptomes are so diverse. Looking at the results from 
our transcriptome studies in the setting of bacterial infection and Western diet, it 
is again clear that the platelet transcriptome is capable of differential expression, 
with many genes increasing and decreasing in response to inflammatory stimuli. 
However, with the time scale of observation (weeks) it is possible, and probably 
more likely, that these transcripts’ changes are due to new platelet production by 
megakaryocytes and differential sorting during production in response to the 
inflammation as opposed to RNA uptake (Figure 4.1b). Indeed, analyses of 
changing transcripts do not show the unique vascular-related profile seen with 
small platelets (though since these results are total platelet population results, it 
would be possible that the profile is there but is not as detectable due to large 
platelet expression levels).  
 Additionally, it is possible that the small platelets themselves function in 
uptake and are not linked to large platelets at all. It could be that large platelets 
are more hemostatic and act in the traditional role of clotting while small platelets 
perform the diverse non-vascular roles we have observed. This could mean that 
small platelets are made with these more non-vascular profiles (though the lack 
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of these transcripts in megakaryocytes speaks against this) (Figure 4.1c) or it 
could mean that only small platelets perform RNA uptake (Figure 4.1d). It would 
be ideal to sort these populations and then perform in vitro clot experiments to 
see if there is any difference in uptake; however, this experiment would be 
difficult due to time constraints and the likelihood of platelets being activated post 
sorting. 
 
An alternative importance to platelet RNA uptake 
Even if RNA uptake itself has minimal impact on vascular health, it could create a 
unique opportunity for therapeutic and diagnostic development. Just as studies of 
extracellular RNA profiling and disease relevance are quickly expanding, so too 
could platelet RNA profiling be used in aiding biomarker assessment. Correlating 
the presence of specific non-platelet derived RNA in isolated platelet fractions to 
disease states (such as has been shown already in the study of tumor-educated 
platelets (133-136)), could result in significant biomarker development for a 
multitude of diseases. Additionally, since platelets are more readily obtained from 
patients than other cellular samples, they may present a unique method by which 
to monitor previously difficult to diagnose phenotypes with minimally invasive 
methods. 
 
Future Steps 
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It is clear there are many unanswered questions to what platelet RNA changes in 
various phenotypic and disease settings mean and how to address how platelet 
RNA impacts both platelet and vascular function. We have observed distinct 
expression changes with inflammatory stimuli, dependent on time and specific 
stimuli. Additional analysis of the differential changes in platelets in response to 
inflammatory stimuli will require repeated tests as well as expansion of 
comparisons to alternative clinical studies to better visualize results across the 
human populations. Evaluation of alternative stimuli will help determine how the 
platelet transcriptome changes broadly in response to inflammation as well as 
specifically in different phenotypes. Finally, additional timepoint analyses as well 
as accompanying megakaryocyte analyses will help determine if changes seen 
are due to differential platelet production or as the result of RNA transfer. 
Work still needs to be done to fully understand the platelet’s ability to take 
up RNA, specifically which RNAs are taken up in healthy and disease specific 
settings. Previously published RNA-sequencing data of HUVECs (222) (Table 
G.1c) as well as RT-qPCR of the our specific HUVECs used in these 
experiments (Table G.1a,b) show that the most expressed transcripts in platelets 
post HUVEC incubation do not represent the most endogenously expressed 
transcripts in HUVECs; instead they range in general expression levels or 
activated expression levels in HUVECs. This suggests that platelet RNA uptake 
is selective and may be transcript specific, as a bulk transfer would have resulted 
in the highest expressed HUVEC RNA overexpressed in platelets post transfer. 
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Furthermore, the specific mechanism by which platelet RNA uptake occurs 
needs further elucidation; it appears to be complex and may be dependent on the 
close proximity established in vitro and in vivo in the vasculature, involve 
microparticle exchange, and be commensurate on stimulation and time. 
Additionally, although we previously demonstrated that the amount of RNA 
transferred to other cells was enough to lead to translation, future studies will 
demonstrate if the RNA taken up by platelets affects the protein content or 
cellular function of donor cells, as has been shown with both platelet mRNA and 
platelet miRNA transfer (122-125) in other groups, or platelets themselves (both 
in terms of function and clearance). The difficulty in answering these questions 
lays with the concurrent phenomenon of platelet RNA transfer: elucidating the 
effects of platelet RNA uptake will first require uncoupling it from platelet RNA 
transfer to prevent confounding results.  Clarifying the complexity of the 
mechanism of platelet mRNA uptake, and how it is related to the unknown 
mechanism of platelet mRNA transfer, will shed light on the overall role of platelet 
RNA transfer and uptake in vivo.  
 Beyond the mechanistic details of what transcripts platelets take up from 
circulation and how this process occurs, understanding the link between platelet 
RNA uptake and platelet subpopulation heterogeneity is imperative for 
elucidating how platelet subpopulations function within the circulation. As 
described, the small platelet RNA transcriptome is distinctly different than that of 
the large platelet RNA population, and as the diversity correlates to vascular cell 
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and apoptosis related profiles, suggests the uptake of RNA from the vasculature. 
Elucidation of just how these differential expression profiles come to exist will 
expand our understanding of the heterogeneous platelet profile dramatically. If 
large platelets become small platelets over time, as some have hypothesized, the 
presence of these transcripts suggest that all platelets take up RNA over time, 
leading to a gradual shift in transcriptome over the platelet’s circulating life 
(Figure 4.1a). If small platelets themselves are actually produced through 
alternative biogenesis (i.e. from different n megakaryocytes), it is possible that 
only this subset is capable of uptake (Figure 4.1d), or that these platelets are 
differentially made to respond differently in circulation (Figure 4.1c). As our 
studies revealed that many aspects of platelet RNA uptake and transfer seem to 
be transcript specific, it could be that the models of platelet RNA uptake and 
platelet subpopulation heterogeneity are both complex and multifaceted, and 
when combined result in a complicated system comprised of elements from all 
these hypotheses in tandem (Figure 4.1e). Either way, understanding how 
platelets perform RNA uptake and which subsets are capable of transfer (as well 
as further understanding the specific difference between these subsets) can help 
us expand our understanding of platelet biology, as well as impact how we use 
platelets in treatment. For example, if only large platelets perform hemostatically, 
while small platelets perform non-traditional functions, platelet transfusion 
treatments could be tailored to the needs of the recipient, allowing for more 
optimal impact and decreased side effects. 
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Limitations 
As discussed in the previous chapters, a number of limitations exist in our current 
ability to study the role RNA plays in platelet function and heterogeneity. 
Because platelets are such unique cells, particularly in size, complexity and 
function, there is a lack of advanced technology for their proper investigation. 
Thorough analyses of the effects of stimulation on platelet transcriptomes will 
require study expansion, both in terms of replicate numbers for in vivo modeling 
as well as additional human clinical data for better comparison studies. 
Continued interrogation of the mechanics of platelet RNA uptake will require 
advancements in small particle detection. Platelet subpopulation studies will 
require improvements in RNA analytics, RT-qPCR and sequencing for low input 
and low quality samples as well as protocol optimization for maximum platelet 
output with minimal platelet agitation, allowing for increased RNA output and thus 
more in-depth analysis and repeated measures. Development of single cell 
techniques for platelet size particles could thoroughly increase our insight into all 
these scientific questions.  
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Concluding Remarks 
Based on their historical role in hemostasis alone, platelets are one of the most 
integral cell types in the body. Their dysregulation leads to some of the most 
common human diseases but, despite this, there is still much we do not know 
about platelet function, both in its traditional and alternative roles. Just as the last 
150 years focused on regulating the platelet’s role in CVD and beginning to 
determine its mechanistic traits, the next 100 years need to be focused on 
understanding how the platelet functions at a molecular level. As advances in our 
ability to interrogate small cell and molecular biology grow, a focus must be 
placed on utilizing and adapting these technologies to platelet biology. 
Understanding the role platelet RNA and platelet RNA uptake play in platelet 
functionality, as well as understanding what platelet RNA can tell us about 
normal homeostasis, will expand our understanding of cardiovascular and other 
diseases. As we begin to understand the relevance of platelet RNA and its 
correlation to platelet subpopulations, we can develop new and potentially more 
effective methods of adapting the power of platelets for therapeutic and 
diagnostic purposes. 
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APPENDIX A: GENE ABBREVIATIONS AND DESCRIPTIONS 
Table A.1: Full list of gene names, abbreviations, descriptions and identifiers. 
Note: Gene identifier only included for species used in these text.  
 
Gene Symbol 
Location 
(Chapter / 
Appendix) 
Description 
Human 
Gene ID 
(Entrez) 
Mouse 
Gene ID 
(Entrez) 
Other  
Gene ID 
(Accession) 
0610010O12Rik 2 
RIKEN cDNA 
0610010O12 gene   66060   
1100001G20Rik 2 
RIKEN cDNA 
1100001G20 gene   66107   
1110002L01Rik 2 
RIKEN cDNA 
1110002L01 gene   100043040   
1110012L19Rik 2 
RIKEN cDNA 
1110012L19 gene   68618   
1110028F11Rik 2 
RIKEN cDNA 
1110028F11 gene   68690   
1190002N15Rik 2 
RIKEN cDNA 
1190002N15 gene   68861   
1700019G17Rik 2 
RIKEN cDNA 
1700019G17 gene   75541   
1700034H14Rik 2 
RIKEN cDNA 
1700034H14 gene   67105   
1700034I23Rik 2 
RIKEN cDNA 
1700034I23 gene   73297   
1810009J06Rik 2 
RIKEN cDNA 
1810009J06 gene   73626   
2010001M09Rik 2 
RIKEN cDNA 
2010001M09 gene   69816   
2010107H07Rik 2 
RIKEN cDNA 
2010107H07 gene   66487   
2310034G01Rik 2 
RIKEN cDNA 
2310034G01 gene   75579   
2400001E08Rik 2 
RIKEN cDNA 
2400001E08 gene   66508   
2410018L13Rik 2 
RIKEN cDNA 
2410018L13 gene   69732   
2810055G20Rik 2 
Mir99ahg; Mir99a and 
Mirlet7c-1 host gene   77994   
2810405K02Rik 2 
RIKEN cDNA 
2810405K02 gene   66469   
4833413D08Rik 2 
RIKEN cDNA 
4833413D08 gene   71425   
4921509C19Rik 2 
RIKEN cDNA 
4921509C19 gene   381393   
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4921524J17Rik 2 
RIKEN cDNA 
4921524J17 gene   66714   
4930433N12Rik 2 
RIKEN cDNA 
4930433N12 gene   114673   
4930520O04Rik 2 
RIKEN cDNA 
4930520O04 gene   75116   
4930524N10Rik 2 
RIKEN cDNA 
4930524N10 gene   75071   
4930562F07Rik 2 
RIKEN cDNA 
4930562F07 gene   75255   
4933426I21Rik 2 
RIKEN cDNA 
4933426I21 gene   71163   
5430413K10Rik 2 
RIKEN cDNA 
5430413K10 gene   433492   
5830417I10Rik 2 
RIKEN cDNA 
5830417I10 gene   100302730   
5830477G23Rik 2 
RIKEN cDNA 
5830477G23 gene   76116   
6230400D17Rik 2 
RIKEN cDNA 
6230400D17 gene   76133   
6530418L21Rik 2 
RIKEN cDNA 
6530418L21 gene   109050   
6720489N17Rik 2 
RIKEN cDNA 
6720489N17 gene   211378   
9030624G23Rik 2 
RIKEN cDNA 
9030624G23 gene   66808   
9330158H04Rik 2 
RIKEN cDNA 
9330158H04 gene   319472   
A530064D06Rik 2 
RIKEN cDNA 
A530064D06 gene   328830   
A630055G03Rik 2 
RIKEN cDNA 
A630055G03 gene   223970   
A630098A13Rik 2 
RIKEN cDNA 
A630098A13 gene   320913   
AA792892 2 
expressed sequence 
AA792892   100554   
Aadac 2 
arylacetamide 
deacetylase (esterase)   67758   
Acot9 2 
acyl-CoA thioesterase 
9   56360   
Acp5 2 
acid phosphatase 5, 
tartrate resistant   11433   
Acsf2 2 
acyl-CoA synthetase 
family member 2   264895   
ACTB 3, B, D actin beta 60 11461   
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Aga 2 
aspartylglucosaminida
se   11593   
Agk 2 acylglycerol kinase   69923   
AGO2 (EIF2C2) 3, B 
argonaute 2, RISC 
catalytic component 27161     
Ahcy 2 
S-
adenosylhomocysteine 
hydrolase   269378   
Ahsg 2 
alpha-2-HS-
glycoprotein   11625   
AI324046 2 
expressed sequence 
AI324046   380795   
AI747699 2 
expressed sequence 
AI747699   381236   
Aif1 2 
allograft inflammatory 
factor 1   11629   
Akr1b10 2 
aldo-keto reductase 
family 1, member B10 
(aldose reductase)   67861   
Alb 2 albumin 213 11657   
Ambp 2 
alpha 1 
microglobulin/bikunin 259 11699   
Angptl3 2 angiopoietin-like 3   30924   
Aph1a 2 
anterior pharynx 
defective 1a homolog 
(C. elegans)   226548   
Apoa1 2 apolipoprotein A-I   11806   
Apoa2 2 apolipoprotein A-II   11807   
Apoa5 2 apolipoprotein A-V   66113   
Apob 2 apolipoprotein B   238055   
Apoc1 2 apolipoprotein C-I   11812   
Apoc2 2 apolipoprotein C-II   11813   
Apoc3 2 apolipoprotein C-III   11814   
Apoc4 2 apolipoprotein C-IV   11425   
Apoe 2 apolipoprotein E   11816   
Apof 2 apolipoprotein F   103161   
Apoh 2 apolipoprotein H   11818   
Apol10a 2 apolipoprotein L 10a   245282   
Apol9b 2 apolipoprotein L 9b   71898   
ARHGAP18 F 
rho GTPase activating 
protein 18 93663     
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Arhgef1 2 
Rho guanine 
nucleotide exchange 
factor (GEF) 1   16801   
Armc10 2 
armadillo repeat 
containing 10   67211   
ASGR1 3, B, F 
asialoglycoprotein 
receptor 1 432     
Ass1 2 
argininosuccinate 
synthetase 1   11898   
AU019823 2 
expressed sequence 
AU019823   270156   
Azgp1 2 
alpha-2-glycoprotein 1, 
zinc   12007   
B2M 3, B, D beta-2-microglobulin 567     
B3gnt8 2 
UDP-GlcNAc:betaGal 
beta-1,3-N-
acetylglucosaminyltran
sferase 8   232984   
Bank1 2 
B-cell scaffold protein 
with ankyrin repeats 1   242248   
BAX 3 
BCL2 associated X, 
apoptosis regulator 581     
BC002059 2 
cDNA sequence 
BC002059   213811   
BC003331 2 
cDNA sequence 
BC003331   226499   
BC061237 2 
cDNA sequence 
BC061237   385138   
BC094916 2 
cDNA sequence 
BC094916   545384   
Bckdk 2 
branched chain 
ketoacid 
dehydrogenase kinase   12041   
BCL2L1 3, B, D BCL2 like 1 598     
BCL2L11 (BIM) 3 BCL2 like 11 10018     
Bgn 2 biglycan   12111   
Bhmt 2 
betaine-homocysteine 
methyltransferase   12116   
Bin3 2 bridging integrator 3   57784   
blv-miR-B2-5p F 
Bovine leukemia virus 
(BLV) microRNA B2     MIMAT0025860 
C130026I21Rik 2 
RIKEN cDNA 
C130026I21 gene   620078   
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C1qb 2 
complement 
component 1, q 
subcomponent, beta 
polypeptide   12260   
C3 2 
complement 
component 3   12266   
C330018D20Rik 2 
RIKEN cDNA 
C330018D20 gene   77422   
C87977 2 
expressed sequence 
C87977   97187   
C8b 2 
complement 
component 8, beta 
polypeptide   110382   
CALR 3, B, F calreticulin 811     
Car1 2 carbonic anhydrase 1   12346   
Car3 2 carbonic anhydrase 3   12350   
Catsperg1 2 
cation channel, sperm-
associated, gamma 1   320225   
Cbx6 2 chromobox homolog 6   494448   
CCL17 3, B 
C-C motif chemokine 
ligand 17 6361     
Ccl3 / CCL3 2, 3, B 
chemokine (C-C motif) 
ligand 3 6348 20302   
Ccl6 2 
chemokine (C-C motif) 
ligand 6   20305   
CCL7 3, B, F 
C-C motif chemokine 
ligand 7 6354     
Ccr2 2 
chemokine (C-C motif) 
receptor 2   12772   
CD163 3, B CD163 molecule 9332     
CD209 3, B CD209 molecule 30835     
Cd209f 2 CD209f antigen   69142   
Cd2ap 2 
CD2-associated 
protein   12488   
Cd3d/ CD3D 2, 3, B 
CD3 antigen, delta 
polypeptide 915 12500   
Cd3g 2 
CD3 antigen, gamma 
polypeptide   12502   
CD40 3, B, D CD40 molecule 958     
CD40LG 3, B CD40 ligand 959     
CD44 3, B 
CD44 molecule (Indian 
blood group) 960     
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Cd53 / CD53 2, 3, B CD53 antigen 963 12508   
Cd5l 2 CD5 antigen-like   11801   
CD63 3, B, F CD63 molecule 967     
CD69 1 CD69 molecule 969     
Cd79a 2 
CD79A antigen 
(immunoglobulin-
associated alpha)   12518   
Cd79b 2 CD79B antigen   15985   
CD81 3, B, F CD81 molecule 975     
CD86 3, B CD86 molecule 942     
Cda 2 cytidine deaminase   72269   
Cdkn1a 2 
cyclin-dependent 
kinase inhibitor 1A 
(P21)   12575   
Cdo1 2 
cysteine dioxygenase 
1, cytosolic   12583   
CEACAM3 3 
carcinoembryonic 
antigen related cell 
adhesion molecule 3 1084     
Cenpq 2 centromere protein Q   83815   
Ces3 2 
carboxylesterase 1D; 
carboxylesterase 3   104158   
Cetn4 2 centrin 4   207175   
Cfd 2 
complement factor D 
(adipsin)   11537   
Chchd1 2 
coiled-coil-helix-coiled-
coil-helix domain 
containing 1   66121   
CHD9 F 
chromo-domain 
helicase DNA binding 
protein 9 80205     
Cidec 2 
cell death-inducing 
DFFA-like effector c   14311   
Cldn22 2 claudin 22   75677   
Clec4a3 2 
C-type lectin domain 
family 4, member a3   73149   
Clm3 2 
CMRF-35-like 
molecule 3; cytohesin 
3   382551   
Cnn1 2 calponin 1   12797   
Cnn3 2 calponin 3, acidic   71994   
COL18A1 3, B, F 
collagen type XVIII 
alpha 1 chain 80781     
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COPA 3, B 
coatomer protein 
complex subunit alpha 1314     
Cops6 2 
COP9 (constitutive 
photomorphogenic) 
homolog, subunit 6 
(Arabidopsis thaliana)   26893   
Cp 2 Ceruloplasmin   12870   
Cpamd8 2 
C3 and PZP-like 
alpha-2-macroglobulin 
domain-containing 
protein 8; Mug2, 
murinoglobulin 2   17837   
CRLS1 3, B cardiolipin synthase 1 54675     
CRP 3, B, F C-reactive protein 1401     
Csnk2a1 2 
casein kinase 2, alpha 
1 polypeptide   12995   
CX3CL1 3, B, F 
C-X3-C motif 
chemokine ligand 1 6376     
CXADR 3, B, F 
CXADR, Ig-like cell 
adhesion molecule 1525     
CXCL1 3, B, F 
C-X-C motif 
chemokine ligand 1 2919     
CXCL12 3, B, F 
C-X-C motif 
chemokine ligand 12 6387     
Cxcl2 / CXCL2 2, 3, B, F 
chemokine (C-X-C 
motif) ligand 2 2920 20310   
CXCL5 3, B 
C-X-C motif 
chemokine ligand 5 6374     
CXCL6 3, B, F 
C-X-C motif 
chemokine ligand 6 6372     
Cyp1a2 2 
cytochrome P450, 
family 1, subfamily a, 
polypeptide 2   13077   
Cyp2d10 2 
cytochrome P450, 
family 2, subfamily d, 
polypeptide 10   13101   
Cyp2e1 2 
cytochrome P450, 
family 2, subfamily e, 
polypeptide 1   13106   
Cyp2f2 2 
cytochrome P450, 
family 2, subfamily f, 
polypeptide 2   13107   
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Cyp3a11 2 
cytochrome P450, 
family 3, subfamily a, 
polypeptide 11   13112   
Cyp3a44 2 
cytochrome P450, 
family 3, subfamily a, 
polypeptide 44   337924   
Cyp3a59 2 
cytochrome P450, 
subfamily 3A, 
polypeptide 59   100041449   
Cyp4a10 2 
cytochrome P450, 
family 4, subfamily a, 
polypeptide 10   13117   
Cytip 2 
cytohesin 1 interacting 
protein   227929   
D630032N06Rik 2 
RIKEN cDNA 
D630032N06 gene   654810   
Dapl1 2 
death associated 
protein-like 1   76747   
Dcakd 2 
dephospho-CoA 
kinase domain 
containing   68087   
Ddx28 2 
DEAD (Asp-Glu-Ala-
Asp) box polypeptide 
28   71986   
Defb12 2 defensin beta 12   77674   
Degs1 2 
degenerative 
spermatocyte homolog 
1 (Drosophila)   13244   
Diablo 2 
diablo homolog 
(Drosophila)   66593   
DICER1 3, B, F 
dicer 1, ribonuclease 
III 23405     
Dnm3os 2 
dynamin 3, opposite 
strand   474332   
Dock2 2 
dedicator of cyto-
kinesis 2   94176   
Dppa3 2 
developmental 
pluripotency-
associated 3   73708   
Dpy19l3 2 
dpy-19-like 3 (C. 
elegans)   233115   
Dsg1b 2 desmoglein 1 beta   225256   
E030030I06Rik 2 
RIKEN cDNA 
E030030I06 gene   319887   
E330020D12Rik 2 
RIKEN cDNA 
E330020D12 gene   626058   
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Ear2 2 
eosinophil-associated, 
ribonuclease A family, 
member 2   13587   
ebv-miR-BART11-
5p F 
Epstein-Barr Virus 
(EBV) microRNA 
BART11     MIMAT0003421 
ebv-miR-BART19-
3p F 
Epstein-Barr Virus 
(EBV) microRNA 
BART11     MIMAT0003718 
Eif2s1 2 
eukaryotic translation 
initiation factor 2, 
subunit 1 alpha   13665   
Eif4a3 2 
eukaryotic translation 
initiation factor 4A3   192170   
EIF4G1 3, B, F 
eukaryotic translation 
initiation factor 4 
gamma 1 1981     
Eif4h 2 
eukaryotic translation 
initiation factor 4H   22384   
Elovl2 2 
elongation of very long 
chain fatty acids 
(FEN1/Elo2, 
SUR4/Elo3, yeast)-like 
2   54326   
Emr1 2 
EGF-like module-
containing mucin-like 
hormone receptor-like 
1; 
  13733   
Adgre1; adhesion G 
protein-coupled 
receptor E1 
eNOS 1 nitric oxide synthase 3 4846     
EPRS F 
glutamyl-prolyl-tRNA 
synthetase 2058     
Es1 2 
Ces1c, 
carboxylesterase 1c; 
esterase 1   13884   
Es31 2 
Ces3a, 
carboxylesterase 3A; 
esterase 31   382053   
ESAM 3, B 
endothelial cell 
adhesion molecule 90952     
Exosc7 2 exosome component 7   66446   
F2 2 coagulation factor II   14061   
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Fabp1 2 
fatty acid binding 
protein 1, liver 2168 14080   
Fabp5 2 
fatty acid binding 
protein 5, epidermal 2171 16592   
Fads1 2 fatty acid desaturase 1   76267   
Fam111a 2 
family with sequence 
similarity 111, member 
A   107373   
Fam136a 2 
family with sequence 
similarity 136, member 
A   66488   
Fcer2a 2 
Fc receptor, IgE, low 
affinity II, alpha 
polypeptide   14128   
Fcf1 2 
FCF1 small subunit 
(SSU) processome 
component homolog 
(S. cerevisiae)   73736   
Fcgr3 2 
Fc receptor, IgG, low 
affinity III   14131   
FCN1 3, B ficolin 1 2219     
Fdps 2 
farnesyl diphosphate 
synthetase   110196   
Fetub 2 fetuin beta   59083   
Fga 2 fibrinogen alpha chain   14161   
Fgb 2 fibrinogen beta chain   110135   
Fgg 2 
fibrinogen gamma 
chain 2266 99571   
Fgl1 2 
fibrinogen-like protein 
1   234199   
Fkbp4 2 
FK506 binding protein 
4   14228   
FOLR1 3, B folate receptor 1 2348     
Fxyd3 2 
FXYD domain-
containing ion 
transport regulator 3   17178   
G3bp1 2 
Ras-GTPase-
activating protein SH3-
domain binding protein 
1   27041   
GAPDH 3, B, D 
glyceraldehyde-3-
phosphate 
dehydrogenase 2597     
Gc 2 
group specific 
component   14473   
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Gda 2 guanine deaminase   14544   
Gemin8 2 
gem (nuclear 
organelle) associated 
protein 8   237221   
Gimap9 2 
GTPase, IMAP family 
member 9   317758   
Gkap1 2 
G kinase anchoring 
protein 1   56278   
Glo1 2 glyoxalase 1   109801   
Gm10029 2 
predicted pseudogene 
10029   100039532   
Gm10035 2 predicted gene 10035   668178   
Gm10336 2 predicted gene 10336   328186   
Gm10455 2 predicted gene 10455   385277   
Gm10643 2 predicted gene 10643   100038416   
Gm10651 2 
predicted pseudogene 
10651   100043771   
Gm10767 2 predicted gene 10767   100038538   
Gm10878 2 predicted gene 10878   628268   
Gm10880 2 predicted gene 10880   236047   
Gm10883 2 
Igkv8-30; 
immunoglobulin kappa 
chain variable 8-30   384419   
Gm10884 2 predicted gene 10884   434040   
Gm10885 2 
Ighv8-12; 
immunoglobulin heavy 
variable V8-12   780960   
Gm11428 2 predicted gene 11428   100034251   
Gm11710 2 predicted gene 11710   100043123   
Gm11937 2 predicted gene 11937   100041488   
Gm129 2 predicted gene 129   229599   
Gm13034 2 predicted gene 13034   627585   
Gm13139 2 predicted gene 13139   666532   
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Gm13212 2 predicted gene 13212   433801   
Gm13213 2 predicted gene 13213   545683   
Gm13931 2 predicted gene 13931   668825   
Gm1418 2 predicted gene 1418   384514   
Gm14420 2 predicted gene 14420   628308   
Gm14851 2 predicted gene 14851   634825   
Gm15210 2 predicted gene 15210   100042069   
Gm1524 2 predicted gene 1524   385253   
Gm15417 2 predicted gene 15417   545539   
Gm16519 2 predicted gene, 16519   546695   
Gm16527 2 predicted gene, 16527   669780   
Gm189 2 predicted gene 189   235952   
Gm2666 2 predicted gene 2666   100040213   
Gm3643 2 predicted gene 3643   100042057   
Gm4459 2 predicted gene 4459   100043472   
Gm4478 2 predicted gene 4478   100043498   
Gm4738 2 predicted gene 4738   13909   
Gm4759 2 
GTPase, very large 
interferon inducible 1 
pseudogene   209380   
Gm4889 2 predicted gene 4889   234159   
Gm4943 2 
predicted pseudogene 
4943   239760   
Gm4964 2 predicted gene 4964   243420   
Gm5081 2 predicted gene 5081   328099   
Gm5154 2 predicted gene 5154   381818   
Gm5168 2 predicted gene 5168   382275   
Gm5292 2 predicted gene 5292   384179   
Gm5321 2 predicted gene 5321   384525   
Gm5331 2 predicted gene 5331   384622   
Gm5413 2 predicted gene 5413   404743   
Gm5416 2 predicted gene 5416   408196   
Gm5431 2 predicted gene 5431   432555   
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Gm5476 2 
type II keratin Kb17P 
pseudogene   432985   
Gm5514 2 predicted gene 5514   433229   
Gm5571 2 predicted gene 5571   434025   
Gm5629 2 predicted gene 5629   434609   
Gm5637 2 
predicted pseudogene 
5637   434782   
Gm5941 2 predicted gene 5941   546347   
Gm5959 2 predicted gene 5959   546638   
Gm5965 2 predicted gene 5965   546672   
Gm6252 2 predicted gene 6252   621699   
Gm6570 2 predicted gene 6570   625281   
Gm6712 2 predicted gene 6712   626854   
Gm6749 2 
predicted pseudogene 
6749   627371   
Gm6894 2 predicted gene 6894   628541   
Gm6969 2 
predicted pseudogene 
6969   629383   
Gm6981 2 
glyceraldehyde-3-
phosphate 
dehydrogenase 
pseudogene   629557   
Gm7015 2 predicted gene 7015   629906   
Gm7188 2 predicted gene 7188   636752   
Gm7225 2 predicted gene 7225   637939   
Gm7582 2 predicted gene 7582   665317   
Gm8096 2 
3-phosphoglycerate 
dehydrogenase 
pseudogene   666422   
Gm8290 2 predicted gene 8290   666790   
Gm8698 2 predicted gene 8698   667550   
Gm8909 2 predicted gene 8909   667977   
Gm8973 2 predicted gene 8973   668092   
Gm8995 2 predicted gene 8995   668139   
Gm9232 2 predicted gene 9232   668544   
Gm9740 2 predicted gene 9740   780938   
Gm9756 2 
carboxylesterase 2 
pseudogene   667754   
Gm9781 2 predicted gene 9781   100042807   
Gm9803 2 predicted gene 9803   100042179   
Gmeb1 2 
glucocorticoid 
modulatory element 
binding protein 1   56809   
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Gngt2 2 
guanine nucleotide 
binding protein (G 
protein), gamma 
transducing activity 
polypeptide 2   14710   
Gnpda1 2 
glucosamine-6-
phosphate deaminase 
1   26384   
Gnpnat1 2 
glucosamine-
phosphate N-
acetyltransferase 1   54342   
Gnrh1 2 
gonadotropin releasing 
hormone 1   14714   
GP1BB 3, B 
glycoprotein Ib platelet 
beta subunit 2812     
Gpbp1l1 2 
GC-rich promoter 
binding protein 1-like 1   77110   
GPI 3, B 
glucose-6-phosphate 
isomerase 2821     
Gpn2 2 GPN-loop GTPase 2   100210   
Gpnmb 2 
glycoprotein 
(transmembrane) nmb   93695   
Gpr137b-ps 2 
G protein-coupled 
receptor 137B, 
pseudogene   664862   
Gprasp1 2 
G protein-coupled 
receptor associated 
sorting protein 1   67298   
Gpx2 2 
glutathione peroxidase 
2   14776   
Gpx4 2 
glutathione peroxidase 
4   625249   
Grap 2 
GRB2-related adaptor 
protein   71520   
Gsdmc3 2 gasdermin C3   270328   
Gsta3 2 
glutathione S-
transferase, alpha 3   14859   
GSTK1 3 
glutathione S-
transferase kappa 1 373156     
Gstm1 2 
glutathione S-
transferase, mu 1   14862   
Gstm2 2 
glutathione S-
transferase, mu 2   14863   
Gtpbp8 2 
GTP-binding protein 8 
(putative)   66067   
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GUK1 3, D guanylate kinase 1 2987     
H2-DMb1 2 
histocompatibility 2, 
class II, locus Mb1   14999   
H2-Q8 2 
histocompatibility 2, Q 
region locus 8   15019   
H2-T10 2 
histocompatibility 2, T 
region locus 10   15024   
H2-T22 2 
histocompatibility 2, T 
region locus 22   15039   
H3f3a 2 H3 histone, family 3A   15078   
Hamp 2 
hepcidin antimicrobial 
peptide   84506   
Hbq1 2 hemoglobin, theta 1   216635   
hbv-mir-B26-3p-
novel F 
Herpes B virus (HBV) 
microRNA B26     Novel finding 
hbv-miR-B26-5p F 
Herpes B virus (HBV) 
microRNA B26     MIMAT0031771 
hbv-miR-B7-5p F 
Herpes B virus (HBV) 
microRNA B7     MIMAT0031766 
hcmv-miR-US25-
2-3p F 
Human 
cytomegalovirus 
(hCMV) microRNA 
US25-2     MIMAT0001583 
Hdc 2 
histidine 
decarboxylase   15186   
Hebp1 2 heme binding protein 1   15199   
HIF1A F 
hypoxia inducible 
factor 1 alpha subunit 2091     
Higd1a 2 
HIG1 domain family, 
member 1A   56295   
Hint1 2 
histidine triad 
nucleotide binding 
protein 1   15254   
Hist1h2ab 2 histone cluster 1, H2ab   319172   
Hist1h3a 2 histone cluster 1, H3a   360198   
Hist1h4b 2 histone cluster 1, H4b   326620   
Hist1h4f 2 histone cluster 1, H4f   319157   
Hist2h2ab 2 histone cluster 2, H2ab   621893   
Hmox1 2 
heme oxygenase 
(decycling) 1   15368   
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Hnrpdl 2 
heterogeneous nuclear 
ribonucleoprotein D-
like   50926   
Hp 2 haptoglobin   15439   
Hpx 2 hemopexin   15458   
Hrg 2 
histidine-rich 
glycoprotein   94175   
Hrnr 2 hornerin   68723   
hsa-miR-1199-5p F 
human microRNA 
1199 102466515   MIMAT0031119 
hsa-miR-16-5p F human microRNA 16 
406950 / 
406951   MIMAT0000069 
hsa-miR-221-3p F human microRNA 221 407006   MIMAT0000278 
hsa-miR-2681-3p F 
human microRNA 
2681 100616110   MIMAT0013516 
hsa-miR-324-3p F human microRNA 324 442898   MIMAT0000762 
hsa-miR-3663-5p F 
human microRNA 
3663 100500893   MIMAT0018084 
hsa-miR-4482-5p F 
human microRNA 
4482 100616323   MIMAT0019016 
hsa-miR-584-5p F human microRNA 584 693169   MIMAT0003249 
Hsd17b7 2 
hydroxysteroid (17-
beta) dehydrogenase 7   15490   
Hsp90aa1 2 
heat shock protein 90, 
alpha (cytosolic), class 
A member 1   15519   
Hspd1 2 
heat shock protein 1 
(chaperonin)   15510   
hsv1-miR-H1-3p F 
Herpes Simplex Virus 
1 (HSV-1) microRNA 
H1     MIMAT0015220 
hsv1-miR-H14-5p F 
Herpes Simplex Virus 
1 (HSV-1) microRNA-
H14     MIMAT0014691 
hsv1-miR-H1-5p F 
Herpes Simplex Virus 
1 (HSV-1) microRNA-
H1     MIMAT0003744 
hsv1-miR-H3-3p F 
Herpes Simplex Virus 
1 (HSV-1) microRNA-
H3     MIMAT0008400 
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hsv1-miR-H4-3p F 
Herpes Simplex Virus 
1 (HSV-1) microRNA-
H4     MIMAT0008402 
hsv1-miR-H6-3p F 
Herpes Simplex Virus 
1 (HSV-1) microRNA-
H6     MIMAT0008404 
hvt-miR-H14-3p F 
Herpesvirus of turkeys 
microRNA-H14     MIMAT0012867 
I830127L07Rik 2 
RIKEN cDNA 
I830127L07 gene   546643   
ICAM1 
1, 3, B, D, 
F 
intercellular adhesion 
molecule 1 3383 15894   
Idi2 2 
isopentenyl-
diphosphate delta 
isomerase 2   320581   
Ifi203 2 
interferon activated 
gene 203   15950   
Ifi204 2 
interferon activated 
gene 204   15951   
Ifi205 2 
interferon activated 
gene 205   226695   
Ifi27l2a 2 
interferon, alpha-
inducible protein 27 
like 2A   76933   
Ifi30 2 
interferon gamma 
inducible protein 30   65972   
Ifit3 2 
interferon-induced 
protein with 
tetratricopeptide 
repeats 3   15959   
Ifitm1/ IFITM1 1, 2, 3, B 
interferon induced 
transmembrane 
protein 1 8519 68713   
IFITM2 3, B 
interferon induced 
transmembrane 
protein 2 10581     
IFITM3 3, B, F 
interferon induced 
transmembrane 
protein 3 10410     
Ifitm6 2 
interferon induced 
transmembrane 
protein 6   213002   
IFNA1 3, B, F interferon alpha 1 3439     
IFNB1 3, B interferon beta 1 3456     
Igh-1b 2 
immunoglobulin heavy 
chain 1b (serum 
IgG2c)   404711   
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Igh-2 2 
immunoglobulin heavy 
chain 2 (serum IgA)   238447   
Igh-3 2 
immunoglobulin heavy 
chain 3 (serum IgG2b)   16016   
Igh-5 2 
immunoglobulin heavy 
chain 5 (delta-like 
heavy chain)   380797   
Ighg1 2 
immunoglobulin heavy 
constant gamma 1 
(G1m marker)   16017   
Ighv1-69 2 
immunoglobulin heavy 
variable V1-69   619833   
Ighv7-2 2 
immunoglobulin heavy 
variable V7-2   780800   
Igkv10-96 2 
immunoglobulin kappa 
chain variable   692165   
Igkv1-117 2 
immunoglobulin kappa 
chain variable 1-117   16098   
Igkv12-44 2 
immunoglobulin kappa 
chain variable 12-44   545851   
Igkv12-46 2 
immunoglobulin kappa 
chain variable 12-46   692245   
Igkv14-111 2 
immunoglobulin kappa 
chain variable 14-111   545847   
Igk-V19-20 2 
immunoglobulin kappa 
chain variable 19 
(V19)-20   108024   
Igk-V21-12 2 
immunoglobulin kappa 
chain variable 21 
(V21)-12   667914   
Igk-V21-4 2 
immunoglobulin kappa 
chain variable 21 
(V21)-4   626347   
Igk-V8-16 2 
immunoglobulin kappa 
chain variable 8 (V8)-
16   640340   
Igl-C1 2 
immunoglobulin 
lambda chain, constant 
region 1   110785   
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Igl-C2 2 
immunoglobulin 
lambda chain, constant 
region 2   110786   
Igl-J1 2 
immunoglobulin 
lambda chain, joining 
region 1   404737   
Igl-V1 2 
immunoglobulin 
lambda chain, variable 
1   16142   
Igl-V2 2 
immunoglobulin 
lambda chain, variable 
2   110612   
Ikzf3 2 
IKAROS family zinc 
finger 3   22780   
IL10RA 3, B 
interleukin 10 receptor 
subunit alpha 3587     
IL1b / IL1beta 2, 3, B, D IL1B; interleukin 1 beta 3553 16176   
IL1R1 1 
interleukin 1 receptor, 
type 1 3554     
Il28b 2 interleukin 28B   338374   
IL2RB 3, B 
interleukin 2 receptor 
subunit beta 3560     
IL5 3, B interleukin 5 3567     
IL6 1, 3, B, F interleukin 6 3569     
IL8 3, B, F 
C-X-C motif 
chemokine ligand 8 3576     
iltv-miR-I2 F 
Infectious 
laryngotracheitis virus 
(ILTV) microRNA-I2     MIMAT0012725 
Immp1l 2 
IMP1 inner 
mitochondrial 
membrane peptidase-
like (S. cerevisiae)   66541   
ITGA5 3, B, F 
integrin subunit alpha 
5 3678     
ITGAE 3, B 
integrin subunit alpha 
E 3682     
ITGAL 3, B 
integrin subunit alpha 
L 3683     
ITGAM 3, B 
integrin subunit alpha 
M 3684     
ITGB7 3, B integrin subunit beta 7 3695     
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Itih4 2 
inter alpha-trypsin 
inhibitor, heavy chain 4   16427   
KIAA0232 3, B, F KIAA0232 9778     
KIAA1462 3, B, F 
JCAD; junctional 
cadherin 5 associated 57608     
Klhdc5 2 
kelch domain 
containing 5   232539   
Klk1b9 2 
kallikrein 1-related 
peptidase b9   13648   
Klrc1 2 
killer cell lectin-like 
receptor subfamily C, 
member 1   16641   
Klrc2 2 
killer cell lectin-like 
receptor subfamily C, 
member 2   16642   
Kmo 2 
kynurenine 3-
monooxygenase 
(kynurenine 3-
hydroxylase)   98256   
Kng1 2 kininogen 1   16644   
Kng2 2 kininogen 2   385643   
Krt8 2 keratin 8   16691   
Krt81 2 keratin 81   64818   
kshv-miR-K12-
10a-5p F 
Kaposi's sarcoma 
herpesvirus (KSHV) 
microRNA-K12-10a     MIMAT0015212 
kshv-miR-K12-6-
5p F 
Kaposi's sarcoma 
herpesvirus (KSHV) 
microRNA-K12-6     MIMAT0002188 
L2hgdh 2 
L-2-hydroxyglutarate 
dehydrogenase   217666   
LAMP1 3, B 
lysosomal associated 
membrane protein 1 3916     
Lancl3 2 
LanC lantibiotic 
synthetase component 
C-like 3 (bacterial)   236285   
Lce1c 2 
late cornified envelope 
1C   73719   
Lce1i 2 
late cornified envelope 
1I   76585   
LCK 3, B 
LCK proto-oncogene, 
Src family tyrosine 
kinase 3932     
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Lcp1 2 
lymphocyte cytosolic 
protein 1   18826   
LOC100038947 2 
signal-regulatory 
protein beta 1-like   100038947   
LOC100044509 2 
similar to transforming 
growth factor, beta 
receptor III 
(betaglycan, 300kDa)   100044509   
LOC100048057 2 
hypothetical protein 
LOC100048057   100048057   
Lrg1 2 
leucine-rich alpha-2-
glycoprotein 1   76905   
Lsm2 2 
LSM2 homolog, U6 
small nuclear RNA 
associated (S. 
cerevisiae)   27756   
LRP1B F 
LDL receptor related 
protein 1B 53353     
LSP1 3, B, D 
lymphocyte-specific 
protein 1 4046     
Ly6c1 2 
lymphocyte antigen 6 
complex, locus C1   17067   
Ly86 2 lymphocyte antigen 86   17084   
Lypla2 2 lysophospholipase 2   26394   
Lyrm7 2 LYR motif containing 7   75530   
Mageb16 2 
melanoma antigen 
family B, 16   71967   
Man1b1 2 
mannosidase, alpha, 
class 1B, member 1   227619   
Manea 2 
mannosidase, endo-
alpha   242362   
MAP4K4 3, B, F 
mitogen-activated 
protein kinase kinase 
kinase kinase 4 9448     
Marco 2 
macrophage receptor 
with collagenous 
structure   17167   
Mat1a 2 
methionine 
adenosyltransferase I, 
alpha   11720   
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mcmv-miR-M01-4-
3p F 
Mouse 
cytomegalovirus 
(mCMV) microRNA-
M01-4     MIMAT0005539 
mcmv-miR-M23-2-
3p F 
Mouse 
cytomegalovirus 
(mCMV) microRNA-
M23-2     MIMAT0005545 
mcmv-miR-m44-1 F 
Mouse 
cytomegalovirus 
(mCMV) microRNA-
m44-1     MIMAT0005546 
mcmv-miR-m59-1 F 
Mouse 
cytomegalovirus 
(mCMV) microRNA-
m59-1     MIMAT0005548 
mcmv-miR-m59-2 F 
Mouse 
cytomegalovirus 
(mCMV) microRNA-
m59-2     MIMAT0005549 
mdv2-miR-M18-5p F 
Marek's disease virus 
type 2 (MDV2) 
microRNA-M18     MIMAT0004458 
mdv2-miR-M21-3p F 
Marek's disease virus 
type 2 (MDV2) 
microRNA-M21     MIMAT0004464 
mdv2-miR-M24-3p F 
Marek's disease virus 
type 2 (MDV2) 
microRNA-M24     MIMAT0004468 
Me1 2 
malic enzyme 1, 
NADP(+)-dependent, 
cytosolic   17436   
Med29 2 
mediator complex 
subunit 29   67224   
Med4 2 
mediator of RNA 
polymerase II 
transcription, subunit 4 
homolog (yeast)   67381   
Mettl7b 2 
methyltransferase like 
7B   71664   
Mfap1a 2 
microfibrillar-
associated protein 1A   67532   
Mfap5 2 
microfibrillar 
associated protein 5   50530   
Mgp 2 matrix Gla protein   17313   
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Mgst1 2 
microsomal glutathione 
S-transferase 1   56615   
MIC1/C18orf8 F 
macrophage inhibitory 
cytokine 1 29919     
miR-10a 1 microRNA 10a 406902     
miR-126-3p 1 microRNA 126 387145     
miR-148a 1 microRNA 148a 406940     
miR-185 1 microRNA 185 406961     
miR-22 1 microRNA 22 407004     
miR-223 1 microRNA 223 723814     
miR-24 1 microRNA 24 (-1/-2) 
4077012/ 
    407013 
miR-27a-3p B microRNA 27a 407018   MIMAT0000084 
mir31 2 microRNA 31   723895   
miR-320a 1 microRNA 320a 407037     
miR-320b 1 microRNA 320b (-1/-2) 
100302117/
100313769     
miR-423-5p 1 microRNA 423 494335     
miR-490-5p 1 microRNA 490 735279     
mir540 2 microRNA 540   723880   
mir700 2 microRNA 700   735285   
mir713 2 microRNA 713   751548   
MMP2 1 
Matrix 
metallopeptidase 2 4313     
MMP9 3, B 
matrix 
metallopeptidase 9 4318     
Mnd1 2 
meiotic nuclear 
divisions 1 homolog 
(S. cerevisiae)   76915   
Mnda 2 
myeloid cell nuclear 
differentiation antigen   381308   
Mrgpra5 2 
MAS-related GPR, 
member A5   404235   
MRP-14 1 
S100A9; S100 calcium 
binding protein A9 6280     
Mrpl22 2 
mitochondrial 
ribosomal protein L22   216767   
Mrpl33 2 
mitochondrial 
ribosomal protein L33   66845   
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Mrpl42 2 
mitochondrial 
ribosomal protein L42   67270   
Mrps18a 2 
mitochondrial 
ribosomal protein 
S18A   68565   
Mrps26 2 
mitochondrial 
ribosomal protein S26 64949 99045   
Mrps28 2 
mitochondrial 
ribosomal protein S28   66230   
Mrto4 2 
MRT4, mRNA turnover 
4, homolog (S. 
cerevisiae)   69902   
Ms4a6b 2 
membrane-spanning 
4-domains, subfamily 
A, member 6B   69774   
Ms4a6c 2 
membrane-spanning 
4-domains, subfamily 
A, member 6C   73656   
Mt2 2 metallothionein 2   17750   
Mug1 2 murinoglobulin 1   17836   
Mup3 2 major urinary protein 3   17842   
N6amt2 2 
N-6 adenine-specific 
DNA 
methyltransferase 2 
(putative)   68043   
Naa10 2 
N(alpha)-
acetyltransferase 10, 
NatA catalytic subunit 
Nalpha 
acetyltransferase 10   56292   
Naa50 2 
N(alpha)-
acetyltransferase 50, 
NatE catalytic subunit   72117   
NBEAL2 1 neurobeachin like 2 23218     
Ndufs3 2 
NADH dehydrogenase 
(ubiquinone) Fe-S 
protein 3   68349   
198 
 
 
 
 
Nedd9 2 
neural precursor cell 
expressed, 
developmentally down-
regulated gene 9   18003   
Nfil3 2 
nuclear factor, 
interleukin 3, regulated   18030   
NFKB1 3, B 
nuclear factor kappa B 
subunit 1 4790     
NFKBIA 3, B, D, F NFKB inhibitor alpha 4792 18035   
Nmi 2 
N-myc (and STAT) 
interactor   64685   
Nono 2 
non-POU-domain-
containing, octamer 
binding protein   53610   
Npm1 2 nucleophosmin 1   18148   
Npm3-ps1 2 
nucleoplasmin 3, 
pseudogene 1   108176   
Nptxr 2 
neuronal pentraxin 
receptor   73340   
Nr2f6 2 
nuclear receptor 
subfamily 3, group F, 
member 6 2063 13864   
Nsfl1c 2 
NSFL1 (p97) cofactor 
(p47)   386649   
Nt5c3l 2 
5'-nucleotidase, 
cytosolic III-like   68106   
Nudt21 2 
nudix (nucleoside 
diphosphate linked 
moiety X)-type motif 21   68219   
Nup62-il4i1 2 Nup62-Il4i1 protein   100328588   
Nutf2 2 
nuclear transport factor 
2   68051   
Obox2 2 
oocyte specific 
homeobox 2   246792   
Olfr1077-ps1 2 
olfactory receptor 
1077, pseudogene 1   625853   
Olfr1148 2 olfactory receptor 1148   258220   
Olfr1162 2 olfactory receptor 1162   258105   
Olfr1170 2 olfactory receptor 1170   258525   
Olfr1303 2 olfactory receptor 1303   258397   
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Olfr1337 2 olfactory receptor 1337   258306   
Olfr135 2 olfactory receptor 135   258329   
Olfr1371 2 olfactory receptor 1371   276865   
Olfr1418 2 olfactory receptor 1418   258227   
Olfr205 2 olfactory receptor 205   257881   
Olfr224 2 olfactory receptor 224   258198   
Olfr29-ps1 2 
olfactory receptor 29, 
pseudogene 1   29848   
Olfr344 2 olfactory receptor 344   258621   
Olfr399 2 olfactory receptor 399   259006   
Olfr403 2 olfactory receptor 403   404316   
Olfr406-ps 2 
olfactory receptor 406, 
pseudogene   258181   
Olfr441 2 olfactory receptor 441   258649   
Olfr521 2 olfactory receptor 521   258353   
Olfr541 2 olfactory receptor 541   258964   
Olfr57 2 olfactory receptor 57   18357   
Olfr612 2 olfactory receptor 612   545985   
Olfr638 2 olfactory receptor 638   259124   
Olfr744 2 olfactory receptor 744   257884   
Olfr97 2 olfactory receptor 97   258505   
Orm1 2 orosomucoid 1   18405   
Oxct2b 2 
3-oxoacid CoA 
transferase 2B   353371   
PAR1 1 
Protease-activated 
receptor 3; coagulation 
factor II receptor-like 3 2149 14062   
PAR3 1 
Protease-activated 
receptor 1; coagulation 
factor II receptor 2151 14064   
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Pcdha1 2 protocadherin alpha 1   116731   
Pcdha12 2 protocadherin alpha 12   192164   
Pcdha5 2 protocadherin alpha 5   12941   
Pcdha6 2 protocadherin alpha 6   12937   
Pcdha8 2 protocadherin alpha 8   353235   
Pcdhac2 2 
protocadherin alpha 
subfamily C, 2   353237   
Pcdhga1 2 
protocadherin gamma 
subfamily A, 1   93709   
Pcdhga10 2 
protocadherin gamma 
subfamily A, 10   93722   
Pcdhgb5 2 
protocadherin gamma 
subfamily B, 5   93702   
Pcdhgb7 2 
protocadherin gamma 
subfamily B, 7   93704   
PF4 3, D platelet factor 4 5196     
Pfkp 2 
phosphofructokinase, 
platelet   56421   
Phb 2 prohibitin   18673   
Phf11 2 
Phf11a, PHD finger 
protein 11   219131   
Phgdh 2 
3-phosphoglycerate 
dehydrogenase   236539   
Pigr 2 
polymeric 
immunoglobulin 
receptor   18703   
PIK3R1 F 
phosphoinositide-3-
kinase regulatory 
subunit 1 5295     
Pip4k2b 2 
phosphatidylinositol-5-
phosphate 4-kinase, 
type II, beta   108083   
Plekhf1 2 
pleckstrin homology 
domain containing, 
family F (with FYVE 
domain) member 1   72287   
Plg 2 Plasminogen   18815   
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Pnp 2 
purine-nucleoside 
phosphorylase   18950   
Polh 2 
polymerase (DNA 
directed), eta (RAD 30 
related)   80905   
Polr2c 2 
polymerase (RNA) II 
(DNA directed) 
polypeptide C   20021   
Polr2k 2 
polymerase (RNA) II 
(DNA directed) 
polypeptide K   17749   
Polr3g 2 
polymerase (RNA) III 
(DNA directed) 
polypeptide G   67486   
Pram1 2 
PML-RAR alpha-
regulated adaptor 
molecule 1   378460   
Prelp 2 
proline arginine-rich 
end leucine-rich repeat   116847   
Prh1 2 
proline rich protein 
HaeIII subfamily 1   19131   
PRKRA 1 
protein activator of 
interferon induced 
protein kinase 
EIF2AK2 8575     
Prp2 2 proline rich protein 2   83380   
Prps1 2 
phosphoribosyl 
pyrophosphate 
synthetase 1   19139   
prv-miR-LLT3 F 
Pseudorabies virus 
(PRV) microRNA-LLT3     MIMAT0025306 
prv-miR-LLT6 F 
Pseudorabies virus 
(PRV) microRNA-LLT6     MIMAT0025309 
PSIP1 F 
PC4 and SFRS1 
interacting protein 1 11168     
Psma4 2 
proteasome (prosome, 
macropain) subunit, 
alpha type 4   26441   
Psmb3 2 
proteasome (prosome, 
macropain) subunit, 
beta type 3   26446   
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Psmd10 2 
proteasome (prosome, 
macropain) 26S 
subunit, non-ATPase, 
10   53380   
PTGER2 3, B 
prostaglandin E 
receptor 2 5732     
Ptpn5 2 
protein tyrosine 
phosphatase, non-
receptor type 5   19259   
Pygl 2 
liver glycogen 
phosphorylase   110095   
Pzp 2 
pregnancy zone 
protein   11287   
Rab5b 2 
RAB5B, member RAS 
oncogene family   19344   
Rai12 2 
retinoic acid induced 
12   54351   
Rangrf 2 
RAN guanine 
nucleotide release 
factor   57785   
Rassf4 2 
Ras association 
(RalGDS/AF-6) 
domain family member 
4   213391   
Rbm12b 2 
RNA binding motif 
protein 12B   72397   
RBM26 F 
RNA binding motif 
protein 26 64062     
Rbm4b 2 
RNA binding motif 
protein 4B   66704   
Rbmxrt 2 
RNA binding motif 
protein, X 
chromosome 
retrogene   19656   
Rbp2 2 
retinol binding protein 
2, cellular   19660   
Rbp4 2 
retinol binding protein 
4, plasma   19662   
Rbpj 2 
recombination signal 
binding protein for 
immunoglobulin kappa 
J region   19664   
Rdh7 2 
retinol dehydrogenase 
7   54150   
Retnla 2 resistin like alpha   57262   
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Rgs2 2 
regulator of G-protein 
signaling 2   19735   
Rhox4f 2 
reproductive 
homeobox 4F   636177   
Rhox4g 2 
reproductive 
homeobox 4G   664608   
Rilpl2 2 
Rab interacting 
lysosomal protein-like 
2   80291   
rlcv-miR-rL1-14-5p F 
Rhesus 
lymphocryptovirus 
microRNA-rL1-14     MIMAT0003444 
rlcv-miR-rL1-17-3p F 
Rhesus 
lymphocryptovirus 
microRNA-rL1-17     MIMAT0014064 
rlcv-miR-rL1-17-5p F 
Rhesus 
lymphocryptovirus 
microRNA-rL1-17     MIMAT0019185 
rlcv-miR-rL1-29-3p F 
Rhesus 
lymphocryptovirus 
microRNA-rL1-29     MIMAT0016953 
Rnase4 2 
ribonuclease, RNase A 
family 4   58809   
RNF6 F ring finger protein 6 6049     
Rnps1 2 
ribonucleic acid 
binding protein S1   19826   
Rnu3a 2 
U3A small nuclear 
RNA   19850   
Rpl18a 2 ribosomal protein L18A   76808   
Rpl21 2 ribosomal protein L21 6144 19933   
Rps24 2 ribosomal protein S24   20088   
Rps25 2 ribosomal protein S25   75617   
Rps27l 2 
ribosomal protein S27-
like   67941   
Rsph3a 2 
radial spoke 3A 
homolog 
(Chlamydomonas)   66832   
Rwdd1 2 
RWD domain 
containing 1   66521   
RYR2 3, B ryanodine receptor 2 6262     
S100a4 2 
S100 calcium binding 
protein A4   20198   
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S100a6 2 
S100 calcium binding 
protein A6 (calcyclin)   20200   
S100a8 2 
S100 calcium binding 
protein A8 (calgranulin 
A)   20201   
S100a9/ S100A9 1, 2, 3, B, D 
S100 calcium binding 
protein A9 6280 20202   
S100B 3, B 
S100 calcium binding 
protein B 6285     
S1pr1 2 
sphingosine-1-
phosphate receptor 1   13609   
Samhd1 2 
SAM domain and HD 
domain, 1   56045   
Scd1 2 
stearoyl-Coenzyme A 
desaturase 1   20249   
SCGB3A2 F 
secretoglobin family 
3A member 2 117156     
Sco2 2 
SCO cytochrome 
oxidase deficient 
homolog 2 (yeast)   100126824   
SELE 3, B, F selectin E 6401     
SELENBP 3, B, F 
SELENBP1; selenium 
binding protein 1 8991     
Sell 2 selectin, lymphocyte   20343   
SELL 3, B, D selectin L 6402     
SELP 1, 3, B, D selectin P 6403     
Serpina1a 2 
serine (or cysteine) 
peptidase inhibitor, 
clade A, member 1A 5265 20700   
Serpina1b 2 
serine (or cysteine) 
preptidase inhibitor, 
clade A, member 1B   20701   
Serpina1c 2 
serine (or cysteine) 
peptidase inhibitor, 
clade A, member 1C   20702   
Serpina1d 2 
serine (or cysteine) 
peptidase inhibitor, 
clade A, member 1D   20703   
Serpina3i 2 
serine (or cysteine) 
peptidase inhibitor, 
clade A, member 3I   628900   
Serpina3k 2 
serine (or cysteine) 
peptidase inhibitor, 
clade A, member 3K   20714   
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Serpinb9f 2 
serine (or cysteine) 
peptidase inhibitor, 
clade B, member 9f   20709   
Serpinc1 2 
serine (or cysteine) 
peptidase inhibitor, 
clade C (antithrombin), 
member 1   11905   
Serping1 2 
serine (or cysteine) 
peptidase inhibitor, 
clade G, member 1   12258   
SELPLG F selectin P-ligand 6404     
Sesn3 2 sestrin 3   75747   
Set 2 SET translocation   56086   
Sf3b5 2 
splicing factor 3b, 
subunit 5   66125   
Sfn 2 Stratifin   55948   
Sfpi1 2 
SFFV proviral 
integration 1   20375   
Shc1 2 
src homology 2 
domain-containing 
transforming protein 
C1   20416   
Siglece 2 
sialic acid binding Ig-
like lectin E   83382   
SIRPA 3, B, F 
signal regulatory 
protein alpha 140885     
Slc9a5 2 
solute carrier family 9 
(sodium/hydrogen 
exchanger), member 5   277973   
Slfn1 2 schlafen 1   20555   
Slfn2 2 schlafen 2   20556   
SMC5 F 
structural maintenance 
of chromosomes 5 23137     
Sms 2 spermine synthase   20603   
Snora28 2 
small nucleolar RNA, 
H/ACA box 28   100316932   
Snora41 2 
small nucleolar RNA, 
H/ACA box 41   100217464   
Snora73a 2 
small nucleolar RNA, 
H/ACA box 73a   100306944   
Snora73b 2 
small nucleolar RNA, 
H/ACA box 73b   100306945   
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Snord104 2 
small nucleolar RNA, 
C/D box 104   100216537   
Snord35b 2 
small nucleolar RNA, 
C/D box 35B   27212   
Snrpd3 2 
small nuclear 
ribonucleoprotein D3   67332   
Snx20 2 sorting nexin 20   71607   
SOD1 3, B 
superoxide dismutase 
1 6647     
Spib 2 
Spi-B transcription 
factor (Spi-1/PU.1 
related)   272382   
Spic 2 
Spi-C transcription 
factor (Spi-1/PU.1 
related)   20728   
Srrm2 2 
serine/arginine 
repetitive matrix 2   75956   
SRSF2IP F 
serine/arginine-rich 
splicing factor 2, 
interacting protein 9169     
Srsf3 2 
serine/arginine-rich 
splicing factor 3   20383   
Ssxb1 2 
synovial sarcoma, X 
member B, breakpoint 
1   67985   
St3gal6 2 
ST3 beta-galactoside 
alpha-2,3-
sialyltransferase 6   54613   
Stap1 2 
signal transducing 
adaptor family member 
1   56792   
Stard6 2 
StAR-related lipid 
transfer (START) 
domain containing 6   170461   
Stfa2l1 2 stefin A2 like 1   268885   
Taar7a 2 
trace amine-
associated receptor 7A   215856   
Tbc1d22b 2 
TBC1 domain family, 
member 22B   381085   
Tbc1d8b 2 
TBC1 domain family, 
member 8B   245638   
Tcrd-C 2 
T-cell receptor delta, 
constant region   100123473   
Tcrg-C4 2 
T-cell receptor gamma, 
constant 4   107576   
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Tfam 2 
transcription factor A, 
mitochondrial   21780   
TGFB1 3, B 
transforming growth 
factor beta 1 7040     
TGFB2 3, B 
transforming growth 
factor beta 2 7042     
Tgfbi 2 
transforming growth 
factor, beta induced   21810   
Thrsp 2 
thyroid hormone 
responsive SPOT14 
homolog (Rattus)   21835   
TLR10 3, B toll like receptor 10 81793     
Tlr13 2 toll-like receptor 13   279572   
Tlr2 / TLR2 1, 3, B, D toll like receptor 2 7097 24088   
TLR3 3, B, F toll like receptor 3 7098     
TLR4 3, B, F toll like receptor 4 7099     
TLR5 3, B toll like receptor 5 7100     
TLR8 3, B toll like receptor 8 51311     
TLR9 3, B toll like receptor 9 54106     
Tmem159 2 
transmembrane 
protein 159   233806   
Tmx2 2 
thioredoxin-related 
transmembrane 
protein 2   66958   
TNFRSF1B 3, B, F 
TNF receptor 
superfamily member 
1B 7133     
TNFSF10 3, B, F 
TNF superfamily 
member 10 8743     
TNFSF11 3, B 
TNF superfamily 
member 11 8600     
TNFSF14 3, B 
TNF superfamily 
member 14 8740     
Trac 2 
T cell receptor alpha 
constant   100101484   
Traj49 2 
T cell receptor alpha 
joining 49   100124339   
Trappc2 2 
trafficking protein 
particle complex 2   66226   
Trav13-3 2 
T cell receptor alpha 
variable region 13-3   432910   
Trbv4 2 
T cell receptor beta, 
variable 10 (variable 4)   100124660   
Trdj1 2 
T cell receptor delta 
joining 1   100115376   
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Trdv4 2 
T cell receptor delta 
variable 4   100114901   
Trf 2 transferrin   22041   
Trgj4 2 
T cell receptor gamma 
joining 4   100126434   
Trim12 2 
tripartite motif-
containing 12   76681   
Trim34 2 
tripartite motif-
containing 34   94094   
Trim59 2 
tripartite motif-
containing 59   66949   
Try10 2 trypsin 10   436522   
Tsnax 2 
translin-associated 
factor X   53424   
Ttr 2 transthyretin   22139   
Tyms 2 thymidylate synthase   22171   
U2af1 2 
U2 small nuclear 
ribonucleoprotein 
auxiliary factor (U2AF) 
1   108121   
Ube2n 2 
ubiquitin-conjugating 
enzyme E2N   93765   
Ublcp1 2 
ubiquitin-like domain 
containing CTD 
phosphatase 1   79560   
Uevld 2 
UEV and 
lactate/malate 
dehyrogenase 
domains   54122   
Ugt1a2 2 
UDP 
glucuronosyltransferas
e 1 family, polypeptide 
A2   22236   
Ugt1a5 2 
UDP 
glucuronosyltransferas
e 1 family, polypeptide 
A5   394433   
Ugt1a6b 2 
UDP 
glucuronosyltransferas
e 1 family, polypeptide 
A6B   394435   
Ugt2a2 2 
UDP 
glucuronosyltransferas
e 2 family, polypeptide 
A2   552899   
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Ugt2b36 2 
UDP 
glucuronosyltransferas
e 2 family, polypeptide 
B36   231396   
Ugt2b5 2 
UDP 
glucuronosyltransferas
e 2 family, polypeptide 
B5   22238   
UTRN F utropin 7402     
VAMP3 3, B 
vesicle associated 
membrane protein 3 9341     
VAMP5 3, B, F 
vesicle associated 
membrane protein 5 10791     
VAMP7 3, B 
vesicle associated 
membrane protein 7 6845     
VAMP8 3, B 
vesicle associated 
membrane protein 8 8673     
Vaultrc5 2 
vault RNA component 
5   378472   
VCAM1 3, B, F 
vascular cell adhesion 
molecule 1 7412     
VEGFA 1, 3, B, F 
vascular endothelial 
growth factor A 7422     
VEGFB 1, 3, B, F 
vascular endothelial 
growth factor B 7423     
VEGFC 3, B, F 
vascular endothelial 
growth factor C 7424     
VIP 3, B, F 
vasoactive intestinal 
peptide 7432     
Vmn1r175 2 
vomeronasal 1 
receptor 175   622222   
Vmn1r196 2 
vomeronasal 1 
receptor 196   100312484   
Vmn1r213 2 
vomeronasal 1 
receptor 213   171249   
Vmn2r12 2 
vomeronasal 2, 
receptor 12   627569   
Vmn2r66 2 
vomeronasal 2, 
receptor 66   233437   
Vmn2r69 2 
vomeronasal 2, 
receptor 69   330581   
Vmn2r84 2 
vomeronasal 2, 
receptor 84   625068   
Vtn 2 vitronectin 7448 22370   
Wdr53 2 WD repeat domain 53   68980   
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X76971 2 
cDNA sequence 
X76971   634322   
ZC3H13 F 
zinc finger CCCH-type 
containing 13 23091     
Zc4h2 2 
zinc finger, C4H2 
domain containing   245522   
Zcchc17 2 
zinc finger, CCHC 
domain containing 17   619605   
Zcwpw2 2 
zinc finger, CW type 
with PWWP domain 2   100039681   
Zfp422 2 zinc finger protein 422   67255   
Zfp456 2 zinc finger protein 456   408065   
Zfp580 2 zinc finger protein 580   68992   
Zfp59 2 zinc finger protein 59   22717   
Zfp617 2 zinc finger protein 617   170938   
Zfp787 2 zinc finger protein 787   67109   
Zfp825 2 zinc finger protein 825   235956   
Zfp882 2 zinc finger protein 882   382019   
Znrd1 2 
zinc ribbon domain 
containing, 1   66136   
Zswim1 2 
zinc finger, SWIM 
domain containing 1   71971   
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APPENDIX B: PLATELET RNA TRANSFER TO CELLS IN IN VITRO 
MODELING SYSTEMS 
 
Permissions 
Appendix B contains unpublished data from the Freedman Lab. Figure B.1 and 
corresponding results taken from unpublished manuscript, without permission 
required. 
 
• “Platelet activation and miRNA transfer in the regulation of vascular 
homeostasis” Lauren Clancy, Antonina Risitano, Kahraman Tanriverdi, 
David D. McManus, Jesse W. Rowley, Andrew S. Weyrich, Olga Vitseva, 
Lea M. Beaulieu, Jeffrey J. Rade and Jane E. Freedman 
 
Author Contributions 
A.R. designed and performed experiments, analyzed data, and wrote the 
manuscript; K.T. designed and performed experiments, analyzed data; D.D.M. 
and J.J.R. provided the clinical samples and related analysis; J.W.R. performed 
mouse studies and analyzed data; O.V. and L.C. performed experiments; L.M.B. 
participated in the design of the adhesion experiment; J.E.F. and A.S.W. 
designed experiments and edited the manuscript. 
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Summary  
As first described by Risitano et al. and later confirmed by several other labs, 
platelets are capable of transfer of RNAs to other vascular cells (both mRNAs 
and miRNAs) with functional consequences on the recipient cells (114, 120-125). 
Initial studies during this project focused on evaluating the transfer of RNAs from 
platelets to vascular cells under various stimulatory conditions. Results are 
included here as the relevance of platelet RNA transfer to the overall 
phenomenon of platelet RNA communication with vascular cells is evident from 
our experiments; platelet RNA transfer to cells and RNA uptake from cells work 
in tandem to create a bidirectional transfer system, the impact of which on 
vascular health will be determined with further study. 
 
Materials and Methods 
Figure B.1  
Washed platelets were incubated with 10 µM calcein AM (Life Technologies) for 
15 min then resuspended and washed in HBSS (Life Technologies). 
Subsequently, platelets were stimulated with 0.5U/mL thrombin for 10 minutes. 
HUVECs were previously cultured on tissue culture treated-glass slides and 
transfected (using Lipofectamine RNAiMAX technology, according to 
manufacturer’s protocol) with miR-27a-3p mimic, miR-27a-3p inhibitor and 
relative negative controls (scrambled sequences) without any fluorescent labeling 
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(Life Technologies). Using a vacuum-based cell adhesion flow chamber 
(Immunetics, Boston, MA) platelets were passed at a constant rate, for 20 
minutes, over HUVECs (24 hours post transfection) pretreated with 0.5U/mL 
thrombin for 10 minutes as previously described (223). Slides were then 
analyzed by examined by confocal microscopy (Leica Microsystems and Leica 
Confocal Software, Exton, PA) and fluorescence quantification was performed by 
using ImageJ (224). Experimental design mimics that of flow adhesion 
experiment described in Chapter 3 Materials and Methods, “Fluorescent RNA 
transfer in flow adhesion model” and depicted in Figure 3.12. 
Table B.1 
Results from Table B.1 match those described in Table 3.4, with methods fully 
described in Chapter 3, Materials and Methods, “In Vitro Simulated Clot 
Experiments”. While Table 3.4 represents platelet fraction results, Table B.1 
represents HUVEC fraction results. Some of this data is presented in Table G.1 
as well. Full data recorded here to show transcripts of interest for platelet RNA 
transfer to cells. 
 
Results 
Activated endothelial cells internalize platelets under minimal flow 
conditions 
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Figure B.1 depicts the transfer of calcein-AM from platelets to HUVECs under 
flow conditions. In support of previous studies showing platelet binding and 
internalization of platelets by activated HUVECs, the platelet-derived 
fluorescence signal is both contained within the HUVEC cells (platelet 
internalization) and expressed on the cell surface (brighter signals) with as little 
as 20 minutes exposure. Additionally, during these experiments we investigated 
the role miR-27a may have on this internalization, as it can regulate vWF 
expression. HUVECs transfected with miR-27a displayed less fluorescence 
signal (corresponding to decreased vWF and thus decreased platelet adhesion) 
compared to control (image quantification showed a 10% decrease). Conversely, 
the opposite effect is seen with miR-27a inhibitor transfection; miR-27a inhibitor 
transfection results increased fluorescence expression (15% as compared to 
controls, corresponding to decreased endogenous miR-27a, increased vWF 
expression, increased platelet adhesion and thus increased platelet 
internalization). This supports the internalization of platelets and thus platelet 
content by endothelial cells, even under the minimal conditions of the flow 
adhesion model. 
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Figure B.1: Platelet internalization by endothelial cells. HUVEC-platelet adhesion 
assay was examined by confocal microscopy. (A) Unlabeled platelets and HUVECs. 
Scale bar denotes 5 µm for platelets (100X magnification) and 10 µm for HUVECs (40X 
magnification). (B) HUVECs were transfected with miR-27a mimic, miR-27a inhibitor and 
related negative controls. Fluorescence, derived from calcein-labeled platelets, is 
present in the endothelial cytosol and on the cell surface (small brighter dots). 
Differences in fluorescence intensity and localization are highlighted in the insets. Inset 
represents magnified region outlined by the yellow box in each image. Scale bar denotes 
20 µm; 20X magnification. DIC (Differential Interference Contrast).  
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Differential expression of HUVECs post platelet co-incubation suggests 
transfer of numerous platelet-specific transcripts 
Additional studies focused on expression changes in HUVECs post co-incubation 
with isolated human platelets. We hoped to replicate the results seen by Risitano 
et al. (114) using human platelets instead of platelet-like particles (PLP) to better 
estimate the actual transcript changes that may occur in vivo. We hypothesized 
that by evaluating the HUVEC transcriptome post incubation, we could determine 
a transferred RNA transcriptome as well as correlated the outcomes of this 
analysis to our expected (but not actual) results from the platelet subpopulations 
studies. As can be seen, a number of transcript levels changed within HUVECs, 
though whether this change is stimulation, transcription or platelet dependent 
seems to be transcript specific (Table B.1). A number of platelet specific markers, 
particularly CD40LG, P-selectin and GP1BB, transcripts all show increases in 
HUVEC post incubation, suggesting they correlate to platelet internalization 
and/or platelet RNA transfer. Other transcript changes will require additional 
analysis to determine if differential expression is due to platelet RNA transfer, 
platelet signaling or HUVEC stimulation and mRNA processing. 
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Table B.1: RT-qPCR results for transcript panel in endothelial cells (HUVECs) post 
incubation with platelets. Expression fold changes with or without stimulation under 
normal in vitro simulated clot conditions (A) or with pretreatment transcription shutdown 
in HUVECs through α-amanitin treatment (B). RT-qPCR results were normalized to two 
housekeeping genes (CD63 and CD81) with HUVEC alone samples set as experimental 
controls. Red (fold increase) and blue (fold decrease) text coloring denote expression 
fold changes of interest. Gray color coding denotes P< 0.05 (based on a Student’s t-test 
of the replicate 2(- ∆∆Ct) values for each gene in the control group and treatment groups) 
for given value. Legend below table describes sample setup conditions. A) Results 
represent n=6 experiments. B) Results represent n=3 experiments. (Excerpt of these 
results presented in Table G.1).  
 
A) 
HUVEC 
Alone 
Stimulated 
HUVEC 
Unstimulated 
HUVEC Post 
Platelet Incubation 
Stimulated HUVEC 
Post Stimulated 
Platelet Incubation 
ACTB 1 -1.0197 -1.1212 -1.9716 
AGO2 (EIF2C2) 1 1.1905 1.1047 1.0765 
ASGR1 1 1.2464 -3.0331 -2.3947 
B2M 1 1.3725 1.4952 1.6958 
BCL2L1 1 -1.0404 1.2447 1.232 
CALR 1 -1.015 1.3629 1.3086 
CCL17 1 3.2299 -7.3957 -1.4694 
CCL3 1 1.0474 30.8217 3.7429 
CCL7 1 1.3247 3.0455 2.0097 
CD163 1 1.051 1.7062 20.9007 
CD209 1 -11.1748 -6.8835 -3.9354 
CD3D 1 1.051 1.7062 20.9052 
CD40 1 1.1062 1.0383 -1.0744 
CD40 LG 1 1.051 1294.6002 3982.1746 
CD44 1 1.125 1.3539 1.3331 
CD53 1 3.0556 687.6608 294.7269 
CD63 1 1.0328 -1.1215 -1.0987 
CD81 1 -1.0376 1.1302 1.0993 
CD86 1 1.051 4.5961 7.2588 
COL18A1 1 1.0427 1.0897 1.3692 
COPA 1 1.0924 1.1592 1.2424 
CRLS1 1 1.2782 1.1733 1.7428 
CRP 1 -1.7252 1.4299 -1.4451 
CX3CL1 1 2.5058 2.8626 5.7266 
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CXADR 1 -1.0386 1.0371 1.0066 
CXCL1 1 2.1938 8.1581 17.9698 
CXCL12 1 1.0574 1.7565 2.2814 
CXCL2 1 3.7931 6.2366 15.2343 
CXCL5 1 1.5499 9.3657 12.9536 
CXCL6 1 1.3018 1.8489 3.5899 
DICER1 1 -1.1446 1.2915 1.2637 
EIF4G1 1 1.1357 1.1905 1.4735 
ESAM 1 1.0665 1.1928 1.375 
FCN1 1 1.051 257.2454 695.6924 
FOLR1 1 -3.0728 1.3772 -1.0822 
GAPDH 1 1.1302 1.2328 1.0563 
GP1BB 1 1.0084 5.0267 5.8862 
GPI 1 1.2527 1.0458 1.0492 
ICAM1 1 2.4041 3.6179 4.7408 
IFITM1 1 -1.1026 -1.1117 -1.0702 
IFITM2 1 1.0671 1.3826 1.4347 
IFITM3 1 1.1664 1.3856 1.8656 
IFNA1 1 1.7806 8.8671 2.7534 
IFNB1 1 19.6171 2.3913 13.4521 
IL10RA 1 -5.7981 4.4697 -1.6584 
IL1beta 1 5.0559 17.4412 11.3618 
IL2RB 1 -1.3447 1.219 -1.8047 
IL5 1 3.1173 5.1137 9.4402 
IL6 1 1.2691 1.4082 2.3907 
IL8 1 2.7746 9.616 31.6084 
ITGA5 1 1.2111 1.3443 1.2841 
ITGAE 1 1.0396 -1.5128 11.9228 
ITGAL 1 2.6059 870.3528 33.2699 
ITGAM 1 20.2988 1.8959 15.342 
ITGB7 1 12.0804 30.4259 18.1557 
KIAA0232 1 -1.1015 1.3689 1.5487 
KIAA1462 1 1.1502 1.0647 1.0484 
LAMP1 1 -1.0388 1.1552 1.096 
LCK 1 1.0723 1.3752 -1.0161 
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LSP1 1 -1.8727 1.5483 3.0581 
MAP4K4 1 1.1246 1.1753 1.4094 
MMP9 1 40.6716 5.0022 59.1372 
NFKB1 1 1.4177 2.0767 3.1231 
NFKBIA 1 1.6223 4.9257 7.3516 
PTGER2 1 -3.3581 1.3479 4.4997 
RYR2 1 1.051 1.7062 2.9843 
S100A9 1 3.1385 12654.4663 10065.3338 
S100B 1 1.051 6.4433 87.9429 
SELE 1 7.354 18.4109 79.2161 
SELENBP 1 -1.091 -1.0949 -2.5136 
SELL 1 -1.0773 1.3056 -2.3351 
SELP 1 -1.6584 2.5553 3.4953 
SIRPA 1 -1.0739 1.3652 1.4739 
SOD1 1 -1.035 -1.0232 1.0911 
TGFB1 1 1.0551 1.1409 1.0724 
TGFB2 1 1.2953 1.5799 2.9009 
TLR10 1 1.1747 11.6058 2.8717 
TLR2 1 2.9938 2.6005 4.5655 
TLR3 1 -1.0572 1.2253 1.425 
TLR4 1 -1.0331 1.529 1.6517 
TLR5 1 -3.4312 1.2714 -3.2776 
TLR8 1 1.051 1.7062 2.9843 
TLR9 1 -1.1329 -1.0233 1.2283 
TNFRSF1B 1 1.07 1.0277 -2.5518 
TNFSF10 1 -1.0035 1.0125 1.0334 
TNFSF11 1 -1.4623 -4.693 -4.3661 
TNFSF14 1 10.4429 1.7062 2.9843 
VAMP3 1 1.0685 1.2486 1.4327 
VAMP5 1 1.0032 -1.0534 1.2575 
VAMP7 1 -1.0063 1.3657 1.4073 
VAMP8 1 1.0622 1.1836 1.4206 
VCAM1 1 4.4064 4.1857 9.4458 
VEGFA 1 1.1718 2.2279 4.5597 
VEGFB 1 -1.0576 1.1582 1.5174 
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VEGFC 1 1.3295 1.5213 1.8612 
VIP 1 1.1269 1.3431 2.0989 
Platelets + + + + 
Platelet 
Thrombin 
Stimulation - + - + 
EC Incubation - - + + 
EC 
Transcription 
Shutdown - - - - 
EC Thrombin 
Stimulation - - - + 
 
 
B) 
HUVEC 
Alone 
Stimulated 
HUVEC 
Unstimulated 
HUVEC Post 
Platelet Incubation 
Stimulated HUVEC 
Post Stimulated 
Platelet Incubation 
ACTB 1 1.0601 -1.0761 -1.1877 
AGO2 (EIF2C2) 1 -1.8677 1.3052 -1.1039 
ASGR1 1 -1.0636 1.3645 -6.2191 
B2M 1 -1.0687 2.1331 1.8035 
BCL2L1 1 -1.4957 -1.046 -1.0518 
CALR 1 -1.0767 1.179 1.2753 
CCL17 1 -1.0237 12.0984 -4.9572 
CCL3 1 -1.0228 17.0442 20.6187 
CCL7 1 1.1608 1.0418 1.4125 
CD163 1 -1.0228 9.5561 2.7164 
CD209 1 -1.0228 1.4033 2.7164 
CD3D 1 -1.0228 15.3252 27.6313 
CD40 1 -1.3567 1.4593 -1.153 
CD40 LG 1 -1.0228 5203.3792 676.4863 
CD44 1 -1.2037 1.1235 1.2676 
CD53 1 -1.0228 820.8875 373.8394 
CD63 1 -1.2268 1.0035 -1.0599 
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CD81 1 1.2528 1.0004 1.0713 
CD86 1 -1.0228 1.4033 2.7164 
COL18A1 1 -1.1222 -1.053 1.1865 
COPA 1 -1.1403 1.0528 1.0569 
CRLS1 1 -1.0756 1.3501 1.4385 
CRP 1 -202.9364 1.6739 -4.9166 
CX3CL1 1 -1.4493 1.9653 -1.1286 
CXADR 1 -1.3386 -1.2674 -1.0872 
CXCL1 1 -2.7425 1.3297 1.5869 
CXCL12 1 -1.7275 1.1325 -1.1062 
CXCL2 1 -4.5639 -2.1235 1.3596 
CXCL5 1 -1.2027 7.3623 5.1308 
CXCL6 1 -1.0155 1.9935 1.539 
DICER1 1 -1.6335 -1.0973 -1.0908 
EIF4G1 1 -1.1511 1.0719 1.0521 
ESAM 1 -1.1375 -1.0072 1.4959 
FCN1 1 -1.0228 198.4575 2.7164 
FOLR1 1 -10.6667 -1.018 1.9223 
GAPDH 1 -1.059 1.193 1.2349 
GP1BB 1 1.123 13.1186 5.6573 
GPI 1 1.047 1.2925 1.155 
ICAM1 1 -1.5669 1.3233 -1.0825 
IFITM1 1 -2.7425 -1.3877 -1.1973 
IFITM2 1 1.0622 1.3719 1.4613 
IFITM3 1 -1.0297 1.1681 1.5931 
IFNA1 1 1.2254 4.0384 3.9678 
IFNB1 1 -1.0288 -4.368 -2.7301 
IL10RA 1 -5.5681 8.2393 15.168 
IL1beta 1 12.5778 630.6641 64.3389 
IL2RB 1 14.3397 13.7984 2.015 
IL5 1 7.4622 13.32 2.7164 
IL6 1 -3.1481 -2.9711 1.2978 
IL8 1 -1.4783 1.2414 3.0918 
ITGA5 1 -1.2034 1.2942 1.2867 
ITGAE 1 -1.0857 1.3575 2.4742 
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ITGAL 1 -1.0228 1752.9844 500.4801 
ITGAM 1 -9.7967 1.6048 4.6438 
ITGB7 1 4.073 1.5264 4.4965 
KIAA0232 1 -2.8643 -1.6315 -1.5547 
KIAA1462 1 -1.8408 -1.3315 -1.5228 
LAMP1 1 -1.2422 -1.0302 1.2044 
LCK 1 -1.4037 -3.5985 -1.7437 
LSP1 1 -1.3964 4.3528 3.6542 
MAP4K4 1 -1.2553 -1.0763 1.1067 
MMP9 1 10.6261 1.4359 3.9312 
NFKB1 1 -1.4657 1.2878 1.207 
NFKBIA 1 -4.5694 -1.4427 -1.0459 
PTGER2 1 -1.0228 11.0449 228.6747 
RYR2 1 -1.0228 1.4033 2.7164 
S100A9 1 -1.0228 18042.0499 19563.48 
S100B 1 -1.0228 13.9873 272.7551 
SELE 1 -2.6831 2.3852 2.4984 
SELENBP 1 -1.1724 -1.0319 -1.008 
SELL 1 -1.285 1.1707 1.1727 
SELP 1 -1.3416 4.338 3.7433 
SIRPA 1 -1.2221 -1.0044 1.0852 
SOD1 1 -1.1247 -1.0368 1.4196 
TGFB1 1 -1.0227 1.0645 -1.0265 
TGFB2 1 -1.384 1.1537 1.4572 
TLR10 1 1.0248 5.8247 4.2836 
TLR2 1 -1.6044 1.3143 -5.8816 
TLR3 1 -1.2187 1.3126 1.4144 
TLR4 1 -1.8745 -1.151 -1.0423 
TLR5 1 1.4175 1.3366 -2.9435 
TLR8 1 -1.0228 1.4033 2.7164 
TLR9 1 1.0965 1.7337 1.7259 
TNFRSF1B 1 -1.0581 -1.0884 -1.2453 
TNFSF10 1 -2.0334 -1.6254 -1.4332 
TNFSF11 1 -9.3157 -1.0271 -2.5552 
TNFSF14 1 10.8385 1.4033 39.895 
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VAMP3 1 -1.0844 1.2268 1.2652 
VAMP5 1 1.0059 -1.0016 1.062 
VAMP7 1 -1.1488 1.166 1.1997 
VAMP8 1 -1.0432 1.1835 1.1849 
VCAM1 1 -2.666 1.3689 -1.1246 
VEGFA 1 -2.0494 -1.3374 1.0987 
VEGFB 1 -1.068 1.2741 1.4029 
VEGFC 1 -1.1601 1.2458 1.2944 
VIP 1 -1.1167 1.2831 2.3546 
Platelets + + + + 
Platelet 
Thrombin 
Stimulation - + - + 
EC Incubation - - + + 
EC 
Transcription 
Shutdown - - - - 
EC Thrombin 
Stimulation - - - + 
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APPENDIX C: PLATELET SUBPOPULATION TRANSCRIPTOME RESULTS 
 
Permissions 
Appendix C references a table excerpt from a published manuscript, included 
with permission:  
 
• Clancy L, Beaulieu LM, Tanriverdi K, Freedman JE. (2017).The role of 
RNA uptake in platelet heterogeneity. Thromb Haemost, 117(5), 948-961 
o Permission Information: Copyright Permission No 116/06/2017 
 
Author Contributions 
L.C. performed all experiments and analyses unless noted below. L.C. wrote 
manuscript. J.E.F. oversaw overall project development and coordination. L.M.B 
performed initial platelet sorting experiments. K.T. performed high throughput 
gene expression analyses. All authors commented on the interpretation of 
results, and reviewed and approved the manuscript.  
 
File Information 
Cuffdiff expression analysis results of sequencing data for large (Ot7226) versus 
small (Ot7227) platelets.  
File available online at www.thrombosis-online.com 
(TH117.5_Clancy_Suppl_Table1) 
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APPENDIX D: ADDITIONAL STATISTICAL ANALYSES 
Post publication, it was suggested that a number of figures from the published 
manuscript cited in Chapter 3 (“The role of RNA uptake in platelet heterogeneity”) 
should be re-evaluated with non-parametric statistical tests due to non-Gaussian 
distributions. As these results were already published, the figures and statistics 
were not altered in the original chapter of this dissertation; however, for clarity, 
additional statistical tests are included here. It is worth noting that for several 
studies, non-parametric testing will not accurately determine significance due to 
sample size. 
• Figure 3.2 and Table 3.1: Statistical analyses were performed within 
DAVID program and therefore not reanalyzed here. 
• Figure 3.3: 
o Original Test: Unpaired parametric two-tailed t-test 
o Additional Test: Unpaired Mann-Whitney test 
o Results: 
Gene Original Statistical 
Results 
Additional Statistical 
Results 
ACTB ****p<0.0001 *p=0.0286 
B2M ***p=0.0009 *p=0.0286 
GAPDH ***p=0.0005 *p=0.0286 
BCL2L1 **p=0.0056 *p=0.0286 
PF4 **p=0.0012 *p=0.0286 
CD40 ****p<0.0001 *p=0.0286 
SELP **p=0.0030 *p=0.0286 
GUK1 p=0.3012 p=0.4857 
LSP1 p=0.2521 p=0.3714 
NFKBIA p=0.1348 p=0.4286 
SELL p=0.3084 p=0.4286 
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• Figure 3.5: 
o Original Test: Unpaired parametric two-tailed t-test 
o Additional Test: Unpaired Mann-Whitney test 
o Results: 
Gene Original Statistical 
Results 
Additional Statistical 
Results 
Actb n/a p>0.9999 
Il1b p=0.0131 p=0.1000 
S100a9 p=0.0040 p=0.1000 
Tlr2 p=0.0345 p=0.1000 
Icam1 p=0.0441 p=0.1000 
Nfkbia P=0.0111 p=0.1000 
 
• Figure 3.6: 
o Original Test: Unpaired parametric ordinary one-way ANOVA 
o Additional Test: Unpaired, non-parametric Kruskal-Wallis test, 
Dunn’s follow up 
o Results 
Original Statistical Results Additional Statistical Results 
p=0.0226 p=0.2526 
 
o Additional Note: Use of a different housekeeping gene (ACTB) for 
RT-qPCR calculations results in significant findings regardless of 
statistical method. 
Housekeeping Gene Original Statistical 
Results 
Additional Statistical 
Results 
Actb p=0.0047 p=0.0361 
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Actb and Gapdh 
Combined 
p=0.0045 p=0.0268 
 
• Figure 3.7: 
o Original Test: Unpaired parametric t test 
o Additional Test: Unpaired, non-parametric Mann-Whitney test 
o Results: 
Data Results Original Statistical 
Results 
Additional Statistical 
Results 
% Events in Platelet 
Population 
p=0.3103 p=0.2857 
% CD41+ p=0.8196 p>0.9999 
Geometric Mean p=0.0227 p=0.0556 
 
• Table 3.4: Statistical analyses were performed within the RT2 Profiler PCR 
Array Data Analysis tool version 3.5 and therefore not reanalyzed here. 
 
• Figure 3.8: 
o Original Test: Unpaired parametric two-tailed t-test 
o Additional Test: Unpaired non-parametric Mann-Whitney test 
o Results: 
Original Statistical 
Results 
Additional Statistical 
Results 
p<0.0001 p=0.1000 
 
• Figure 3.9: 
o Original Test: Parametric ordinary one-way ANOVA 
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o Additional Test: Unpaired nonparametric Kruskal Wallis with Dunn’s 
follow up 
o Results: 
 Original Statistical 
Results 
Additional Statistical 
Results 
P value p<0.0001 p=0.0044 
Multiple 
Comparisons 
All individual 
comparisons 
significant 
All individual 
comparisons non-
significant 
 
• Figure 3.10: 
o Original Test: Multiple unpaired t-tests with discovery determined 
using original FDR method of Benjamini and Hochberg, Q=1%, 
each row individually assuming no consistent SD 
o Additional Test: Individual unpaired nonparametric, Mann-Whitney 
test, two-tailed 
o Results: 
 Original Statistical 
Results 
Additional Statistical 
Results 
HUVEC 29 transcripts, p<0.005 
12 transcripts, p<0.0001 
All 29 transcripts still 
significant (p=0.0286) 
THP1 19 transcripts, p<0.005 
12 transcripts, p<0.0001 
All 19 transcripts still 
significant (p=0.0286) 
 
• Table 3.5: 
o Original results match analyses from Figure 3.10. Reanalysis of 
Figure 3.10 showed all targets still significant, regardless of 
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statistical test. Therefore no additional analysis of table 3.5 is 
required. 
• Figure 3.13: 
o Original Test: Unpaired parametric ordinary one-way ANOVA 
o Additional Test: Unpaired nonparametric Kruskal-Wallis test with 
Dunn’s follow up 
o Results: 
 Original Statistical 
Results 
Additional Statistical 
Results 
p value p=<0.0001 p=<0.001 
Multiple 
Comparisons 
Various significance 
but all column 
comparisons of 
interest significant 
All individual 
comparison still 
significant except 
10’ Unstim and 10’ 
Stim to 30’ Stim 
 
o Additional Notes: Data set for Figure 3.13 has a sample size n=20. 
Though results are not parametric, this sample size should allow for 
accurate analysis by parametric test. 
• Figure 3.15: 
o Original Test: Unpaired parametric ordinary one-way ANOVA 
o Additional Test: Unpaired nonparametric Kruskal-Wallis test with 
Dunn’s follow up 
o Results: 
 Original Statistical 
Results 
Additional 
Statistical Results 
p value p<0.0001 p=0.0092 
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Multiple 
comparisons 
All column 
comparisons 
significant to varying 
degrees 
Individual column 
comparisons no 
longer significant 
except for one 
 
• Figure 3.16: 
o Original Test: Unpaired parametric ordinary one-way ANOVA 
o Additional Test: Unpaired nonparametric Kruskal-Wallis test with 
Dunn’s follow up 
o Results: 
 Original Statistical 
Results 
Additional 
Statistical Results 
p value p=0.0001 p=0.0102 
Multiple 
comparisons 
All column 
comparisons 
significant to final 
column 
Not all individual 
column 
comparisons 
significant  
 
• Figure 3.17: 
o Original Test: Unpaired parametric two-way ANOVA, α =0.05, with 
Tukey’s multiple comparison follow up 
o Additional Test: Unpaired nonparametric Kruskal-Wallis test with 
Dunn’s follow up, on each gene individually 
o Results: 
 Original Statistical 
Results 
Additional 
Statistical Results 
p value Interaction p=0.0005 
Row Factor p<0.0001 
Column Factor 
p<0.0001 
BIM p=0.0003 
BAX p=0.0001 
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Multiple 
comparisons 
All control to treatment 
multiple comparisons 
significant (p<0.01) 
Most of individual 
comparisons not 
significant  
 
• Figure 3.1, 3.4, 3.11, 3.12, 3.14, Table 3.2, 3.3: Had no associated 
statistical analyses 
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Table E.1: DAVID gene ontology (GO) functional analysis of small and large 
platelet RNA profiles. Listing of associated GO terms and Benjamini corrected p-values 
for small (A) and large (B) platelet RNA profiles. In-depth analysis of biological process 
(BP) results of DAVID analysis of small and large platelet RNA profiles. Italics denote 
common processes associated with both populations’ RNA. 
 
(A) Small Platelet RNA: DAVID Functional Annotation Chart 
Term P-Value 
Fold 
Enrichment 
Benjamini 
Corrected P-
value 
DNA metabolic process 3.05E-05 1.55 5.77E-03 
Proteolysis involved in cellular 
protein catabolic process 2.95E-05 1.50 5.89E-03 
Modification-dependent 
macromolecule catabolic process 3.70E-05 1.50 6.04E-03 
Modification-dependent protein 
catabolic process 3.70E-05 1.50 6.04E-03 
tRNA metabolic process 3.40E-05 2.26 6.10E-03 
Cellular protein catabolic process 3.62E-05 1.49 6.19E-03 
Protein catabolic process  2.94E-05 1.49 6.20E-03 
Cell cycle 4.00E-05 1.42 6.24E-03 
ncRNA processing 4.22E-05 1.95 6.31E-03 
T cell activation 4.77E-05 2.19 6.85E-03 
Apoptosis 5.53E-05 1.48 7.63E-03 
Programmed cell death 6.16E-05 1.47 8.18E-03 
Cellular response to stress 9.57E-05 1.48 1.22E-02 
Golgi vesicle transport 1.03E-04 2.10 1.27E-02 
Cell death 1.18E-04 1.41 1.40E-02 
Mitotic Cell Cycle 1.61E-04 1.59 1.80E-02 
Death 1.57E-04 1.40 1.80E-02 
Protein modification by small 
protein conjugation or removal 1.76E-04 1.94 1.90E-02 
Ribonucleoprotein complex 
biogenesis 1.90E-04 1.88 2.00E-02 
Chromosome organization 2.56E-04 1.48 2.53E-02 
Organelle fission 2.50E-04 1.75 2.54E-02 
Protein modification by small 
protein conjugation   2.84E-04 2.02 2.59E-02 
Lymphocyte Apoptosis 2.81E-04 6.22 2.63E-02 
Positive regulation of cell death 2.77E-04 1.51 2.66E-02 
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Positive regulation of programmed 
cell death 4.06E-04 1.50 3.59E-02 
Protein amino acid acetylation 4.27E-04 2.73 3.68E-02 
Leukocyte activation 4.54E-04 1.69 3.81E-02 
Induction of apoptosis 4.90E-04 1.58 4.02E-02 
Induction of programmed cell death 5.30E-04 1.58 4.25E-02 
Positive regulation of apoptosis 5.43E-04 1.49 4.25E-02 
M phase of mitotic cell cycle 5.79E-04 1.71 4.43E-02 
Positive regulation of immune 
system process 5.92E-04 1.68 4.44E-02 
Translation 6.61E-04 1.56 4.84E-02 
RNA biosynthetic process 6.98E-04 1.59 5.00E-02 
Protein amino acid acylation 7.29E-04 2.52 5.02E-02 
B cell apoptosis 7.25E-04 8.89 5.09E-02 
Chromatin organization 8.52E-04 1.50 5.73E-02 
Histone modification 9.28E-04 1.97 5.80E-02 
Ribosome biogenesis 9.28E-04 1.97 5.80E-02 
Lymphocyte differentiation 9.17E-04 2.07 5.83E-02 
Histone H4 acetylation 9.09E-04 4.00 5.88E-02 
Transcription, DNA-dependent 8.95E-04 1.58 5.90E-02 
Histone H2A acetylation 1.01E-03 5.18 6.20E-02 
Regulation of cell cycle 1.13E-03 1.53 6.66E-02 
rRNA processing 1.12E-03 2.13 6.70E-02 
Hemopoietic or lymphoid organ 
development 1.19E-03 1.61 6.88E-02 
Leukocyte differentiation 1.27E-03 1.90 7.24E-02 
Cell cycle process 1.34E-03 1.38 7.47E-02 
Immune system development 1.37E-03 1.58 7.53E-02 
Homeostasis of number of cells 1.44E-03 2.04 7.68E-02 
Mitosis 1.42E-03 1.66 7.71E-02 
Nuclear division 1.42E-03 1.66 7.71E-02 
Protein polyubiquitination 1.47E-03 3.42 7.72E-02 
Nucleoside metabolic process 1.54E-03 2.36 7.85E-02 
Covalent chromatin modification 1.52E-03 1.90 7.86E-02 
B cell activation 1.58E-03 2.22 7.91E-02 
Hemopoiesis 1.69E-03 1.62 8.32E-02 
Cofactor metabolic process 1.83E-03 1.69 8.86E-02 
rRNA metabolic process 1.97E-03 2.04 9.15E-02 
B cell differentiation 1.92E-03 2.59 9.16E-02 
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Histone acetylation 1.92E-03 2.59 9.16E-02 
RNA modification 1.92E-03 2.59 9.16E-02 
Regulation of lymphocyte activation 1.95E-03 1.80 9.18E-02 
Chromatin modification 2.04E-03 1.56 9.33E-02 
Glycoprotein catabolic process 2.32E-03 3.95 1.04E-01 
Transcription from RNA 
polymerase II promoter 2.56E-03 1.60 1.12E-01 
Ribonucleoside monophosphate 
biosynthetic process 2.60E-03 3.48 1.12E-01 
Lymphocyte homeostasis 2.65E-03 3.17 1.12E-01 
Positive regulation of ligase activity 2.55E-03 2.19 1.13E-01 
Induction of apoptosis by 
extracellular signals 2.95E-03 1.90 1.23E-01 
Protein ubiquitination 3.11E-03 1.87 1.26E-01 
Cell activation 3.10E-03 1.52 1.28E-01 
Nuclear mRNA splicing, via 
spliceosome 3.26E-03 1.74 1.31E-01 
RNA splicing, via transesterification 
reactions 3.26E-03 1.74 1.31E-01 
RNA splicing, via transesterification 
reactions with bulged adenosine as 
nucleophile 3.26E-03 1.74 1.31E-01 
I-kappaB kinase/NF-kappaB 
cascade 3.56E-03 2.26 1.40E-01 
Amino acid activation 3.97E-03 2.51 1.53E-01 
tRNA aminoacylation 3.97E-03 2.51 1.53E-01 
tRNA aminoacylation for protein 
translation 3.97E-03 2.51 1.53E-01 
DNA replication 4.05E-03 1.64 1.54E-01 
Oxidoreduction coenzyme 
metabolic process 4.13E-03 2.39 1.56E-01 
Proteasomal protein catabolic 
process 4.25E-03 1.92 1.56E-01 
Proteasomal ubiquitin-dependent 
protein catabolic process 4.25E-03 1.92 1.56E-01 
Attachment of GPI anchor to 
protein 4.21E-03 6.35 1.57E-01 
Ribonucleoside monophosphate 
metabolic process 4.68E-03 3.20 1.69E-01 
236 
 
 
 
 
Ubiquitin-dependent protein 
catabolic process 4.74E-03 1.54 1.70E-01 
Positive regulation of protein 
ubiquitination 5.03E-03 2.01 1.77E-01 
Leukocyte homeostasis 5.11E-03 2.72 1.78E-01 
Cell division 5.34E-03 1.48 1.84E-01 
ER to Golgi vesicle-mediated 
transport 5.53E-03 2.54 1.88E-01 
Immune response-regulating cell 
surface receptor signaling pathway 5.53E-03 2.54 1.88E-01 
Lymphocyte proliferation 5.53E-03 2.54 1.88E-01 
Regulation of leukocyte activation 5.76E-03 1.66 1.91E-01 
Negative regulation of cellular 
protein metabolic process 5.73E-03 1.63 1.92E-01 
Coenzyme metabolic process 6.27E-03 1.68 2.03E-01 
T cell homeostasis 6.27E-03 3.39 2.04E-01 
Regulation of cell activation 6.82E-03 1.63 2.16E-01 
Vesicle-mediated transport 7.17E-03 1.31 2.19E-01 
Regulation of protein ubiquitination 7.24E-03 1.87 2.19E-01 
Erythrocyte development 7.17E-03 4.44 2.20E-01 
Negative regulation of 
macromolecule metabolic process 7.05E-03 1.27 2.21E-01 
Cell proliferation 7.13E-03 1.37 2.21E-01 
Erythrocyte maturation 7.67E-03 5.56 2.28E-01 
Viral reproductive process 7.85E-03 2.15 2.29E-01 
Regulation of ligase activity 7.82E-03 1.98 2.30E-01 
Immune response-regulating signal 
transduction 8.04E-03 2.22 2.30E-01 
Leukocyte proliferation 8.04E-03 2.42 2.32E-01 
Mononuclear cell proliferation 8.04E-03 2.42 2.32E-01 
tRNA processing 9.41E-03 1.99 2.60E-01 
Immune response-activating cell 
surface receptor signaling pathway 9.37E-03 2.51 2.61E-01 
Positive regulation of ubiquitin-
protein ligase activity 9.94E-03 2.03 2.71E-01 
Negative regulation of protein 
metabolic process 1.01E-02 1.57 2.71E-01 
DNA repair 1.09E-02 1.44 2.89E-01 
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Immune response-activating signal 
transduction 1.12E-02 2.22 2.93E-01 
T cell differentiation 1.20E-02 2.05 3.07E-01 
Regulation of protein binding 1.24E-02 2.76 3.14E-01 
Activation of caspase activity by 
cytochrome c 1.26E-02 4.94 3.14E-01 
Negative regulation of protein 
modification process 1.27E-02 1.72 3.15E-01 
Heterocycle biosynthetic process 1.25E-02 2.11 3.15E-01 
RNA polyadenylation 1.50E-02 3.81 3.54E-01 
Neuron apoptosis 1.49E-02 3.27 3.56E-01 
Negative regulation of 
macromolecule biosynthetic 
process 1.57E-02 1.28 3.67E-01 
Negative regulation of protein 
ubiquitination 1.64E-02 1.92 3.75E-01 
M phase 1.63E-02 1.38 3.75E-01 
Regulation of cell death 1.72E-02 1.22 3.84E-01 
Nucleotide-excision repair 1.74E-02 2.10 3.85E-01 
Chromosome segregation 1.71E-02 1.87 3.85E-01 
Positive regulation of ubiquitin-
protein ligase activity during mitotic 
cell cycle 1.76E-02 1.96 3.86E-01 
Erythrocyte differentiation 1.87E-02 2.27 4.02E-01 
Positive regulation of endothelial 
cell proliferation 2.04E-02 3.56 4.21E-01 
Regulation of programmed cell 
death 2.04E-02 1.22 4.22E-01 
Regulation of T cell activation 2.01E-02 1.67 4.23E-01 
Regulation of cellular protein 
metabolic process 2.03E-02 1.29 4.23E-01 
Cofactor biosynthetic process 2.19E-02 1.74 4.39E-01 
Positive regulation of lymphocyte 
activation 2.19E-02 1.74 4.39E-01 
Fatty acid beta-oxidation using 
acyl-CoA oxidase 2.18E-02 5.93 4.40E-01 
Positive regulation of interleukin-12 
production 2.18E-02 5.93 4.40E-01 
Mitochondrial membrane 
organization 2.24E-02 2.50 4.44E-01 
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Negative regulation of biosynthetic 
process 2.31E-02 1.26 4.52E-01 
Protein folding 2.39E-02 1.51 4.61E-01 
Golgi organization 2.45E-02 2.96 4.67E-01 
Release of cytochrome c from 
mitochondria 2.45E-02 2.96 4.67E-01 
Regulation of ubiquitin-protein 
ligase activity during mitotic cell 
cycle 2.51E-02 1.88 4.72E-01 
Viral reproduction 2.51E-02 1.88 4.72E-01 
Anaphase-promoting complex-
dependent proteasomal ubiquitin-
dependent protein catabolic 
process 2.71E-02 1.91 4.76E-01 
Negative regulation of ubiquitin-
protein ligase activity during mitotic 
cell cycle 2.71E-02 1.91 4.76E-01 
Regulation of ubiquitin-protein 
ligase activity 2.57E-02 1.82 4.77E-01 
Negative regulation of cellular 
biosynthetic process 2.70E-02 1.25 4.77E-01 
Antigen receptor-mediated 
signaling pathway 2.67E-02 2.42 4.78E-01 
Regulation of apoptosis 2.66E-02 1.21 4.78E-01 
B cell homeostasis 2.74E-02 4.04 4.78E-01 
mRNA cleavage 2.74E-02 4.04 4.78E-01 
mRNA polyadenylation 2.74E-02 4.04 4.78E-01 
Regulation of mitochondrial 
membrane permeability 2.74E-02 4.04 4.78E-01 
Chromatin assembly or 
disassembly 2.57E-02 1.61 4.79E-01 
mRNA 3'-end processing 2.70E-02 3.33 4.79E-01 
Positive regulation of leukocyte 
activation 2.65E-02 1.68 4.79E-01 
RNA 3'-end processing 2.63E-02 2.63 4.80E-01 
T cell proliferation 2.63E-02 2.63 4.80E-01 
Protein tetramerization 2.63E-02 2.28 4.81E-01 
Positive regulation of caspase 
activity 2.92E-02 1.96 4.96E-01 
Positive regulation of peptidase 
activity 2.92E-02 1.96 4.96E-01 
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Ribonucleoside metabolic process 2.92E-02 2.13 4.98E-01 
Macromolecular complex subunit 
organization 3.01E-02 1.21 5.04E-01 
Phosphoinositide biosynthetic 
process 3.06E-02 2.22 5.06E-01 
Initiation of viral infection 3.06E-02 2.83 5.08E-01 
Vesicle targeting 3.06E-02 2.83 5.08E-01 
DNA damage response, signal 
transduction 3.17E-02 1.78 5.09E-01 
Peptide metabolic process 3.14E-02 2.01 5.10E-01 
Phosphoinositide metabolic 
process 3.12E-02 1.83 5.10E-01 
GPI anchor biosynthetic process 3.16E-02 2.35 5.10E-01 
Negative regulation of translation 3.16E-02 2.35 5.10E-01 
DNA catabolic process 3.29E-02 1.93 5.20E-01 
Cell cycle phase 3.31E-02 1.29 5.20E-01 
Negative regulation of ligase 
activity 3.40E-02 1.86 5.25E-01 
Negative regulation of ubiquitin-
protein ligase activity 3.40E-02 1.86 5.25E-01 
Positive regulation of protein 
metabolic process 3.39E-02 1.39 5.27E-01 
Positive regulation of filopodium 
assembly 3.51E-02 5.08 5.34E-01 
Regulation of filopodium assembly 3.51E-02 5.08 5.34E-01 
Activation of caspase activity 3.56E-02 1.98 5.35E-01 
Induction of apoptosis by 
intracellular signals 3.56E-02 1.98 5.35E-01 
Negative regulation of lymphocyte 
activation 3.56E-02 1.98 5.35E-01 
Maintenance of protein location in 
cell 3.55E-02 2.17 5.37E-01 
DNA packaging 3.66E-02 1.60 5.44E-01 
Protein kinase cascade 3.79E-02 1.30 5.44E-01 
GPI anchor metabolic process 3.71E-02 2.29 5.44E-01 
Maintenance of protein location 3.82E-02 2.04 5.45E-01 
Negative regulation of cell 
activation 3.70E-02 1.89 5.45E-01 
Glycerophospholipid biosynthetic 
process 3.78E-02 1.83 5.46E-01 
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T cell receptor signaling pathway 3.76E-02 2.71 5.47E-01 
Monosaccharide metabolic process 3.78E-02 1.40 5.48E-01 
Positive regulation of cell activation 4.04E-02 1.60 5.64E-01 
Pyridine nucleotide metabolic 
process 4.08E-02 2.12 5.65E-01 
Positive regulation of cytokine 
production 4.21E-02 1.68 5.73E-01 
Negative regulation of immune 
system process 4.23E-02 1.71 5.73E-01 
Lipid modification 4.20E-02 1.80 5.74E-01 
Erythrocyte homeostasis 4.34E-02 2.00 5.80E-01 
Purine nucleoside monophosphate 
biosynthetic process 4.38E-02 2.96 5.82E-01 
Purine ribonucleoside 
monophosphate biosynthetic 
process 4.38E-02 2.96 5.82E-01 
Regulation of erythrocyte 
differentiation 4.38E-02 2.96 5.82E-01 
Macromolecular complex assembly 4.47E-02 1.20 5.87E-01 
Viral infectious cycle 4.67E-02 2.07 6.01E-01 
Regulation of establishment of 
protein localization 4.97E-02 1.54 6.21E-01 
Negative regulation of translational 
initiation 4.96E-02 3.42 6.22E-01 
Negative regulation of leukocyte 
activation 5.04E-02 1.87 6.24E-01 
Regulation of DNA metabolic 
process 5.10E-02 1.56 6.27E-01 
Regulation of protein transport 5.10E-02 1.56 6.27E-01 
rRNA modification 5.15E-02 4.44 6.29E-01 
Apoptotic mitochondrial changes 5.26E-02 2.29 6.35E-01 
Protein amino acid N-linked 
glycosylation 5.30E-02 2.02 6.36E-01 
Myeloid cell differentiation 5.44E-02 1.62 6.44E-01 
Regulation of B cell activation 5.50E-02 1.92 6.46E-01 
Regulation of caspase activity 5.60E-02 1.69 6.51E-01 
Response to cytokine stimulus 5.60E-02 1.69 6.51E-01 
Mitochondrion organization 5.76E-02 1.48 6.60E-01 
Cellular macromolecular complex 
subunit organization 5.93E-02 1.27 6.67E-01 
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Nitrogen compound biosynthetic 
process 5.91E-02 1.29 6.68E-01 
Hexose metabolic process 6.02E-02 1.39 6.71E-01 
Glycerolipid biosynthetic process 6.12E-02 1.67 6.74E-01 
Spliceosome assembly 6.11E-02 2.22 6.75E-01 
Phospholipid biosynthetic process 6.23E-02 1.57 6.79E-01 
Nucleobase, nucleoside and 
nucleotide biosynthetic process 6.35E-02 1.38 6.82E-01 
Nucleobase, nucleoside, nucleotide 
and nucleic acid biosynthetic 
process 6.35E-02 1.38 6.82E-01 
Pseudouridine synthesis 6.34E-02 3.17 6.84E-01 
DNA damage response, signal 
transduction by p53 class mediator 6.43E-02 2.39 6.85E-01 
Protein homotetramerization 6.43E-02 2.39 6.85E-01 
Negative regulation of alpha-beta T 
cell proliferation 6.49E-02 6.67 6.87E-01 
Purine nucleoside monophosphate 
metabolic process 6.58E-02 2.67 6.90E-01 
Purine ribonucleoside 
monophosphate metabolic process 6.58E-02 2.67 6.90E-01 
Negative regulation of cell cycle 6.67E-02 1.65 6.94E-01 
Positive regulation of cellular 
protein metabolic process 6.71E-02 1.34 6.94E-01 
Glycerophospholipid metabolic 
process 6.79E-02 1.51 6.97E-01 
Protein amino acid lipidation 6.86E-02 1.84 6.99E-01 
Positive regulation of protein 
modification process 6.97E-02 1.38 7.03E-01 
Establishment of vesicle 
localization 7.03E-02 2.15 7.05E-01 
Positive regulation of B cell 
activation 7.03E-02 2.15 7.05E-01 
Myeloid cell homeostasis 7.09E-02 3.95 7.07E-01 
Positive regulation of DNA 
recombination 7.09E-02 3.95 7.07E-01 
Positive regulation of isotype 
switching 7.09E-02 3.95 7.07E-01 
Purine deoxyribonucleotide 
metabolic process 7.09E-02 3.95 7.07E-01 
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Regulation of transcription from 
RNA polymerase III promoter 7.09E-02 3.95 7.07E-01 
Regulation of endopeptidase 
activity 7.25E-02 1.63 7.13E-01 
Nicotinamide metabolic process 7.37E-02 2.00 7.18E-01 
Nicotinamide nucleotide metabolic 
process 7.37E-02 2.00 7.18E-01 
Regulation of cyclin-dependent 
protein kinase activity 7.61E-02 1.81 7.28E-01 
Proteolysis 7.86E-02 1.13 7.36E-01 
Transcription initiation 7.86E-02 1.61 7.38E-01 
Positive regulation of T cell 
activation 8.04E-02 1.64 7.43E-01 
Negative regulation of gene 
expression 8.13E-02 1.20 7.45E-01 
Establishment of organelle 
localization 8.20E-02 1.67 7.47E-01 
Alkaloid metabolic process 8.30E-02 1.95 7.50E-01 
Regulation of mitotic cell cycle 8.51E-02 1.40 7.53E-01 
Maintenance of location in cell 8.41E-02 1.85 7.53E-01 
RNA elongation from RNA 
polymerase II promoter 8.41E-02 1.85 7.53E-01 
Nucleosome assembly 8.50E-02 1.59 7.54E-01 
Cellular macromolecular complex 
assembly 8.48E-02 1.26 7.55E-01 
Regulation of homeostatic process 8.60E-02 1.48 7.55E-01 
Regulation of translation 8.69E-02 1.43 7.58E-01 
Positive regulation of 
macromolecule metabolic process 8.87E-02 1.14 7.62E-01 
Regulation of protein modification 
process 8.87E-02 1.27 7.63E-01 
Glucose metabolic process 9.00E-02 1.39 7.66E-01 
Hemoglobin metabolic process 9.31E-02 3.56 7.71E-01 
RNA methylation 9.31E-02 3.56 7.71E-01 
Activation of pro-apoptotic gene 
products 9.28E-02 2.42 7.71E-01 
Nucleotide-excision repair, DNA 
damage removal 9.28E-02 2.42 7.71E-01 
Cellular amide metabolic process 9.25E-02 1.75 7.71E-01 
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Positive regulation of DNA 
metabolic process 9.25E-02 1.75 7.71E-01 
RNA localization 9.23E-02 1.51 7.72E-01 
Regulation of protein localization 9.22E-02 1.42 7.73E-01 
Small GTPase mediated signal 
transduction 9.56E-02 1.25 7.76E-01 
Dephosphorylation 9.51E-02 1.39 7.77E-01 
Nucleosome organization 9.56E-02 1.53 7.77E-01 
Branched chain family amino acid 
metabolic process 9.65E-02 2.78 7.77E-01 
tRNA modification 9.65E-02 2.78 7.77E-01 
Purine nucleoside metabolic 
process 9.97E-02 2.15 7.82E-01 
Purine ribonucleoside metabolic 
process 9.97E-02 2.15 7.82E-01 
Ribonucleotide metabolic process 9.91E-02 1.39 7.83E-01 
Cellular response to extracellular 
stimulus 9.95E-02 1.67 7.83E-01 
Regulation of peptidase activity 9.89E-02 1.55 7.83E-01 
Regulation of peptidase activity 9.89E-02 1.55 7.83E-01 
Nucleotide biosynthetic process 9.87E-02 1.34 7.84E-01 
(B) Large Platelet RNA: DAVID Functional Annotation Chart 
Term P-Value 
Fold 
Enrichment 
Benjamini 
Corrected P-
value 
Cellular macromolecular complex 
assembly 1.41E-04 2.83 2.27E-01 
Protein-DNA complex assembly 6.59E-04 4.68 3.31E-01 
Cellular macromolecular complex 
subunit organization 5.77E-04 2.52 4.10E-01 
Chromatin assembly 2.38E-03 4.35 5.81E-01 
Nucleosome assembly 1.94E-03 4.50 5.89E-01 
Macromolecular complex assembly 3.65E-03 1.85 6.15E-01 
Platelet activation 4.36E-03 7.39 6.32E-01 
Nucleosome organization 3.46E-03 4.07 6.53E-01 
Regulation of translational initiation 
in response to stress 8.66E-03 20.27 7.06E-01 
Response to wounding 8.37E-03 1.87 7.22E-01 
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DNA packaging 1.19E-02 3.23 7.23E-01 
Response to organic substance 9.98E-03 1.71 7.30E-01 
Axon ensheathment 1.15E-02 5.63 7.34E-01 
Ensheathment of neurons 1.15E-02 5.63 7.34E-01 
Macromolecular complex subunit 
organization 8.25E-03 1.73 7.48E-01 
Regulation of translation in 
response to stress 1.14E-02 17.74 7.53E-01 
Chromosome organization 7.11E-03 1.95 7.65E-01 
Myelination 8.11E-03 6.22 7.74E-01 
Response to bacterium 2.12E-02 2.45 8.05E-01 
Blood coagulation 2.08E-02 3.25 8.11E-01 
Coagulation 2.08E-02 3.25 8.11E-01 
Cell cycle 2.26E-02 1.58 8.13E-01 
Cell cycle process 1.65E-02 1.76 8.15E-01 
Defense response 2.02E-02 1.69 8.17E-01 
Chromatin assembly or 
disassembly 1.79E-02 2.98 8.25E-01 
Wound healing 2.00E-02 2.48 8.27E-01 
Regulation of action potential in 
neuron 2.68E-02 4.38 8.30E-01 
Negative regulation of cellular 
component organization 3.07E-02 2.66 8.32E-01 
Regulation of cellular component 
biogenesis 3.07E-02 2.66 8.32E-01 
Response to heat 3.01E-02 4.22 8.35E-01 
Protein localization 1.96E-02 1.56 8.36E-01 
Hemostasis 2.66E-02 3.07 8.39E-01 
Regulation of translation 2.59E-02 2.76 8.43E-01 
Carboxylic acid catabolic process 2.99E-02 2.98 8.43E-01 
Organic acid catabolic process 2.99E-02 2.98 8.43E-01 
Negative regulation of protein 
complex assembly 3.42E-02 5.56 8.46E-01 
Regulation of homeostatic process 3.35E-02 2.90 8.48E-01 
Chromatin organization 2.98E-02 1.88 8.52E-01 
Positive regulation of tumor 
necrosis factor production 3.88E-02 9.46 8.66E-01 
Regulation of cytokine production 3.79E-02 2.35 8.68E-01 
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Regulation of cardiac muscle 
contraction by calcium ion signaling 4.17E-02 47.30 8.71E-01 
Regulation of cardiac muscle 
contraction by regulation of the 
release of sequestered calcium ion 4.17E-02 47.30 8.71E-01 
Release of sequestered calcium ion 
into cytosol by sarcoplasmic 
reticulum 4.17E-02 47.30 8.71E-01 
Positive regulation of cytokine 
production 4.14E-02 3.15 8.76E-01 
Regulation of protein complex 
assembly 4.14E-02 3.15 8.76E-01 
Cell cycle phase 5.53E-02 1.71 9.16E-01 
Response to unfolded protein 6.26E-02 3.33 9.19E-01 
Cellular amino acid catabolic 
process 5.51E-02 3.48 9.20E-01 
Regulation of action potential 5.51E-02 3.48 9.20E-01 
Membrane organization 6.03E-02 1.74 9.20E-01 
Regulation of release of 
sequestered calcium ion into 
cytosol by sarcoplasmic reticulum 6.19E-02 31.53 9.21E-01 
Response to redox state 6.19E-02 31.53 9.21E-01 
Sarcoplasmic reticulum calcium ion 
transport 6.19E-02 31.53 9.21E-01 
Cell cycle arrest 6.65E-02 2.76 9.23E-01 
Interphase of mitotic cell cycle 6.65E-02 2.76 9.23E-01 
Mitochondrion organization 7.17E-02 2.40 9.23E-01 
Regulation of myeloid cell 
differentiation 6.00E-02 3.38 9.24E-01 
Golgi vesicle transport 5.87E-02 2.53 9.24E-01 
Interphase 7.33E-02 2.68 9.24E-01 
Regulation of translational initiation 5.48E-02 4.61 9.24E-01 
Glutamine family amino acid 
catabolic process 6.55E-02 7.10 9.24E-01 
Defense response to bacterium 8.79E-02 2.53 9.25E-01 
Protein polymerization 8.40E-02 3.86 9.25E-01 
Positive regulation of cell activation 8.54E-02 2.56 9.25E-01 
Response to endogenous stimulus 8.70E-02 1.64 9.26E-01 
Response to glucose stimulus 6.87E-02 4.20 9.26E-01 
Male meiosis 7.14E-02 6.76 9.26E-01 
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Regulation of cellular protein 
metabolic process 7.81E-02 1.60 9.27E-01 
Regulation of erythrocyte 
differentiation 5.42E-02 7.88 9.27E-01 
Amine catabolic process 8.22E-02 3.03 9.27E-01 
Positive regulation of binding 8.22E-02 3.03 9.27E-01 
Positive regulation of translation 8.38E-02 6.17 9.27E-01 
Microtubule-based movement 9.05E-02 2.51 9.28E-01 
Ubiquitin-dependent protein 
catabolic process 7.07E-02 1.95 9.28E-01 
Maintenance of protein location 8.01E-02 3.94 9.28E-01 
Response to hexose stimulus 7.62E-02 4.03 9.28E-01 
Response to monosaccharide 
stimulus 7.62E-02 4.03 9.28E-01 
Positive regulation of inflammatory 
response to antigenic stimulus 8.17E-02 23.65 9.29E-01 
Regulation of body fluid levels 7.78E-02 2.35 9.29E-01 
Glutamine family amino acid 
metabolic process 9.64E-02 3.64 9.32E-01 
Response to temperature stimulus 9.79E-02 2.85 9.32E-01 
Programmed cell death 9.53E-02 1.47 9.32E-01 
Negative regulation of organelle 
organization 9.47E-02 2.88 9.34E-01 
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Summary 
MicroRNAs (miRNAs) are small non-coding sequences regulating many 
processes in humans. Select species of viruses also encode miRNAs to evade 
host immunity and optimize an efficient viral cycle.  We sequenced plasma RNA 
from 40 participants of the Framingham Heart Study (FHS; visit 8) and, in 
addition to human miRNAs, identified 19 viral miRNAs from 11 different viruses, 
most not known to cause productive human infection. To validate this 
observation, viral miRNA expression was measured in the entire cohort (n=2763) 
utilizing high-throughput RT-qPCR.  Association with concurrently measured 
inflammatory biomarkers and mRNA by gene array was determined. There were 
16 viral miRNA-human mRNA co-expression pairs and an association with 
inflammatory biomarkers. To validate transfer, expression of viral miRNA was 
confirmed in murine plasma after infection with two different viruses. In summary, 
using a large cohort, we report for the first time that miRNAs from viruses are 
widely detected in the human circulation. 
 
Introduction 
As described, microRNAs (miRNAs) are 19 to 24 nucleotide single-stranded 
noncoding RNA sequences that are present in all multicellular organisms and 
regulate a vast number of biological processes (225, 226). miRNAs can regulate 
gene expression by binding to messenger RNA (mRNA) of transcribed genes 
thereby reducing gene expression. With the exception of the seeded sequence of 
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~6 nucleotides on the 5’ end, miRNAs do not have to align perfectly with the 
targeted mRNA sequence to achieve their function (226). As a result, one miRNA 
has the potential to post-transcriptionally regulate up to 300 different mRNA 
transcripts that may be related to a broad variety of processes (227, 228). Thus, 
an understanding of the regulatory complexity of miRNAs is central to 
comprehending wide-ranging biological pathways. 
In addition to multicellular organisms, select viruses encode and express 
miRNAs (228, 229). These select viruses include most DNA viruses from the 
Herpesviridae (230), Polyomaviridae and Adenoviridae (231) families.  Studies 
have shown that, in target cells, changes in expression of different viral miRNAs 
may play a role in the regulation of either lytic or latent infection. Whereas most 
subfamilies of herpesviruses cause a productive infection in single species, some 
herpesviruses have a broad range of hosts.  Herpes infections are characterized 
by the establishment of a lifelong, dormant state that can periodically reactivate 
and cause recurrent infection (230). 
 Herpesviruses are large enveloped viruses that can be categorized into 
three subfamilies, alpha, beta, and gamma, depending on their viral biology and 
genome sequence. Alphaherpesviruses such as Herpes simplex viruses (HSV) 1 
and 2 have a broad host range, short replicative cycle and establish latent 
infection in neurons. Betaherpesviruses such as Cytomegaloviruses (CMV) have 
large genomes that are well adapted to their respective hosts, have a long 
replicative cycle, and limited host range. Both human (hCMV) and mouse 
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(mCMV) viruses establish latency in hematopoietic progenitor cells and cause 
mild symptoms in immunocompetent organisms (228, 232). 
Gammaherpesviruses have a very restricted host range and are linked to human 
malignancies. Epstein-Barr virus (EBV) and Kaposi’s sarcoma-associated 
herpesvirus (KSHV) are human gammaherpesviruses and establish latency 
predominantly in B-cells (233, 234). EBV is associated with Hodgkin’s and 
Burkitt’s lymphoma and nasopharyngeal carcinoma, while KSHV causes 
lymphoma and Kaposi’s sarcoma (235, 236). All of these human DNA viruses 
can generate miRNAs in their host target cells that mediate viral replication and 
latency; however, the potential chronic expression and overall effect of these viral 
miRNAs in humans has yet to be established. Conversely, DNA viruses from the 
papillomavirus and poxvirus families as well as RNA viruses are not currently 
known to generate viral miRNA. Rather, most of these viruses directly manipulate 
host miRNA balance in order to regulate their infectious state (228, 237). For 
instance, RNA viruses such as influenza are not known to code for their own 
miRNAs but to affect the host’s miRNA pool, thereby, regulating its infectious 
state (238, 239).  An exception to this rule may be select RNA retroviruses such 
as bovine leukemia virus (BLV) that have an RNA genome encoding a conserved 
cluster of miRNAs (240).   
Viruses can increase the inflammatory state of the host beyond the target 
tissue or cell of replication.  How viruses achieve global inflammation is still 
unclear. In addition, select DNA viruses are known to incorporate into the host 
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genome, raising the risk for cancer.  As part of the NIH Common Fund-
sponsored Extracellular RNA Communication Consortium, we previously 
reported that, in a large observational cohort, plasma contains a broad number of 
human extracellular RNA including miRNAs (241). Further analysis of the plasma 
RNA sequencing led to the identification of 19 viral miRNAs from 11 different 
viruses and these findings were further studied in the entire cohort. Here, we 
report that viral miRNAs in human plasma associate with advancing age and 
select inflammatory biomarkers. To establish that viral infection directly leads to 
plasma viral miRNA expression, we conducted murine studies demonstrating that 
miRNAs from alpha- and betaherpesviruses are detectable in plasma post-
infection. 
 
Materials and Methods 
Study cohort 
The Framingham Heart Study (FHS) is a community-based, prospective study of 
cardiovascular disease and its risk factors. Cohorts undergo an examination at 
the FHS once every ~4-8 years and have been extensively phenotyped over 
multiple examinations with a wide variety of noninvasive tests. For the present 
study we used data and plasma samples from the 8th visit of the offspring (and 
their spouses) of the Original FHS participants (FHS Offspring cohort). The 
participants have an extraordinary wealth of clinical data available allowing us to 
examine the relation of disease and risk factors to gene expression. The FHS 
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protocol was approved by Boston University Medical Center and by UMass 
Medical School Institutional Review Boards; all participants provided informed 
consent. 
 
Study design 
As previously described, we determined the broadest number of exRNAs in 
human plasma by performing RNA sequencing on 40 previously stored samples 
from FHS participants (Offspring Cohort, Visit 8) (212). Full methods were 
previously published (212). We identified 19 viral miRNAs in plasma samples of 
40 participants that were confirmed in the entire FHS cohort (n=2763) by RT-
qPCR (see below). Basic characteristics of the full cohort can be found in Table 
F.1. Summary of the study design and findings can be found in the Graphical 
abstract.  
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Table F.1. Characteristics of the FHS Offspring Cohort (Visit 8, N=2763). 
Age (years) 66.8±9 
Women, n (%) 1499 (54%) 
Body Mass Index (BMI)  28.3±5 
Systolic BP (SBP) 129±17 
Diastolic BP (DBP) 74±10 
Hypertension (HT) 661 (24%) 
Coronary Heart Disease (CHD) 286 (10%) 
Cancer (any) 441 (16%) 
  
Biomarkers   
P-Selectin, ng/ml 41±14 
C-Reactive Protein, mg/L 3±7 
Tumor Necrosis Factor Receptor II, pg/ml 2687±1123 
Intercellular Adhesion Molecule 1, ng/ml 298±102 
Interleukin-6, pg/ml 3±3 
Monocyte Chemotactic Protein 1, pg/ml 388±141 
Osteoprotegerin, pmol/l 5±2 
 
Values are presented as mean ± standard deviation (SD) unless N (%) is indicated. 
 
Biomarker assessment 
Biomarker levels were measured in the 2763 participants of the FHS cohort. A 
detailed description for the detection of circulatory biomarkers has been 
previously described (242-244). Briefly, P-Selectin, C-reactive protein (CRP) and 
osteoprotegerin were detected in plasma (243, 244). Levels of Interleukin-6 (IL6), 
soluble Intercellular Adhesion Molecule 1 (sICAM1), Monocyte Chemotactic 
Protein 1 (MCP1) and soluble Tumor Necrosis Factor Receptor II (sTNFRII) were 
measured in serum (243, 244). Biomarker levels are provided in Table F.1. 
 
Plasma RNA isolation (human and mice) 
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RNA isolation from human plasma was performed as previously described (212). 
Briefly, RNA samples were isolated from 1 mL plasma using a miRCURY RNA 
Isolation Kit –Biofluids (Exiqon, Denmark). Murine plasma RNA was isolated from 
100 µl of plasma using the miRNeasy Serum/Plasma Kit (Qiagen, Germany).  
The RNA isolation was carried out via an automated QIAcube system (Qiagen, 
Germany).  RNA samples were eluted in 14 µl and stored at -80°C. 
 
Template Preparation for RNA Sequencing 
An Ion Chef System, Ion PI Chip Kit v3 and Hi-Q Chef kits were used for 
template preparation as previously described (212). The entire procedure was 
automated using the Ion Chef System. At the end of the template preparation, 
loaded PI Chips (Life Technologies, USA) were sequenced (212). RNA 
Sequencing was performed on an Ion Proton System as described (212) using 
the Ion PI Hi-Q Chef Kit (Life Technologies, USA).  
 
Sequencing Data Analysis Using the Genboree Sequencing Pipeline  
Detailed procedures for this analysis using the exceRpt tool available on the 
Genboree Workbench [http://www.genboree.org/] are published in (212).  After 
alignment to endogenous sequences and removal of all contaminants with 
endogenous sequences, the software aligned the remaining sequences to 
exogenous small RNAs. Reads not mapped to any exogenous small RNAs were 
255 
 
 
aligned again using sRNAbench to the complete set of viral miRNA sequences 
available in miRBase.  
 
RT-qPCR for viral miRNAs in human plasma 
A detailed description of this procedure was previously provided (212). Briefly, 
reverse transcription was performed using the miScript SYBR Green PCR Kit 
(Qiagen, Germany). Viral miRNA primers were purchased from Qiagen (MD, 
USA). Pre-amplification was done using miScript Microfluidics PreAMP Kit 
(Qiagen, MD, USA). RT-qPCR was resolved by Dynamic Arrays (Fluidigm, CA, 
USA) using primers designed by Qiagen (Table F.2). 
 
Table F.2: Primers used to screen the FHS cohort by RT-qPCR (related to Table 
F.6). 
  
Viral 
miRNA 
Sequence Virus Company 
TaqMan/ 
SYBR Green 
ebv-miR-
BART11-5p 
CAGTTTGGTG
CGCTAGTTG 
Epstein-Barr Virus 
(EBV) 
Qiagen SYBR Green 
kshv-miR-
K12-10a-5p 
GCTTGGGGC
GATACCAC 
Kaposi's sarcoma 
herpesvirus (KSHV) 
Qiagen SYBR Green 
kshv-miR-
K12-6-5p 
CAGCACCTAA
TCCATCGG 
Kaposi's sarcoma 
herpesvirus (KSHV) 
Qiagen SYBR Green 
hbv-miR-
B26-5p 
TGAGTTCGGG
CAGCAG 
Herpes B virus (HBV) Qiagen SYBR Green 
hbv-miR-
B7-5p 
GGCCTCGGG
TTCGCTT 
Herpes B virus (HBV) Qiagen SYBR Green 
mcmv-miR-
m59-2 
CCCGAAGAG
CCCTCACA 
Mouse 
cytomegalovirus 
(mCMV) 
Qiagen SYBR Green 
prv-miR-
LLT3 
GCACACGCC
CCTCTCG 
Pseudorabies virus 
(PRV) 
Qiagen SYBR Green 
prv-miR-
LLT6 
CGTACCGACC
CGCCTA 
Pseudorabies virus 
(PRV) 
Qiagen SYBR Green 
mdv2-miR- GTTTTCTCTC (MDV2) Qiagen SYBR Green 
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M18-5p AGGCTGGCAT 
blv-miR-B2-
5p 
ATGACTGAGT
GTAGCGC 
Bovine leukemia virus 
(BLV) 
Qiagen SYBR Green 
iltv-miR-I2 
TGTGCGATAG
GAGCCGA 
Infectious 
laryngotracheitis virus 
(ILTV) 
Qiagen SYBR Green 
 
mRNA expression profiling 
Whole blood mRNA expression was measured in 2446 participants in the FHS 
(Offspring Cohort, Visit 8), using Affymetrix exon array ST 1.0 platform, as 
previously described (245). This platform included 17,318 mRNA transcripts. A 
robust multichip analysis (RMA) algorithm was applied using Affymetrix Power 
Tools (APT) for generation of signal values (i.e., log-2 transformed expression 
intensity) to yield an initially normalized dataset.  
 
Detection of viral miRNAs in murine plasma 
Animals: Twelve-week-old male C57BL/6J mice were obtained from The Jackson 
Laboratory.  All experimental procedures were approved by the Institutional 
Animal Care and Use Committee at the University of Massachusetts Medical 
School.   
HSV1 Infection, Harvest and qPCR: Twenty mice were inoculated intravenously 
via the tail vein with either saline or HSV1-KOS at 1 x 106 pfu per mouse. Purified 
HSV1-KOS was provided by Dr. David Knipe (Harvard Medical School). At 24 
hours post-inoculation, five mice from each group were euthanized by carbon 
dioxide asphyxiation and blood was obtained via cardiac puncture. RNA was 
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isolated as described above and eluted in 14 µl.  RNA was normalized to 10 ng 
per cDNA reaction.  cDNA was synthesized using the Universal cDNA Synthesis 
Kit II (EXIQON, USA) on a Veriti Thermal Cycler (Applied Biosystems, Inc., 
USA).  Plasma cDNA was diluted 1:40 and qPCR was performed on a 7900HT 
Fast Real-Time PCR System using the ExiLENT SYBR® Green Master Mix and 
twenty-six MicroRNA LNA™ PCR primer sets for HSV1 (EXIQON, USA, Table 
F.3).   
 
Table F.3: Primers used for screening viral miRNAs in mice (related to Table F.10). 
miRNA Virus Company 
TaqMan/ 
SYBR 
Green 
Catalog 
Number 
Assay ID 
hsv1-miR-H1-3p HSV-1 Exiqon 
SYBR 
Green 
205826 N/A 
hsv1-miR-H3-3p HSV-1 Exiqon 
SYBR 
Green 
205811 N/A 
hsv1-miR-H4-3p HSV-1 Exiqon 
SYBR 
Green 
205740 N/A 
hsv1-miR-H6-3p HSV-1 Exiqon 
SYBR 
Green 
205796 N/A 
hsv1-miR-H14-
5p 
HSV-1 Exiqon 
SYBR 
Green 
205848 N/A 
mcmv-miR-m59-
1 
mCMV 
Applied 
Biosystems 
TaqMan 4440885 005484_mat 
mcmv-miR-m59-
2 
mCMV 
Applied 
Biosystems 
TaqMan 4440885 006856_mat 
mcmv-miR-M01-
4-3p 
mCMV 
Applied 
Biosystems 
TaqMan 4440885 006883_mat 
mcmv-miR-M23-
2-3p 
mCMV 
Applied 
Biosystems 
TaqMan 4440885 007525_mat 
mcmv-miR-m44-
1 
mCMV 
Applied 
Biosystems 
TaqMan 4440885 466213_mat 
 
mCMV Inoculation, Harvest and qPCR  
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Twenty mice were inoculated intraperitoneally with either saline or mCMV (Smith 
Strain) at 1 x 105 pfu per mouse.  At 24 hours and 7 days post-inoculation, five 
mice from each group were euthanized by carbon dioxide asphyxiation and blood 
was obtained via cardiac puncture. RNA was isolated as described above, 3 µl of 
the total 14µl RNA-eluate was used per cDNA reaction, with the exception of 
mcmv-miR-m59-1 and mcmv-miR-m59-2 which were normalized to 10 ng of RNA 
per cDNA reaction.  cDNA was synthesized using the TaqMan® MicroRNA 
Reverse Transcription Kit (Applied Biosystems, USA) and TaqMan™ MicroRNA 
RT Assays for mCMV (Table S5) (Applied Biosystems, USA). qPCR was 
performed on a 7900HT Fast Real-Time PCR System using the TaqMan 2X 
Universal PCR Master Mix II, No AmpErase UNG (Applied Biosystems, USA) 
and the TaqMan™ MicroRNA TM Assays (Table F.3).  
 
Statistics 
All statistical analyses were performed using STATA 13.0. Descriptive statistics 
are displayed as mean ± SD for continuous variables and count (percentage) for 
categorical variables. The RT-qPCR results cycle threshold (Ct) values were 
normalized (∆Ct) by the global mean of expressed results to account for inter-
individual sample differences.  miRNAs not expressed were assigned a Ct value 
of 23 (any miRNA giving undetermined values in 23 cycles) to allow for RT-qPCR 
protocol/machine background. Ordinary least squares linear regression models 
were used to test for association with the normalized Ct value of each viral 
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miRNA and each phenotype (i.e. biomarkers, clinical factors, and disease 
status).  The distributions of biomarker assay levels in the restricted sample were 
not normally distributed and were consequently natural log (ln) transformed for 
statistical analysis. To account for the number of statistical comparisons 
conducted, we employed false discovery rate (FDR=5%) correction for the 
number of phenotypes tested (7 biomarkers and 8 clinical factors, Table F.1) 
within each of the viral miRNAs.   
 
Viral miRNA - mRNA co-expression analysis 
Co-expression analysis was performed only in the FHS participants for whom 
both viral miRNA and mRNA data were available (N=2395). Two analyses were 
performed for each viral miRNA-mRNA pair (11 viral miRNA x 17,318 mRNA): 1. 
Dichotomous analysis: coding viral miRNAs as expressed (1) vs. not expressed 
(0); 2. Continuous analysis: analysis included only samples in which viral miRNA 
were expressed. A linear mixed model implemented in “lmekin” function of R 
(246, 247) was used to model mRNA as a response variable and viral miRNA as 
an independent variable, adjusting for age, sex, technical covariates for mRNA 
expression profiling measurements described previously (248), imputed cell 
counts (248), and family structure. Benjamini-Hochberg methods were used to 
calculate FDR or Bonferroni-corrected P<0.05.) 
 
In silico prediction of viral miRNA targets 
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Viral miRNA targets were predicted using the VIRmiRNA online database tool 
(http://crdd.osdd.net/servers/virmirna) by exactly matching the 7mer seeded 
region of a vmiRNA with the untranslated region and coding region of mRNAs 
(249).  
 
Results 
Identification of viral miRNAs in human plasma 
As previously described (18), we performed small RNA sequencing from plasma 
of 40 FHS participants. After a series of alignments to human miRNA, tRNA, 
piRNA, and snoRNA, reads that were not mapped to any of these sequence 
types were then aligned to the available non-human genomes in exceRpt small 
RNA-seq Pipeline (www.genboree.org, as of 2015).  We identified 19 different 
viral miRNAs from 11 different viruses that had variable expression in the plasma 
of the 40 participants (Figure F.1; Table F.4; Table F.5).  
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Figure F.1: Graphic of workflow for viral miRNA study.
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Table F.4: Viral miRNAs identified by sequencing in the plasma of 40 participants 
in the FHS (Offspring Cohort, visit 8). 
 
Viral miRNA 
Sequencing 
Nucleotide (NT) 
sequence 
Nt 
# 
Homology 
with other 
viral 
miRNA 
(Score, p-
value) 
Homology 
with 
human 
miRNA 
(Score, e-
value) 
N 
Mean 
rpm     
ebv-miR-
BART11-5p 
11 1.56 
UCAGACAGUUUG
GUGCGCUAGUUG 
24 
rlcv-miR-
rL1-14-5p 
(70, 1.3) 
  
kshv-miR-
K12-10a-5p 
11 2.86 
GGCUUGGGGCGA
UACCACCACU 
22     
kshv-miR-
K12-6-5p 
12 1.33 
CCAGCAGCACCU
AAUCCAUCGG 
22   
hsa-miR-
324-3p (60, 
9.1) 
hcmv-miR-
US25-2-3p 
40 110.66 
AUCCACUUGGAG
AGCUCCCGCGGU 
24     
hbv-mir-B26-
3p-novel 
2 2.6 
GCGCGCCGGCGG
CCCGGGCTCG 
22 
hbv-miR-
B26-5p (64, 
4.2) 
hsa-miR-
1199-5p 
(65, 3.5) 
hbv-miR-
B26-5p 
6 1.73 
UGAGUUCGGGCA
GCAGGCGCGU 
22     
hbv-miR-B7-
5p 
4 1.39 
UUCUGGGCCUCG
GGUUCGCUUC 
22     
mcmv-miR-
m59-2 
9 1.47 
CCCGAAGAGCCC
UCACAGAGCC 
22     
prv-miR-
LLT3 
30 9 
CGCACACGCCCC
UCUCGCGCAC 
22     
prv-miR-
LLT6 
8 2.96 
CGUACCGACCCG
CCUACCAGG 
21     
mdv2-miR-
M18-5p 
7 1.43 
UGUUUUCUCUCA
GGCUGGCAUUG 
23     
mdv2-miR-
M21-3p 
6 1.24 
GAGCACCACGCC
GAUGGACGGAGA 
24   
hsa-miR-
3663-5p 
(61, 7.5) 
mdv2-miR-
M24-3p 
27 6.38 
UUAGAUGCCGUC
AGGGAAAGAU 
22     
rlcv-miR-rL1-
17-3p 
10 1.51 
UGCUUCGCCCUC
UCCAUCAUAA 
22   
hsa-miR-
2681-3p 
(60, 9.1) 
rlcv-miR-rL1-
17-5p 
3 1.14 
UGAUGGACAGCG
GGGAAGUGCACU 
24 
hsv1-miR-
H1-5p (60, 
9.0) 
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rlcv-miR-rL1-
29-3p 
10 1.74 
UUUUGUUUGCUU
GGGACUGCAG 
22 
ebv-miR-
BART19-3p 
(91, 0.02) 
hsa-miR-
584-5p (68, 
2.0) 
blv-miR-B2-
5p 
15 3.49 
AUGACUGAGUGU
AGCGCAGAGA 
22     
hvt-miR-H14-
3p 
4 1.28 
AGCUACAUUGCC
CGCUGGGUUUC 
23   
hsa-miR-
221-3p 
(97,0.007) 
hsa-miR-
4482-5p 
(63, 4.7) 
iltv-miR-I2 1 1.34 
GGAAGGCUGUGC
GAUAGGAGCCGA 
24     
 
*Viral miRNAs with any similarities to host miRNAs or to miRNAs coming from other 
human viruses were eliminated from all further analysis; similarity scores and p-values 
were determined using www.mirbase.org with E-value cutoff =10 and maximum number 
of hits=100; Just “N” in the heather- is the number of people in which a miRNA were 
detected by sequencing; rpm-reads per million; Nt-nucleotide 
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Table F.5: Human Herpesvirus family and viruses (in black) that gave rise to the 
miRNAs detected in the plasma of the FHS participants (Offspring cohort, visit 8); 
classification and miRNAs (related to Table F.4). 
Abbreviation Other names 
Virus 
type/Family 
Host 
Mature 
miRNA 
(#) 
References  
HSV1 
Herpes 
Simplex Virus 
1; HHV-1 
DNA; Alpha 
Herpesvirus 
human 27 
PMID:20181707; 
PMID:22661375; 
PMID:23512275 
HSV2 
Herpes 
Simplex Virus 
1; HHV-2 
DNA; Alpha 
Herpesvirus 
human 24 
PMID:20181707; 
PMID:19889786 
VZV* 
Varicella-zoster 
virus, HHV3 
DNA; Alpha 
Herpesvirus 
human none PMID:19889786 
EBV 
Epstein-Barr 
virus; HHV4 
DNA; 
Gamma 
Herpesvirus 
human 44 PMID:17604727 
hCMV 
Human cyto-
megalovirus;  
HHV5 
DNA; Beta 
Herpesvirus 
human 26 
PMID:22013051; 
PMID:22715351 
HHV-6A & 6B 
Roseolovirus; 
HHV6 
DNA; Beta 
Herpesvirus 
human 8 (6B) PMID:22114334 
HHV-7 
Roseolovirus; 
HHV7 
DNA; Beta 
Herpesvirus 
human 
none 
known 
PMID:22114334 
KSHV 
Kaposi-
sarcoma virus; 
HHV8 
DNA; 
Gamma 
Herpesvirus 
human 28 PMID:22114334 
HBV 
Herpes B Virus 
Cercopithecine 
HV 1 
DNA virus; 
Alpha 
Herpesvirus 
simian 
zoonotically-
human 
15 
PMID:19144716; 
PMID:21543500 
mCMV 
Mouse 
cytomegaloviru
s; MuHV-1 
DNA; Beta 
Herpesvirus 
murine 29 
PMID:17928340; 
PMID:17942535 
PRV 
Pseudorabies 
virus; 
SuHV-1 
DNA; Alpha 
Herpesvirus 
swine 13 PMID:22292087 
MDV2 
Marek’s 
disease virus, 
type 2; GaHV-3 
DNA; Alpha 
Herpesvirus 
avian 
(chicken and 
turkey) 
36 
PMID: 17459919 
PMID:19328516 
ILTV 
Infectious 
laryngotracheiti
s virus; GaHV-
1 
DNA; Alpha 
Herpesvirus 
avian 
(chicken, 
turkey and 
others) 
10 
PMID:19728068; 
PMID:19328516 
BLV 
Bovine 
leukemia virus 
ssRNA-RT; 
Retroviridae 
bovine 10 
PMID:23345446 
PMID:22308400 
 
*Human HHV3 has no LAT ortholog and it does not encode miRNA and it was not 
detected in the FHS. Only viruses in black font were detected in the plasma of the FHS 
participants. 
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All of the viral miRNAs were products of DNA viruses with the exception of one 
miRNA that originated from bovine leukemia virus (BLV). BLV is a retrovirus with 
a single-stranded RNA-RT genome that is able to integrate into the DNA of the 
B-cell of its host as a DNA intermediate. All miRNAs from DNA viruses came 
from the Herpesviridae family (Table F.4; Table F.5). Four of the viral miRNAs 
originated from three viruses that use humans as a host (EBV, KSHV, and 
HCMV). Three viral miRNAs originated from Herpes B Virus, of which the natural 
host is thought to be macaque monkeys and, though rare in humans, can be 
fatal.  The remaining 12 miRNAs that we identified originated from viruses that 
are not known to cause any productive infections in humans but, instead, target 
other animals as hosts. These are swine (PRV, two miRNA), bovine (BLV, one 
miRNA), avian (MDV2, three miRNA; HVT-1 one miRNA and ILTV-1 one 
miRNA), mice (mCMV, one miRNA), and simian (HBV, three miRNA; RLCV, 
three miRNA) viruses (Table F.4; Table F.5). The presence of these miRNAs was 
confirmed by RT-qPCR in the plasma of FHS participants (Offspring Cohort, Visit 
8). The presence of viral miRNAs varied from 2.2% (ebv-miR-BART11-5p) to 
99.7% (mdv2-miR-M18-5p) in the entire cohort of 2763 participants (Table F.6). 
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Table F.6: Viral miRNA expression in the FHS Offspring Cohort (Visit 8, N=2763) 
confirmed by qPCR. 
 
Viral miRNA N % 
Ct Values 
(mean ± SD) 
ebv-miR-BART11-5p 60 2.2% 21.3 ±1 
kshv-miR-K12-10a-5p 325 11.8% 21.2 ±1 
kshv-miR-K12-6-5p 766 27.7% 20.9 ±1 
hbv-miR-B26-5p 171 6.2% 21.0 ±1 
hbv-miR-B7-5p 101 3.7% 20.9 ±2 
mcmv-miR-m59-2 227 8.2% 21.3 ±1 
prv-miR-LLT3 80 2.9% 21.3 ±1 
prv-miR-LLT6 92 3.3% 21.0 ±1 
mdv2-miR-M18-5p 2,754 99.7% 17.7 ±1 
blv-miR-B2-5p 66 2.4% 21.3 ±1 
iltv-miR-I2 2,641 95.6% 19.7 ±1 
hsa-miR-16-5p 2716 98.3% 13.5 ±2 
 
*miRNA levels were determined in the plasma of the participants by quantitative qPCR. 
Viral miRNAs: hcmv-miR-US25-2-3p and mdv2-miR-M24-3p were detected in less than 
0.7% in the plasma of the participants and were omitted from all further analysis. Human 
miRNA has-mir-16-5p Ct values here are used as a reference to compare host vs. viral 
miRNA Ct values. 
 
Homology of plasma viral miRNAs with miRNAs originating from host or 
other viruses 
Since the observed broad presence of viral miRNAs in human plasma was 
unexpected, we wanted to confirm our findings and eliminate any false positive 
results due to homology between detected miRNAs, host miRNAs and viral 
miRNAs coming from human viruses. To test similarity of viral miRNA to all 
known miRNAs, we utilized the mirbase.org search engine and known miRNA 
sequences (Table F.4).  Turkey herpesvirus (HVT) viral miRNA, hvt-miR-H14-3p, 
was 97% similar to human has-miR-221-3p, and all three Rhesus 
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lymphocryptovirus (rLCV) simian viral miRNAs were similar to a variable extent to 
viral miRNA of EBV origin, HSV-1 origin or of human origin. For stringency, we 
eliminated all viral miRNAs that had any similarities with host or with viral 
miRNAs that come from viruses that use humans as a host. Two of the miRNAs 
detected by RT-qPCR in less than 0.7% of the 2763 participants were also 
eliminated from further analysis. The distribution of the remaining 11 viral 
miRNAs in the plasma of FHS participants (Offspring Cohort, Visit 8) was 
confirmed by RT-qPCR as outlined in Table E.6. The characteristics of the 
participant population in this study are outlined in Table F.1. 
 
Human Plasma Viral miRNA expression associates with circulating 
inflammatory biomarkers  
Many viral infections induce inflammation and/or thrombosis.  Thus, we 
evaluated if any of the plasma viral miRNAs identified associate with circulating 
inflammatory or pro-thrombotic biomarkers previously measured from the same 
blood draw used for the viral miRNA measurements. Nine of the 11 viral miRNAs 
were associated with at least one inflammatory biomarker (Table F.7, Table F.8). 
Viral miRNA from avian MDV2 virus, mdv2-miR-M18-5p, was associated with all 
4 inflammatory biomarkers. Not surprisingly, viral miRNAs originating from 
Kaposi’s sarcoma-associated herpesvirus (kshv-miR-k12-10a-5p, khsv-miR-k12-
6-5p) and Herpes B virus (hbv-miR-B26-5p) were associated positively with 
soluble TNF-alpha receptor II protein presence. In addition, avian viral miRNAs, 
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iltv-miR-I2 and mdv2-miR-M18-5p, also were associated with elevated sTNFRII 
presence. Seven out of the 11 viral miRNAs were associated with soluble 
intercellular adhesion molecule-1 (sICAM-1) and two out of the 11 were 
associated with reduced levels of osteoprotegerin. Two out of the 11 miRNAs, 
one originating from Herpes B virus (hbv-miR-B7-5p) and one from Marek’s 
disease virus type 2 (mdv2-miR-m18-5p), associated with changes in pro-
thrombotic P-selectin (Table F.7; Table F.8). In this cohort, none of the miRNAs 
was associated with IL6, C-reactive protein, chronic heart disease (CHD), 
hypertension, or cancer (Table F.8 and F.9).  
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Table F.7:  Significant association of viral miRNAs with inflammatory and pro-
thrombotic biomarkers.  
 
sICAM1 sTNFRII OPG MCP1 P-Selectin 
 
fold change 
(95%CI) 
fold change 
(95%CI) 
fold change 
(95%CI) 
fold change 
(95%CI) 
fold change 
(95%CI) 
blv-miR-
B2-5p 
0.97 
(0.95 -0.99), 
p=0.01  
ebv-miR-
BART11-
5p 
0.95 
(0.93 -0.98), 
p=01.0e-04*  
hbv-miR-
B26-5p 
0.97 
(0.94 -1.00), 
p=0.03 
1.05 
(1.01 -1.08), 
p=0.01  
hbv-miR-
B7-5p 
0.97 
(0.95 -1.00), 
p=0.03  
1.03 
(1.00 -1.06), 
p=0.03 
iltv-miR-I2 1.05 
(1.02 -1.08), 
p=0.003* 
1.04 
(1.00 -1.07), 
p=0.03  
kshv-miR-
K12-10a-
5p 
1.06 
(1.02 -1.11), 
p=0.002* 
kshv-miR-
K12-6-5p 
1.12 
(1.07 -1.18), 
p=3.6e-06* 
0.92 
(0.88 -0.96), 
p=03.0e-04* 
mcmv-miR-
m59-2 
mdv2-miR-
M18-5p 
1.06 
(1.04 -1.09), 
p=6.2e-08* 
1.06 
(1.04 -1.09), 
p=1.7e-06* 
0.96 
(0.93 -0.98), 
p=03.0e-04* 
1.03 
(1.00 - 1.05), 
p=0.02 
0.97 
(0.95 -1.00), 
p=0.03 
prv-miR-
LLT3 
0.96 
(0.93 -0.98), 
p=04.0e-04*  
prv-miR-
LLT6           
 
All associations were significant at p<0.05. Those surviving corrections for multiple 
comparisons are marked with *. Full results are available in Table S3. 
Fold-change values for quantitative measures are for a 1 SD change in that value. 
Biomarker values were log-transformed for association analyses; P-selectin- platelet 
selectin; sTNFRII-soluble  tumor necrosis factor alpha receptor II; sICAM1- soluble 
intercellular adhesion molecule 1; MCP1- Monocyte chemotactic protein 1: OPG- 
Osteoprotegerin, aka tumor necrosis factor receptor superfamily 11B (TNFRSF11B). 
 
  
 
Table F.8: Association analyses for all biomarkers and viral miRNAs (related to Table F.7).   
 
Viral 
miRNA 
P-selectin 
fold change 
(95%CI) 
CRP 
fold change 
(95%CI) 
sTNFR II 
fold change 
(95%CI) 
sICAM-1 
fold change 
(95%CI) 
IL6 
fold change 
(95%CI) 
MCP1 
fold change 
(95%CI) 
OPG 
fold change 
(95%CI) 
blv-miR-
B2-5p 
1.02 
(0.99 - 1.05), 
p=0.1 
0.99 
(0.96 - 1.01), 
p=0.3 
1.02 
(0.99 - 1.04), 
p=0.3 
0.97 
(0.95 - 0.99), 
p=0.01 
0.98 
(0.96 - 1.01), 
p=0.2 
0.99 
(0.97 - 1.02), 
p=0.5 
1.00 
(0.97 - 1.02), 
p=0.8 
ebv-miR-
BART11-
5p 
1.01 
(0.99 - 1.04), 
p=0.3 
0.99 
(0.97 - 1.02), 
p=0.7 
1.01 
(0.98 - 1.04), 
p=0.5 
0.95 
(0.93 - 0.98), 
p=01.0e-04**** 
0.98 
(0.96 - 1.01), 
p=0.2 
0.99 
(0.96 - 1.01), 
p=0.4 
1.00 
(0.97 - 1.02), 
p=0.8 
hbv-miR-
B26-5p 
1.03 
(0.99 - 1.06), 
p=0.1 
0.99 
(0.96 - 1.02), 
p=0.6 
1.05 
(1.01 - 1.08), 
p=0.01 
0.97 
(0.94 - 1.00), 
p=0.03 
0.99 
(0.96 - 1.02), 
p=0.7 
0.99 
(0.96 - 1.02), 
p=0.4 
0.99 
(0.96 - 1.02), 
p=0.6 
hbv-miR-
B7-5p 
1.03 
(1.00 - 1.06), 
p=0.03 
0.99 
(0.96 - 1.02), 
p=0.4 
1.03 
(1.00 - 1.06), 
p=0.1 
0.97 
(0.95 - 1.00), 
p=0.03 
0.98 
(0.96 - 1.01), 
p=0.2 
1.00 
(0.97 - 1.03), 
p=0.9 
0.98 
(0.96 - 1.01), 
p=0.3 
iltv-miR-I2 
1.02 
(0.99 - 1.05), 
p=0.3 
1.02 
(0.99 - 1.05), 
p=0.2 
1.04 
(1.00 - 1.07), 
p=0.03 
1.05 
(1.02 - 1.08), 
p=0.003**** 
1.02 
(0.99 - 1.05), 
p=0.2 
1.01 
(0.98 - 1.04), 
p=0.7 
0.99 
(0.96 - 1.02), 
p=0.6 
kshv-miR-
K12-10a-
5p 
1.02 
(0.99 - 1.06), 
p=0.2 
1.00 
(0.97 - 1.04), 
p=0.9 
1.06 
(1.02 - 1.11), 
p=0.002**** 
0.98 
(0.95 - 1.02), 
p=0.3 
1.00 
(0.97 - 1.04), 
p=0.8 
0.98 
(0.95 - 1.02), 
p=0.4 
0.98 
(0.94 - 1.01), 
p=0.2 
kshv-miR-
K12-6-5p 
1.00 
(0.95 - 1.05), 
p=0.9 
1.01 
(0.96 - 1.05), 
p=0.8 
1.12 
(1.07 - 1.18),  
p=3.6e-06**** 
1.01 
(0.96 - 1.05), 
p=0.8 
1.02 
(0.98 - 1.07), 
p=0.3 
1.02 
(0.98 - 1.07), 
p=0.3 
0.92 
(0.88 - 0.96), 
p=03.0e-
04**** 
mcmv-
miR-m59-
2 
1.03 
(1.00 - 1.06), 
p=0.1 
0.99 
(0.96 - 1.03), 
p=0.8 
1.02 
(0.99 - 1.05), 
p=0.3 
0.97 
(0.94 - 1.00), 
p=0.1 
0.99 
(0.96 - 1.02), 
p=0.5 
1.01 
(0.97 - 1.04), 
p=0.7 
0.98 
(0.95 - 1.01), 
p=0.3 
mdv2-
miR-M18-
0.97 
(0.95 - 1.00), 
1.00 
(0.98 - 1.02), 
1.06 
(1.04 - 1.09),  
1.06 
(1.04 - 1.09), 
1.00 
(0.98 - 1.03), 
1.03 
(1.00 - 1.05), 
0.96 
(0.93 - 0.98), 
  
 
5p p=0.03 p=0.9 p=1.7e-06**** p=6.2e-08**** p=0.7 p=0.02 p=03.0e-
04**** 
prv-miR-
LLT3 
1.02 
(1.00 - 1.05), 
p=0.1 
0.99 
(0.96 - 1.01), 
p=0.3 
1.01 
(0.99 - 1.04), 
p=0.3 
0.96 
(0.93 - 0.98), 
p=04.0e-04**** 
0.98 
(0.96 - 1.00), 
p=0.1 
0.99 
(0.97 - 1.02), 
p=0.5 
1.00 
(0.98 - 1.03), 
p=0.9 
Prv-miR-
LLT6 
1.02 
(0.99 - 1.05), 
p=0.1 
0.99 
(0.97 - 1.02), 
p=0.6 
1.03 
(1.00 - 1.05), 
p=0.1 
0.98 
(0.95 - 1.00), 
p=0.1 
0.98 
(0.96 - 1.01), 
p=0.2 
0.99 
(0.96 - 1.02), 
p=0.4 
0.99 
(0.97 - 1.02), 
p=0.6 
 
Fold-change values for quantitative measures are for a 1 SD change in that value. Associations are considered significant at 
p<0.05. Those surviving corrections for multiple comparisons are marked with ****. Biomarker values were log-transformed for 
association analyses. Abbreviations:  P-selectin- platelet selectin; CRP-C-reactive protein; sTNFRII-soluble Tumor Necrosis 
Factor Alpha Receptor II; sICAM1- soluble Intercellular Adhesion Molecule 1; IL6-interleukin 6; MCP1- Monocyte Chemotactic 
Protein 1: OPG- Osteoprotegerin, aka Tumor Necrosis Factor Receptor Superfamily 11B (TNFRSF11B). 
 
Table F.9: Association of viral miRNAs with CHD and cancer (related to Table F.7). 
Viral miRNA 
Age 
fold change  
(95%CI) 
Sex (Female) 
fold change  
(95%CI) 
Hypertension 
fold change  
(95%CI) 
CHD 
fold change  
(95%CI) 
Cancer 
fold change  
(95%CI) 
blv-miR-B2-5p 
0.98 
(0.96 - 1.01), 
p=0.2 
1.01 
(0.96 - 1.06), 
p=0.7 
0.96 
(0.91 - 1.02), 
p=0.2 
0.97 
(0.90 - 1.05), 
p=0.5 
1.04 
(0.98 - 1.11), 
p=0.2 
ebv-miR-
BART11-5p 
0.99 
(0.97 - 1.01), 
p=0.4 
1.02 
(0.97 - 1.07), 
p=0.5 
0.97 
(0.91 - 1.02), 
p=0.2 
0.99 
(0.92 - 1.07), 
p=0.8 
1.03 
(0.97 - 1.10), 
p=0.3 
hbv-miR-B26-5p 
0.97 
(0.94 - 1.00), 
p=0.04 
1.04 
(0.97 - 1.10), 
p=0.3 
0.96 
(0.90 - 1.03), 
p=0.3 
1.00 
(0.91 - 1.11), 
p=0.9 
1.03 
(0.95 - 1.12), 
p=0.5 
hbv-miR-B7-5p 
0.98 
(0.95 - 1.00), 
p=0.1 
1.02 
(0.97 - 1.07), 
p=0.4 
1.01 
(0.95 - 1.07), 
p=0.9 
1.02 
(0.94 - 1.11), 
p=0.7 
1.03 
(0.96 - 1.11), 
p=0.4 
  
 
iltv-miR-I2 
0.97 
(0.94 - 1.00), 
p=0.1 
1.05 
(0.99 - 1.11), 
p=0.1 
0.98 
(0.91 - 1.05), 
p=0.5 
0.97 
(0.88 - 1.07), 
p=0.5 
0.98 
(0.90 - 1.06), 
p=0.6 
kshv-miR-K12-
10a-5p 
0.97 
(0.93 - 1.00), 
p=0.1 
1.02 
(0.95 - 1.09), 
p=0.7 
0.96 
(0.89 - 1.05), 
p=0.4 
0.96 
(0.86 - 1.08), 
p=0.5 
1.08 
(0.98 - 1.19), 
p=0.1 
kshv-miR-K12-6-
5p 
0.95 
(0.91 - 0.99), 
p=0.01 
1.00 
(0.91 - 1.09), 
p=0.9 
0.99 
(0.89 - 1.10), 
p=0.8 
0.95 
(0.83 - 1.10), 
p=0.5 
0.97 
(0.86 - 1.10), 
p=0.7 
mcmv-miR-m59-2 
0.98 
(0.95 - 1.01), 
p=0.2 
1.03 
(0.97 - 1.09), 
p=0.4 
0.96 
(0.89 - 1.03), 
p=0.3 
0.97 
(0.88 - 1.07), 
p=0.6 
1.07 
(0.98 - 1.16), 
p=0.1 
mdv2-miR-M18-
5p 
0.97 
(0.95 - 1.00), 
p=0.02 
1.02 
(0.98 - 1.07), 
p=0.3 
1.00 
(0.95 - 1.05), 
p=0.9 
0.99 
(0.92 - 1.07), 
p=0.8 
0.96 
(0.91 - 1.03), 
p=0.3 
prv-miR-LLT3 
0.98 
(0.96 - 1.00), 
p=0.1 
1.03 
(0.98 - 1.09), 
p=0.2 
0.98 
(0.93 - 1.04), 
p=0.6 
0.96 
(0.89 - 1.04), 
p=0.4 
1.05 
(0.98 - 1.12), 
p=0.2 
prv-miR-LLT6 
0.98 
(0.96 - 1.01), 
p=0.2 
1.02 
(0.97 - 1.08), 
p=0.4 
0.97 
(0.91 - 1.03), 
p=0.3 
0.98 
(0.90 - 1.07), 
p=0.7 
1.00 
(0.94 - 1.08), 
p=0.9 
 
Fold-change values for quantitative measures are for a 1 SD change in that value. Associations are considered significant at 
p<0.05. CHD = coronary heart disease 
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Plasma viral miRNAs modestly associate with age but not with sex 
Certain DNA viral infections are known to cause proliferative neoplasms which 
increase with age. Here, we sought to determine if presence of viral miRNA 
associates with age and sex.  Interestingly, three of the viral miRNAs associated 
inversely with age (Table F.9). These were hbv-miR-B26-5p, kshv-miR-K12-6-5p 
and mdv2-miR-M18-5p. None of the viral miRNAs were associated with sex 
(Table F.9). 
 
 
Co-expression analysis of plasma viral miRNA and blood cell mRNA 
transcripts; predicted gene targets  
In cells, viral miRNAs target specific mRNAs dependent on their seeded 
sequence.  Since we found viral miRNAs present in plasma we wanted to assess 
co-expression of plasma viral miRNAs with whole blood derived mRNA 
transcripts in the same FHS participants. For that purpose we utilized 17,318 
whole blood mRNA transcripts from the same FHS participants at the same visit. 
Using dichotomous analysis we identified three viral miRNA-mRNA pairs (Table 
F.10). We also performed a continuous analysis for viral miRNA-mRNA pairs. 
Using Bonferroni corrected p<0.05, we identified 13 viral miRNA-mRNA co-
expression pairs for genes related to immune response, viral integration, 
apoptosis, cell mobility and RNA-splicing (Table F.10). To identify possible 
molecular targets, we used the VIRmiRNA online tool (see Methods) to predict 
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human gene targets. We identified two target genes for two of the13 viral 
miRNAs. These were LRP1B for blv-miR-B2-5P and SELPLG for iltv-miR-I2.   
 
Table F.10:  Co-expression of plasma viral miRNA with whole blood mRNA 
transcripts assessed by using dichotomous or continuous model analysis and a 
cut off of Bonferroni p <0.05 corrected for all 17,318 transcripts.  
 
Viral 
miRNA 
Human mRNA 
Transcript 
ID 
Beta 
Correlation 
p-value 
Disease 
associate
d with 
gene 
target 
Function of 
gene target 
mcmv-
miR-
m59-2* 
 2340423 0.13 3.44E-07 not known 
not known 
blv-miR-
B2-5p* 
LRP1B 
(LDL receptor 
related protein 
1B) 
2578790 
 
0.06 1.64E-06 
Endocervi
cal 
carcinoma 
Potential cell 
surface 
receptor that 
binds and 
internalizes 
ligands in 
receptor-
mediated 
endocytosis 
manner 
iltv-miR-
I2* 
CHD9 
(Chromo-
domain 
Helicase DNA 
Binding Protein 
9) 
3660858 -0.08 2.53E-06 not known 
transcriptional 
coactivator for 
PPARA/ binds 
to A/T-rich 
DNA  
mdv2-
miR-
M18-5p 
SMC5 
(Structural 
Maintenance 
Of 
Chromosomes 
5) 
3174224 0.02 1.67E-07 
Viral 
pneumoni
a    
and Corne
lia De 
Lange 
Syndrome 
1 
Core 
component of 
the SMC5-
SMC6 
complex, 
involved in 
repair of DNA 
double-strand 
breaks by 
homologous 
recombination
; SMC5-SMC6 
may prevent 
transcription 
of episomal 
viral DNA 
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iltv-miR-
I2 
SRSF2IP 
(Serine/Arginin
e-Rich Splicing 
Factor 2, 
Interacting 
Protein) 
3452145 0.02 2.10E-07 
Alternative 
splicing in 
autism 
spectrum 
disorder  
Plays a role in 
pre-mRNA 
alternative 
splicing by 
regulating 
spliceosome 
assembly. 
Related 
pathways are 
apoptosis 
modulation 
and signaling 
mdv2-
miR-
M18-5p 
PIK3R1 
(Phosphoinositi
de-3-Kinase 
Regulatory 
Subunit 1) 
2813060 0.02 2.67E-07 
Short 
Syndrome
 and  
Agammag
lobulinemi
a 7, 
Autosomal 
Recessive 
(severe 
infections 
in the first 
years of 
life). 
Coordinates a 
diverse range 
of cell 
functions 
including 
proliferation 
and survival 
mdv2-
miR-
M18-5p 
UTRN 
(Utropin) 
2929168 0.02 4.23E-07 
Duchene 
Muscular 
Dystrophy
; Becker 
Muscular 
Dystrophy 
Participates in 
post-synaptic 
membrane 
maintenance 
and 
acetylcholine 
receptor 
clustering 
mdv2-
miR-
M18-5p 
ZC3H13 
(Zinc Finger 
CCCH-Type 
Containing 13) 
3512769 0.02 5.65E-07  
Involved in 
RNA 
processing 
and cell cycle 
as part of the 
WTAP 
complex  
iltv-miR-
I2 
RBM26 
(RNA Binding 
Motif Protein 
26) 
3519119 0.02 7.74E-07  
Involved in 
nucleic acid 
binding and n
ucleotide 
binding 
hbv-
miR-
B26-5p 
SCGB3A2 
(Secretoglobin 
Family 3A 
Member 2) 
2834472 -0.22 1.23E-06 
Asthma a
nd Asthm
a 
Susceptibi
lity 
A secreted 
lung 
surfactant 
protein and a 
downstream 
target of 
thyroid 
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transcription 
factor; related 
pathways 
are Vesicle-
mediated 
transport and 
Binding and 
Uptake of 
Ligands by 
Scavenger 
Receptors 
iltv-miR-
I2 
PSIP1 
(PC4 And 
SFRS1 
Interacting 
Protein 1) 
3199790 0.02 1.42E-06 HIV-1 
Cellular 
cofactor for 
lentiviral 
integration; 
Transcriptiona
l coactivator 
involved in 
neuroepithelial 
stem cell 
differentiation 
and 
neurogenesis. 
Involved in 
particular in 
lens epithelial 
cell gene 
regulation and 
stress 
responses. 
kshv-
miR-
K12-
10a-5p 
MIC1/C18orf8 
(Macrophage 
Inhibitory 
Cytokine 1) 
3781734 0.07 1.61E-06  
Colon cancer 
associated 
protein 
mdv2-
miR-
M18-5p 
EPRS 
(Glutamyl-
Prolyl-TRNA 
Synthetase) 
2456746 0.02 1.87E-06 
Aqueous 
Misdirecti
on and Se
paration 
Anxiety 
Disorder 
Catalyzes the 
attachment of 
the cognate 
amino acid to 
the 
corresponding 
tRNA in a two-
step reaction: 
the amino acid 
is first 
activated by 
ATP to form a 
covalent 
intermediate 
with AMP and 
is then 
transferred to 
the acceptor 
end of the 
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cognate tRNA. 
 
iltv-miR-
I2 
HIF1A 
(Hypoxia 
Inducible 
Factor 1 Alpha 
Subunit) 
3539070 0.02 2.11E-06 
Hypoxia a
nd Retinal 
Ischemia 
Functions as a 
master 
transcriptional 
regulator of 
the adaptive 
response to 
hypoxia. 
Under hypoxic 
conditions, 
activates the 
transcription 
of many 
genes 
including 
genes related 
to glucose 
metabolism 
mdv2-
miR-
M18-5p 
RNF6 
(Ring Finger 
Protein 6) 
3506431 0.02 2.38E-06 
Esophage
al Cancer 
Potential 
tumor 
suppressor; 
related 
pathways 
are Immune 
System and Cl
ass I MHC 
mediated 
antigen 
processing 
and 
presentation 
ebv-
miR-
BART11
-5p 
ARHGAP18 
(Rho GTPase 
Activating 
Protein 18) 
2973694 0.23 2.74E-06 
 Penicillios
is 
Rho GTPase 
activating 
protein that 
suppresses F-
actin 
polymerization 
by inhibiting 
Rho; 
Regulates cell 
shape, 
spreading, 
and migration  
 
*Only 3 miRNAs-mRNA pairs were significantly co-expressed by dichotomous model; 
the rest were co-expressed by continuous model. 
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Viral miRNA presence is detectable post DNA-virus infection in mice 
In cells of infected tissues, viral miRNA levels fluctuate as the viral infection 
switches from lytic to latent; however, there is no uniform consensus whether 
viral miRNAs are released into the circulation of the host or if they can be 
detected in plasma. To confirm that viral infections may lead to an increase in 
viral miRNA balance in the plasma, we infected mice with an alphaherpesvirus 
(HSV1) or a betaherpesvirus (mCMV). Both infections led to a detectable 
increase of select miRNAs in the plasma at 24h post infection (Table F.11). Since 
the alphaherpesvirus  infection was only used as a proof of concept, we infected 
mice intravenously (i.v.) with HSV1 and screened for miRNAs as previously 
described for cells (229). Although i.v. HSV1 infection is not the physiological 
route of infection, in certain genetically modified cases it can lead to lethality 
(250).  HSV1 infection led to detectable presence of hsv1-miR-H6-3p and hsv1-
mir-H1-3p only in the plasma of the infected mice; no other viral miRNAs tested 
showed specific detection (Table F.11).  
  
279 
 
 
Table F.11: Infections with alpha (HSV1) and beta (mCMV) DNA viruses in mice 
generates viral miRNA in plasma 24h post infection. 
Infection miRNA Control 
(raw Ct) 
Virus 
(Ct) 
no cDNA 
control 
NTC % of mice 
expressing 
viral miRNA 
(n = 5/group) 
HSV1 hsv1-miR-
H6-3p 
u.d 29.9 ± 1 u.d u.d 80% 
hsv1-miR-
H1-3p 
u.d 33.9 ± 2 u.d u.d 80% 
hsv1-miR-
H14-5p 
u.d 
34.10 ± 
1 
u.d u.d 40% 
hsv1-miR-
H3-3p 
35.8 ± 2 35.5 ± 2 u.d 35.2 60%; 40% 
hsv1-miR-
H4-3p 
u.d u.d u.d u.d 100% 
mCMV mcmv-miR-
23-2-3p 
u.d 
33.2 ± 
0.3 
u.d u.d 100% 
mcmv- miR 
-59-2 
39.1 ± 0.5 
38.8 ± 
0.5 
u.d u.d 80%; 100% 
mcmv- miR 
-59-1 
u.d u.d u.d u.d 100% 
mcmv- 
miR-M01-4-
3p 
u.d u.d u.d u.d 100% 
mcmv- 
miR-m44-1 
30.0 ± 0.5 
30.0 ± 
1.1 
u.d u.d 100% 
  
u.d.-undetermined, i.e. there were no values generated by the qPCR machine 
generated. The background of the machine for SYBR green is Ct=38 and for Taqman 
Ct=40. HSV-1 miRNA was measured using SYBR green and 1:40 dilution of RNA (100 
µl of plasma, eluted in 14 µl); mCMV miRNA were measured using Taqman primers  and 
3 µl undiluted RNA (100 µlof plasma, eluted in 14 µl). 
“no cDNA” control-negative control run with the RT reaction; includes cDNA synthesis 
master mix, water, and TaqMan MicroRNA 5X RT Assay, with no RNA added to the well.  
“NTC”-no template control-negative control run with the qPCR step; includes TaqMan 2X 
Universal PCR Master Mix, TaqMan MicroRNA 20X TM Assay, water, with no cDNA 
added to the well.  
 
 
Similarly, after intraperitoneal injection with mCMV, a betaherpesvirus, mcmv-
miR-m23-3p was detectable only in the plasma of the infected mice (Table F.10). 
As previously reported (251), mcmv-miR-m59-2 detection by qPCR exhibited 
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non-specificity in mice, as there was no difference between control and virus-
injected mice (Table F.11). Since mice are maintained in pathogen-free 
conditions, the detection of certain viral miRNAs in the plasma of non-infected 
mice may be due to primer specificity and/or similarity between the viral miRNA 
and mouse miRNAs. Taken together, these in vivo experiments suggest that viral 
miRNA can be detected in plasma post infection.  
 
Discussion 
MicroRNAs (miRNA) play an important regulatory role in gene expression. 
Numerous studies have shown that tumor cells can secrete miRNAs in plasma 
and can affect cells of distant origin.  This is the first study to describe the 
presence of different viral miRNAs in human plasma at steady state. It is 
important to stress that this study cannot test for infectious profile as a result of 
miRNA presence and only demonstrates that select viral miRNAs are circulating 
at the time of participant visit. Though not established from these findings, it is 
possible that identifying viral miRNAs in human plasma could predict recurrent 
infection cycles as well as to identify miRNAs that may impact wide-ranging 
biological processes (252).  The genomes of certain viruses are also known to 
encode miRNAs that may contribute to the regulation of the lytic vs. latent stages 
of the viral life cycle in their target cell (228). This suggests that establishing the 
basal human plasma miRNome could both provide insight into disease 
phenotypes as well as predict recurrent infectious cycles. Using a large cohort of 
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2763 participants in the FHS and an unbiased sequencing approach, we 
identified circulating viral miRNAs originating from DNA viruses and one from an 
RNA-retrovirus. Interestingly, most of the 11 viral miRNAs found in the FHS 
cohort are expressed during the latent phase of their respective viruses (253-
257). The presence of these viral miRNAs in plasma was associated with 
inflammatory and thrombotic biomarkers. Targeted murine experiments confirmed 
that viral infections lead to the presence of select viral miRNAs in plasma. Since 
systemic-wide inflammation beyond the infected tissue during viral infections is 
poorly understood, circulating miRNAs may provide valuable information about 
infection progression and control.  
 In this study, all miRNAs originating from viruses using humans as a host 
were DNA viruses from the Herpesviridae family. Human plasma had detectable 
miRNAs only for beta and gammaherpesviruses. Our sequencing results showed 
the presence of hcmv-miR-US25mir-B25-2-3p in the plasma of all 40 participants 
included in the sequencing evaluation; however, by qPCR we were able to detect 
this miRNA in less than 0.7% of the entire cohort. The discrepancy between 
sequencing and RT-qPCR could be due to primer inability to target low levels of 
the miRNA. Human CMV is a betaherpesvirus that causes a persistent human 
infection and hcmv-miR-US25-2-3p is known to reduce viral replication by 
downregulation of host eukaryotic translation initiation factor 4A1 (258). By RT-
qPCR we were also able to confirm presence of miRNAs coming from human 
viruses of the Gammaherpesvirinae subfamily (KSHV and EBV). In host cells, 
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two of the detected KSHV miRNAs are known to regulate cytokine secretion, cell 
survival, KSHV gene expression (kshv-miR-12-10a-5p) and endothelial cell 
reprogramming (kshv-miR-12-6-5p) (259-263). Interestingly, in two small cohorts 
of septic patients plasma (EDTA) levels of different KSHV miRNAs were also 
elevated, as one of them (kshv-miR-K12-12) exhibited higher levels in patients 
with African descent (264, 265).  EBV, in turn, is a B-cell herpesvirus associated 
with many diverse B-cell lymphomas. The miRNA detected here, ebv-miR-
BART11-5p, targets early B-cell factor 1, which is known to be critical for B-cell 
germinal center formation (CD40; BCR; PAX5) (266).  Other EBV miRNAs have 
also been detected in plasma of patients with chronic lymphocytic leukemia 
(CLL) and correlate with shorter survival in two independent small cohorts (267).  
All miRNAs coming from human viruses associated with inflammatory biomarkers 
such as sICAM1, sTNFRII and osteoprotegerin.  
In addition to viral miRNA originating from human viruses, we also 
detected two miRNA from HBV. The natural host for HBV is rhesus monkeys and 
the infection that it causes is mild and self-limiting (253). HBV has also been 
reported to infect humans zoonotically leading to certain neurological 
complications (253). HBV miRNAs were first identified in 2011 but their functional 
target in their natural host or in humans are not well understood. It has been 
suggested that hbv-miR-7-5p has late expression kinetics in viral replication and 
may, therefore, be involved in latency (253). Here we report that HBV miRNA 
present in human plasma associate with the inflammatory biomarkers sTNFRII 
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and sICAM1 (hbv-mir-B26-5p and hbv-mir-B7-5p) and with the prothrombotic P-
selectin (hbv-mir-B7-5p). 
In addition, we were able to detect miRNA from viruses that are not known 
to cause infection in humans. The natural hosts for these viruses are mice and 
domestic animal species such as chickens, turkey, swine and cattle. There is 
evidence that murine CMV has the potential to cross over the species barrier with 
the help of human CMV proteins (232); however, there are no reports on how this 
crossover may affect humans.  Although we were able to detect one mCMV 
miRNA in the plasma of the FHS participants, this miRNA did not associate with 
any of the measured inflammatory biomarkers or phenotypical assessments.  
When it comes to the other viruses targeting domestic animals, three of them are 
from the Alphaherpesvirinae subfamily. For instance, MDV2  (and HVT) is an 
avian virus that is used for flock vaccination against Marek’s disease 
characterized by T-cell lymphoma (268). Similarly, attenuated  forms of the Gallid 
herpes virus 1 (ILTV) are used to vaccinate against infectious laryngotracheitis  
in chickens (269). There are no reports in the literature indicating that any of 
these avian viruses can cross over to humans, although alphaherpesviruses are 
promiscuous across species. Two of the viral miRNAs detected in the human 
plasma originate from Suid herpesvirus 1 (SuHV1, or pseudorabies virus) known 
to cause Aujeszky’s disease in swine (270). Aujeszky’s disease is characterized 
by severe neurological symptoms and death particularly in young animals.  The 
animals that recover can carry the virus latently with reoccurring shedding (270). 
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SuHV1 is known to be able to cross the species barrier and establish infection in 
other mammals such as cattle, sheep, dogs and others. Infections in humans are 
not well documented although there are limited cases in which neutralizing 
antibodies against the virus were detected in humans (271). In this study we 
were able to detect two miRNAs in human plasma and one of them associated 
with soluble ICAM-1. One of the miRNAs detected here came from BLV, a 
retrovirus using cattle as a host. During its replication BLV goes through a DNA-
stage and has the ability to integrate into the host’s DNA (272).  In humans,  
antibodies against cattle virus BLV have been detected and elevated presence of 
BLV-DNA has been described in the epithelium of breast cancer patients (273). It 
has been postulated that BLV may be transmitted from cattle to humans by 
eating undercooked meat or drinking raw milk (272). It is unclear how these BLV 
viral miRNAs appear in human plasma; however, food ingestion or indirect 
contact may be possible routes of transmission. This study suggests that these 
viruses may enter human hosts, may sufficiently propagate to generate viral 
miRNA within the human bloodstream and the presence of these viral miRNAs 
associates with inflammatory and, in some cases, prothrombotic biomarkers.  
Although the data is greatly strengthened by the size of the human 
population, a limitation of the cohort is the inadequate number of participants with 
documented oncological conditions, as participants with cancer comprised only 
16% of the entire sample.  The FHS was originally designed to study 
cardiovascular disease progression and this limited our ability to detect 
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associations with cancer or specific type of cancers.  The analysis of an 
oncology-focused cohort for viral miRNA is warranted, particularly because many 
DNA and some RNA viral infections have been directly or indirectly associated 
with various types of cancer. There is increasing evidence that hCMV may be 
involved in the initiation and progression of breast cancer (240).  EBV and KSHV 
are known to induce malignant phenotypes in immunocompromised hosts (233, 
236).  From the non-human viruses, BLV causes lymphoma in cattle. A recent 
case control study of 239 donors has shown that the frequency of BLV-DNA in 
mammary epithelium from women with breast cancer was significantly higher 
than in normal controls (272).  The relationship between DNA viral infections and 
cancer has long been described in the literature, although the exact mechanisms 
are still under investigation.  
 Viral infections and many types of disease are characterized by an 
increase in inflammation. Regardless of the viral host target, nine of the eleven 
viral miRNAs that we identified in plasma were associated with at least one 
inflammatory marker and a number of these markers suggest connections 
between viral miRNA and disease states. Five of the viral miRNA associated with 
elevated levels of sTNFRII in plasma. Soluble TNFRII modulates biological 
functions of TNF-alpha by competing with cell surface receptors. Since TNF-
alpha is a primary cytokine and levels fluctuate, levels of sTNFRs show high 
accuracy in measuring inflammation and prognosis of disease. It has been 
proposed that sTNFRII levels are a useful quantification of TH1 immune 
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response. In HIV and sepsis, levels of sTNFRII strongly correlate with 
progression of disease (274). Seven out of the eleven viral miRNAs also 
associated with changes in the levels of sICAM-1. sICAM-1 is an intracellular 
adhesion molecule and is released in plasma with increased inflammation and 
tissue damage. Circulating levels of sICAM1 have not only been associated with 
coronary heart and vascular disease but with infectious diseases such as 
malaria, sepsis, and dengue hemorrhagic fever, with severity of disease (275). 
Elevated serum levels of sICAM1 have also been associated with immune 
suppression in patients with chronic liver disease (276) and, in our study, seven 
out of the 11 viral miRNAs associated with sICAM1. Osteoprotegerin is a 
member of the tumor necrosis factor receptor superfamily and was initially 
discovered as a contributor to bone turnover homeostasis (277).  Interestingly, 
patients with multiple myeloma have significantly lower levels of osteoprotegerin 
(278-280), and viruses such as KSHV are known to modulate osteoprotegerin 
levels in a COX2-dependent manner (281). Two of the viral miRNAs in this study, 
kshv-miR-K12-6-5p and mdv2-miR-M18-5p, significantly associated with 
osteoprotegerin. In summary, the overall presence of viral miRNAs in this human 
cohort is consistent with increased systemic inflammation.  
The presence of viral miRNAs in human plasma has not been previously 
described in a large cohort and it is unclear what cells and what genes these 
miRNAs may target. Using whole blood mRNA transcripts measured concurrently 
with the viral miRNAs, we were able to identify novel co-expression relationships 
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between seven viral miRNAs and sixteen whole blood mRNAs. Additionally, by 
utilizing the seven nucleotide seeding sequence of each miRNA, we were able to 
predict two gene targets for miRNAs originating from non-human viruses, i.e. 
cattle BLV and avian ILTV.   Our findings highlight the need for future molecular 
studies assessing targets and potential disease-related mechanisms for these 
plasma miRNAs in humans. 
 Using an unbiased, non-targeted approach, we were able to identify 19 
different known viral miRNAs by sequencing, and we confirmed their presence by 
RT-qPCR in the plasma of the FHS Offspring Cohort Visit 8. There are, however, 
certain limitations to our study. First and foremost, we can only identify viral 
miRNAs that had already been identified and deposited to the Genboree 
database prior to our analysis. Thus, miRNA from other viruses may also be 
present but would not have been identified due to limitations in sequence 
information. In addition, there is a potential for primer cross-reactivity although 
this is mitigated in our study by the use of RT-qPCR in a very large number of 
samples to confirm the deep sequencing findings.  Another important and related 
technical limitation is the small size of viral miRNAs and their similarity to host 
miRNA or to the miRNAs of other human viruses. Because of this concern we 
omitted hbv-mir-B26-3p-novel, mdv2-miR-M21-3p, rlcv-miR-rL1-17-3p, rlcv-miR-
rL1-17-5p, rlcv-miR-rL1-29-3p, and hvt-miR-H14-3p from our full analyses and 
kept all miRNAs from human viruses. However, this does not necessarily mean 
that they are not present in the circulation and do not have an association with 
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inflammation or disease phenotypes.  Because the fundamental observation that 
viral miRNAs are widely distributed in a human population has never been 
reported, we performed, as a proof of concept, murine viral infections to show 
presence of viral miRNA in the plasma post infection. However, this system itself 
presents an additional study limitation as, by design, it is modelling acute viral 
miRNA infection and does not assess the potential chronic findings associated 
with the observational cohort.  Limitations of the co-expression model analysis 
have been previously described (282) and further work is necessary to prove 
mRNA targets, cell of interest and physiological implication for these viral 
miRNAs. Finally, the FHS Offspring Cohort Visit 8 population is older and of 
European descent and future ongoing studies in our laboratory are exploring 
whether these specific findings hold up in a racially and ethnically diverse sample 
as well as in younger individuals.  
 In conclusion, this is the first large study to identify expression of viral 
miRNAs in human plasma originating from viruses that can infect humans as well 
as animals to which humans are exposed or may consume.  These miRNAs, 
regardless of primary host target, associated with inflammatory and thrombotic 
biomarkers but did not associate with specific disease phenotypes. Further 
studies are necessary to include broader, more inclusive populations as well as 
to understand the mechanistic relationship between plasma viral miRNA, 
inflammation and cancer. 
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APPENDIX G: GENE EXPRESSION OF HUMAN UMBILICAL VEIN 
ENDOTHELIAL CELLS (HUVECs) 
 
Permissions 
Appendix G is a table excerpt from a published manuscript, included with 
permission.  
 
• Clancy L, Beaulieu LM, Tanriverdi K, Freedman JE. (2017).The role of 
RNA uptake in platelet heterogeneity. Thromb Haemost, 117(5), 948-961 
o Permission Information: Copyright Permission No 116/06/2017 
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results, and reviewed and approved the manuscript.  
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Table G.1: Differential gene expression in HUVECs. RT-qPCR results for 
genes of interest in HUVECs after platelet incubation under normal in vitro 
simulated clot conditions (A) or with pretreatment transcription shutdown in 
HUVECs (B). RT-qPCR normalized to two genes, CD63 and CD81, with HUVEC 
alone samples as experimental controls. Additional table legend below table 
denotes sample setup conditions. A) Results represent n=6 experiments. B) 
Results represent n=3 experiments. C) RNA sequencing of genes of interest from 
HUVEC RNA profile previously published (222).  
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A)
ECs Alone Stimulated Ecs
Unstimulated ECs 
Post Platelet 
Stimulated ECs 
Post Stimulated 
CXADR 1.0 -1.0 1.0 1.0
COL18A1 1.0 1.0 1.1 1.4
SELE 1.0 7.4 18.4 79.2
ICAM1 1.0 2.4 3.6 4.7
ITGA5 1.0 1.2 1.3 1.3
TLR3 1.0 -1.1 1.2 1.4
CXCL1 1.0 2.2 8.2 18.0
CXCL12 1.0 1.1 1.8 2.3
TLR4 1.0 -1.0 1.5 1.7
KIAA1462 1.0 1.2 1.1 1.0
CX3CL1 1.0 2.5 2.9 5.7
IL6 1.0 1.3 1.4 2.4
VCAM1 1.0 4.4 4.2 9.4
CD81 1.0 -1.0 1.1 1.1
CXCL2 1.0 3.8 6.2 15.2
EIF4G1 1.0 1.1 1.2 1.5
TNFSF10 1.0 -1.0 1.0 1.0
CALR 1.0 -1.0 1.4 1.3
ASGR1 1.0 1.2 -3.0 -2.4
VEGFA 1.0 1.2 2.2 4.6
IL8 1.0 2.8 9.6 31.6
SIRPA 1.0 -1.1 1.4 1.5
VEGFB 1.0 -1.1 1.2 1.5
VAMP5 1.0 1.0 -1.1 1.3
VIP 1.0 1.1 1.3 2.1
CRP 1.0 -1.7 1.4 -1.4
IFNA1 1.0 1.8 8.9 2.8
TNFRSF1B 1.0 1.1 1.0 -2.6
CCL7 1.0 1.3 3.0 2.0
NFKBIA 1.0 1.6 4.9 7.4
CD63 1.0 1.0 -1.1 -1.1
SELENBP1 1.0 -1.1 -1.1 -2.5
DICER1 1.0 -1.1 1.3 1.3
KIAA0232 1.0 -1.1 1.4 1.5
IFITM3 1.0 1.2 1.4 1.9
MAP4K4 1.0 1.1 1.2 1.4
CXCL6 1.0 1.3 1.8 3.6
VEGFC 1.0 1.3 1.5 1.9
Platelets - - + +
Platelet Thrombin Stimulation - - - +
EC Incubation + + + +
EC Transcription Shutdown - - - -
EC Thrombin Stimulation - + - +
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B)
ECs Alone Stimulated Ecs
Unstimulated ECs 
Post Platelet 
Stimulated ECs 
Post Stimulated 
CXADR 1 1.1 1.1 1.2
COL18A1 1 1.0 1.1 1.3
SELE 1 2.6 6.4 6.7
ICAM1 1 1.0 2.1 1.4
ITGA5 1 1.6 1.6 1.5
TLR3 1 1.7 1.6 1.7
CXCL1 1 2.2 3.6 4.4
CXCL12 1 1.5 2.0 1.6
TLR4 1 1.3 1.6 1.8
KIAA1462 1 1.2 1.4 1.2
CX3CL1 1 1.4 2.8 1.3
IL6 1 2.4 1.1 4.1
VCAM1 1 1.9 3.6 2.4
CD81 1 -1.2 -1.3 -1.2
CXCL2 1 3.2 2.1 6.2
EIF4G1 1 1.3 1.2 1.2
TNFSF10 1 1.4 1.3 1.4
CALR 1 1.1 1.3 1.4
ASGR1 1 1.8 1.5 -5.8
VEGFA 1 1.6 1.5 2.3
IL8 1 2.1 1.8 4.6
SIRPA 1 1.5 1.2 1.3
VEGFB 1 1.3 1.4 1.5
VAMP5 1 1.2 -1.0 1.1
VIP 1 2.2 1.4 2.6
CRP 1 20.3 339.7 41.3
IFNA1 1 1.5 3.3 3.2
TNFRSF1B 1 -1.2 -1.0 -1.2
CCL7 1 -1.4 -1.1 1.2
NFKBIA 1 1.9 3.2 4.4
CD63 1 1.1 1.2 1.2
SELENBP1 1 1.2 1.1 1.2
DICER1 1 1.2 1.5 1.5
KIAA0232 1 1.5 1.8 1.8
IFITM3 1 1.4 1.2 1.6
MAP4K4 1 1.2 1.2 1.4
CXCL6 1 1.2 2.0 1.6
VEGFC 1 1.4 1.4 1.5
Platelets - - + +
Platelet Thrombin Stimulation - - - +
EC Incubation + + + +
EC Transcripton Shutdown + + + +
EC Thrombin Stimulation - + - +
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C)
RPKM Avg
CXADR 0.7
COL18A1 133.5
SELE 4.4
ICAM1 21.0
ITGA5 404.2
TLR3 0.6
CXCL1 10.8
CXCL12 0.1
TLR4 24.2
KIAA1462 12.4
CX3CL1 1.1
IL6 2.7
VCAM1 12.5
CD81 35.5
CXCL2 4.0
EIF4G1 71.6
TNFSF10 21.6
CALR 925.4
ASGR1 1.2
VEGFA 2.0
IL8 21.3
SIRPA 20.0
VEGFB 28.1
VAMP5 64.8
VIP 1.2
CRP 0.0
IFNA1 0.0
TNFRSF1B 25.7
CCL7 0.7
NFKBIA 23.5
CD63 169.1
SELENBP1 6.0
DICER1 5.5
KIAA0232 6.0
IFITM3 163.2
MAP4K4 45.2
CXCL6 1.0
VEGFC 13.8
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